Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@jax.org
ID | JAX:10000003 |
Name | Advanced Solid Tumor |
Definition | A malignant solid tumor |
Source | The Jackson Laboratory (a custom term added that does not corresond to an existing term in the disease ontology) |
Alt Ids | |
Path | Advanced Solid Tumor |
Molecular Profile | Therapy | Indication/Tumor Type | Response Type | Profile Response Detail |
---|---|---|---|---|
PIK3CA mutant | CUDC-907 | Advanced Solid Tumor | sensitive | detail... |
PIK3CA wild-type | PX-866 | Advanced Solid Tumor | sensitive | detail... |
PIK3CA mutant | PX-866 | Advanced Solid Tumor | sensitive | detail... |
TP53 mutant | Bevacizumab | Advanced Solid Tumor | sensitive | detail... |
FGFR2 act mut | Debio 1347 | Advanced Solid Tumor | sensitive | detail... |
PIK3CA act mut | Taselisib | Advanced Solid Tumor | conflicting | detail... |
PIK3CA mutant | M2698 | Advanced Solid Tumor | sensitive | detail... |
TP53 positive | MVAp53 | Advanced Solid Tumor | sensitive | detail... |
BRAF V600E | PLX8394 | Advanced Solid Tumor | sensitive | detail... |
BRAF L597R | Trametinib | Advanced Solid Tumor | sensitive | detail... |
BRAF L597R | Vemurafenib | Advanced Solid Tumor | sensitive | detail... |
BRAF L597S | Vemurafenib | Advanced Solid Tumor | sensitive | detail... |
BRAF L597S | Trametinib | Advanced Solid Tumor | sensitive | detail... |
BRAF K601E | Trametinib | Advanced Solid Tumor | sensitive | detail... |
BRAF K601E | Vemurafenib | Advanced Solid Tumor | conflicting | detail... |
BRAF mutant | Dabrafenib | Advanced Solid Tumor | sensitive | detail... |
TP53 wild-type | Pazopanib + Vorinostat | Advanced Solid Tumor | decreased response | detail... |
RET mutant | Ponatinib | Advanced Solid Tumor | sensitive | detail... |
BRAF act mut | Binimetinib + Encorafenib | Advanced Solid Tumor | sensitive | detail... |
BRAF act mut | PLX8394 | Advanced Solid Tumor | sensitive | detail... |
FGFR3 R248C | Vofatamab | Advanced Solid Tumor | sensitive | detail... |
FGFR3 S249C | Vofatamab | Advanced Solid Tumor | sensitive | detail... |
FGFR3 G372C | Vofatamab | Advanced Solid Tumor | sensitive | detail... |
FGFR3 Y375C | Vofatamab | Advanced Solid Tumor | sensitive | detail... |
FGFR3 K652E | Vofatamab | Advanced Solid Tumor | sensitive | detail... |
MDM2 T16A | Nutlin-3a | Advanced Solid Tumor | predicted - resistant | detail... |
MDM2 P20L | Nutlin-3a | Advanced Solid Tumor | predicted - resistant | detail... |
MDM2 M62V | Nutlin-3a | Advanced Solid Tumor | predicted - resistant | detail... |
MDM2 M62A | Nutlin-3a | Advanced Solid Tumor | predicted - resistant | detail... |
STK11 wild-type | Metformin | Advanced Solid Tumor | sensitive | detail... |
MDM2 L82P | Nutlin-3a | Advanced Solid Tumor | predicted - resistant | detail... |
STK11 loss | Metformin | Advanced Solid Tumor | no benefit | detail... |
MDM2 Q24R | Nutlin-3a | Advanced Solid Tumor | predicted - resistant | detail... |
FGFR3 mutant | Infigratinib | Advanced Solid Tumor | sensitive | detail... |
TP53 loss | Adavosertib | Advanced Solid Tumor | sensitive | detail... |
PTEN negative | Talazoparib | Advanced Solid Tumor | conflicting | detail... |
PIK3CA mutant | XL147 | Advanced Solid Tumor | sensitive | detail... |
JAK1 F635V | Ruxolitinib | Advanced Solid Tumor | sensitive | detail... |
RET G691S | Dovitinib | Advanced Solid Tumor | predicted - sensitive | detail... |
FGFR1 act mut | Debio 1347 | Advanced Solid Tumor | sensitive | detail... |
FGFR3 act mut | Debio 1347 | Advanced Solid Tumor | sensitive | detail... |
PIK3CA act mut | BAY1125976 | Advanced Solid Tumor | sensitive | detail... |
PTEN loss | BAY1125976 | Advanced Solid Tumor | sensitive | detail... |
PIK3CA act mut | Everolimus | Advanced Solid Tumor | sensitive | detail... |
PIK3CA E542K | Sirolimus | Advanced Solid Tumor | sensitive | detail... |
PIK3CA act mut | Metformin | Advanced Solid Tumor | sensitive | detail... |
PIK3CA E545K | Sirolimus | Advanced Solid Tumor | sensitive | detail... |
PIK3CA E545K | Alpelisib | Advanced Solid Tumor | sensitive | detail... |
PIK3CA mutant | Onatasertib | Advanced Solid Tumor | sensitive | detail... |
PIK3CA act mut | Ipatasertib + Paclitaxel | Advanced Solid Tumor | sensitive | detail... |
PIK3CA act mut | Afuresertib | Advanced Solid Tumor | sensitive | detail... |
JAK3 V722I | Tofacitinib | Advanced Solid Tumor | sensitive | detail... |
PIK3CA C420R | Sirolimus | Advanced Solid Tumor | sensitive | detail... |
PIK3CA mutant | Alpelisib | Advanced Solid Tumor | sensitive | detail... |
PIK3CA mutant | Carboxyamidotriazole Orotate | Advanced Solid Tumor | sensitive | detail... |
PIK3CA mutant | Serabelisib | Advanced Solid Tumor | sensitive | detail... |
PIK3CA mutant | VS-5584 | Advanced Solid Tumor | sensitive | detail... |
RB1 positive | Ribociclib | Advanced Solid Tumor | predicted - sensitive | detail... |
HRAS G12V | Cetuximab | Advanced Solid Tumor | resistant | detail... |
HRAS G12V | Panitumumab | Advanced Solid Tumor | resistant | detail... |
FLT3 D835Y | Midostaurin | Advanced Solid Tumor | sensitive | detail... |
RET S891A | Sorafenib | Advanced Solid Tumor | sensitive | detail... |
RET M918T | Sorafenib | Advanced Solid Tumor | sensitive | detail... |
RET C634R | Sorafenib | Advanced Solid Tumor | sensitive | detail... |
BRAF mutant | Obatoclax | Advanced Solid Tumor | sensitive | detail... |
NRAS mutant | Obatoclax | Advanced Solid Tumor | sensitive | detail... |
RET C634R | Ponatinib | Advanced Solid Tumor | sensitive | detail... |
RET V804L | Ponatinib | Advanced Solid Tumor | sensitive | detail... |
RET V804M | Ponatinib | Advanced Solid Tumor | sensitive | detail... |
EML4 - ALK ALK I1171T | Ceritinib | Advanced Solid Tumor | sensitive | detail... |
PIK3CA mutant | Sapanisertib | Advanced Solid Tumor | sensitive | detail... |
EML4 - ALK ALK C1156Y | Crizotinib | Advanced Solid Tumor | resistant | detail... |
EML4 - ALK ALK C1156Y | Ensartinib | Advanced Solid Tumor | sensitive | detail... |
EML4 - ALK ALK L1196M | Crizotinib | Advanced Solid Tumor | resistant | detail... |
EML4 - ALK ALK L1196M | Ensartinib | Advanced Solid Tumor | sensitive | detail... |
EML4 - ALK ALK S1206Y | Ceritinib | Advanced Solid Tumor | sensitive | detail... |
EML4 - ALK ALK L1152R | Crizotinib | Advanced Solid Tumor | resistant | detail... |
RET V804M | Sorafenib | Advanced Solid Tumor | sensitive | detail... |
FLT3 Y572C | Midostaurin | Advanced Solid Tumor | sensitive | detail... |
FLT3 S451F | Midostaurin | Advanced Solid Tumor | decreased response | detail... |
FLT3 V592G | Midostaurin | Advanced Solid Tumor | sensitive | detail... |
FLT3 R834Q | Midostaurin | Advanced Solid Tumor | sensitive | detail... |
FLT3 R834Q | PD98059 | Advanced Solid Tumor | sensitive | detail... |
PIK3CA M1043V | Sirolimus | Advanced Solid Tumor | sensitive | detail... |
PIK3CA mutant | BAY1082439 | Advanced Solid Tumor | sensitive | detail... |
FLT3 exon 14 ins FLT3 D839G | Pexidartinib | Advanced Solid Tumor | resistant | detail... |
FLT3 exon 14 ins FLT3 Y842C | Pexidartinib | Advanced Solid Tumor | resistant | detail... |
FGFR3 amp | Ponatinib | Advanced Solid Tumor | predicted - sensitive | detail... |
KIT V560D | Sorafenib | Advanced Solid Tumor | sensitive | detail... |
KIT V560D | Dasatinib | Advanced Solid Tumor | sensitive | detail... |
KIT V560G | Nilotinib | Advanced Solid Tumor | sensitive | detail... |
FGFR2 N550K | Dovitinib | Advanced Solid Tumor | resistant | detail... |
FGFR2 N550S | Dovitinib | Advanced Solid Tumor | decreased response | detail... |
FGFR2 N550H | Dovitinib | Advanced Solid Tumor | decreased response | detail... |
FGFR2 V565I | Dovitinib | Advanced Solid Tumor | resistant | detail... |
FGFR2 E566G | Dovitinib | Advanced Solid Tumor | resistant | detail... |
FGFR2 L618M | Dovitinib | Advanced Solid Tumor | decreased response | detail... |
FGFR2 K660E | Dovitinib | Advanced Solid Tumor | resistant | detail... |
FGFR2 I548V | Dovitinib | Advanced Solid Tumor | decreased response | detail... |
FGFR2 M538I | Dovitinib | Advanced Solid Tumor | decreased response | detail... |
FGFR2 M536I | Dovitinib | Advanced Solid Tumor | decreased response | detail... |
FGFR2 N550H | PD173074 | Advanced Solid Tumor | resistant | detail... |
FGFR2 E566G | PD173074 | Advanced Solid Tumor | resistant | detail... |
FGFR2 M536I | PD173074 | Advanced Solid Tumor | decreased response | detail... |
FGFR2 M538I | PD173074 | Advanced Solid Tumor | decreased response | detail... |
FGFR2 I548V | PD173074 | Advanced Solid Tumor | decreased response | detail... |
FGFR2 N550S | PD173074 | Advanced Solid Tumor | decreased response | detail... |
FGFR2 L618M | PD173074 | Advanced Solid Tumor | decreased response | detail... |
FGFR2 V565I | Ponatinib | Advanced Solid Tumor | resistant | detail... |
FGFR2 M538I | Ponatinib | Advanced Solid Tumor | decreased response | detail... |
FGFR2 K660E | Ponatinib | Advanced Solid Tumor | sensitive | detail... |
FGFR2 M536I | Ponatinib | Advanced Solid Tumor | sensitive | detail... |
FGFR2 I548V | Ponatinib | Advanced Solid Tumor | sensitive | detail... |
FGFR2 N550H | Ponatinib | Advanced Solid Tumor | sensitive | detail... |
FGFR2 N550K | Ponatinib | Advanced Solid Tumor | sensitive | detail... |
FGFR2 N550S | Ponatinib | Advanced Solid Tumor | sensitive | detail... |
FGFR2 E566G | Ponatinib | Advanced Solid Tumor | sensitive | detail... |
FGFR2 S267_D273dup | Infigratinib | Advanced Solid Tumor | sensitive | detail... |
FGFR2 W290_I291delinsC | Infigratinib | Advanced Solid Tumor | sensitive | detail... |
FGFR2 S267_D273dup | Ponatinib | Advanced Solid Tumor | sensitive | detail... |
FGFR2 W290_I291delinsC | Ponatinib | Advanced Solid Tumor | sensitive | detail... |
PIK3CA mutant | A-443654 | Advanced Solid Tumor | sensitive | detail... |
PIK3CA E545K | A66 | Advanced Solid Tumor | resistant | detail... |
PIK3CA H1047R | A66 | Advanced Solid Tumor | sensitive | detail... |
PIK3CA mutant | AT-7867 | Advanced Solid Tumor | sensitive | detail... |
PIK3CA mutant | Taselisib | Advanced Solid Tumor | sensitive | detail... |
EML4 - ALK ALK C1156Y | Alectinib | Advanced Solid Tumor | sensitive | detail... |
ALK C1156Y | Alectinib | Advanced Solid Tumor | sensitive | detail... |
RET Y806C | Ponatinib | Advanced Solid Tumor | sensitive | detail... |
RET A883F | Ponatinib | Advanced Solid Tumor | sensitive | detail... |
RET Y791F | Ponatinib | Advanced Solid Tumor | sensitive | detail... |
RET E768D | Ponatinib | Advanced Solid Tumor | sensitive | detail... |
RET L790F | Ponatinib | Advanced Solid Tumor | sensitive | detail... |
RET D898V | Ponatinib | Advanced Solid Tumor | sensitive | detail... |
RET M918T | Ponatinib | Advanced Solid Tumor | sensitive | detail... |
RET C634Y | Ponatinib | Advanced Solid Tumor | sensitive | detail... |
RET E884K | Ponatinib | Advanced Solid Tumor | sensitive | detail... |
RET S891A | Ponatinib | Advanced Solid Tumor | sensitive | detail... |
FLT3 exon 14 ins | Midostaurin | Advanced Solid Tumor | sensitive | detail... |
FLT3 wild-type | Midostaurin | Advanced Solid Tumor | sensitive | detail... |
FGFR2 S252W | Dovitinib | Advanced Solid Tumor | conflicting | detail... |
FGFR2 N550K | PD173074 | Advanced Solid Tumor | resistant | detail... |
FGFR2 V565I | PD173074 | Advanced Solid Tumor | resistant | detail... |
FGFR2 L618M | Ponatinib | Advanced Solid Tumor | sensitive | detail... |
FGFR2 K660E | PD173074 | Advanced Solid Tumor | decreased response | detail... |
PIK3CA mutant | Bevacizumab + Pegylated liposomal doxorubicin + Temsirolimus | Advanced Solid Tumor | sensitive | detail... |
FBXW7 inact mut | Entinostat | Advanced Solid Tumor | sensitive | detail... |
FBXW7 inact mut | Docetaxel | Advanced Solid Tumor | resistant | detail... |
FBXW7 inact mut | Belinostat | Advanced Solid Tumor | sensitive | detail... |
FBXW7 inact mut | REC-2282 | Advanced Solid Tumor | sensitive | detail... |
EML4 - ALK ALK V1180L | Alectinib | Advanced Solid Tumor | resistant | detail... |
EML4 - ALK ALK I1171T | Alectinib | Advanced Solid Tumor | conflicting | detail... |
EML4 - ALK ALK V1180L | TAE684 | Advanced Solid Tumor | sensitive | detail... |
EML4 - ALK ALK I1171T | TAE684 | Advanced Solid Tumor | sensitive | detail... |
EML4 - ALK ALK V1180L | Ceritinib | Advanced Solid Tumor | sensitive | detail... |
EML4 - ALK | Ceritinib | Advanced Solid Tumor | sensitive | detail... |
EML4 - ALK | Brigatinib | Advanced Solid Tumor | sensitive | detail... |
EML4 - ALK ALK V1180L | Brigatinib | Advanced Solid Tumor | sensitive | detail... |
EML4 - ALK ALK I1171T | Brigatinib | Advanced Solid Tumor | predicted - sensitive | detail... |
EML4 - ALK | ASP3026 | Advanced Solid Tumor | sensitive | detail... |
EML4 - ALK ALK V1180L | ASP3026 | Advanced Solid Tumor | sensitive | detail... |
EML4 - ALK ALK I1171T | ASP3026 | Advanced Solid Tumor | resistant | detail... |
TP53 mutant | Pazopanib + Vorinostat | Advanced Solid Tumor | sensitive | detail... |
RET E768D | Vandetanib | Advanced Solid Tumor | sensitive | detail... |
RET L790F | Vandetanib | Advanced Solid Tumor | sensitive | detail... |
RET Y791F | Vandetanib | Advanced Solid Tumor | sensitive | detail... |
RET S891A | Vandetanib | Advanced Solid Tumor | sensitive | detail... |
RET M918T | Vandetanib | Advanced Solid Tumor | sensitive | detail... |
RET A883F | Vandetanib | Advanced Solid Tumor | sensitive | detail... |
RET V804L | Vandetanib | Advanced Solid Tumor | resistant | detail... |
RET V804M | Vandetanib | Advanced Solid Tumor | resistant | detail... |
RET C634R | Vandetanib | Advanced Solid Tumor | sensitive | detail... |
RET C634R RET V804G | Vandetanib | Advanced Solid Tumor | sensitive | detail... |
FGFR1 act mut | Ponatinib | Advanced Solid Tumor | sensitive | detail... |
FGFR2 act mut | Ponatinib | Advanced Solid Tumor | sensitive | detail... |
FGFR3 act mut | Ponatinib | Advanced Solid Tumor | sensitive | detail... |
FGFR1 act mut | Dovitinib | Advanced Solid Tumor | sensitive | detail... |
FGFR2 act mut | Dovitinib | Advanced Solid Tumor | sensitive | detail... |
FGFR3 act mut | Dovitinib | Advanced Solid Tumor | sensitive | detail... |
FGFR1 act mut | Cediranib | Advanced Solid Tumor | decreased response | detail... |
FGFR2 act mut | Cediranib | Advanced Solid Tumor | decreased response | detail... |
FGFR3 act mut | Cediranib | Advanced Solid Tumor | decreased response | detail... |
FGFR1 act mut | Nintedanib | Advanced Solid Tumor | decreased response | detail... |
FGFR2 act mut | Nintedanib | Advanced Solid Tumor | decreased response | detail... |
FGFR3 act mut | Nintedanib | Advanced Solid Tumor | decreased response | detail... |
FGFR2 act mut | Brivanib | Advanced Solid Tumor | decreased response | detail... |
FGFR1 act mut | Brivanib | Advanced Solid Tumor | no benefit | detail... |
FGFR3 act mut | Brivanib | Advanced Solid Tumor | no benefit | detail... |
KIT D816V | Ponatinib | Advanced Solid Tumor | resistant | detail... |
FLT3 exon 14 ins | Cabozantinib | Advanced Solid Tumor | predicted - sensitive | detail... |
KIT D816V | Sunitinib | Advanced Solid Tumor | resistant | detail... |
KIT D816V | Nilotinib | Advanced Solid Tumor | decreased response | detail... |
KIT D816V | Imatinib | Advanced Solid Tumor | resistant | detail... |
KIT D816V | Cabozantinib | Advanced Solid Tumor | resistant | detail... |
KIT D816H | Regorafenib | Advanced Solid Tumor | resistant | detail... |
KIT D816V | Quizartinib | Advanced Solid Tumor | resistant | detail... |
RET rearrange | RXDX-105 | Advanced Solid Tumor | sensitive | detail... |
PTEN del | GSK2636771 | Advanced Solid Tumor | no benefit | detail... |
PIK3CA mutant | AZD8835 | Advanced Solid Tumor | sensitive | detail... |
PIK3CA mutant | Uprosertib | Advanced Solid Tumor | predicted - sensitive | detail... |
RB1 loss | Palbociclib | Advanced Solid Tumor | no benefit | detail... |
TP53 R175H | ReACp53 | Advanced Solid Tumor | sensitive | detail... |
FGFR2 wild-type | AZ6089 | Advanced Solid Tumor | predicted - sensitive | detail... |
FGFR3 over exp | LY2874455 | Advanced Solid Tumor | sensitive | detail... |
FGFR3 K650E | PD98059 | Advanced Solid Tumor | sensitive | detail... |
FGFR1 act mut | Erdafitinib | Advanced Solid Tumor | predicted - sensitive | detail... |
FGFR2 act mut | Erdafitinib | Advanced Solid Tumor | predicted - sensitive | detail... |
FGFR3 act mut | Erdafitinib | Advanced Solid Tumor | predicted - sensitive | detail... |
FGFR3 fusion | Futibatinib | Advanced Solid Tumor | predicted - sensitive | detail... |
FGFR1 V561M | FIIN-1 | Advanced Solid Tumor | sensitive | detail... |
FGFR1 fusion | Dovitinib | Advanced Solid Tumor | sensitive | detail... |
PIK3CA Q546K | Trametinib | Advanced Solid Tumor | sensitive | detail... |
PIK3CA N345K | Trametinib | Advanced Solid Tumor | sensitive | detail... |
PIK3CA H1047R | Trametinib | Advanced Solid Tumor | sensitive | detail... |
PIK3CA G1049R | Trametinib | Advanced Solid Tumor | sensitive | detail... |
PIK3CA E545K | Trametinib | Advanced Solid Tumor | sensitive | detail... |
KIT H697Y | Sunitinib | Advanced Solid Tumor | sensitive | detail... |
KIT H697Y | Imatinib | Advanced Solid Tumor | decreased response | detail... |
KIT V560del | Imatinib | Advanced Solid Tumor | sensitive | detail... |
KIT V560del | Sunitinib | Advanced Solid Tumor | sensitive | detail... |
PTEN del | Onatasertib | Advanced Solid Tumor | sensitive | detail... |
CSF3R T640N | Ruxolitinib | Advanced Solid Tumor | sensitive | detail... |
CSF3R T618I | Ruxolitinib | Advanced Solid Tumor | sensitive | detail... |
FLT3 exon 14 ins | Pexidartinib | Advanced Solid Tumor | sensitive | detail... |
FLT3 exon 14 ins FLT3 F691L | Pexidartinib | Advanced Solid Tumor | sensitive | detail... |
FLT3 D835V | Pexidartinib | Advanced Solid Tumor | resistant | detail... |
FLT3 exon 14 ins FLT3 D835Y | Pexidartinib | Advanced Solid Tumor | resistant | detail... |
FLT3 exon 14 ins FLT3 D835V | Pexidartinib | Advanced Solid Tumor | resistant | detail... |
FLT3 exon 14 ins FLT3 D835F | Pexidartinib | Advanced Solid Tumor | resistant | detail... |
FLT3 exon 14 ins FLT3 Y842H | Pexidartinib | Advanced Solid Tumor | resistant | detail... |
FLT3 exon 14 ins FLT3 M664I | Pexidartinib | Advanced Solid Tumor | decreased response | detail... |
FLT3 exon 14 ins FLT3 M664I FLT3 F691L | Pexidartinib | Advanced Solid Tumor | resistant | detail... |
FLT3 exon 14 ins FLT3 N676S | Pexidartinib | Advanced Solid Tumor | resistant | detail... |
FLT3 exon 14 ins FLT3 N676S FLT3 F691L | Pexidartinib | Advanced Solid Tumor | resistant | detail... |
FLT3 exon 14 ins FLT3 D698N | Pexidartinib | Advanced Solid Tumor | resistant | detail... |
FLT3 exon 14 ins FLT3 F691L FLT3 D698N | Pexidartinib | Advanced Solid Tumor | resistant | detail... |
FLT3 exon 14 ins FLT3 R834Q | Pexidartinib | Advanced Solid Tumor | resistant | detail... |
FLT3 exon 14 ins FLT3 F691L FLT3 R834Q | Pexidartinib | Advanced Solid Tumor | resistant | detail... |
FLT3 exon 14 ins FLT3 D835E | Pexidartinib | Advanced Solid Tumor | resistant | detail... |
FLT3 exon 14 ins FLT3 F691L FLT3 D835E | Pexidartinib | Advanced Solid Tumor | resistant | detail... |
FLT3 exon 14 ins FLT3 D835G | Pexidartinib | Advanced Solid Tumor | resistant | detail... |
FLT3 exon 14 ins FLT3 F691L FLT3 D835G | Pexidartinib | Advanced Solid Tumor | resistant | detail... |
FLT3 exon 14 ins FLT3 F691L FLT3 D835H | Pexidartinib | Advanced Solid Tumor | resistant | detail... |
FLT3 exon 14 ins FLT3 D835H | Pexidartinib | Advanced Solid Tumor | resistant | detail... |
FLT3 exon 14 ins FLT3 D835N | Pexidartinib | Advanced Solid Tumor | resistant | detail... |
FLT3 exon 14 ins FLT3 F691L FLT3 D835N | Pexidartinib | Advanced Solid Tumor | resistant | detail... |
FLT3 exon 14 ins FLT3 F691L FLT3 D835Y | Pexidartinib | Advanced Solid Tumor | resistant | detail... |
FLT3 exon 14 ins FLT3 F691L FLT3 D839A | Pexidartinib | Advanced Solid Tumor | resistant | detail... |
FLT3 exon 14 ins FLT3 D839A | Pexidartinib | Advanced Solid Tumor | resistant | detail... |
FLT3 exon 14 ins FLT3 F691L FLT3 D839G | Pexidartinib | Advanced Solid Tumor | resistant | detail... |
FLT3 exon 14 ins FLT3 D839H | Pexidartinib | Advanced Solid Tumor | resistant | detail... |
FLT3 exon 14 ins FLT3 D839N | Pexidartinib | Advanced Solid Tumor | resistant | detail... |
FLT3 exon 14 ins FLT3 F691L FLT3 D839N | Pexidartinib | Advanced Solid Tumor | resistant | detail... |
FLT3 exon 14 ins FLT3 N841K | Pexidartinib | Advanced Solid Tumor | resistant | detail... |
FLT3 exon 14 ins FLT3 F691L FLT3 N841K | Pexidartinib | Advanced Solid Tumor | resistant | detail... |
FLT3 exon 14 ins FLT3 F691L FLT3 Y842C | Pexidartinib | Advanced Solid Tumor | resistant | detail... |
FLT3 exon 14 ins FLT3 F691L FLT3 Y842H | Pexidartinib | Advanced Solid Tumor | resistant | detail... |
FLT3 exon 14 ins FLT3 Y842S | Pexidartinib | Advanced Solid Tumor | resistant | detail... |
FLT3 exon 14 ins FLT3 F691L FLT3 Y842S | Pexidartinib | Advanced Solid Tumor | resistant | detail... |
FLT3 exon 14 ins FLT3 R845G | Pexidartinib | Advanced Solid Tumor | resistant | detail... |
FLT3 exon 14 ins FLT3 F691L FLT3 R845G | Pexidartinib | Advanced Solid Tumor | resistant | detail... |
FLT3 exon 14 ins FLT3 G846R | Pexidartinib | Advanced Solid Tumor | resistant | detail... |
FLT3 exon 14 ins FLT3 F691L FLT3 G846R | Pexidartinib | Advanced Solid Tumor | resistant | detail... |
PTEN dec exp | GSK2636771 | Advanced Solid Tumor | sensitive | detail... |
TP53 R248Q | Ganetespib | Advanced Solid Tumor | sensitive | detail... |
TP53 R175H | Alvespimycin + Vorinostat | Advanced Solid Tumor | sensitive | detail... |
FLT3 D835Y | Pexidartinib | Advanced Solid Tumor | resistant | detail... |
PTEN loss | SAR260301 | Advanced Solid Tumor | no benefit | detail... |
RET C634Y | HG-6-63-01 | Advanced Solid Tumor | sensitive | detail... |
RET C634Y | XMD15-44 | Advanced Solid Tumor | sensitive | detail... |
RET C634Y | ALW-II-41-27 | Advanced Solid Tumor | sensitive | detail... |
RET M918T | HG-6-63-01 | Advanced Solid Tumor | sensitive | detail... |
RET M918T | XMD15-44 | Advanced Solid Tumor | sensitive | detail... |
RET M918T | ALW-II-41-27 | Advanced Solid Tumor | sensitive | detail... |
PIK3CA mutant | Apitolisib | Advanced Solid Tumor | predicted - sensitive | detail... |
PIK3CA act mut | GSK1059615 | Advanced Solid Tumor | sensitive | detail... |
EML4 - ALK ALK I1171S | Crizotinib | Advanced Solid Tumor | resistant | detail... |
EML4 - ALK ALK I1171S | Ceritinib | Advanced Solid Tumor | conflicting | detail... |
EML4 - ALK ALK I1171S | Alectinib | Advanced Solid Tumor | resistant | detail... |
EML4 - ALK ALK I1171S | Brigatinib | Advanced Solid Tumor | conflicting | detail... |
EML4 - ALK ALK I1171S | ASP3026 | Advanced Solid Tumor | resistant | detail... |
EML4 - ALK ALK I1171S | AZD3463 | Advanced Solid Tumor | resistant | detail... |
EML4 - ALK ALK F1174L | Crizotinib | Advanced Solid Tumor | conflicting | detail... |
EML4 - ALK ALK F1174L | Ceritinib | Advanced Solid Tumor | resistant | detail... |
EML4 - ALK ALK F1174L | Alectinib | Advanced Solid Tumor | sensitive | detail... |
EML4 - ALK ALK F1174L | Brigatinib | Advanced Solid Tumor | conflicting | detail... |
EML4 - ALK ALK F1174L | ASP3026 | Advanced Solid Tumor | resistant | detail... |
EML4 - ALK ALK F1174L | AZD3463 | Advanced Solid Tumor | sensitive | detail... |
EML4 - ALK ALK R1192P | Crizotinib | Advanced Solid Tumor | sensitive | detail... |
EML4 - ALK ALK R1192P | Ceritinib | Advanced Solid Tumor | resistant | detail... |
EML4 - ALK ALK R1192P | Alectinib | Advanced Solid Tumor | sensitive | detail... |
EML4 - ALK ALK R1192P | Brigatinib | Advanced Solid Tumor | sensitive | detail... |
EML4 - ALK ALK R1192P | ASP3026 | Advanced Solid Tumor | resistant | detail... |
EML4 - ALK ALK R1192P | AZD3463 | Advanced Solid Tumor | sensitive | detail... |
EML4 - ALK ALK T1151M | Crizotinib | Advanced Solid Tumor | sensitive | detail... |
EML4 - ALK ALK T1151M | Alectinib | Advanced Solid Tumor | sensitive | detail... |
EML4 - ALK ALK T1151M | Brigatinib | Advanced Solid Tumor | sensitive | detail... |
EML4 - ALK ALK T1151M | AZD3463 | Advanced Solid Tumor | sensitive | detail... |
EML4 - ALK ALK T1151M | Ceritinib | Advanced Solid Tumor | resistant | detail... |
EML4 - ALK ALK T1151M | ASP3026 | Advanced Solid Tumor | resistant | detail... |
EML4 - ALK ALK G1269A | Crizotinib | Advanced Solid Tumor | resistant | detail... |
EML4 - ALK ALK G1269A | Ceritinib | Advanced Solid Tumor | sensitive | detail... |
EML4 - ALK ALK G1269A | Alectinib | Advanced Solid Tumor | conflicting | detail... |
EML4 - ALK ALK G1269A | ASP3026 | Advanced Solid Tumor | resistant | detail... |
EML4 - ALK ALK G1269A | Brigatinib | Advanced Solid Tumor | sensitive | detail... |
EML4 - ALK ALK G1269A | AZD3463 | Advanced Solid Tumor | sensitive | detail... |
ATM loss | YU238259 | Advanced Solid Tumor | sensitive | detail... |
TP53 wild-type | CTX-1 | Advanced Solid Tumor | sensitive | detail... |
TP53 loss | CTX-1 | Advanced Solid Tumor | decreased response | detail... |
TP53 mutant | CTX-1 | Advanced Solid Tumor | sensitive | detail... |
TP53 wild-type | CTX-1 + Nutlin-3a | Advanced Solid Tumor | sensitive | detail... |
EML4 - ALK ALK C1156Y | Entrectinib | Advanced Solid Tumor | sensitive | detail... |
EML4 - ALK ALK L1196M | Entrectinib | Advanced Solid Tumor | conflicting | detail... |
EML4 - ALK ALK G1202R | Entrectinib | Advanced Solid Tumor | resistant | detail... |
EML4 - ALK ALK G1269A | Entrectinib | Advanced Solid Tumor | predicted - resistant | detail... |
EML4 - ALK ALK L1198F | Crizotinib | Advanced Solid Tumor | sensitive | detail... |
EML4 - ALK ALK C1156Y ALK L1198F | Crizotinib | Advanced Solid Tumor | sensitive | detail... |
EML4 - ALK ALK C1156Y | Lorlatinib | Advanced Solid Tumor | sensitive | detail... |
EML4 - ALK | Lorlatinib | Advanced Solid Tumor | sensitive | detail... |
EML4 - ALK ALK C1156Y ALK L1198F | Lorlatinib | Advanced Solid Tumor | resistant | detail... |
EML4 - ALK ALK L1198F | Lorlatinib | Advanced Solid Tumor | predicted - sensitive | detail... |
EML4 - ALK | Alectinib | Advanced Solid Tumor | sensitive | detail... |
EML4 - ALK ALK L1198F | Alectinib | Advanced Solid Tumor | conflicting | detail... |
EML4 - ALK ALK C1156Y ALK L1198F | Alectinib | Advanced Solid Tumor | resistant | detail... |
EML4 - ALK ALK C1156Y | Ceritinib | Advanced Solid Tumor | predicted - sensitive | detail... |
EML4 - ALK ALK L1198F | Ceritinib | Advanced Solid Tumor | conflicting | detail... |
EML4 - ALK ALK C1156Y ALK L1198F | Ceritinib | Advanced Solid Tumor | resistant | detail... |
EML4 - ALK ALK C1156Y ALK L1198F | Brigatinib | Advanced Solid Tumor | conflicting | detail... |
EML4 - ALK ALK C1156Y | Brigatinib | Advanced Solid Tumor | sensitive | detail... |
EML4 - ALK ALK L1198F | Brigatinib | Advanced Solid Tumor | sensitive | detail... |
EML4 - ALK ALK F1174C | Crizotinib | Advanced Solid Tumor | resistant | detail... |
EML4 - ALK ALK F1174C ALK L1198F | Crizotinib | Advanced Solid Tumor | sensitive | detail... |
EML4 - ALK ALK F1174C | Lorlatinib | Advanced Solid Tumor | sensitive | detail... |
EML4 - ALK ALK F1174C ALK L1198F | Lorlatinib | Advanced Solid Tumor | resistant | detail... |
EML4 - ALK ALK F1174C | Brigatinib | Advanced Solid Tumor | sensitive | detail... |
EML4 - ALK ALK F1174C ALK L1198F | Brigatinib | Advanced Solid Tumor | resistant | detail... |
EML4 - ALK ALK F1174C | Ceritinib | Advanced Solid Tumor | conflicting | detail... |
EML4 - ALK ALK F1174C ALK L1198F | Ceritinib | Advanced Solid Tumor | resistant | detail... |
EML4 - ALK ALK F1174C | Alectinib | Advanced Solid Tumor | conflicting | detail... |
EML4 - ALK ALK F1174C ALK L1198F | Alectinib | Advanced Solid Tumor | resistant | detail... |
EML4 - ALK ALK L1196M | Alectinib | Advanced Solid Tumor | conflicting | detail... |
EML4 - ALK ALK L1196M | Brigatinib | Advanced Solid Tumor | sensitive | detail... |
EML4 - ALK ALK L1196M ALK L1198F | Crizotinib | Advanced Solid Tumor | resistant | detail... |
EML4 - ALK ALK L1196M ALK L1198F | Ceritinib | Advanced Solid Tumor | resistant | detail... |
EML4 - ALK ALK L1196M ALK L1198F | Alectinib | Advanced Solid Tumor | resistant | detail... |
EML4 - ALK ALK L1196M ALK L1198F | Lorlatinib | Advanced Solid Tumor | resistant | detail... |
EML4 - ALK ALK L1196M ALK L1198F | Brigatinib | Advanced Solid Tumor | resistant | detail... |
EML4 - ALK ALK L1196M | Lorlatinib | Advanced Solid Tumor | conflicting | detail... |
EML4 - ALK ALK G1202R | Crizotinib | Advanced Solid Tumor | resistant | detail... |
EML4 - ALK ALK G1202R | Alectinib | Advanced Solid Tumor | resistant | detail... |
EML4 - ALK ALK G1202R | Ceritinib | Advanced Solid Tumor | resistant | detail... |
EML4 - ALK ALK G1202R | Brigatinib | Advanced Solid Tumor | conflicting | detail... |
EML4 - ALK ALK L1198F ALK G1202R | Crizotinib | Advanced Solid Tumor | sensitive | detail... |
EML4 - ALK ALK L1198F ALK G1202R | Lorlatinib | Advanced Solid Tumor | resistant | detail... |
EML4 - ALK ALK L1198F ALK G1202R | Alectinib | Advanced Solid Tumor | resistant | detail... |
EML4 - ALK ALK L1198F ALK G1202R | Brigatinib | Advanced Solid Tumor | resistant | detail... |
EML4 - ALK ALK L1198F ALK G1202R | Ceritinib | Advanced Solid Tumor | resistant | detail... |
EML4 - ALK ALK G1269A | Lorlatinib | Advanced Solid Tumor | sensitive | detail... |
EML4 - ALK ALK L1198F ALK G1269A | Crizotinib | Advanced Solid Tumor | sensitive | detail... |
EML4 - ALK ALK L1198F ALK G1269A | Brigatinib | Advanced Solid Tumor | sensitive | detail... |
EML4 - ALK ALK L1198F ALK G1269A | Lorlatinib | Advanced Solid Tumor | resistant | detail... |
EML4 - ALK ALK L1198F ALK G1269A | Ceritinib | Advanced Solid Tumor | resistant | detail... |
EML4 - ALK ALK L1198F ALK G1269A | Alectinib | Advanced Solid Tumor | resistant | detail... |
JAK2 V617F | Ruxolitinib + ZSTK474 | Advanced Solid Tumor | sensitive | detail... |
JAK2 over exp | Ruxolitinib + ZSTK474 | Advanced Solid Tumor | sensitive | detail... |
JAK2 over exp | Pictilisib + Ruxolitinib | Advanced Solid Tumor | sensitive | detail... |
JAK2 V617F | Pictilisib + Ruxolitinib | Advanced Solid Tumor | sensitive | detail... |
JAK2 over exp | Dactolisib + Ruxolitinib | Advanced Solid Tumor | sensitive | detail... |
JAK2 V617F | Dactolisib + Ruxolitinib | Advanced Solid Tumor | sensitive | detail... |
JAK2 V617F | Ruxolitinib + TGX-221 | Advanced Solid Tumor | sensitive | detail... |
JAK2 over exp | Ruxolitinib + TGX-221 | Advanced Solid Tumor | sensitive | detail... |
ALK wild-type | Repotrectinib | Advanced Solid Tumor | sensitive | detail... |
ALK G1202R | Repotrectinib | Advanced Solid Tumor | sensitive | detail... |
ALK L1196M | Repotrectinib | Advanced Solid Tumor | sensitive | detail... |
ALK G1128A | Brigatinib | Advanced Solid Tumor | sensitive | detail... |
ALK I1171N | Brigatinib | Advanced Solid Tumor | sensitive | detail... |
ALK F1174L | Brigatinib | Advanced Solid Tumor | sensitive | detail... |
ALK R1192P | Brigatinib | Advanced Solid Tumor | sensitive | detail... |
ALK F1245C | Brigatinib | Advanced Solid Tumor | sensitive | detail... |
ALK R1275Q | Brigatinib | Advanced Solid Tumor | sensitive | detail... |
ALK Y1278S | Brigatinib | Advanced Solid Tumor | sensitive | detail... |
ALK G1269A | Brigatinib | Advanced Solid Tumor | sensitive | detail... |
PIK3CA H1047R | Sirolimus | Advanced Solid Tumor | sensitive | detail... |
RET C634R | Pz-1 | Advanced Solid Tumor | sensitive | detail... |
RET M918T | Pz-1 | Advanced Solid Tumor | sensitive | detail... |
RET V804L | Pz-1 | Advanced Solid Tumor | predicted - sensitive | detail... |
RET V804M | Pz-1 | Advanced Solid Tumor | predicted - sensitive | detail... |
HRAS G12V | Pz-1 | Advanced Solid Tumor | sensitive | detail... |
BRAF mutant | XL147 | Advanced Solid Tumor | decreased response | detail... |
KIT act mut | PLX9486 | Advanced Solid Tumor | sensitive | detail... |
ATM inact mut | E7449 | Advanced Solid Tumor | sensitive | detail... |
POLD1 inact mut | E7449 | Advanced Solid Tumor | sensitive | detail... |
ROS1 rearrange | Entrectinib | Advanced Solid Tumor | predicted - sensitive | detail... |
ALK fusion | Entrectinib | Advanced Solid Tumor | sensitive | detail... |
KIT V654A | Imatinib | Advanced Solid Tumor | resistant | detail... |
KIT V559D | Ponatinib | Advanced Solid Tumor | sensitive | detail... |
KIT V560G | Ponatinib | Advanced Solid Tumor | sensitive | detail... |
KIT T670I | Ponatinib | Advanced Solid Tumor | sensitive | detail... |
KIT D816H | Ponatinib | Advanced Solid Tumor | sensitive | detail... |
KIT D820E | Ponatinib | Advanced Solid Tumor | sensitive | detail... |
KIT A829P | Ponatinib | Advanced Solid Tumor | sensitive | detail... |
KIT V654A | Ponatinib | Advanced Solid Tumor | sensitive | detail... |
KIT V560D | Ponatinib | Advanced Solid Tumor | sensitive | detail... |
KIT V560D | Sunitinib | Advanced Solid Tumor | sensitive | detail... |
KIT V560D | Imatinib | Advanced Solid Tumor | sensitive | detail... |
KIT V560D | Regorafenib | Advanced Solid Tumor | sensitive | detail... |
KIT exon9 | Ponatinib | Advanced Solid Tumor | sensitive | detail... |
KIT exon9 | Sunitinib | Advanced Solid Tumor | sensitive | detail... |
KIT exon9 | Imatinib | Advanced Solid Tumor | resistant | detail... |
KIT exon9 | Regorafenib | Advanced Solid Tumor | resistant | detail... |
KIT W557_K558del | Ponatinib | Advanced Solid Tumor | sensitive | detail... |
KIT W557_K558del | Sunitinib | Advanced Solid Tumor | sensitive | detail... |
KIT W557_K558del | Imatinib | Advanced Solid Tumor | sensitive | detail... |
KIT W557_K558del | Regorafenib | Advanced Solid Tumor | sensitive | detail... |
KIT P551_K558del | Ponatinib | Advanced Solid Tumor | sensitive | detail... |
KIT P551_K558del | Sunitinib | Advanced Solid Tumor | sensitive | detail... |
KIT P551_K558del | Imatinib | Advanced Solid Tumor | sensitive | detail... |
KIT P551_K558del | Regorafenib | Advanced Solid Tumor | sensitive | detail... |
KIT P551_E554del | Ponatinib | Advanced Solid Tumor | sensitive | detail... |
KIT T417_D419delinsI | Imatinib | Advanced Solid Tumor | conflicting | detail... |
KIT P551_E554del | Sunitinib | Advanced Solid Tumor | resistant | detail... |
KIT P551_E554del | Imatinib | Advanced Solid Tumor | resistant | detail... |
KIT P551_E554del | Regorafenib | Advanced Solid Tumor | resistant | detail... |
KIT K558delinsNP | Ponatinib | Advanced Solid Tumor | sensitive | detail... |
KIT K558delinsNP | Sunitinib | Advanced Solid Tumor | sensitive | detail... |
KIT K558delinsNP | Imatinib | Advanced Solid Tumor | sensitive | detail... |
KIT K558delinsNP | Regorafenib | Advanced Solid Tumor | sensitive | detail... |
KIT W557_K558del KIT V654A | Ponatinib | Advanced Solid Tumor | sensitive | detail... |
KIT W557_K558del KIT V654A | Sunitinib | Advanced Solid Tumor | sensitive | detail... |
KIT W557_K558del KIT V654A | Imatinib | Advanced Solid Tumor | no benefit | detail... |
KIT W557_K558del KIT V654A | Regorafenib | Advanced Solid Tumor | resistant | detail... |
KIT W557_K558del KIT T670I | Ponatinib | Advanced Solid Tumor | sensitive | detail... |
KIT W557_K558del KIT T670I | Sunitinib | Advanced Solid Tumor | sensitive | detail... |
KIT W557_K558del KIT T670I | Imatinib | Advanced Solid Tumor | no benefit | detail... |
KIT W557_K558del KIT T670I | Regorafenib | Advanced Solid Tumor | decreased response | detail... |
KIT W557_K558del KIT D816H | Ponatinib | Advanced Solid Tumor | sensitive | detail... |
KIT W557_K558del KIT D816H | Sunitinib | Advanced Solid Tumor | decreased response | detail... |
KIT W557_K558del KIT D816H | Imatinib | Advanced Solid Tumor | decreased response | detail... |
KIT W557_K558del KIT D816H | Regorafenib | Advanced Solid Tumor | decreased response | detail... |
BRAF T529I BRAF V600E | SB590885 | Advanced Solid Tumor | predicted - resistant | detail... |
BRAF V600E | SB590885 | Advanced Solid Tumor | sensitive | detail... |
BRAF T529M BRAF V600E | SB590885 | Advanced Solid Tumor | predicted - resistant | detail... |
BRAF T529N BRAF V600E | RAF265 | Advanced Solid Tumor | resistant | detail... |
BRAF T529I BRAF V600E | RAF265 | Advanced Solid Tumor | predicted - sensitive | detail... |
BRAF T529M BRAF V600E | RAF265 | Advanced Solid Tumor | predicted - sensitive | detail... |
BRAF V600E | RAF265 | Advanced Solid Tumor | sensitive | detail... |
BRAF T529N BRAF V600E | SB590885 | Advanced Solid Tumor | resistant | detail... |
BRAF T529M BRAF V600E | PLX4720 | Advanced Solid Tumor | predicted - resistant | detail... |
BRAF T529I BRAF V600E | PLX4720 | Advanced Solid Tumor | predicted - resistant | detail... |
BRAF V600E | PLX4720 | Advanced Solid Tumor | sensitive | detail... |
BRAF T529N BRAF V600E | PLX4720 | Advanced Solid Tumor | resistant | detail... |
BRAF T529N BRAF V600E | Sorafenib | Advanced Solid Tumor | conflicting | detail... |
BRAF T529M BRAF V600E | Sorafenib | Advanced Solid Tumor | predicted - sensitive | detail... |
BRAF T529I BRAF V600E | Sorafenib | Advanced Solid Tumor | predicted - sensitive | detail... |
BRAF T529N BRAF V600E | CI-1040 | Advanced Solid Tumor | sensitive | detail... |
BRAF T529M BRAF V600E | CI-1040 | Advanced Solid Tumor | predicted - sensitive | detail... |
BRAF T529I BRAF V600E | CI-1040 | Advanced Solid Tumor | sensitive | detail... |
BRAF V600E | CI-1040 | Advanced Solid Tumor | sensitive | detail... |
KIT W557G | Imatinib | Advanced Solid Tumor | sensitive | detail... |
KIT Y578C | Imatinib | Advanced Solid Tumor | sensitive | detail... |
KIT W557C KIT Y578C | Imatinib | Advanced Solid Tumor | sensitive | detail... |
KIT W557_K558del KIT D816G | Ponatinib | Advanced Solid Tumor | resistant | detail... |
KIT W557_K558del KIT D820A | Ponatinib | Advanced Solid Tumor | sensitive | detail... |
KIT W557_K558del KIT D820G | Ponatinib | Advanced Solid Tumor | sensitive | detail... |
KIT W557_K558del KIT N822K | Ponatinib | Advanced Solid Tumor | sensitive | detail... |
KIT W557_K558del KIT A829P | Ponatinib | Advanced Solid Tumor | sensitive | detail... |
KIT W557_K558del KIT D816G | Sunitinib | Advanced Solid Tumor | resistant | detail... |
KIT W557_K558del KIT D820A | Sunitinib | Advanced Solid Tumor | resistant | detail... |
KIT W557_K558del KIT D820G | Sunitinib | Advanced Solid Tumor | resistant | detail... |
KIT W557_K558del KIT N822K | Sunitinib | Advanced Solid Tumor | resistant | detail... |
KIT W557_K558del KIT A829P | Sunitinib | Advanced Solid Tumor | resistant | detail... |
KIT W557_K558del KIT D816G | Imatinib | Advanced Solid Tumor | resistant | detail... |
KIT W557_K558del KIT D820A | Imatinib | Advanced Solid Tumor | resistant | detail... |
KIT W557_K558del KIT D820G | Imatinib | Advanced Solid Tumor | resistant | detail... |
KIT W557_K558del KIT N822K | Imatinib | Advanced Solid Tumor | resistant | detail... |
KIT W557_K558del KIT A829P | Imatinib | Advanced Solid Tumor | resistant | detail... |
KIT W557_K558del KIT D816G | Regorafenib | Advanced Solid Tumor | resistant | detail... |
KIT W557_K558del KIT D820A | Regorafenib | Advanced Solid Tumor | conflicting | detail... |
KIT W557_K558del KIT D820G | Regorafenib | Advanced Solid Tumor | resistant | detail... |
KIT W557_K558del KIT N822K | Regorafenib | Advanced Solid Tumor | conflicting | detail... |
KIT W557_K558del KIT A829P | Regorafenib | Advanced Solid Tumor | conflicting | detail... |
FGFR1 mutant | Pemigatinib | Advanced Solid Tumor | sensitive | detail... |
PTEN dec exp | Pemetrexed Disodium + Sorafenib | Advanced Solid Tumor | predicted - sensitive | detail... |
JAK3 V674A | Ruxolitinib | Advanced Solid Tumor | sensitive | detail... |
JAK3 L857P | Ruxolitinib | Advanced Solid Tumor | decreased response | detail... |
JAK3 Y100A JAK3 L857P | Ruxolitinib | Advanced Solid Tumor | decreased response | detail... |
JAK3 L857P | NIBR3049 | Advanced Solid Tumor | sensitive | detail... |
JAK3 Y100A JAK3 L857P | NIBR3049 | Advanced Solid Tumor | sensitive | detail... |
JAK3 V674A | NIBR3049 | Advanced Solid Tumor | decreased response | detail... |
JAK3 V674A | Tofacitinib | Advanced Solid Tumor | sensitive | detail... |
JAK3 L857P | Tofacitinib | Advanced Solid Tumor | sensitive | detail... |
JAK3 Y100A JAK3 L857P | Tofacitinib | Advanced Solid Tumor | sensitive | detail... |
FGFR3 K650E | AZD4547 | Advanced Solid Tumor | decreased response | detail... |
FGFR3 N540K | AZD4547 | Advanced Solid Tumor | resistant | detail... |
FGFR3 K650E | Erdafitinib | Advanced Solid Tumor | sensitive | detail... |
FGFR3 N540K | Erdafitinib | Advanced Solid Tumor | sensitive | detail... |
BRAF V600E | Lifirafenib | Advanced Solid Tumor | sensitive | detail... |
BRAF wild-type | Lifirafenib | Advanced Solid Tumor | no benefit | detail... |
TP53 mutant | KRT-232 | Advanced Solid Tumor | resistant | detail... |
TP53 wild-type | KRT-232 | Advanced Solid Tumor | sensitive | detail... |
EML4 - ALK ALK L1152R | Lorlatinib | Advanced Solid Tumor | sensitive | detail... |
EML4 - ALK ALK S1206Y | Lorlatinib | Advanced Solid Tumor | sensitive | detail... |
EML4 - ALK ALK F1174L | Lorlatinib | Advanced Solid Tumor | sensitive | detail... |
TP53 positive | p28 | Advanced Solid Tumor | predicted - sensitive | detail... |
ALK R1275Q | Lorlatinib | Advanced Solid Tumor | sensitive | detail... |
ALK F1174L | Lorlatinib | Advanced Solid Tumor | sensitive | detail... |
ALK F1245C | Lorlatinib | Advanced Solid Tumor | sensitive | detail... |
FGFR2 mutant | Pemigatinib | Advanced Solid Tumor | sensitive | detail... |
FGFR3 mutant | Pemigatinib | Advanced Solid Tumor | sensitive | detail... |
FGFR2 wild-type | PRN1371 | Advanced Solid Tumor | sensitive | detail... |
FGFR2 K660E | PRN1371 | Advanced Solid Tumor | sensitive | detail... |
FGFR2 K660N | PRN1371 | Advanced Solid Tumor | sensitive | detail... |
FGFR2 N550K | PRN1371 | Advanced Solid Tumor | sensitive | detail... |
FGFR3 over exp | PRN1371 | Advanced Solid Tumor | sensitive | detail... |
FGFR3 K650M | PRN1371 | Advanced Solid Tumor | sensitive | detail... |
ATM inact mut | Veliparib | Advanced Solid Tumor | sensitive | detail... |
HRAS G12V | Rigosertib Sodium | Advanced Solid Tumor | sensitive | detail... |
PIK3CA E545K | Rigosertib Sodium | Advanced Solid Tumor | sensitive | detail... |
PIK3CA H1047R | Rigosertib Sodium | Advanced Solid Tumor | sensitive | detail... |
EML4 - ALK ALK I1171N | Crizotinib | Advanced Solid Tumor | predicted - resistant | detail... |
EML4 - ALK ALK I1171N | Ceritinib | Advanced Solid Tumor | sensitive | detail... |
EML4 - ALK ALK I1171N | Alectinib | Advanced Solid Tumor | resistant | detail... |
EML4 - ALK ALK I1171N | Brigatinib | Advanced Solid Tumor | sensitive | detail... |
EML4 - ALK ALK I1171N | Lorlatinib | Advanced Solid Tumor | conflicting | detail... |
EML4 - ALK ALK I1171S | Lorlatinib | Advanced Solid Tumor | sensitive | detail... |
EML4 - ALK ALK I1171T | Crizotinib | Advanced Solid Tumor | predicted - resistant | detail... |
EML4 - ALK ALK I1171T | Lorlatinib | Advanced Solid Tumor | sensitive | detail... |
EML4 - ALK ALK L1196M | Ceritinib | Advanced Solid Tumor | sensitive | detail... |
EML4 - ALK ALK G1202R | Lorlatinib | Advanced Solid Tumor | conflicting | detail... |
EML4 - ALK ALK G1202del | Crizotinib | Advanced Solid Tumor | decreased response | detail... |
EML4 - ALK ALK G1202del | Ceritinib | Advanced Solid Tumor | decreased response | detail... |
EML4 - ALK ALK G1202del | Alectinib | Advanced Solid Tumor | resistant | detail... |
EML4 - ALK ALK G1202del | Brigatinib | Advanced Solid Tumor | decreased response | detail... |
EML4 - ALK ALK G1202del | Lorlatinib | Advanced Solid Tumor | sensitive | detail... |
EML4 - ALK ALK D1203N | Crizotinib | Advanced Solid Tumor | predicted - resistant | detail... |
EML4 - ALK ALK D1203N | Ceritinib | Advanced Solid Tumor | sensitive | detail... |
EML4 - ALK ALK D1203N | Alectinib | Advanced Solid Tumor | sensitive | detail... |
EML4 - ALK ALK D1203N | Brigatinib | Advanced Solid Tumor | sensitive | detail... |
EML4 - ALK ALK D1203N | Lorlatinib | Advanced Solid Tumor | sensitive | detail... |
EML4 - ALK ALK E1210K | Ceritinib | Advanced Solid Tumor | sensitive | detail... |
EML4 - ALK ALK E1210K | Alectinib | Advanced Solid Tumor | conflicting | detail... |
EML4 - ALK ALK E1210K | Brigatinib | Advanced Solid Tumor | sensitive | detail... |
EML4 - ALK ALK E1210K | Lorlatinib | Advanced Solid Tumor | sensitive | detail... |
EML4 - ALK ALK F1174C ALK D1203N | Crizotinib | Advanced Solid Tumor | resistant | detail... |
EML4 - ALK ALK F1174C ALK D1203N | Alectinib | Advanced Solid Tumor | resistant | detail... |
EML4 - ALK ALK F1174C ALK D1203N | Brigatinib | Advanced Solid Tumor | decreased response | detail... |
EML4 - ALK ALK F1174C ALK D1203N | Lorlatinib | Advanced Solid Tumor | decreased response | detail... |
EML4 - ALK ALK D1203N ALK E1210K | Crizotinib | Advanced Solid Tumor | decreased response | detail... |
EML4 - ALK ALK D1203N ALK E1210K | Ceritinib | Advanced Solid Tumor | decreased response | detail... |
EML4 - ALK ALK D1203N ALK E1210K | Alectinib | Advanced Solid Tumor | resistant | detail... |
EML4 - ALK ALK D1203N ALK E1210K | Brigatinib | Advanced Solid Tumor | decreased response | detail... |
EML4 - ALK ALK D1203N ALK E1210K | Lorlatinib | Advanced Solid Tumor | sensitive | detail... |
EML4 - ALK ALK F1174C ALK D1203N | Ceritinib | Advanced Solid Tumor | resistant | detail... |
KIT D816V | BPR1J373 | Advanced Solid Tumor | predicted - sensitive | detail... |
FGFR2 positive | Aprutumab ixadotin | Advanced Solid Tumor | sensitive | detail... |
FLT3 exon 14 ins | Brigatinib | Advanced Solid Tumor | sensitive | detail... |
FLT3 exon 14 ins FLT3 D835Y | Brigatinib | Advanced Solid Tumor | sensitive | detail... |
ROS1 fusion | Brigatinib | Advanced Solid Tumor | sensitive | detail... |
FLT3 exon 14 ins FLT3 F691L | Brigatinib | Advanced Solid Tumor | sensitive | detail... |
FLT3 exon 14 ins FLT3 F691I | Brigatinib | Advanced Solid Tumor | decreased response | detail... |
EML4 - ALK ALK T1151dup | Brigatinib | Advanced Solid Tumor | sensitive | detail... |
EML4 - ALK ALK L1152R | Brigatinib | Advanced Solid Tumor | sensitive | detail... |
EML4 - ALK ALK L1152P | Brigatinib | Advanced Solid Tumor | sensitive | detail... |
EML4 - ALK ALK F1174V | Brigatinib | Advanced Solid Tumor | sensitive | detail... |
EML4 - ALK ALK S1206F | Brigatinib | Advanced Solid Tumor | sensitive | detail... |
EML4 - ALK ALK S1206Y | Brigatinib | Advanced Solid Tumor | conflicting | detail... |
EML4 - ALK ALK T1151dup | Crizotinib | Advanced Solid Tumor | resistant | detail... |
EML4 - ALK ALK L1152P | Crizotinib | Advanced Solid Tumor | resistant | detail... |
EML4 - ALK ALK F1174V | Crizotinib | Advanced Solid Tumor | predicted - resistant | detail... |
EML4 - ALK ALK L1152R | Ceritinib | Advanced Solid Tumor | resistant | detail... |
EML4 - ALK ALK L1152P | Ceritinib | Advanced Solid Tumor | resistant | detail... |
FLT3 exon 14 ins FLT3 N676D | Midostaurin | Advanced Solid Tumor | resistant | detail... |
FLT3 exon 14 ins FLT3 F691I | Midostaurin | Advanced Solid Tumor | resistant | detail... |
FLT3 exon 14 ins FLT3 F691I | Sunitinib | Advanced Solid Tumor | decreased response | detail... |
FLT3 exon 14 ins FLT3 A848P | Sunitinib | Advanced Solid Tumor | resistant | detail... |
FLT3 exon 14 ins FLT3 F691I | Sorafenib | Advanced Solid Tumor | resistant | detail... |
FLT3 exon 14 ins FLT3 F691L | Sorafenib | Advanced Solid Tumor | resistant | detail... |
FLT3 exon 14 ins FLT3 A848P | Sorafenib | Advanced Solid Tumor | decreased response | detail... |
FLT3 exon 14 ins FLT3 Y842H | Sorafenib | Advanced Solid Tumor | decreased response | detail... |
FLT3 exon 14 ins FLT3 N676D | Quizartinib | Advanced Solid Tumor | decreased response | detail... |
FLT3 exon 14 ins FLT3 Y842H | Quizartinib | Advanced Solid Tumor | decreased response | detail... |
FLT3 exon 14 ins FLT3 A848P | Quizartinib | Advanced Solid Tumor | decreased response | detail... |
FLT3 exon 14 ins FLT3 F691I | Quizartinib | Advanced Solid Tumor | resistant | detail... |
FLT3 exon 14 ins FLT3 F691L | Quizartinib | Advanced Solid Tumor | resistant | detail... |
TP53 mutant | Adavosertib | Advanced Solid Tumor | predicted - sensitive | detail... |
BRAF G464E | Vemurafenib | Advanced Solid Tumor | resistant | detail... |
BRAF G464V | Vemurafenib | Advanced Solid Tumor | resistant | detail... |
BRAF G464R | Vemurafenib | Advanced Solid Tumor | resistant | detail... |
BRAF G469A | Vemurafenib | Advanced Solid Tumor | resistant | detail... |
BRAF G469V | Vemurafenib | Advanced Solid Tumor | resistant | detail... |
BRAF L597V | Vemurafenib | Advanced Solid Tumor | resistant | detail... |
BRAF L597Q | Vemurafenib | Advanced Solid Tumor | resistant | detail... |
BRAF K601T | Vemurafenib | Advanced Solid Tumor | resistant | detail... |
BRAF K601N | Vemurafenib | Advanced Solid Tumor | resistant | detail... |
FLT3 exon 14 ins FLT3 F691L | MRX-2843 | Advanced Solid Tumor | sensitive | detail... |
FLT3 exon 14 ins FLT3 D835Y | MRX-2843 | Advanced Solid Tumor | sensitive | detail... |
FLT3 D835Y | MRX-2843 | Advanced Solid Tumor | sensitive | detail... |
FLT3 D835V | MRX-2843 | Advanced Solid Tumor | sensitive | detail... |
FLT3 exon 14 ins FLT3 Y842H | MRX-2843 | Advanced Solid Tumor | sensitive | detail... |
FLT3 exon 14 ins FLT3 Y842C | MRX-2843 | Advanced Solid Tumor | sensitive | detail... |
FLT3 exon 14 ins FLT3 D835F | MRX-2843 | Advanced Solid Tumor | sensitive | detail... |
FLT3 exon 14 ins FLT3 D835V | MRX-2843 | Advanced Solid Tumor | sensitive | detail... |
HRAS mutant | Selumetinib | Advanced Solid Tumor | predicted - sensitive | detail... |
HRAS mutant | Binimetinib | Advanced Solid Tumor | predicted - sensitive | detail... |
HRAS mutant | Everolimus | Advanced Solid Tumor | predicted - sensitive | detail... |
HRAS Q61L | Everolimus | Advanced Solid Tumor | sensitive | detail... |
HRAS Q61R | Everolimus | Advanced Solid Tumor | sensitive | detail... |
HRAS G12V | Everolimus | Advanced Solid Tumor | sensitive | detail... |
HRAS Q61R | Binimetinib | Advanced Solid Tumor | sensitive | detail... |
HRAS Q61L | Binimetinib | Advanced Solid Tumor | sensitive | detail... |
HRAS G12V | Binimetinib | Advanced Solid Tumor | sensitive | detail... |
HRAS G12V | Binimetinib + Everolimus | Advanced Solid Tumor | sensitive | detail... |
HRAS Q61L | Binimetinib + Everolimus | Advanced Solid Tumor | sensitive | detail... |
BRAF mutant | Tovorafenib | Advanced Solid Tumor | predicted - sensitive | detail... |
NRAS G12D | N-Arachidonoyl Dopamine | Advanced Solid Tumor | sensitive | detail... |
HRAS Q61L | NS1 | Advanced Solid Tumor | sensitive | detail... |
NRAS G12D | NS1 | Advanced Solid Tumor | no benefit | detail... |
STK11 inact mut | Selumetinib | Advanced Solid Tumor | sensitive | detail... |
STK11 inact mut | Trametinib | Advanced Solid Tumor | sensitive | detail... |
STK11 inact mut | Refametinib | Advanced Solid Tumor | sensitive | detail... |
STK11 inact mut | CI-1040 | Advanced Solid Tumor | sensitive | detail... |
STK11 inact mut | PD-0325901 | Advanced Solid Tumor | sensitive | detail... |
PTEN inact mut | Capivasertib | Advanced Solid Tumor | sensitive | detail... |
PTEN loss | Capivasertib | Advanced Solid Tumor | sensitive | detail... |
IDH1 R132H | Talazoparib | Advanced Solid Tumor | sensitive | detail... |
IDH1 R132H | Berzosertib | Advanced Solid Tumor | sensitive | detail... |
IDH1 R132H | Olaparib | Advanced Solid Tumor | sensitive | detail... |
IDH1 R132H | Niraparib | Advanced Solid Tumor | sensitive | detail... |
IDH1 R132H | Rucaparib | Advanced Solid Tumor | sensitive | detail... |
IDH1 R132H | Cisplatin + Talazoparib | Advanced Solid Tumor | sensitive | detail... |
IDH1 R132H | AGI-5198 + Talazoparib | Advanced Solid Tumor | decreased response | detail... |
TP53 wild-type | Siremadlin | Advanced Solid Tumor | predicted - sensitive | detail... |
FGFR3 L608V | Infigratinib | Advanced Solid Tumor | decreased response | detail... |
FGFR3 K650E | Infigratinib | Advanced Solid Tumor | decreased response | detail... |
FGFR3 N540K | Infigratinib | Advanced Solid Tumor | resistant | detail... |
FGFR3 V555L | Infigratinib | Advanced Solid Tumor | decreased response | detail... |
FGFR3 V555M | Infigratinib | Advanced Solid Tumor | resistant | detail... |
FGFR3 L608V | Ponatinib | Advanced Solid Tumor | sensitive | detail... |
FGFR3 V555M | Ponatinib | Advanced Solid Tumor | sensitive | detail... |
FGFR3 N540K | Ponatinib | Advanced Solid Tumor | sensitive | detail... |
FGFR3 K650E | Ponatinib | Advanced Solid Tumor | sensitive | detail... |
FGFR3 K650E | Dovitinib | Advanced Solid Tumor | conflicting | detail... |
FGFR3 N540K | Dovitinib | Advanced Solid Tumor | sensitive | detail... |
FGFR3 V555M | Dovitinib | Advanced Solid Tumor | sensitive | detail... |
FGFR3 L608V | Dovitinib | Advanced Solid Tumor | sensitive | detail... |
FGFR3 L608V | AZD4547 | Advanced Solid Tumor | decreased response | detail... |
FGFR3 V555M | AZD4547 | Advanced Solid Tumor | resistant | detail... |
FGFR3 L608V | Debio 1347 | Advanced Solid Tumor | decreased response | detail... |
FGFR3 V555M | Debio 1347 | Advanced Solid Tumor | decreased response | detail... |
FGFR3 N540K | Debio 1347 | Advanced Solid Tumor | decreased response | detail... |
FGFR3 K650E | Debio 1347 | Advanced Solid Tumor | sensitive | detail... |
FGFR3 L608V | FIIN-2 | Advanced Solid Tumor | sensitive | detail... |
FGFR3 K650E | FIIN-2 | Advanced Solid Tumor | sensitive | detail... |
FGFR3 V555M | FIIN-2 | Advanced Solid Tumor | decreased response | detail... |
FGFR3 N540K | FIIN-2 | Advanced Solid Tumor | decreased response | detail... |
FGFR3 L608V | LY2874455 | Advanced Solid Tumor | sensitive | detail... |
FGFR3 V555M | LY2874455 | Advanced Solid Tumor | sensitive | detail... |
FGFR3 K650E | LY2874455 | Advanced Solid Tumor | sensitive | detail... |
FGFR3 N540K | LY2874455 | Advanced Solid Tumor | decreased response | detail... |
FGFR2 V564F | Infigratinib | Advanced Solid Tumor | resistant | detail... |
FGFR2 V564F | Debio 1347 | Advanced Solid Tumor | sensitive | detail... |
FGFR2 V564F | AZD4547 | Advanced Solid Tumor | resistant | detail... |
FGFR2 V564I | Debio 1347 | Advanced Solid Tumor | resistant | detail... |
FGFR2 V564L | Debio 1347 | Advanced Solid Tumor | resistant | detail... |
BRAF V600E | PF-00477736 + PF3644022 | Advanced Solid Tumor | predicted - sensitive | detail... |
CDKN2A loss | PF-00477736 + PF3644022 | Advanced Solid Tumor | predicted - sensitive | detail... |
BRAF mutant | PF-00477736 + PF3644022 | Advanced Solid Tumor | predicted - sensitive | detail... |
ALK rearrange | Belizatinib | Advanced Solid Tumor | sensitive | detail... |
EML4 - ALK ALK L1196M | Repotrectinib | Advanced Solid Tumor | sensitive | detail... |
EML4 - ALK ALK G1202R | Repotrectinib | Advanced Solid Tumor | sensitive | detail... |
MAP2K1 L115P | CI-1040 | Advanced Solid Tumor | resistant | detail... |
MAP2K1 L115A | CI-1040 | Advanced Solid Tumor | decreased response | detail... |
MAP2K1 F53S | CI-1040 | Advanced Solid Tumor | sensitive | detail... |
MAP2K1 I103N | CI-1040 | Advanced Solid Tumor | decreased response | detail... |
PTEN loss | Everolimus | Advanced Solid Tumor | no benefit | detail... |
RET C634R RET V804M | Vandetanib | Advanced Solid Tumor | resistant | detail... |
RET C634R RET Y806C | Vandetanib | Advanced Solid Tumor | resistant | detail... |
RET C634R RET Y806E | Vandetanib | Advanced Solid Tumor | resistant | detail... |
RET C634R RET Y806F | Vandetanib | Advanced Solid Tumor | predicted - sensitive | detail... |
TP53 wild-type | MK-8242 | Advanced Solid Tumor | unknown | detail... |
TP53 positive | Serdemetan | Advanced Solid Tumor | sensitive | detail... |
ATM del ATR dec exp | PJ34 | Advanced Solid Tumor | decreased response | detail... |
JAK3 R172Q | Tofacitinib | Advanced Solid Tumor | sensitive | detail... |
JAK3 L156P | Tofacitinib | Advanced Solid Tumor | sensitive | detail... |
JAK3 E183G | Tofacitinib | Advanced Solid Tumor | sensitive | detail... |
JAK3 A572V | Tofacitinib | Advanced Solid Tumor | sensitive | detail... |
BRAF mutant | KO-947 | Advanced Solid Tumor | predicted - sensitive | detail... |
NRAS mutant | KO-947 | Advanced Solid Tumor | predicted - sensitive | detail... |
BRAF mutant | CC-90003 | Advanced Solid Tumor | no benefit | detail... |
NRAS mutant | CC-90003 | Advanced Solid Tumor | no benefit | detail... |
TP53 wild-type | ALRN-6924 | Advanced Solid Tumor | predicted - sensitive | detail... |
BRAF F247L | Trametinib | Advanced Solid Tumor | sensitive | detail... |
BRAF F247L | Dabrafenib | Advanced Solid Tumor | sensitive | detail... |
MDM2 amp | N/A | Advanced Solid Tumor | no benefit | detail... |
BRAF F595L | Vemurafenib | Advanced Solid Tumor | resistant | detail... |
BRAF D594N | Vemurafenib | Advanced Solid Tumor | predicted - resistant | detail... |
JAK1 S646P | Ruxolitinib | Advanced Solid Tumor | sensitive | detail... |
JAK3 I87T | JANEX-1 | Advanced Solid Tumor | sensitive | detail... |
KIT N822I | Imatinib | Advanced Solid Tumor | resistant | detail... |
KIT N822I | Dasatinib | Advanced Solid Tumor | sensitive | detail... |
KIT V559D | Dasatinib | Advanced Solid Tumor | sensitive | detail... |
KIT V559D | Imatinib | Advanced Solid Tumor | sensitive | detail... |
KIT V560D | Motesanib Diphosphate | Advanced Solid Tumor | sensitive | detail... |
KIT M552_V559del | Motesanib Diphosphate | Advanced Solid Tumor | sensitive | detail... |
KIT Y823D | Motesanib Diphosphate | Advanced Solid Tumor | sensitive | detail... |
KIT V560D KIT V654A | Motesanib Diphosphate | Advanced Solid Tumor | sensitive | detail... |
KIT V560D KIT T670I | Motesanib Diphosphate | Advanced Solid Tumor | sensitive | detail... |
KIT W557_K558del | Nilotinib | Advanced Solid Tumor | sensitive | detail... |
KIT W557_K558del | Dasatinib | Advanced Solid Tumor | sensitive | detail... |
KIT W557_K558del KIT T670I | Dasatinib | Advanced Solid Tumor | resistant | detail... |
KIT W557_K558del KIT T670I | Nilotinib | Advanced Solid Tumor | resistant | detail... |
KIT W557_K558del KIT T670I | Sorafenib | Advanced Solid Tumor | sensitive | detail... |
KIT V560del KIT V654A | Nilotinib | Advanced Solid Tumor | sensitive | detail... |
KIT V559D KIT D820Y | Nilotinib | Advanced Solid Tumor | sensitive | detail... |
KIT V559D KIT D820Y | Dasatinib | Advanced Solid Tumor | sensitive | detail... |
KIT V559D KIT D820Y | Sorafenib | Advanced Solid Tumor | sensitive | detail... |
KIT exon17 | Avapritinib | Advanced Solid Tumor | sensitive | detail... |
ALK rearrange | ASP3026 | Advanced Solid Tumor | sensitive | detail... |
BRAF V600E/K PTEN loss | PX-866 + Vemurafenib | Advanced Solid Tumor | predicted - sensitive | detail... |
EML4 - ALK ALK L1198P | Crizotinib | Advanced Solid Tumor | resistant | detail... |
EML4 - ALK ALK L1198P | TAE684 | Advanced Solid Tumor | resistant | detail... |
EML4 - ALK ALK D1203N | TAE684 | Advanced Solid Tumor | resistant | detail... |
HRAS G12V | SR9009 | Advanced Solid Tumor | predicted - sensitive | detail... |
HRAS G12V | SR9011 | Advanced Solid Tumor | predicted - sensitive | detail... |
FGFR1 V561M | PRN1371 | Advanced Solid Tumor | sensitive | detail... |
FGFR1 over exp | PRN1371 | Advanced Solid Tumor | sensitive | detail... |
FGFR2 over exp | PRN1371 | Advanced Solid Tumor | sensitive | detail... |
FGFR2 W290C | Infigratinib | Advanced Solid Tumor | sensitive | detail... |
FGFR2 K660E | Infigratinib | Advanced Solid Tumor | sensitive | detail... |
FGFR2 K660N | Infigratinib | Advanced Solid Tumor | sensitive | detail... |
FGFR2 W290C | Ponatinib | Advanced Solid Tumor | sensitive | detail... |
FGFR2 K660N | Ponatinib | Advanced Solid Tumor | sensitive | detail... |
FGFR3 S249C | Ponatinib | Advanced Solid Tumor | sensitive | detail... |
FGFR3 R248C | Infigratinib | Advanced Solid Tumor | sensitive | detail... |
FGFR3 S249C | Infigratinib | Advanced Solid Tumor | sensitive | detail... |
FGFR3 S249C | Dovitinib | Advanced Solid Tumor | conflicting | detail... |
FGFR3 R248C | Dovitinib | Advanced Solid Tumor | conflicting | detail... |
FGFR2 W290C | Pazopanib | Advanced Solid Tumor | sensitive | detail... |
FGFR2 K660N | Pazopanib | Advanced Solid Tumor | sensitive | detail... |
FGFR2 K660E | Pazopanib | Advanced Solid Tumor | sensitive | detail... |
FGFR3 R248C | Pazopanib | Advanced Solid Tumor | sensitive | detail... |
FGFR2 W290C | Cediranib | Advanced Solid Tumor | sensitive | detail... |
FGFR2 K660N | Cediranib | Advanced Solid Tumor | sensitive | detail... |
FGFR2 K660E | Cediranib | Advanced Solid Tumor | sensitive | detail... |
FGFR2 K660E | AZD4547 | Advanced Solid Tumor | sensitive | detail... |
FGFR2 K660N | AZD4547 | Advanced Solid Tumor | sensitive | detail... |
FGFR2 W290C | AZD4547 | Advanced Solid Tumor | sensitive | detail... |
FGFR2 K660E | Lenvatinib | Advanced Solid Tumor | sensitive | detail... |
FGFR2 K660N | Lenvatinib | Advanced Solid Tumor | sensitive | detail... |
FGFR2 W290C | Lenvatinib | Advanced Solid Tumor | sensitive | detail... |
FGFR2 over exp | Derazantinib | Advanced Solid Tumor | sensitive | detail... |
FGFR1 over exp | Derazantinib | Advanced Solid Tumor | sensitive | detail... |
KIT over exp | Derazantinib | Advanced Solid Tumor | sensitive | detail... |
BRAF mutant | RAF709 | Advanced Solid Tumor | sensitive | detail... |
NRAS mutant | RAF709 | Advanced Solid Tumor | sensitive | detail... |
EML4 - ALK ALK C1156Y ALK I1171T | Lorlatinib | Advanced Solid Tumor | resistant | detail... |
EML4 - ALK ALK C1156Y ALK F1174C | Lorlatinib | Advanced Solid Tumor | resistant | detail... |
EML4 - ALK ALK C1156Y ALK F1174I | Lorlatinib | Advanced Solid Tumor | resistant | detail... |
EML4 - ALK ALK C1156Y ALK F1174V | Lorlatinib | Advanced Solid Tumor | resistant | detail... |
EML4 - ALK ALK C1156Y ALK L1196M | Lorlatinib | Advanced Solid Tumor | resistant | detail... |
EML4 - ALK ALK C1156Y ALK D1203N | Lorlatinib | Advanced Solid Tumor | resistant | detail... |
EML4 - ALK ALK C1156Y ALK L1256F | Lorlatinib | Advanced Solid Tumor | resistant | detail... |
EML4 - ALK ALK C1156Y ALK G1269A | Lorlatinib | Advanced Solid Tumor | resistant | detail... |
EML4 - ALK ALK I1171S ALK L1196M | Lorlatinib | Advanced Solid Tumor | resistant | detail... |
EML4 - ALK ALK F1174C ALK L1196M | Lorlatinib | Advanced Solid Tumor | resistant | detail... |
EML4 - ALK ALK F1174L ALK L1196M | Lorlatinib | Advanced Solid Tumor | resistant | detail... |
EML4 - ALK ALK F1174V ALK L1196M | Lorlatinib | Advanced Solid Tumor | resistant | detail... |
EML4 - ALK ALK I1179V ALK L1196M | Lorlatinib | Advanced Solid Tumor | resistant | detail... |
EML4 - ALK ALK L1196M ALK L1256F | Lorlatinib | Advanced Solid Tumor | resistant | detail... |
EML4 - ALK ALK F1174C ALK G1269A | Lorlatinib | Advanced Solid Tumor | resistant | detail... |
EML4 - ALK ALK L1196M ALK G1202R | Lorlatinib | Advanced Solid Tumor | resistant | detail... |
EML4 - ALK ALK I1171T ALK G1269A | Lorlatinib | Advanced Solid Tumor | resistant | detail... |
EML4 - ALK ALK I1171N ALK G1269A | Lorlatinib | Advanced Solid Tumor | resistant | detail... |
EML4 - ALK ALK L1196M ALK G1269A | Lorlatinib | Advanced Solid Tumor | resistant | detail... |
FGFR1 amp | AZD4547 | Advanced Solid Tumor | unknown | detail... |
FGFR2 amp | AZD4547 | Advanced Solid Tumor | unknown | detail... |
ROS1 fusion | Repotrectinib | Advanced Solid Tumor | predicted - sensitive | detail... |
ROS1 fusion ROS1 G2032R | Repotrectinib | Advanced Solid Tumor | predicted - sensitive | detail... |
ALK fusion | Repotrectinib | Advanced Solid Tumor | predicted - sensitive | detail... |
MAP2K1 F53L | Selumetinib | Advanced Solid Tumor | sensitive | detail... |
MAP2K1 Q56P | Selumetinib | Advanced Solid Tumor | sensitive | detail... |
MAP2K1 K57N | Selumetinib | Advanced Solid Tumor | sensitive | detail... |
MAP2K1 C121S | Selumetinib | Advanced Solid Tumor | sensitive | detail... |
MAP2K1 F129L | Selumetinib | Advanced Solid Tumor | sensitive | detail... |
MAP2K1 I111S | Selumetinib | Advanced Solid Tumor | sensitive | detail... |
MAP2K1 V211D | Selumetinib | Advanced Solid Tumor | resistant | detail... |
MAP2K1 V211D | PLX4720 | Advanced Solid Tumor | sensitive | detail... |
MAP2K1 F53L | PLX4720 | Advanced Solid Tumor | sensitive | detail... |
MAP2K1 K57N | PLX4720 | Advanced Solid Tumor | sensitive | detail... |
MAP2K1 I111S | PLX4720 | Advanced Solid Tumor | sensitive | detail... |
MAP2K1 C121S | PLX4720 | Advanced Solid Tumor | sensitive | detail... |
MAP2K1 F129L | PLX4720 | Advanced Solid Tumor | sensitive | detail... |
MAP2K1 V211D | PD98059 | Advanced Solid Tumor | resistant | detail... |
MAP2K1 F53L | PD98059 | Advanced Solid Tumor | resistant | detail... |
MAP2K1 Q56P | PD98059 | Advanced Solid Tumor | resistant | detail... |
MAP2K1 K57N | PD98059 | Advanced Solid Tumor | resistant | detail... |
MAP2K1 I111S | PD98059 | Advanced Solid Tumor | resistant | detail... |
MAP2K1 C121S | PD98059 | Advanced Solid Tumor | resistant | detail... |
MAP2K1 F129L | PD98059 | Advanced Solid Tumor | resistant | detail... |
MAP2K1 V211D | Regorafenib | Advanced Solid Tumor | resistant | detail... |
MAP2K1 F53L | Regorafenib | Advanced Solid Tumor | resistant | detail... |
MAP2K1 Q56P | Regorafenib | Advanced Solid Tumor | resistant | detail... |
MAP2K1 K57N | Regorafenib | Advanced Solid Tumor | resistant | detail... |
MAP2K1 I111S | Regorafenib | Advanced Solid Tumor | resistant | detail... |
MAP2K1 C121S | Regorafenib | Advanced Solid Tumor | resistant | detail... |
MAP2K1 F129L | Regorafenib | Advanced Solid Tumor | resistant | detail... |
MAP2K1 V211D | GDC0879 | Advanced Solid Tumor | resistant | detail... |
MAP2K1 F53L | GDC0879 | Advanced Solid Tumor | resistant | detail... |
MAP2K1 Q56P | GDC0879 | Advanced Solid Tumor | resistant | detail... |
MAP2K1 K57N | GDC0879 | Advanced Solid Tumor | resistant | detail... |
MAP2K1 I111S | GDC0879 | Advanced Solid Tumor | resistant | detail... |
MAP2K1 C121S | GDC0879 | Advanced Solid Tumor | resistant | detail... |
MAP2K1 F129L | GDC0879 | Advanced Solid Tumor | resistant | detail... |
MAP2K1 V211D | AZD8330 | Advanced Solid Tumor | resistant | detail... |
MAP2K1 F53L | AZD8330 | Advanced Solid Tumor | resistant | detail... |
MAP2K1 Q56P | AZD8330 | Advanced Solid Tumor | resistant | detail... |
MAP2K1 K57N | AZD8330 | Advanced Solid Tumor | resistant | detail... |
MAP2K1 I111S | AZD8330 | Advanced Solid Tumor | resistant | detail... |
MAP2K1 C121S | AZD8330 | Advanced Solid Tumor | resistant | detail... |
MAP2K1 F129L | AZD8330 | Advanced Solid Tumor | resistant | detail... |
MAP2K1 Q56P | PLX4720 | Advanced Solid Tumor | sensitive | detail... |
KIT V559D | Flumatinib | Advanced Solid Tumor | sensitive | detail... |
KIT V559D | Sunitinib | Advanced Solid Tumor | sensitive | detail... |
KIT V559_V560del | Sunitinib | Advanced Solid Tumor | sensitive | detail... |
KIT V559_V560del | Imatinib | Advanced Solid Tumor | sensitive | detail... |
KIT V559_V560del | Flumatinib | Advanced Solid Tumor | sensitive | detail... |
KIT A502_Y503dup | Imatinib | Advanced Solid Tumor | sensitive | detail... |
KIT A502_Y503dup | Flumatinib | Advanced Solid Tumor | sensitive | detail... |
KIT A502_Y503dup | Sunitinib | Advanced Solid Tumor | sensitive | detail... |
KIT V559D KIT V654A | Sunitinib | Advanced Solid Tumor | sensitive | detail... |
KIT V559D KIT T670I | Sunitinib | Advanced Solid Tumor | sensitive | detail... |
KIT V559D KIT N822K | Sunitinib | Advanced Solid Tumor | no benefit | detail... |
KIT V559D KIT Y823D | Sunitinib | Advanced Solid Tumor | no benefit | detail... |
KIT V559D KIT A829P | Sunitinib | Advanced Solid Tumor | no benefit | detail... |
KIT V560D KIT V654A | Flumatinib | Advanced Solid Tumor | resistant | detail... |
KIT V560D KIT T670I | Flumatinib | Advanced Solid Tumor | resistant | detail... |
KIT V559D KIT D820G | Flumatinib | Advanced Solid Tumor | sensitive | detail... |
KIT V559D KIT N822K | Flumatinib | Advanced Solid Tumor | sensitive | detail... |
KIT V559D KIT Y823D | Flumatinib | Advanced Solid Tumor | sensitive | detail... |
KIT I571_D579dup | Sunitinib | Advanced Solid Tumor | predicted - resistant | detail... |
KIT V559D KIT A829P | Flumatinib | Advanced Solid Tumor | sensitive | detail... |
KIT I571_D579dup | Imatinib | Advanced Solid Tumor | predicted - resistant | detail... |
KIT I571_D579dup | Flumatinib | Advanced Solid Tumor | predicted - resistant | detail... |
KIT V559D KIT Y823D | Imatinib | Advanced Solid Tumor | no benefit | detail... |
KIT D816V | Flumatinib | Advanced Solid Tumor | resistant | detail... |
KIT D816Y | Flumatinib | Advanced Solid Tumor | resistant | detail... |
KIT D816Y | Sunitinib | Advanced Solid Tumor | resistant | detail... |
KIT D816Y | Imatinib | Advanced Solid Tumor | resistant | detail... |
KIT D816H | Flumatinib | Advanced Solid Tumor | predicted - sensitive | detail... |
KIT D816H | Sunitinib | Advanced Solid Tumor | predicted - sensitive | detail... |
KIT N822K | Imatinib | Advanced Solid Tumor | resistant | detail... |
KIT N822K | Flumatinib | Advanced Solid Tumor | predicted - sensitive | detail... |
KIT N822K | Sunitinib | Advanced Solid Tumor | predicted - sensitive | detail... |
KIT T417_D419delinsI | Flumatinib | Advanced Solid Tumor | sensitive | detail... |
KIT T417_D419delinsI | Sunitinib | Advanced Solid Tumor | sensitive | detail... |
CD274 amp | unspecified PD-1 antibody | Advanced Solid Tumor | predicted - sensitive | detail... |
CD274 amp | unspecified PD-L1 antibody | Advanced Solid Tumor | predicted - sensitive | detail... |
RET M918T | Selpercatinib | Advanced Solid Tumor | sensitive | detail... |
CSF3R T618I | Ibrutinib | Advanced Solid Tumor | sensitive | detail... |
CSF3R Q741* | Ibrutinib | Advanced Solid Tumor | sensitive | detail... |
CSF3R Q741* | Ruxolitinib | Advanced Solid Tumor | sensitive | detail... |
CSF3R T618I | Ibrutinib + Ruxolitinib | Advanced Solid Tumor | sensitive | detail... |
CSF3R Q741* | Ibrutinib + Ruxolitinib | Advanced Solid Tumor | sensitive | detail... |
KIT D816F | Imatinib | Advanced Solid Tumor | resistant | detail... |
EML4 - ALK | Crizotinib | Advanced Solid Tumor | sensitive | detail... |
EML4 - ALK | Ensartinib | Advanced Solid Tumor | sensitive | detail... |
CSF3R N610H | Ruxolitinib | Advanced Solid Tumor | sensitive | detail... |
CSF3R N610S | Ruxolitinib | Advanced Solid Tumor | sensitive | detail... |
CSF3R N610S | Trametinib | Advanced Solid Tumor | predicted - sensitive | detail... |
CSF3R N610H | Trametinib | Advanced Solid Tumor | predicted - sensitive | detail... |
BRAF V600E | Vemurafenib | Advanced Solid Tumor | sensitive | detail... |
BRAF G596R | Vemurafenib | Advanced Solid Tumor | no benefit | detail... |
BRAF N581S | Vemurafenib | Advanced Solid Tumor | no benefit | detail... |
BRAF G466V | Vemurafenib | Advanced Solid Tumor | no benefit | detail... |
BRAF G606E | Vemurafenib | Advanced Solid Tumor | no benefit | detail... |
BRAF P731T | Vemurafenib | Advanced Solid Tumor | no benefit | detail... |
EML4 - ALK | Repotrectinib | Advanced Solid Tumor | sensitive | detail... |
BRAF N486_T491delinsK | Cobimetinib | Advanced Solid Tumor | predicted - sensitive | detail... |
TP53 mutant | Unspecified VEGFR inhibitor | Advanced Solid Tumor | sensitive | detail... |
KIT W557_K558del KIT D816H | AZD3229 | Advanced Solid Tumor | sensitive | detail... |
EML4 - ALK | Iruplinalkib | Advanced Solid Tumor | sensitive | detail... |
EML4 - ALK ALK L1196M | Iruplinalkib | Advanced Solid Tumor | sensitive | detail... |
EML4 - ALK ALK C1156Y | Iruplinalkib | Advanced Solid Tumor | sensitive | detail... |
FGFR1 amp | Debio 1347 | Advanced Solid Tumor | predicted - sensitive | detail... |
FGFR2 amp | Debio 1347 | Advanced Solid Tumor | predicted - sensitive | detail... |
FGFR3 amp | Debio 1347 | Advanced Solid Tumor | predicted - sensitive | detail... |
FGFR1 fusion | Debio 1347 | Advanced Solid Tumor | predicted - sensitive | detail... |
FGFR2 fusion | Debio 1347 | Advanced Solid Tumor | predicted - sensitive | detail... |
FGFR3 fusion | Debio 1347 | Advanced Solid Tumor | predicted - sensitive | detail... |
FGFR1 mutant | Debio 1347 | Advanced Solid Tumor | predicted - sensitive | detail... |
FGFR2 mutant | Debio 1347 | Advanced Solid Tumor | predicted - sensitive | detail... |
FGFR3 mutant | Debio 1347 | Advanced Solid Tumor | predicted - sensitive | detail... |
ATM negative | BAY1895344 | Advanced Solid Tumor | predicted - sensitive | detail... |
ATM inact mut | BAY1895344 | Advanced Solid Tumor | predicted - sensitive | detail... |
BRAF mutant | LXH 254 | Advanced Solid Tumor | predicted - sensitive | detail... |
CD274 positive | CDX-527 | Advanced Solid Tumor | predicted - sensitive | detail... |
MAP2K1 V211D | Binimetinib | Advanced Solid Tumor | predicted - resistant | detail... |
MAP2K1 V211D | Cobimetinib | Advanced Solid Tumor | predicted - resistant | detail... |
BRAF V504_R506dup | Sorafenib | Advanced Solid Tumor | predicted - resistant | detail... |
BRAF V504_R506dup | Vemurafenib | Advanced Solid Tumor | resistant | detail... |
BRAF V504_R506dup | Trametinib | Advanced Solid Tumor | sensitive | detail... |
KIT L576P | Axitinib | Advanced Solid Tumor | sensitive | detail... |
KIT V559D | Axitinib | Advanced Solid Tumor | sensitive | detail... |
KIT V559A | Axitinib | Advanced Solid Tumor | sensitive | detail... |
KIT V559G | Axitinib | Advanced Solid Tumor | sensitive | detail... |
KIT V654A | Axitinib | Advanced Solid Tumor | sensitive | detail... |
KIT V559D KIT V654A | Axitinib | Advanced Solid Tumor | sensitive | detail... |
KIT T670I | Axitinib | Advanced Solid Tumor | sensitive | detail... |
KIT A829P | Axitinib | Advanced Solid Tumor | sensitive | detail... |
KIT V654A | Sunitinib | Advanced Solid Tumor | sensitive | detail... |
KIT T670I | Sunitinib | Advanced Solid Tumor | sensitive | detail... |
BRAF mut TP53 wild-type | Pimasertib + SAR405838 | Advanced Solid Tumor | predicted - sensitive | detail... |
NRAS mut TP53 wild-type | Pimasertib + SAR405838 | Advanced Solid Tumor | predicted - sensitive | detail... |
CD274 positive | Toripalimab-tpzi | Advanced Solid Tumor | predicted - sensitive | detail... |
EML4 - ALK ALK S1206Y | Alectinib | Advanced Solid Tumor | conflicting | detail... |
EML4 - ALK ALK T1151dup | Alectinib | Advanced Solid Tumor | sensitive | detail... |
EML4 - ALK ALK L1152R | ASP3026 | Advanced Solid Tumor | resistant | detail... |
EML4 - ALK ALK L1152R | Alectinib | Advanced Solid Tumor | sensitive | detail... |
EML4 - ALK ALK C1156Y | ASP3026 | Advanced Solid Tumor | sensitive | detail... |
EML4 - ALK ALK L1196M | ASP3026 | Advanced Solid Tumor | resistant | detail... |
EML4 - ALK ALK G1202R | ASP3026 | Advanced Solid Tumor | resistant | detail... |
EML4 - ALK ALK S1206Y | ASP3026 | Advanced Solid Tumor | resistant | detail... |
EML4 - ALK ALK S1206Y | Crizotinib | Advanced Solid Tumor | resistant | detail... |
CD274 over exp | PF-06801591 | Advanced Solid Tumor | predicted - sensitive | detail... |
MDM2 amp TP53 wild-type | KRT-232 | Advanced Solid Tumor | predicted - sensitive | detail... |
PIK3CA H1047R | Alpelisib | Advanced Solid Tumor | predicted - sensitive | detail... |
KIT V654A KIT D816V | Midostaurin | Advanced Solid Tumor | resistant | detail... |
KIT T670I KIT D816V | Midostaurin | Advanced Solid Tumor | decreased response | detail... |
KIT N655K KIT D816V | Midostaurin | Advanced Solid Tumor | resistant | detail... |
KIT Y672C KIT D816V | Midostaurin | Advanced Solid Tumor | decreased response | detail... |
KIT D677N KIT D816V | Midostaurin | Advanced Solid Tumor | resistant | detail... |
KIT D816V | Midostaurin | Advanced Solid Tumor | sensitive | detail... |
KIT D816V | Avapritinib | Advanced Solid Tumor | sensitive | detail... |
KIT V654A KIT D816V | Avapritinib | Advanced Solid Tumor | predicted - sensitive | detail... |
KIT N655K KIT D816V | Avapritinib | Advanced Solid Tumor | predicted - sensitive | detail... |
KIT Y672C KIT D816V | Avapritinib | Advanced Solid Tumor | predicted - sensitive | detail... |
KIT D677N KIT D816V | Avapritinib | Advanced Solid Tumor | predicted - sensitive | detail... |
KIT T670I KIT D816V | Avapritinib | Advanced Solid Tumor | resistant | detail... |
KIT T670A KIT D816V | Avapritinib | Advanced Solid Tumor | sensitive | detail... |
KIT T670V KIT D816V | Avapritinib | Advanced Solid Tumor | predicted - resistant | detail... |
KIT T670A KIT D816V | Midostaurin | Advanced Solid Tumor | sensitive | detail... |
KIT T670V KIT D816V | Midostaurin | Advanced Solid Tumor | sensitive | detail... |
KIT V560D KIT V654A | Avapritinib | Advanced Solid Tumor | decreased response | detail... |
POLE mutant | unspecified CTLA4 antibody | Advanced Solid Tumor | predicted - sensitive | detail... |
POLE mutant | unspecified PD-1 antibody | Advanced Solid Tumor | predicted - sensitive | detail... |
POLE mutant | unspecified PD-L1 antibody | Advanced Solid Tumor | predicted - sensitive | detail... |
POLD1 mutant | unspecified CTLA4 antibody | Advanced Solid Tumor | predicted - sensitive | detail... |
POLD1 mutant | unspecified PD-1 antibody | Advanced Solid Tumor | predicted - sensitive | detail... |
POLD1 mutant | unspecified PD-L1 antibody | Advanced Solid Tumor | predicted - sensitive | detail... |
KIT D816V | Ripretinib | Advanced Solid Tumor | sensitive | detail... |
KIT D816V | Regorafenib | Advanced Solid Tumor | resistant | detail... |
PIK3CA mutant | Alpelisib + Infigratinib | Advanced Solid Tumor | no benefit | detail... |
HRAS G12V | WM-8014 | Advanced Solid Tumor | sensitive | detail... |
BRAF V600X | Dabrafenib | Advanced Solid Tumor | predicted - sensitive | detail... |
FLT3 exon 14 ins | LAM-003 | Advanced Solid Tumor | sensitive | detail... |
FLT3 exon 14 ins FLT3 F691L | LAM-003 | Advanced Solid Tumor | sensitive | detail... |
FLT3 exon 14 ins | Crenolanib | Advanced Solid Tumor | sensitive | detail... |
EML4 - ALK ALK C1156Y ALK G1269A | Brigatinib | Advanced Solid Tumor | sensitive | detail... |
EML4 - ALK ALK C1156Y ALK G1269A | Crizotinib | Advanced Solid Tumor | resistant | detail... |
EML4 - ALK ALK C1156Y ALK G1269A | Alectinib | Advanced Solid Tumor | resistant | detail... |
EML4 - ALK ALK C1156Y ALK G1269A | Entrectinib | Advanced Solid Tumor | resistant | detail... |
EML4 - ALK ALK F1174L ALK G1202R | Lorlatinib | Advanced Solid Tumor | resistant | detail... |
EML4 - ALK ALK L1196M ALK D1203N | Lorlatinib | Advanced Solid Tumor | resistant | detail... |
JAK2 V617F JAK2 R971G | Ruxolitinib | Advanced Solid Tumor | resistant | detail... |
JAK2 V617F JAK2 L983F | Ruxolitinib | Advanced Solid Tumor | resistant | detail... |
JAK2 V617F JAK2 E987D | Ruxolitinib | Advanced Solid Tumor | resistant | detail... |
TP53 R181E | Nutlin-3a | Advanced Solid Tumor | no benefit | detail... |
TP53 R181E | Doxorubicin + Nutlin-3a | Advanced Solid Tumor | sensitive | detail... |
TP53 R181E | Doxorubicin + SAR405838 | Advanced Solid Tumor | sensitive | detail... |
TP53 R181E | Doxorubicin + Idasanutlin | Advanced Solid Tumor | sensitive | detail... |
TP53 R181E | Doxorubicin + RG7112 | Advanced Solid Tumor | sensitive | detail... |
JAK2 V617F JAK2 Y931C | Fedratinib | Advanced Solid Tumor | sensitive | detail... |
JAK2 V617F JAK2 Y931C JAK2 S1025C | Fedratinib | Advanced Solid Tumor | resistant | detail... |
JAK2 V617F JAK2 Y931C JAK2 Y1045W | Fedratinib | Advanced Solid Tumor | resistant | detail... |
JAK2 V617F JAK2 Y931C JAK2 F1061W | Fedratinib | Advanced Solid Tumor | resistant | detail... |
JAK2 V617F JAK2 Y931C JAK2 V1075F | Fedratinib | Advanced Solid Tumor | resistant | detail... |
BRAF mutant | LY3009120 | Advanced Solid Tumor | no benefit | detail... |
NRAS mutant | LY3009120 | Advanced Solid Tumor | no benefit | detail... |
EML4 - ALK | Taletrectinib | Advanced Solid Tumor | sensitive | detail... |
EML4 - ALK ALK I1171S ALK G1269A | Crizotinib | Advanced Solid Tumor | resistant | detail... |
EML4 - ALK ALK I1171S ALK G1269A | Alectinib | Advanced Solid Tumor | resistant | detail... |
EML4 - ALK ALK I1171S ALK G1269A | Lorlatinib | Advanced Solid Tumor | resistant | detail... |
EML4 - ALK ALK I1171S ALK G1269A | Ceritinib | Advanced Solid Tumor | sensitive | detail... |
EML4 - ALK ALK I1171S ALK G1269A | Brigatinib | Advanced Solid Tumor | sensitive | detail... |
RET R886W | Sorafenib | Advanced Solid Tumor | sensitive | detail... |
CD274 positive | Pembrolizumab | Advanced Solid Tumor | predicted - sensitive | detail... |
BRAF mutant | Trametinib | Advanced Solid Tumor | no benefit | detail... |
BRAF G466V | Trametinib | Advanced Solid Tumor | no benefit | detail... |
ARID1A mutant | unspecified PD-1 antibody | Advanced Solid Tumor | predicted - sensitive | detail... |
ARID1A mutant | unspecified PD-L1 antibody | Advanced Solid Tumor | predicted - sensitive | detail... |
RET fusion | Pralsetinib | Advanced Solid Tumor | predicted - sensitive | detail... |
FGFR3 act mut | AZD4547 | Advanced Solid Tumor | predicted - sensitive | detail... |
FGFR2 act mut | AZD4547 | Advanced Solid Tumor | predicted - sensitive | detail... |
EML4 - ALK | TPX-0131 | Advanced Solid Tumor | sensitive | detail... |
EML4 - ALK ALK G1202R | TPX-0131 | Advanced Solid Tumor | sensitive | detail... |
EML4 - ALK ALK L1198F | TPX-0131 | Advanced Solid Tumor | sensitive | detail... |
EML4 - ALK ALK I1171N | TPX-0131 | Advanced Solid Tumor | resistant | detail... |
EML4 - ALK ALK I1171S | TPX-0131 | Advanced Solid Tumor | resistant | detail... |
EML4 - ALK ALK I1171T | TPX-0131 | Advanced Solid Tumor | resistant | detail... |
EML4 - ALK ALK G1269S | TPX-0131 | Advanced Solid Tumor | resistant | detail... |
EML4 - ALK ALK G1269A | TPX-0131 | Advanced Solid Tumor | sensitive | detail... |
EML4 - ALK ALK L1196M ALK L1198F | TPX-0131 | Advanced Solid Tumor | sensitive | detail... |
EML4 - ALK ALK C1156Y ALK L1198F | TPX-0131 | Advanced Solid Tumor | sensitive | detail... |
EML4 - ALK ALK C1156Y ALK G1202R | TPX-0131 | Advanced Solid Tumor | sensitive | detail... |
EML4 - ALK ALK L1196M ALK G1202R | TPX-0131 | Advanced Solid Tumor | sensitive | detail... |
EML4 - ALK ALK L1198F ALK G1202R | TPX-0131 | Advanced Solid Tumor | sensitive | detail... |
EML4 - ALK ALK G1202R ALK G1269A | TPX-0131 | Advanced Solid Tumor | sensitive | detail... |
EML4 - ALK ALK G1202R ALK L1204V ALK G1269A | TPX-0131 | Advanced Solid Tumor | sensitive | detail... |
EML4 - ALK ALK L1198F ALK G1202R ALK G1269A | TPX-0131 | Advanced Solid Tumor | sensitive | detail... |
KIT C809G | Imatinib | Advanced Solid Tumor | predicted - resistant | detail... |
MAP2K1 E41_L54del | Trametinib | Advanced Solid Tumor | sensitive | detail... |
MAP2K1 E41_L54del | Selumetinib | Advanced Solid Tumor | sensitive | detail... |
MAP2K1 E41_L54del | Cobimetinib | Advanced Solid Tumor | sensitive | detail... |
MAP2K1 E41_L54del | LY3009120 | Advanced Solid Tumor | no benefit | detail... |
JAK3 T1022I | Tofacitinib | Advanced Solid Tumor | sensitive | detail... |
FLT3 exon 14 ins FLT3 D698N | Gilteritinib | Advanced Solid Tumor | resistant | detail... |
FLT3 exon 14 ins FLT3 N676T | Quizartinib | Advanced Solid Tumor | resistant | detail... |
FLT3 exon 14 ins FLT3 N676T | Midostaurin | Advanced Solid Tumor | resistant | detail... |
ATM inact mut | Radiotherapy | Advanced Solid Tumor | predicted - sensitive | detail... |
BRAF V600X | Lifirafenib | Advanced Solid Tumor | predicted - sensitive | detail... |
KIT W557_K558del KIT V654A | AZD3229 | Advanced Solid Tumor | sensitive | detail... |
KIT W557_K558del KIT V654A | Avapritinib | Advanced Solid Tumor | resistant | detail... |
KIT W557_K558del KIT V654A | Ripretinib | Advanced Solid Tumor | resistant | detail... |
KIT V560D | AZD3229 | Advanced Solid Tumor | sensitive | detail... |
KIT V560D | Avapritinib | Advanced Solid Tumor | sensitive | detail... |
KIT V560D | Ripretinib | Advanced Solid Tumor | sensitive | detail... |
KIT A502_Y503dup | AZD3229 | Advanced Solid Tumor | sensitive | detail... |
KIT A502_Y503dup | Regorafenib | Advanced Solid Tumor | sensitive | detail... |
KIT A502_Y503dup | Avapritinib | Advanced Solid Tumor | sensitive | detail... |
KIT A502_Y503dup | Ripretinib | Advanced Solid Tumor | sensitive | detail... |
KIT W557_K558del | AZD3229 | Advanced Solid Tumor | sensitive | detail... |
KIT W557_K558del | Avapritinib | Advanced Solid Tumor | sensitive | detail... |
KIT W557_K558del | Ripretinib | Advanced Solid Tumor | sensitive | detail... |
KIT W557_K558del KIT T670I | AZD3229 | Advanced Solid Tumor | sensitive | detail... |
KIT V560D KIT V654A | AZD3229 | Advanced Solid Tumor | sensitive | detail... |
KIT V560D KIT V654A | Sunitinib | Advanced Solid Tumor | sensitive | detail... |
KIT V560D KIT V654A | Imatinib | Advanced Solid Tumor | resistant | detail... |
KIT V560D KIT V654A | Regorafenib | Advanced Solid Tumor | resistant | detail... |
KIT V560D KIT V654A | Ripretinib | Advanced Solid Tumor | decreased response | detail... |
KIT A502_Y503dup KIT V654A | AZD3229 | Advanced Solid Tumor | sensitive | detail... |
KIT A502_Y503dup KIT V654A | Sunitinib | Advanced Solid Tumor | sensitive | detail... |
KIT A502_Y503dup KIT V654A | Imatinib | Advanced Solid Tumor | resistant | detail... |
KIT A502_Y503dup KIT V654A | Regorafenib | Advanced Solid Tumor | resistant | detail... |
KIT A502_Y503dup KIT V654A | Avapritinib | Advanced Solid Tumor | resistant | detail... |
KIT A502_Y503dup KIT V654A | Ripretinib | Advanced Solid Tumor | decreased response | detail... |
KIT W557_K558del KIT T670I | Avapritinib | Advanced Solid Tumor | resistant | detail... |
KIT W557_K558del KIT T670I | Ripretinib | Advanced Solid Tumor | decreased response | detail... |
KIT W557_K558del KIT D816H | Avapritinib | Advanced Solid Tumor | sensitive | detail... |
KIT W557_K558del KIT D816H | Ripretinib | Advanced Solid Tumor | sensitive | detail... |
KIT W557_K558del KIT N822K | AZD3229 | Advanced Solid Tumor | sensitive | detail... |
KIT W557_K558del KIT N822K | Ripretinib | Advanced Solid Tumor | sensitive | detail... |
KIT W557_K558del KIT N822K | Avapritinib | Advanced Solid Tumor | sensitive | detail... |
KIT W557_K558del KIT D820A | Avapritinib | Advanced Solid Tumor | sensitive | detail... |
KIT W557_K558del KIT D820A | Ripretinib | Advanced Solid Tumor | sensitive | detail... |
KIT W557_K558del KIT D820A | AZD3229 | Advanced Solid Tumor | sensitive | detail... |
KIT W557_K558del KIT Y823D | Ripretinib | Advanced Solid Tumor | decreased response | detail... |
KIT W557_K558del KIT Y823D | Regorafenib | Advanced Solid Tumor | predicted - sensitive | detail... |
KIT W557_K558del KIT Y823D | Avapritinib | Advanced Solid Tumor | decreased response | detail... |
KIT W557_K558del KIT Y823D | Sunitinib | Advanced Solid Tumor | resistant | detail... |
KIT W557_K558del KIT Y823D | Imatinib | Advanced Solid Tumor | resistant | detail... |
KIT W557_K558del KIT Y823D | AZD3229 | Advanced Solid Tumor | sensitive | detail... |
KIT W557_K558del KIT A829P | AZD3229 | Advanced Solid Tumor | sensitive | detail... |
KIT W557_K558del KIT A829P | Ripretinib | Advanced Solid Tumor | sensitive | detail... |
KIT W557_K558del KIT A829P | Avapritinib | Advanced Solid Tumor | sensitive | detail... |
KIT V560D KIT D816H | AZD3229 | Advanced Solid Tumor | sensitive | detail... |
KIT V560D KIT D816H | Imatinib | Advanced Solid Tumor | resistant | detail... |
KIT V560D KIT D816H | Sunitinib | Advanced Solid Tumor | resistant | detail... |
KIT V560D KIT D816H | Regorafenib | Advanced Solid Tumor | resistant | detail... |
KIT V560D KIT D820A | Avapritinib | Advanced Solid Tumor | decreased response | detail... |
KIT V560D KIT D816H | Avapritinib | Advanced Solid Tumor | decreased response | detail... |
KIT V560D KIT D816H | Ripretinib | Advanced Solid Tumor | sensitive | detail... |
KIT V560D KIT D820A | Ripretinib | Advanced Solid Tumor | sensitive | detail... |
KIT V560D KIT D820A | AZD3229 | Advanced Solid Tumor | sensitive | detail... |
KIT V560D KIT D820A | Imatinib | Advanced Solid Tumor | resistant | detail... |
KIT V560D KIT D820A | Sunitinib | Advanced Solid Tumor | resistant | detail... |
KIT V560D KIT D820A | Regorafenib | Advanced Solid Tumor | sensitive | detail... |
KIT A502_Y503dup KIT D816H | Imatinib | Advanced Solid Tumor | resistant | detail... |
KIT A502_Y503dup KIT D816H | Sunitinib | Advanced Solid Tumor | resistant | detail... |
KIT A502_Y503dup KIT D816H | Regorafenib | Advanced Solid Tumor | resistant | detail... |
KIT A502_Y503dup KIT D816H | AZD3229 | Advanced Solid Tumor | sensitive | detail... |
KIT A502_Y503dup KIT D816H | Avapritinib | Advanced Solid Tumor | sensitive | detail... |
KIT A502_Y503dup KIT D816H | Ripretinib | Advanced Solid Tumor | decreased response | detail... |
FGFR1 over exp | Rogaratinib | Advanced Solid Tumor | predicted - sensitive | detail... |
FGFR2 over exp | Rogaratinib | Advanced Solid Tumor | predicted - sensitive | detail... |
FGFR3 over exp | Rogaratinib | Advanced Solid Tumor | predicted - sensitive | detail... |
IDH1 R132L | DS-1001b | Advanced Solid Tumor | predicted - sensitive | detail... |
IDH1 R132G | DS-1001b | Advanced Solid Tumor | predicted - sensitive | detail... |
IDH1 R132S | DS-1001b | Advanced Solid Tumor | predicted - sensitive | detail... |
IDH1 R132C | DS-1001b | Advanced Solid Tumor | predicted - sensitive | detail... |
IDH1 R132H | DS-1001b | Advanced Solid Tumor | predicted - sensitive | detail... |
HRAS G12V HRAS R135K | NS1 | Advanced Solid Tumor | resistant | detail... |
HRAS G12V HRAS R135A | NS1 | Advanced Solid Tumor | resistant | detail... |
KIT wild-type | PLX9486 | Advanced Solid Tumor | sensitive | detail... |
KIT D816V | PLX9486 | Advanced Solid Tumor | sensitive | detail... |
KIT V560G KIT D816V | Imatinib | Advanced Solid Tumor | resistant | detail... |
KIT V560G KIT D816V | PLX9486 | Advanced Solid Tumor | sensitive | detail... |
PIK3CA act mut | Palbociclib + Taselisib | Advanced Solid Tumor | predicted - sensitive | detail... |
KIT W557_K558del | Cabozantinib | Advanced Solid Tumor | sensitive | detail... |
KIT T670I | Regorafenib | Advanced Solid Tumor | sensitive | detail... |
KIT T670I | Cabozantinib | Advanced Solid Tumor | sensitive | detail... |
KIT N655K | Imatinib | Advanced Solid Tumor | predicted - sensitive | detail... |
KIT N655K | Sunitinib | Advanced Solid Tumor | decreased response | detail... |
KIT N655K | Regorafenib | Advanced Solid Tumor | decreased response | detail... |
KIT N655K | Cabozantinib | Advanced Solid Tumor | decreased response | detail... |
KIT N655K | Avapritinib | Advanced Solid Tumor | predicted - sensitive | detail... |
KIT N655K | Ripretinib | Advanced Solid Tumor | predicted - sensitive | detail... |
KIT T670I | Imatinib | Advanced Solid Tumor | resistant | detail... |
BRAF V600E | Trametinib | Advanced Solid Tumor | predicted - sensitive | detail... |
FGFR2 fusion | Futibatinib | Advanced Solid Tumor | predicted - sensitive | detail... |
FGFR1 amp | Futibatinib | Advanced Solid Tumor | predicted - sensitive | detail... |
FGFR2 amp | Futibatinib | Advanced Solid Tumor | predicted - sensitive | detail... |
EML4 - ALK | Entrectinib | Advanced Solid Tumor | sensitive | detail... |
EML4 - ALK | Gilteritinib | Advanced Solid Tumor | sensitive | detail... |
EML4 - ALK ALK I1171N | Entrectinib | Advanced Solid Tumor | resistant | detail... |
EML4 - ALK ALK I1171T | Entrectinib | Advanced Solid Tumor | resistant | detail... |
EML4 - ALK ALK I1171S | Entrectinib | Advanced Solid Tumor | resistant | detail... |
EML4 - ALK ALK I1171N | Gilteritinib | Advanced Solid Tumor | sensitive | detail... |
EML4 - ALK ALK I1171T | Gilteritinib | Advanced Solid Tumor | sensitive | detail... |
EML4 - ALK ALK I1171S | Gilteritinib | Advanced Solid Tumor | sensitive | detail... |
EML4 - ALK ALK T1151K | Gilteritinib | Advanced Solid Tumor | sensitive | detail... |
EML4 - ALK ALK C1156Y | Gilteritinib | Advanced Solid Tumor | sensitive | detail... |
EML4 - ALK ALK T1151K | Entrectinib | Advanced Solid Tumor | sensitive | detail... |
EML4 - ALK ALK T1151K | Lorlatinib | Advanced Solid Tumor | sensitive | detail... |
EML4 - ALK ALK T1151K | Brigatinib | Advanced Solid Tumor | sensitive | detail... |
EML4 - ALK ALK T1151K | Ceritinib | Advanced Solid Tumor | sensitive | detail... |
EML4 - ALK ALK T1151K | Alectinib | Advanced Solid Tumor | sensitive | detail... |
EML4 - ALK ALK T1151K | Crizotinib | Advanced Solid Tumor | predicted - resistant | detail... |
EML4 - ALK ALK V1180L | Crizotinib | Advanced Solid Tumor | sensitive | detail... |
EML4 - ALK ALK V1180L | Lorlatinib | Advanced Solid Tumor | sensitive | detail... |
EML4 - ALK ALK V1180L | Entrectinib | Advanced Solid Tumor | sensitive | detail... |
EML4 - ALK ALK V1180L | Gilteritinib | Advanced Solid Tumor | sensitive | detail... |
EML4 - ALK ALK F1174I | Crizotinib | Advanced Solid Tumor | predicted - resistant | detail... |
EML4 - ALK ALK F1174V | Alectinib | Advanced Solid Tumor | sensitive | detail... |
EML4 - ALK ALK F1174I | Alectinib | Advanced Solid Tumor | sensitive | detail... |
EML4 - ALK ALK F1174I | Ceritinib | Advanced Solid Tumor | sensitive | detail... |
EML4 - ALK ALK F1174V | Ceritinib | Advanced Solid Tumor | sensitive | detail... |
EML4 - ALK ALK F1174I | Brigatinib | Advanced Solid Tumor | sensitive | detail... |
EML4 - ALK ALK F1174I | Lorlatinib | Advanced Solid Tumor | sensitive | detail... |
EML4 - ALK ALK F1174V | Lorlatinib | Advanced Solid Tumor | sensitive | detail... |
EML4 - ALK ALK F1174I | Gilteritinib | Advanced Solid Tumor | sensitive | detail... |
EML4 - ALK ALK F1174V | Gilteritinib | Advanced Solid Tumor | sensitive | detail... |
EML4 - ALK ALK F1174V | Entrectinib | Advanced Solid Tumor | resistant | detail... |
EML4 - ALK ALK F1174I | Entrectinib | Advanced Solid Tumor | resistant | detail... |
EML4 - ALK ALK L1198F | Gilteritinib | Advanced Solid Tumor | sensitive | detail... |
EML4 - ALK ALK L1198F | Entrectinib | Advanced Solid Tumor | sensitive | detail... |
EML4 - ALK ALK L1196Q | Crizotinib | Advanced Solid Tumor | resistant | detail... |
EML4 - ALK ALK L1196Q | Alectinib | Advanced Solid Tumor | resistant | detail... |
EML4 - ALK ALK L1196Q | Entrectinib | Advanced Solid Tumor | resistant | detail... |
EML4 - ALK ALK L1196Q | Lorlatinib | Advanced Solid Tumor | sensitive | detail... |
EML4 - ALK ALK L1196Q | Ceritinib | Advanced Solid Tumor | sensitive | detail... |
EML4 - ALK ALK L1196Q | Brigatinib | Advanced Solid Tumor | sensitive | detail... |
EML4 - ALK ALK L1196M | Gilteritinib | Advanced Solid Tumor | sensitive | detail... |
EML4 - ALK ALK L1196Q | Gilteritinib | Advanced Solid Tumor | sensitive | detail... |
EML4 - ALK ALK G1202R | Gilteritinib | Advanced Solid Tumor | resistant | detail... |
EML4 - ALK ALK D1203N | Entrectinib | Advanced Solid Tumor | resistant | detail... |
EML4 - ALK ALK D1203N | Gilteritinib | Advanced Solid Tumor | predicted - resistant | detail... |
EML4 - ALK ALK F1245V | Ceritinib | Advanced Solid Tumor | sensitive | detail... |
EML4 - ALK ALK F1245V | Crizotinib | Advanced Solid Tumor | sensitive | detail... |
EML4 - ALK ALK F1245V | Alectinib | Advanced Solid Tumor | sensitive | detail... |
EML4 - ALK ALK F1245V | Brigatinib | Advanced Solid Tumor | sensitive | detail... |
EML4 - ALK ALK F1245V | Lorlatinib | Advanced Solid Tumor | sensitive | detail... |
EML4 - ALK ALK F1245V | Entrectinib | Advanced Solid Tumor | resistant | detail... |
EML4 - ALK ALK F1245V | Gilteritinib | Advanced Solid Tumor | sensitive | detail... |
EML4 - ALK ALK L1256F | Crizotinib | Advanced Solid Tumor | resistant | detail... |
EML4 - ALK ALK L1256F | Gilteritinib | Advanced Solid Tumor | sensitive | detail... |
EML4 - ALK ALK L1256F | Alectinib | Advanced Solid Tumor | sensitive | detail... |
EML4 - ALK ALK L1256F | Ceritinib | Advanced Solid Tumor | resistant | detail... |
EML4 - ALK ALK L1256F | Brigatinib | Advanced Solid Tumor | sensitive | detail... |
EML4 - ALK ALK L1256F | Lorlatinib | Advanced Solid Tumor | resistant | detail... |
EML4 - ALK ALK L1256F | Entrectinib | Advanced Solid Tumor | resistant | detail... |
EML4 - ALK ALK G1269A | Gilteritinib | Advanced Solid Tumor | sensitive | detail... |
EML4 - ALK ALK I1171N ALK F1174I | Crizotinib | Advanced Solid Tumor | resistant | detail... |
EML4 - ALK ALK I1171N ALK F1174I | Alectinib | Advanced Solid Tumor | resistant | detail... |
EML4 - ALK ALK I1171N ALK F1174I | Ceritinib | Advanced Solid Tumor | resistant | detail... |
EML4 - ALK ALK I1171N ALK F1174I | Brigatinib | Advanced Solid Tumor | resistant | detail... |
EML4 - ALK ALK I1171N ALK F1174I | Lorlatinib | Advanced Solid Tumor | resistant | detail... |
EML4 - ALK ALK I1171N ALK F1174I | Entrectinib | Advanced Solid Tumor | resistant | detail... |
EML4 - ALK ALK I1171N ALK F1174I | Gilteritinib | Advanced Solid Tumor | sensitive | detail... |
EML4 - ALK ALK I1171N ALK F1174L | Gilteritinib | Advanced Solid Tumor | sensitive | detail... |
EML4 - ALK ALK I1171N ALK F1174L | Brigatinib | Advanced Solid Tumor | sensitive | detail... |
EML4 - ALK ALK I1171N ALK F1174L | Entrectinib | Advanced Solid Tumor | resistant | detail... |
EML4 - ALK ALK I1171N ALK F1174L | Ceritinib | Advanced Solid Tumor | sensitive | detail... |
EML4 - ALK ALK I1171N ALK F1174L | Alectinib | Advanced Solid Tumor | resistant | detail... |
EML4 - ALK ALK I1171N ALK F1174L | Crizotinib | Advanced Solid Tumor | predicted - resistant | detail... |
EML4 - ALK ALK I1171N ALK F1174L | Lorlatinib | Advanced Solid Tumor | sensitive | detail... |
EML4 - ALK ALK I1171N ALK L1198H | Crizotinib | Advanced Solid Tumor | predicted - resistant | detail... |
EML4 - ALK ALK I1171N ALK L1198F | Crizotinib | Advanced Solid Tumor | conflicting | detail... |
EML4 - ALK ALK I1171N ALK L1198F | Alectinib | Advanced Solid Tumor | resistant | detail... |
EML4 - ALK ALK I1171N ALK L1198H | Alectinib | Advanced Solid Tumor | resistant | detail... |
EML4 - ALK ALK I1171N ALK L1198H | Ceritinib | Advanced Solid Tumor | resistant | detail... |
EML4 - ALK ALK I1171N ALK L1198F | Ceritinib | Advanced Solid Tumor | resistant | detail... |
EML4 - ALK ALK I1171N ALK L1198F | Brigatinib | Advanced Solid Tumor | resistant | detail... |
EML4 - ALK ALK I1171N ALK L1198H | Brigatinib | Advanced Solid Tumor | predicted - resistant | detail... |
EML4 - ALK ALK I1171N ALK L1198F | Entrectinib | Advanced Solid Tumor | predicted - resistant | detail... |
EML4 - ALK ALK I1171N ALK L1198H | Entrectinib | Advanced Solid Tumor | resistant | detail... |
EML4 - ALK ALK I1171N ALK L1198F | Lorlatinib | Advanced Solid Tumor | resistant | detail... |
EML4 - ALK ALK I1171N ALK L1198H | Lorlatinib | Advanced Solid Tumor | resistant | detail... |
EML4 - ALK ALK I1171N ALK L1198F | Gilteritinib | Advanced Solid Tumor | sensitive | detail... |
EML4 - ALK ALK I1171N ALK L1198H | Gilteritinib | Advanced Solid Tumor | sensitive | detail... |
EML4 - ALK ALK I1171N ALK L1196M | Gilteritinib | Advanced Solid Tumor | sensitive | detail... |
EML4 - ALK ALK I1171N ALK L1196M | Entrectinib | Advanced Solid Tumor | resistant | detail... |
EML4 - ALK ALK I1171N ALK L1196M | Lorlatinib | Advanced Solid Tumor | resistant | detail... |
EML4 - ALK ALK I1171N ALK L1196M | Brigatinib | Advanced Solid Tumor | sensitive | detail... |
EML4 - ALK ALK I1171N ALK L1196M | Ceritinib | Advanced Solid Tumor | sensitive | detail... |
EML4 - ALK ALK I1171N ALK L1196M | Alectinib | Advanced Solid Tumor | resistant | detail... |
EML4 - ALK ALK I1171N ALK L1196M | Crizotinib | Advanced Solid Tumor | resistant | detail... |
EML4 - ALK ALK I1171N ALK G1269A | Crizotinib | Advanced Solid Tumor | resistant | detail... |
EML4 - ALK ALK I1171N ALK G1269A | Alectinib | Advanced Solid Tumor | resistant | detail... |
EML4 - ALK ALK I1171N ALK G1269A | Entrectinib | Advanced Solid Tumor | resistant | detail... |
EML4 - ALK ALK I1171S ALK G1269A | Entrectinib | Advanced Solid Tumor | resistant | detail... |
EML4 - ALK ALK I1171S ALK G1269A | Gilteritinib | Advanced Solid Tumor | sensitive | detail... |
EML4 - ALK ALK I1171N ALK G1269A | Gilteritinib | Advanced Solid Tumor | sensitive | detail... |
EML4 - ALK ALK I1171N ALK G1269A | Ceritinib | Advanced Solid Tumor | sensitive | detail... |
EML4 - ALK ALK I1171N ALK G1269A | Brigatinib | Advanced Solid Tumor | sensitive | detail... |
EML4 - ALK ALK I1171N ALK L1256F | Crizotinib | Advanced Solid Tumor | resistant | detail... |
EML4 - ALK ALK I1171N ALK L1256F | Gilteritinib | Advanced Solid Tumor | sensitive | detail... |
EML4 - ALK ALK I1171N ALK L1256F | Entrectinib | Advanced Solid Tumor | resistant | detail... |
EML4 - ALK ALK I1171N ALK L1256F | Lorlatinib | Advanced Solid Tumor | resistant | detail... |
EML4 - ALK ALK I1171N ALK L1256F | Brigatinib | Advanced Solid Tumor | sensitive | detail... |
EML4 - ALK ALK I1171N ALK L1256F | Ceritinib | Advanced Solid Tumor | resistant | detail... |
EML4 - ALK ALK I1171N ALK L1256F | Alectinib | Advanced Solid Tumor | sensitive | detail... |
EML4 - ALK ALK L1196M ALK G1202R | Entrectinib | Advanced Solid Tumor | resistant | detail... |
EML4 - ALK ALK L1196M ALK G1202R | Gilteritinib | Advanced Solid Tumor | resistant | detail... |
EML4 - ALK ALK L1196M ALK G1202R | Brigatinib | Advanced Solid Tumor | resistant | detail... |
EML4 - ALK ALK L1196M ALK G1202R | Alectinib | Advanced Solid Tumor | resistant | detail... |
EML4 - ALK ALK L1196M ALK G1202R | Crizotinib | Advanced Solid Tumor | resistant | detail... |
EML4 - ALK ALK L1196M ALK G1202R | Ceritinib | Advanced Solid Tumor | resistant | detail... |
RET over exp | Cabozantinib | Advanced Solid Tumor | predicted - sensitive | detail... |
EML4 - ALK ALK L1198F ALK G1202R | Entrectinib | Advanced Solid Tumor | resistant | detail... |
EML4 - ALK ALK L1198F ALK G1202R | Gilteritinib | Advanced Solid Tumor | sensitive | detail... |
EML4 - ALK ALK L1196M ALK D1203N | Crizotinib | Advanced Solid Tumor | resistant | detail... |
EML4 - ALK ALK L1196M ALK D1203N | Brigatinib | Advanced Solid Tumor | predicted - resistant | detail... |
EML4 - ALK ALK L1196M ALK D1203N | Entrectinib | Advanced Solid Tumor | resistant | detail... |
EML4 - ALK ALK L1196M ALK D1203N | Gilteritinib | Advanced Solid Tumor | predicted - resistant | detail... |
EML4 - ALK ALK L1196M ALK D1203N | Alectinib | Advanced Solid Tumor | resistant | detail... |
EML4 - ALK ALK L1196M ALK D1203N | Ceritinib | Advanced Solid Tumor | resistant | detail... |
EML4 - ALK ALK D1203N ALK F1245V | Ceritinib | Advanced Solid Tumor | predicted - resistant | detail... |
EML4 - ALK ALK D1203N ALK F1245V | Lorlatinib | Advanced Solid Tumor | sensitive | detail... |
EML4 - ALK ALK D1203N ALK F1245V | Entrectinib | Advanced Solid Tumor | resistant | detail... |
EML4 - ALK ALK D1203N ALK F1245V | Gilteritinib | Advanced Solid Tumor | predicted - resistant | detail... |
EML4 - ALK ALK D1203N ALK F1245V | Alectinib | Advanced Solid Tumor | sensitive | detail... |
EML4 - ALK ALK D1203N ALK F1245V | Brigatinib | Advanced Solid Tumor | sensitive | detail... |
EML4 - ALK ALK D1203N ALK F1245V | Crizotinib | Advanced Solid Tumor | resistant | detail... |
PTEN mutant | Talazoparib | Advanced Solid Tumor | no benefit | detail... |
PIK3CA act mut | TAS-117 | Advanced Solid Tumor | no benefit | detail... |
PIK3CA act mut | LY3023414 + Prexasertib | Advanced Solid Tumor | predicted - sensitive | detail... |
FGFR1 mutant | ICP-192 | Advanced Solid Tumor | predicted - sensitive | detail... |
FGFR2 mutant | ICP-192 | Advanced Solid Tumor | predicted - sensitive | detail... |
FGFR3 mutant | ICP-192 | Advanced Solid Tumor | predicted - sensitive | detail... |
TP53 Y220C | PC14586 | Advanced Solid Tumor | predicted - sensitive | detail... |
BRAF mutant | Binimetinib + Encorafenib | Advanced Solid Tumor | predicted - sensitive | detail... |
MLH1 negative | Dostarlimab-gxly | Advanced Solid Tumor | sensitive | detail... |
PMS2 negative | Dostarlimab-gxly | Advanced Solid Tumor | sensitive | detail... |
MSH2 negative | Dostarlimab-gxly | Advanced Solid Tumor | sensitive | detail... |
MSH6 negative | Dostarlimab-gxly | Advanced Solid Tumor | sensitive | detail... |
NRAS act mut | Selumetinib | Advanced Solid Tumor | no benefit | detail... |
HRAS act mut | Selumetinib | Advanced Solid Tumor | no benefit | detail... |
BRAF V600E | Selumetinib | Advanced Solid Tumor | no benefit | detail... |
RET V804M RET M918T | Selpercatinib | Advanced Solid Tumor | predicted - sensitive | detail... |
RET V804M RET G810C RET M918T | Selpercatinib | Advanced Solid Tumor | resistant | detail... |
RET V804M RET G810S RET M918T | Selpercatinib | Advanced Solid Tumor | resistant | detail... |
NRAS G12X | Binimetinib | Advanced Solid Tumor | no benefit | detail... |
NRAS G13X | Binimetinib | Advanced Solid Tumor | no benefit | detail... |
NRAS Q61X | Binimetinib | Advanced Solid Tumor | unknown | detail... |
RB1 positive | Dalpiciclib | Advanced Solid Tumor | sensitive | detail... |
RB1 dec exp | Dalpiciclib | Advanced Solid Tumor | no benefit | detail... |
NRAS Q61R | Belvarafenib | Advanced Solid Tumor | sensitive | detail... |
EML4 - ALK ALK G1269S | Crizotinib | Advanced Solid Tumor | resistant | detail... |
EML4 - ALK ALK S1206R | Crizotinib | Advanced Solid Tumor | resistant | detail... |
FGFR2 N549H | E7090 | Advanced Solid Tumor | sensitive | detail... |
FGFR2 N549H | Futibatinib | Advanced Solid Tumor | sensitive | detail... |
FGFR2 N549K | AZD4547 | Advanced Solid Tumor | resistant | detail... |
FGFR2 N549K | Infigratinib | Advanced Solid Tumor | resistant | detail... |
FGFR2 N549K | Erdafitinib | Advanced Solid Tumor | resistant | detail... |
FGFR2 N549K | Pemigatinib | Advanced Solid Tumor | resistant | detail... |
FGFR2 N549K | E7090 | Advanced Solid Tumor | conflicting | detail... |
FGFR2 N549D | AZD4547 | Advanced Solid Tumor | resistant | detail... |
FGFR2 N549D | Infigratinib | Advanced Solid Tumor | resistant | detail... |
FGFR2 N549D | Erdafitinib | Advanced Solid Tumor | resistant | detail... |
FGFR2 N549D | Futibatinib | Advanced Solid Tumor | sensitive | detail... |
FGFR2 N549D | Pemigatinib | Advanced Solid Tumor | resistant | detail... |
FGFR3 K650N | Infigratinib | Advanced Solid Tumor | sensitive | detail... |
FGFR3 K650N | E7090 | Advanced Solid Tumor | sensitive | detail... |
FGFR3 K650N | Erdafitinib | Advanced Solid Tumor | sensitive | detail... |
FGFR3 K650N | Futibatinib | Advanced Solid Tumor | sensitive | detail... |
FGFR3 K650N | Pemigatinib | Advanced Solid Tumor | sensitive | detail... |
FGFR2 N549K | Dovitinib | Advanced Solid Tumor | resistant | detail... |
FGFR2 N549D | Dovitinib | Advanced Solid Tumor | resistant | detail... |
FGFR3 K650T | Dovitinib | Advanced Solid Tumor | predicted - resistant | detail... |
FGFR3 K650M | Dovitinib | Advanced Solid Tumor | resistant | detail... |
FGFR3 K650M | AZD4547 | Advanced Solid Tumor | resistant | detail... |
FGFR1 N546K | AZD4547 | Advanced Solid Tumor | predicted - resistant | detail... |
FGFR1 N546K | Infigratinib | Advanced Solid Tumor | predicted - resistant | detail... |
FGFR1 N546K | Erdafitinib | Advanced Solid Tumor | predicted - resistant | detail... |
FGFR1 N546K | Futibatinib | Advanced Solid Tumor | predicted - resistant | detail... |
FGFR1 N546K | Pemigatinib | Advanced Solid Tumor | predicted - resistant | detail... |
FGFR1 N546K | Dovitinib | Advanced Solid Tumor | predicted - resistant | detail... |
FGFR2 N549S | Infigratinib | Advanced Solid Tumor | sensitive | detail... |
FGFR2 N549S | E7090 | Advanced Solid Tumor | sensitive | detail... |
FGFR2 N549S | Erdafitinib | Advanced Solid Tumor | sensitive | detail... |
FGFR2 N549S | Futibatinib | Advanced Solid Tumor | sensitive | detail... |
FGFR2 N549S | Pemigatinib | Advanced Solid Tumor | sensitive | detail... |
FGFR2 N549S | Dovitinib | Advanced Solid Tumor | resistant | detail... |
FGFR1 K656E | Dovitinib | Advanced Solid Tumor | predicted - resistant | detail... |
FGFR1 K656E | Pemigatinib | Advanced Solid Tumor | conflicting | detail... |
FGFR1 K656E | Erdafitinib | Advanced Solid Tumor | conflicting | detail... |
FGFR1 K656E | Infigratinib | Advanced Solid Tumor | conflicting | detail... |
FGFR1 K656M | AZD4547 | Advanced Solid Tumor | predicted - resistant | detail... |
FGFR1 K656M | E7090 | Advanced Solid Tumor | predicted - resistant | detail... |
FGFR1 K656M | Dovitinib | Advanced Solid Tumor | predicted - resistant | detail... |
FGFR2 S252W | Pemigatinib | Advanced Solid Tumor | predicted - sensitive | detail... |
FGFR2 S252W | Futibatinib | Advanced Solid Tumor | predicted - sensitive | detail... |
FGFR2 S252W | Erdafitinib | Advanced Solid Tumor | predicted - sensitive | detail... |
FGFR2 S252W | E7090 | Advanced Solid Tumor | predicted - sensitive | detail... |
FGFR2 S252W | Infigratinib | Advanced Solid Tumor | predicted - sensitive | detail... |
FGFR2 S252W | AZD4547 | Advanced Solid Tumor | predicted - sensitive | detail... |
FGFR2 Y375C | AZD4547 | Advanced Solid Tumor | predicted - sensitive | detail... |
FGFR2 Y375C | Infigratinib | Advanced Solid Tumor | predicted - sensitive | detail... |
FGFR2 Y375C | E7090 | Advanced Solid Tumor | predicted - sensitive | detail... |
FGFR2 Y375C | Erdafitinib | Advanced Solid Tumor | predicted - sensitive | detail... |
FGFR2 Y375C | Futibatinib | Advanced Solid Tumor | predicted - sensitive | detail... |
FGFR2 Y375C | Pemigatinib | Advanced Solid Tumor | predicted - sensitive | detail... |
FGFR2 Y375C | Dovitinib | Advanced Solid Tumor | predicted - resistant | detail... |
FGFR2 C382R | AZD4547 | Advanced Solid Tumor | predicted - sensitive | detail... |
FGFR2 C382R | Infigratinib | Advanced Solid Tumor | predicted - sensitive | detail... |
FGFR2 C382R | Erdafitinib | Advanced Solid Tumor | predicted - sensitive | detail... |
FGFR2 C382R | Futibatinib | Advanced Solid Tumor | predicted - sensitive | detail... |
FGFR2 C382R | Pemigatinib | Advanced Solid Tumor | predicted - sensitive | detail... |
FGFR2 C382R | Dovitinib | Advanced Solid Tumor | predicted - resistant | detail... |
FGFR2 K659E | Infigratinib | Advanced Solid Tumor | predicted - sensitive | detail... |
FGFR2 K659E | Erdafitinib | Advanced Solid Tumor | predicted - sensitive | detail... |
FGFR2 K659E | Futibatinib | Advanced Solid Tumor | predicted - sensitive | detail... |
FGFR2 K659E | Dovitinib | Advanced Solid Tumor | predicted - resistant | detail... |
FGFR2 K659N | Dovitinib | Advanced Solid Tumor | predicted - resistant | detail... |
FGFR2 K659N | Pemigatinib | Advanced Solid Tumor | predicted - sensitive | detail... |
FGFR2 K659N | Futibatinib | Advanced Solid Tumor | predicted - sensitive | detail... |
FGFR2 K659N | Erdafitinib | Advanced Solid Tumor | predicted - sensitive | detail... |
FGFR2 K659N | E7090 | Advanced Solid Tumor | predicted - sensitive | detail... |
FGFR2 K659N | Infigratinib | Advanced Solid Tumor | predicted - sensitive | detail... |
FGFR2 K659N | AZD4547 | Advanced Solid Tumor | predicted - sensitive | detail... |
FGFR3 S249C | E7090 | Advanced Solid Tumor | predicted - resistant | detail... |
FGFR3 G370C | Dovitinib | Advanced Solid Tumor | predicted - resistant | detail... |
FGFR3 G370C | E7090 | Advanced Solid Tumor | predicted - resistant | detail... |
FGFR3 G370C | Infigratinib | Advanced Solid Tumor | predicted - sensitive | detail... |
FGFR3 S371C | Infigratinib | Advanced Solid Tumor | predicted - sensitive | detail... |
FGFR3 S371C | E7090 | Advanced Solid Tumor | predicted - resistant | detail... |
FGFR3 S371C | Dovitinib | Advanced Solid Tumor | predicted - resistant | detail... |
FGFR3 Y373C | Dovitinib | Advanced Solid Tumor | predicted - resistant | detail... |
FGFR3 Y373C | E7090 | Advanced Solid Tumor | predicted - resistant | detail... |
FGFR3 Y373C | Infigratinib | Advanced Solid Tumor | predicted - sensitive | detail... |
FGFR3 G380R | Infigratinib | Advanced Solid Tumor | predicted - sensitive | detail... |
FGFR3 G380R | Erdafitinib | Advanced Solid Tumor | predicted - sensitive | detail... |
FGFR3 G380R | Pemigatinib | Advanced Solid Tumor | predicted - sensitive | detail... |
FGFR3 G380R | Dovitinib | Advanced Solid Tumor | predicted - resistant | detail... |
FGFR3 A391E | Infigratinib | Advanced Solid Tumor | predicted - sensitive | detail... |
FGFR3 A391E | AZD4547 | Advanced Solid Tumor | predicted - sensitive | detail... |
FGFR3 A391E | Erdafitinib | Advanced Solid Tumor | predicted - sensitive | detail... |
FGFR3 A391E | Pemigatinib | Advanced Solid Tumor | predicted - sensitive | detail... |
FGFR3 A391E | Dovitinib | Advanced Solid Tumor | predicted - resistant | detail... |
BRAF L485_P490del | Vemurafenib | Advanced Solid Tumor | predicted - resistant | detail... |
BRAF L485_P490del | LY3009120 | Advanced Solid Tumor | predicted - sensitive | detail... |
FGFR2 V564M | Infigratinib | Advanced Solid Tumor | resistant | detail... |
MLH1 negative | Pembrolizumab | Advanced Solid Tumor | sensitive | detail... |
PMS2 negative | Pembrolizumab | Advanced Solid Tumor | sensitive | detail... |
MSH2 negative | Pembrolizumab | Advanced Solid Tumor | sensitive | detail... |
MSH6 negative | Pembrolizumab | Advanced Solid Tumor | sensitive | detail... |
FGFR1 S125L | AZD4547 | Advanced Solid Tumor | predicted - sensitive | detail... |
FGFR1 S125L | Infigratinib | Advanced Solid Tumor | predicted - sensitive | detail... |
FGFR1 S125L | E7090 | Advanced Solid Tumor | predicted - sensitive | detail... |
FGFR1 S125L | Erdafitinib | Advanced Solid Tumor | predicted - sensitive | detail... |
FGFR1 S125L | Futibatinib | Advanced Solid Tumor | predicted - sensitive | detail... |
FGFR1 S125L | Pemigatinib | Advanced Solid Tumor | predicted - sensitive | detail... |
FGFR1 S125L | Dovitinib | Advanced Solid Tumor | predicted - resistant | detail... |
FGFR1 T141R | AZD4547 | Advanced Solid Tumor | predicted - sensitive | detail... |
FGFR1 T141R | Infigratinib | Advanced Solid Tumor | predicted - sensitive | detail... |
FGFR1 T141R | E7090 | Advanced Solid Tumor | predicted - sensitive | detail... |
FGFR1 T141R | Erdafitinib | Advanced Solid Tumor | predicted - sensitive | detail... |
FGFR1 T141R | Futibatinib | Advanced Solid Tumor | predicted - sensitive | detail... |
FGFR1 T141R | Pemigatinib | Advanced Solid Tumor | predicted - sensitive | detail... |
FGFR1 P150S | Pemigatinib | Advanced Solid Tumor | predicted - sensitive | detail... |
FGFR1 P150S | E7090 | Advanced Solid Tumor | predicted - sensitive | detail... |
FGFR1 P150S | Infigratinib | Advanced Solid Tumor | predicted - sensitive | detail... |
FGFR1 P150S | AZD4547 | Advanced Solid Tumor | predicted - sensitive | detail... |
FGFR1 R250W | AZD4547 | Advanced Solid Tumor | predicted - sensitive | detail... |
FGFR1 R250W | Infigratinib | Advanced Solid Tumor | predicted - sensitive | detail... |
FGFR1 R250W | E7090 | Advanced Solid Tumor | predicted - sensitive | detail... |
FGFR1 R250W | Erdafitinib | Advanced Solid Tumor | predicted - sensitive | detail... |
FGFR1 R250W | Futibatinib | Advanced Solid Tumor | predicted - sensitive | detail... |
FGFR1 R250W | Pemigatinib | Advanced Solid Tumor | predicted - sensitive | detail... |
FGFR1 A268S | Pemigatinib | Advanced Solid Tumor | predicted - sensitive | detail... |
FGFR1 A268S | Erdafitinib | Advanced Solid Tumor | predicted - sensitive | detail... |
FGFR1 A268S | E7090 | Advanced Solid Tumor | predicted - resistant | detail... |
FGFR1 A268S | Infigratinib | Advanced Solid Tumor | predicted - sensitive | detail... |
FGFR1 A268S | AZD4547 | Advanced Solid Tumor | predicted - sensitive | detail... |
MAP2K1 L98_K104delinsQ | Trametinib | Advanced Solid Tumor | resistant | detail... |
MAP2K1 L98_K104delinsQ | MK2206 | Advanced Solid Tumor | resistant | detail... |
MAP2K1 L98_K104delinsQ | U0126 | Advanced Solid Tumor | resistant | detail... |
MAP2K1 L98_K104delinsQ | SCH772984 | Advanced Solid Tumor | resistant | detail... |
FGFR1 A21T | AZD4547 | Advanced Solid Tumor | predicted - sensitive | detail... |
FGFR1 A21T | Infigratinib | Advanced Solid Tumor | predicted - sensitive | detail... |
FGFR1 A21T | E7090 | Advanced Solid Tumor | predicted - sensitive | detail... |
FGFR1 A21T | Erdafitinib | Advanced Solid Tumor | predicted - sensitive | detail... |
FGFR1 A21T | Futibatinib | Advanced Solid Tumor | predicted - sensitive | detail... |
FGFR1 A21T | Pemigatinib | Advanced Solid Tumor | predicted - sensitive | detail... |
FGFR1 T26I | Pemigatinib | Advanced Solid Tumor | predicted - sensitive | detail... |
FGFR1 T26I | Dovitinib | Advanced Solid Tumor | predicted - sensitive | detail... |
FGFR1 T26I | Futibatinib | Advanced Solid Tumor | predicted - sensitive | detail... |
FGFR1 T26I | Erdafitinib | Advanced Solid Tumor | predicted - sensitive | detail... |
FGFR1 T26I | E7090 | Advanced Solid Tumor | predicted - sensitive | detail... |
FGFR1 T26I | Infigratinib | Advanced Solid Tumor | predicted - sensitive | detail... |
FGFR1 T26I | AZD4547 | Advanced Solid Tumor | predicted - resistant | detail... |
FGFR1 A121D | AZD4547 | Advanced Solid Tumor | predicted - sensitive | detail... |
FGFR1 A121D | Infigratinib | Advanced Solid Tumor | predicted - sensitive | detail... |
FGFR1 A121D | E7090 | Advanced Solid Tumor | predicted - sensitive | detail... |
FGFR1 A121D | Erdafitinib | Advanced Solid Tumor | predicted - sensitive | detail... |
FGFR1 A121D | Futibatinib | Advanced Solid Tumor | predicted - sensitive | detail... |
FGFR1 A121D | Pemigatinib | Advanced Solid Tumor | predicted - sensitive | detail... |
FGFR1 A121D | Dovitinib | Advanced Solid Tumor | predicted - resistant | detail... |
FGFR1 D128N | AZD4547 | Advanced Solid Tumor | predicted - sensitive | detail... |
FGFR1 D128N | Infigratinib | Advanced Solid Tumor | predicted - sensitive | detail... |
FGFR1 D128N | E7090 | Advanced Solid Tumor | predicted - sensitive | detail... |
FGFR1 D128N | Erdafitinib | Advanced Solid Tumor | predicted - sensitive | detail... |
FGFR1 D128N | Pemigatinib | Advanced Solid Tumor | predicted - sensitive | detail... |
FGFR1 D128V | Pemigatinib | Advanced Solid Tumor | predicted - sensitive | detail... |
FGFR1 D128V | Futibatinib | Advanced Solid Tumor | predicted - sensitive | detail... |
FGFR1 D128V | Erdafitinib | Advanced Solid Tumor | predicted - sensitive | detail... |
FGFR1 D128V | E7090 | Advanced Solid Tumor | predicted - sensitive | detail... |
FGFR1 D128V | Infigratinib | Advanced Solid Tumor | predicted - sensitive | detail... |
FGFR1 D128V | AZD4547 | Advanced Solid Tumor | predicted - sensitive | detail... |
FGFR1 D133N | AZD4547 | Advanced Solid Tumor | predicted - sensitive | detail... |
FGFR1 D133N | Infigratinib | Advanced Solid Tumor | predicted - sensitive | detail... |
FGFR1 D133N | E7090 | Advanced Solid Tumor | predicted - sensitive | detail... |
FGFR1 D133N | Erdafitinib | Advanced Solid Tumor | predicted - sensitive | detail... |
FGFR1 D133N | Futibatinib | Advanced Solid Tumor | predicted - sensitive | detail... |
FGFR1 D133N | Pemigatinib | Advanced Solid Tumor | predicted - sensitive | detail... |
FGFR1 R189C | AZD4547 | Advanced Solid Tumor | predicted - sensitive | detail... |
FGFR1 R189C | Infigratinib | Advanced Solid Tumor | predicted - sensitive | detail... |
FGFR1 R189C | Dovitinib | Advanced Solid Tumor | predicted - resistant | detail... |
FGFR1 S238N | Dovitinib | Advanced Solid Tumor | predicted - resistant | detail... |
FGFR1 S238N | Pemigatinib | Advanced Solid Tumor | predicted - sensitive | detail... |
FGFR1 S238N | Futibatinib | Advanced Solid Tumor | predicted - sensitive | detail... |
FGFR1 S238N | Erdafitinib | Advanced Solid Tumor | predicted - sensitive | detail... |
FGFR1 S238N | E7090 | Advanced Solid Tumor | predicted - sensitive | detail... |
FGFR1 S238N | Infigratinib | Advanced Solid Tumor | predicted - resistant | detail... |
FGFR1 S238N | AZD4547 | Advanced Solid Tumor | predicted - resistant | detail... |
FGFR1 T319A | AZD4547 | Advanced Solid Tumor | predicted - sensitive | detail... |
FGFR1 T319A | Infigratinib | Advanced Solid Tumor | predicted - sensitive | detail... |
FGFR1 T319A | E7090 | Advanced Solid Tumor | predicted - resistant | detail... |
FGFR1 T319A | Erdafitinib | Advanced Solid Tumor | predicted - sensitive | detail... |
FGFR1 T319A | Pemigatinib | Advanced Solid Tumor | predicted - sensitive | detail... |
FGFR1 T319A | Dovitinib | Advanced Solid Tumor | predicted - resistant | detail... |
FGFR1 D320N | AZD4547 | Advanced Solid Tumor | predicted - sensitive | detail... |
FGFR1 D320N | Infigratinib | Advanced Solid Tumor | predicted - sensitive | detail... |
FGFR1 D320N | E7090 | Advanced Solid Tumor | predicted - sensitive | detail... |
FGFR1 D320N | Erdafitinib | Advanced Solid Tumor | predicted - sensitive | detail... |
FGFR1 D320N | Futibatinib | Advanced Solid Tumor | predicted - sensitive | detail... |
FGFR1 D320N | Pemigatinib | Advanced Solid Tumor | predicted - sensitive | detail... |
FGFR1 T340M | Pemigatinib | Advanced Solid Tumor | predicted - sensitive | detail... |
FGFR1 T340M | Futibatinib | Advanced Solid Tumor | predicted - sensitive | detail... |
FGFR1 T340M | Erdafitinib | Advanced Solid Tumor | predicted - sensitive | detail... |
FGFR1 T340M | E7090 | Advanced Solid Tumor | predicted - sensitive | detail... |
FGFR1 T340M | Infigratinib | Advanced Solid Tumor | predicted - sensitive | detail... |
FGFR1 T340M | AZD4547 | Advanced Solid Tumor | predicted - sensitive | detail... |
FGFR1 S436F | AZD4547 | Advanced Solid Tumor | predicted - sensitive | detail... |
FGFR1 S436F | Infigratinib | Advanced Solid Tumor | predicted - sensitive | detail... |
FGFR1 S436F | E7090 | Advanced Solid Tumor | predicted - resistant | detail... |
FGFR1 S436F | Erdafitinib | Advanced Solid Tumor | predicted - sensitive | detail... |
FGFR1 S436F | Futibatinib | Advanced Solid Tumor | predicted - sensitive | detail... |
FGFR1 S436F | Pemigatinib | Advanced Solid Tumor | predicted - sensitive | detail... |
PIK3CA act mut | Docetaxel + Ipatasertib | Advanced Solid Tumor | predicted - sensitive | detail... |
PIK3CA act mut | Fluorouracil + Ipatasertib + Leucovorin + Oxaliplatin | Advanced Solid Tumor | predicted - sensitive | detail... |
FGFR1 R445W | AZD4547 | Advanced Solid Tumor | predicted - sensitive | detail... |
FGFR1 R445W | Infigratinib | Advanced Solid Tumor | predicted - sensitive | detail... |
FGFR1 R445W | E7090 | Advanced Solid Tumor | predicted - sensitive | detail... |
FGFR1 R445W | Erdafitinib | Advanced Solid Tumor | predicted - sensitive | detail... |
FGFR1 R445W | Pemigatinib | Advanced Solid Tumor | predicted - sensitive | detail... |
FGFR1 M456V | Dovitinib | Advanced Solid Tumor | predicted - resistant | detail... |
FGFR1 M456V | Pemigatinib | Advanced Solid Tumor | predicted - sensitive | detail... |
FGFR1 M456V | Futibatinib | Advanced Solid Tumor | predicted - sensitive | detail... |
FGFR1 M456V | Erdafitinib | Advanced Solid Tumor | predicted - sensitive | detail... |
FGFR1 M456V | E7090 | Advanced Solid Tumor | predicted - sensitive | detail... |
FGFR1 M456V | Infigratinib | Advanced Solid Tumor | predicted - sensitive | detail... |
FGFR1 M456V | AZD4547 | Advanced Solid Tumor | predicted - sensitive | detail... |
FGFR1 E467K | AZD4547 | Advanced Solid Tumor | predicted - sensitive | detail... |
FGFR1 E467K | Infigratinib | Advanced Solid Tumor | predicted - sensitive | detail... |
FGFR1 E467K | E7090 | Advanced Solid Tumor | predicted - sensitive | detail... |
FGFR1 E467K | Erdafitinib | Advanced Solid Tumor | predicted - sensitive | detail... |
FGFR1 E467K | Futibatinib | Advanced Solid Tumor | predicted - sensitive | detail... |
FGFR1 E467K | Pemigatinib | Advanced Solid Tumor | predicted - sensitive | detail... |
MDM2 amp TP53 wild-type | ALRN-6924 | Advanced Solid Tumor | predicted - sensitive | detail... |
FGFR1 G703S | Pemigatinib | Advanced Solid Tumor | predicted - sensitive | detail... |
FGFR1 G703S | Erdafitinib | Advanced Solid Tumor | predicted - sensitive | detail... |
FGFR1 G703S | E7090 | Advanced Solid Tumor | predicted - sensitive | detail... |
FGFR1 G703S | Infigratinib | Advanced Solid Tumor | predicted - sensitive | detail... |
FGFR1 G703S | AZD4547 | Advanced Solid Tumor | predicted - sensitive | detail... |
FGFR1 E592G | AZD4547 | Advanced Solid Tumor | predicted - sensitive | detail... |
FGFR1 E592G | Infigratinib | Advanced Solid Tumor | predicted - sensitive | detail... |
FGFR1 E592G | E7090 | Advanced Solid Tumor | predicted - sensitive | detail... |
FGFR1 E592G | Erdafitinib | Advanced Solid Tumor | predicted - sensitive | detail... |
FGFR1 E592G | Pemigatinib | Advanced Solid Tumor | predicted - sensitive | detail... |
FGFR1 S588T | Pemigatinib | Advanced Solid Tumor | predicted - sensitive | detail... |
FGFR1 S588T | Futibatinib | Advanced Solid Tumor | predicted - sensitive | detail... |
FGFR1 S588T | Erdafitinib | Advanced Solid Tumor | predicted - sensitive | detail... |
FGFR1 S588T | E7090 | Advanced Solid Tumor | predicted - sensitive | detail... |
FGFR1 S588T | AZD4547 | Advanced Solid Tumor | predicted - sensitive | detail... |
FGFR1 R475Q | AZD4547 | Advanced Solid Tumor | predicted - sensitive | detail... |
FGFR1 R475Q | Infigratinib | Advanced Solid Tumor | predicted - sensitive | detail... |
FGFR1 R475Q | Futibatinib | Advanced Solid Tumor | predicted - sensitive | detail... |
FGFR1 R475Q | Pemigatinib | Advanced Solid Tumor | predicted - sensitive | detail... |
FGFR1 P483L | AZD4547 | Advanced Solid Tumor | predicted - sensitive | detail... |
FGFR1 P483L | Infigratinib | Advanced Solid Tumor | predicted - sensitive | detail... |
FGFR1 P483L | E7090 | Advanced Solid Tumor | predicted - sensitive | detail... |
FGFR1 P483L | Erdafitinib | Advanced Solid Tumor | predicted - sensitive | detail... |
FGFR1 P483L | Futibatinib | Advanced Solid Tumor | predicted - resistant | detail... |
FGFR1 P483L | Pemigatinib | Advanced Solid Tumor | predicted - sensitive | detail... |
RET M918T | LOX-18228 | Advanced Solid Tumor | predicted - sensitive | detail... |
EML4 - ALK ALK L1196M ALK G1202R | NUV-655 | Advanced Solid Tumor | sensitive | detail... |
EML4 - ALK | NUV-655 | Advanced Solid Tumor | predicted - sensitive | detail... |
EML4 - ALK ALK G1202R | NUV-655 | Advanced Solid Tumor | predicted - sensitive | detail... |
EML4 - ALK ALK G1202R ALK G1269A | NUV-655 | Advanced Solid Tumor | predicted - sensitive | detail... |
FGFR1 V751A | AZD4547 | Advanced Solid Tumor | predicted - sensitive | detail... |
FGFR1 V751A | Infigratinib | Advanced Solid Tumor | predicted - sensitive | detail... |
FGFR1 V751A | E7090 | Advanced Solid Tumor | predicted - sensitive | detail... |
FGFR1 V751A | Erdafitinib | Advanced Solid Tumor | predicted - sensitive | detail... |
FGFR1 V751A | Futibatinib | Advanced Solid Tumor | predicted - sensitive | detail... |
FGFR1 V751A | Pemigatinib | Advanced Solid Tumor | predicted - sensitive | detail... |
FGFR1 R809Q | Pemigatinib | Advanced Solid Tumor | predicted - sensitive | detail... |
FGFR1 R809Q | Futibatinib | Advanced Solid Tumor | predicted - sensitive | detail... |
FGFR1 R809Q | Erdafitinib | Advanced Solid Tumor | predicted - sensitive | detail... |
FGFR1 R809Q | E7090 | Advanced Solid Tumor | predicted - sensitive | detail... |
FGFR1 R809Q | Infigratinib | Advanced Solid Tumor | predicted - sensitive | detail... |
FGFR1 R809Q | AZD4547 | Advanced Solid Tumor | predicted - sensitive | detail... |
FGFR2 R6P | AZD4547 | Advanced Solid Tumor | predicted - sensitive | detail... |
FGFR2 R6P | Infigratinib | Advanced Solid Tumor | predicted - sensitive | detail... |
FGFR2 R6P | E7090 | Advanced Solid Tumor | predicted - sensitive | detail... |
FGFR2 R6P | Erdafitinib | Advanced Solid Tumor | predicted - sensitive | detail... |
FGFR2 R6P | Futibatinib | Advanced Solid Tumor | predicted - sensitive | detail... |
FGFR2 R6P | Pemigatinib | Advanced Solid Tumor | predicted - sensitive | detail... |
FGFR2 R6P | Dovitinib | Advanced Solid Tumor | predicted - resistant | detail... |
FGFR2 L33S | Dovitinib | Advanced Solid Tumor | predicted - resistant | detail... |
FGFR2 L33S | Pemigatinib | Advanced Solid Tumor | predicted - sensitive | detail... |
MAP2K1 I111A | CI-1040 | Advanced Solid Tumor | decreased response | detail... |
MAP2K1 I111D | CI-1040 | Advanced Solid Tumor | predicted - resistant | detail... |
MAP2K1 I111P | CI-1040 | Advanced Solid Tumor | predicted - resistant | detail... |
MAP2K1 I111R | CI-1040 | Advanced Solid Tumor | predicted - resistant | detail... |
MAP2K1 I139G | CI-1040 | Advanced Solid Tumor | predicted - resistant | detail... |
MAP2K1 I139R | CI-1040 | Advanced Solid Tumor | decreased response | detail... |
MAP2K1 I139N | CI-1040 | Advanced Solid Tumor | decreased response | detail... |
MAP2K1 L118G | CI-1040 | Advanced Solid Tumor | decreased response | detail... |
MAP2K1 L118Q | CI-1040 | Advanced Solid Tumor | predicted - resistant | detail... |
MAP2K1 L118P | CI-1040 | Advanced Solid Tumor | predicted - resistant | detail... |
MAP2K1 L118D | CI-1040 | Advanced Solid Tumor | predicted - resistant | detail... |
FGFR2 L33S | AZD4547 | Advanced Solid Tumor | predicted - sensitive | detail... |
FGFR2 L33S | Infigratinib | Advanced Solid Tumor | predicted - sensitive | detail... |
FGFR2 L33S | E7090 | Advanced Solid Tumor | predicted - sensitive | detail... |
FGFR2 L33S | Erdafitinib | Advanced Solid Tumor | predicted - sensitive | detail... |
FGFR2 L33S | Futibatinib | Advanced Solid Tumor | predicted - sensitive | detail... |
FGFR2 C62Y | AZD4547 | Advanced Solid Tumor | predicted - sensitive | detail... |
FGFR2 C62Y | Infigratinib | Advanced Solid Tumor | predicted - sensitive | detail... |
FGFR2 C62Y | E7090 | Advanced Solid Tumor | predicted - sensitive | detail... |
FGFR2 C62Y | Erdafitinib | Advanced Solid Tumor | predicted - sensitive | detail... |
FGFR2 C62Y | Futibatinib | Advanced Solid Tumor | predicted - sensitive | detail... |
FGFR2 C62Y | Pemigatinib | Advanced Solid Tumor | predicted - sensitive | detail... |
FGFR2 C62Y | Dovitinib | Advanced Solid Tumor | predicted - resistant | detail... |
FGFR2 A67V | AZD4547 | Advanced Solid Tumor | predicted - sensitive | detail... |
FGFR2 A67V | Infigratinib | Advanced Solid Tumor | predicted - sensitive | detail... |
FGFR2 A67V | E7090 | Advanced Solid Tumor | predicted - sensitive | detail... |
FGFR2 A67V | Erdafitinib | Advanced Solid Tumor | predicted - sensitive | detail... |
FGFR2 A67V | Futibatinib | Advanced Solid Tumor | predicted - sensitive | detail... |
FGFR2 A67V | Pemigatinib | Advanced Solid Tumor | predicted - sensitive | detail... |
FGFR2 N82K | AZD4547 | Advanced Solid Tumor | predicted - sensitive | detail... |
FGFR2 N82K | Infigratinib | Advanced Solid Tumor | predicted - sensitive | detail... |
FGFR2 N82K | E7090 | Advanced Solid Tumor | predicted - sensitive | detail... |
FGFR2 N82K | Erdafitinib | Advanced Solid Tumor | predicted - sensitive | detail... |
FGFR2 N82K | Futibatinib | Advanced Solid Tumor | predicted - sensitive | detail... |
FGFR2 N82K | Pemigatinib | Advanced Solid Tumor | predicted - sensitive | detail... |
FGFR2 D101Y | Pemigatinib | Advanced Solid Tumor | predicted - sensitive | detail... |
FGFR2 D101Y | Futibatinib | Advanced Solid Tumor | predicted - sensitive | detail... |
FGFR2 D101Y | Erdafitinib | Advanced Solid Tumor | predicted - sensitive | detail... |
FGFR2 D101Y | E7090 | Advanced Solid Tumor | predicted - sensitive | detail... |
FGFR2 D101Y | Infigratinib | Advanced Solid Tumor | predicted - sensitive | detail... |
FGFR2 D101Y | AZD4547 | Advanced Solid Tumor | predicted - sensitive | detail... |
FGFR2 D101Y | Dovitinib | Advanced Solid Tumor | predicted - resistant | detail... |
FGFR2 E160K | Dovitinib | Advanced Solid Tumor | predicted - resistant | detail... |
FGFR2 E160K | Pemigatinib | Advanced Solid Tumor | predicted - sensitive | detail... |
FGFR2 E160K | Futibatinib | Advanced Solid Tumor | predicted - sensitive | detail... |
FGFR2 E160K | Erdafitinib | Advanced Solid Tumor | predicted - sensitive | detail... |
FGFR2 E160K | E7090 | Advanced Solid Tumor | predicted - sensitive | detail... |
FGFR2 E160K | Infigratinib | Advanced Solid Tumor | predicted - sensitive | detail... |
FGFR2 E160K | AZD4547 | Advanced Solid Tumor | predicted - sensitive | detail... |
FGFR2 E163K | AZD4547 | Advanced Solid Tumor | predicted - sensitive | detail... |
FGFR2 E163K | Infigratinib | Advanced Solid Tumor | predicted - sensitive | detail... |
FGFR2 E163K | E7090 | Advanced Solid Tumor | predicted - sensitive | detail... |
FGFR2 E163K | Erdafitinib | Advanced Solid Tumor | predicted - sensitive | detail... |
FGFR2 E163K | Futibatinib | Advanced Solid Tumor | predicted - sensitive | detail... |
FGFR2 E163K | Pemigatinib | Advanced Solid Tumor | predicted - sensitive | detail... |
FGFR2 E163K | Dovitinib | Advanced Solid Tumor | predicted - resistant | detail... |
FGFR2 M186T | AZD4547 | Advanced Solid Tumor | predicted - sensitive | detail... |
FGFR2 M186T | Infigratinib | Advanced Solid Tumor | predicted - sensitive | detail... |
FGFR2 M186T | E7090 | Advanced Solid Tumor | predicted - sensitive | detail... |
FGFR2 M186T | Erdafitinib | Advanced Solid Tumor | predicted - sensitive | detail... |
FGFR2 M186T | Futibatinib | Advanced Solid Tumor | predicted - sensitive | detail... |
FGFR2 M186T | Pemigatinib | Advanced Solid Tumor | predicted - sensitive | detail... |
FGFR2 M186T | Dovitinib | Advanced Solid Tumor | predicted - resistant | detail... |
FGFR2 R203C | Dovitinib | Advanced Solid Tumor | predicted - resistant | detail... |
FGFR2 R203C | Pemigatinib | Advanced Solid Tumor | predicted - sensitive | detail... |
FGFR2 R203C | Futibatinib | Advanced Solid Tumor | predicted - sensitive | detail... |
FGFR2 R203C | Erdafitinib | Advanced Solid Tumor | predicted - sensitive | detail... |
FGFR2 R203C | E7090 | Advanced Solid Tumor | predicted - sensitive | detail... |
FGFR2 R203C | Infigratinib | Advanced Solid Tumor | predicted - sensitive | detail... |
FGFR2 R203C | AZD4547 | Advanced Solid Tumor | predicted - sensitive | detail... |
FGFR2 R203H | AZD4547 | Advanced Solid Tumor | predicted - sensitive | detail... |
FGFR2 R203H | Infigratinib | Advanced Solid Tumor | predicted - sensitive | detail... |
FGFR2 R203H | E7090 | Advanced Solid Tumor | predicted - sensitive | detail... |
FGFR2 R203H | Erdafitinib | Advanced Solid Tumor | predicted - sensitive | detail... |
FGFR2 R203H | Futibatinib | Advanced Solid Tumor | predicted - sensitive | detail... |
FGFR2 R203H | Pemigatinib | Advanced Solid Tumor | predicted - sensitive | detail... |
FGFR2 R210Q | Pemigatinib | Advanced Solid Tumor | predicted - sensitive | detail... |
FGFR2 R210Q | Futibatinib | Advanced Solid Tumor | predicted - sensitive | detail... |
FGFR2 R210Q | Erdafitinib | Advanced Solid Tumor | predicted - sensitive | detail... |
FGFR2 R210Q | E7090 | Advanced Solid Tumor | predicted - sensitive | detail... |
FGFR2 R210Q | Infigratinib | Advanced Solid Tumor | predicted - sensitive | detail... |
FGFR2 R210Q | AZD4547 | Advanced Solid Tumor | predicted - sensitive | detail... |
FGFR2 Q212K | AZD4547 | Advanced Solid Tumor | predicted - sensitive | detail... |
FGFR2 Q212K | Infigratinib | Advanced Solid Tumor | predicted - sensitive | detail... |
FGFR2 Q212K | E7090 | Advanced Solid Tumor | predicted - sensitive | detail... |
FGFR2 Q212K | Erdafitinib | Advanced Solid Tumor | predicted - sensitive | detail... |
FGFR2 Q212K | Futibatinib | Advanced Solid Tumor | predicted - sensitive | detail... |
FGFR2 Q212K | Pemigatinib | Advanced Solid Tumor | predicted - sensitive | detail... |
FGFR2 Q212K | Dovitinib | Advanced Solid Tumor | predicted - resistant | detail... |
FGFR2 G227E | AZD4547 | Advanced Solid Tumor | predicted - sensitive | detail... |
FGFR2 G227E | Infigratinib | Advanced Solid Tumor | predicted - sensitive | detail... |
FGFR2 G227E | E7090 | Advanced Solid Tumor | predicted - sensitive | detail... |
FGFR2 G227E | Erdafitinib | Advanced Solid Tumor | predicted - sensitive | detail... |
FGFR2 G227E | Futibatinib | Advanced Solid Tumor | predicted - sensitive | detail... |
FGFR2 G227E | Pemigatinib | Advanced Solid Tumor | predicted - sensitive | detail... |
FGFR2 G227E | Dovitinib | Advanced Solid Tumor | predicted - resistant | detail... |
FGFR2 H242Y | AZD4547 | Advanced Solid Tumor | predicted - sensitive | detail... |
FGFR2 H242Y | Infigratinib | Advanced Solid Tumor | predicted - sensitive | detail... |
FGFR2 H242Y | E7090 | Advanced Solid Tumor | predicted - sensitive | detail... |
FGFR2 H242Y | Erdafitinib | Advanced Solid Tumor | predicted - sensitive | detail... |
FGFR2 H242Y | Futibatinib | Advanced Solid Tumor | predicted - sensitive | detail... |
FGFR2 H242Y | Pemigatinib | Advanced Solid Tumor | predicted - sensitive | detail... |
FGFR2 R251Q | Pemigatinib | Advanced Solid Tumor | predicted - sensitive | detail... |
FGFR2 R251Q | Futibatinib | Advanced Solid Tumor | predicted - sensitive | detail... |
FGFR2 R251Q | Erdafitinib | Advanced Solid Tumor | predicted - sensitive | detail... |
FGFR2 R251Q | E7090 | Advanced Solid Tumor | predicted - sensitive | detail... |
FGFR2 R251Q | Infigratinib | Advanced Solid Tumor | predicted - sensitive | detail... |
FGFR2 R251Q | AZD4547 | Advanced Solid Tumor | predicted - sensitive | detail... |
ALK positive | Ceritinib | Advanced Solid Tumor | predicted - sensitive | detail... |
FGFR2 G305R | Dovitinib | Advanced Solid Tumor | predicted - resistant | detail... |
FGFR2 G305R | Pemigatinib | Advanced Solid Tumor | predicted - sensitive | detail... |
FGFR2 G305R | Futibatinib | Advanced Solid Tumor | predicted - sensitive | detail... |
FGFR2 G305R | Erdafitinib | Advanced Solid Tumor | predicted - sensitive | detail... |
FGFR2 G305R | E7090 | Advanced Solid Tumor | predicted - sensitive | detail... |
FGFR2 G305R | Infigratinib | Advanced Solid Tumor | predicted - sensitive | detail... |
FGFR2 G305R | AZD4547 | Advanced Solid Tumor | predicted - sensitive | detail... |
FGFR2 P303L | AZD4547 | Advanced Solid Tumor | predicted - sensitive | detail... |
FGFR2 P303L | Infigratinib | Advanced Solid Tumor | predicted - sensitive | detail... |
FGFR2 P303L | E7090 | Advanced Solid Tumor | predicted - sensitive | detail... |
FGFR2 P303L | Erdafitinib | Advanced Solid Tumor | predicted - sensitive | detail... |
FGFR2 P303L | Futibatinib | Advanced Solid Tumor | predicted - sensitive | detail... |
FGFR2 P303L | Pemigatinib | Advanced Solid Tumor | predicted - sensitive | detail... |
FGFR2 P303L | Dovitinib | Advanced Solid Tumor | predicted - resistant | detail... |
FGFR2 P253L | Dovitinib | Advanced Solid Tumor | predicted - resistant | detail... |
FGFR2 P253L | Pemigatinib | Advanced Solid Tumor | predicted - sensitive | detail... |
FGFR2 P253L | Futibatinib | Advanced Solid Tumor | predicted - sensitive | detail... |
FGFR2 P253L | Erdafitinib | Advanced Solid Tumor | predicted - sensitive | detail... |
FGFR2 P253L | E7090 | Advanced Solid Tumor | predicted - sensitive | detail... |
FGFR2 P253L | Infigratinib | Advanced Solid Tumor | predicted - sensitive | detail... |
FGFR2 P253L | AZD4547 | Advanced Solid Tumor | predicted - sensitive | detail... |
FGFR2 P253R | AZD4547 | Advanced Solid Tumor | predicted - sensitive | detail... |
FGFR2 P253R | Infigratinib | Advanced Solid Tumor | predicted - sensitive | detail... |
FGFR2 P253R | E7090 | Advanced Solid Tumor | predicted - sensitive | detail... |
FGFR2 P253R | Erdafitinib | Advanced Solid Tumor | predicted - sensitive | detail... |
FGFR2 P253R | Futibatinib | Advanced Solid Tumor | predicted - sensitive | detail... |
FGFR2 P253R | Pemigatinib | Advanced Solid Tumor | predicted - sensitive | detail... |
FGFR2 P253R | Dovitinib | Advanced Solid Tumor | predicted - resistant | detail... |
FGFR2 A264T | Dovitinib | Advanced Solid Tumor | predicted - resistant | detail... |
FGFR2 A264T | Pemigatinib | Advanced Solid Tumor | predicted - sensitive | detail... |
FGFR2 A264T | Futibatinib | Advanced Solid Tumor | predicted - sensitive | detail... |
FGFR2 A264T | Erdafitinib | Advanced Solid Tumor | predicted - sensitive | detail... |
FGFR2 A264T | E7090 | Advanced Solid Tumor | predicted - sensitive | detail... |
FGFR2 A264T | Infigratinib | Advanced Solid Tumor | predicted - sensitive | detail... |
FGFR2 A264T | AZD4547 | Advanced Solid Tumor | predicted - sensitive | detail... |
FGFR2 W290C | E7090 | Advanced Solid Tumor | predicted - sensitive | detail... |
FGFR2 W290C | Erdafitinib | Advanced Solid Tumor | predicted - sensitive | detail... |
FGFR2 W290C | Futibatinib | Advanced Solid Tumor | predicted - sensitive | detail... |
FGFR2 W290C | Pemigatinib | Advanced Solid Tumor | predicted - sensitive | detail... |
FGFR2 W290C | Dovitinib | Advanced Solid Tumor | predicted - resistant | detail... |
FGFR2 K310R | AZD4547 | Advanced Solid Tumor | predicted - sensitive | detail... |
FGFR2 K310R | Infigratinib | Advanced Solid Tumor | predicted - sensitive | detail... |
FGFR2 K310R | E7090 | Advanced Solid Tumor | predicted - sensitive | detail... |
FGFR2 K310R | Erdafitinib | Advanced Solid Tumor | predicted - sensitive | detail... |
FGFR2 K310R | Futibatinib | Advanced Solid Tumor | predicted - sensitive | detail... |
FGFR2 K310R | Pemigatinib | Advanced Solid Tumor | predicted - sensitive | detail... |
FGFR2 K310R | Dovitinib | Advanced Solid Tumor | predicted - resistant | detail... |
FGFR2 Y328N | Dovitinib | Advanced Solid Tumor | predicted - resistant | detail... |
FGFR2 Y328N | Pemigatinib | Advanced Solid Tumor | predicted - sensitive | detail... |
FGFR2 Y328N | Futibatinib | Advanced Solid Tumor | predicted - sensitive | detail... |
FGFR2 Y328N | Erdafitinib | Advanced Solid Tumor | predicted - sensitive | detail... |
FGFR2 Y328N | E7090 | Advanced Solid Tumor | predicted - sensitive | detail... |
FGFR2 Y328N | Infigratinib | Advanced Solid Tumor | predicted - sensitive | detail... |
FGFR2 Y328N | AZD4547 | Advanced Solid Tumor | predicted - sensitive | detail... |
FGFR2 R330W | AZD4547 | Advanced Solid Tumor | predicted - sensitive | detail... |
FGFR2 R330W | Infigratinib | Advanced Solid Tumor | predicted - sensitive | detail... |
FGFR2 R330W | E7090 | Advanced Solid Tumor | predicted - sensitive | detail... |
FGFR2 R330W | Erdafitinib | Advanced Solid Tumor | predicted - sensitive | detail... |
FGFR2 R330W | Futibatinib | Advanced Solid Tumor | predicted - sensitive | detail... |
FGFR2 R330W | Pemigatinib | Advanced Solid Tumor | predicted - sensitive | detail... |
FGFR2 R330W | Dovitinib | Advanced Solid Tumor | predicted - resistant | detail... |
FGFR2 G364E | AZD4547 | Advanced Solid Tumor | predicted - sensitive | detail... |
FGFR2 G364E | Infigratinib | Advanced Solid Tumor | predicted - sensitive | detail... |
FGFR2 G364E | E7090 | Advanced Solid Tumor | predicted - sensitive | detail... |
FGFR2 G364E | Erdafitinib | Advanced Solid Tumor | predicted - sensitive | detail... |
FGFR2 G364E | Futibatinib | Advanced Solid Tumor | predicted - sensitive | detail... |
FGFR2 G364E | Pemigatinib | Advanced Solid Tumor | predicted - sensitive | detail... |
FGFR2 A371V | Pemigatinib | Advanced Solid Tumor | predicted - sensitive | detail... |
FGFR2 A371V | Futibatinib | Advanced Solid Tumor | predicted - sensitive | detail... |
FGFR2 A371V | Erdafitinib | Advanced Solid Tumor | predicted - sensitive | detail... |
FGFR2 A371V | E7090 | Advanced Solid Tumor | predicted - sensitive | detail... |
FGFR2 A371V | Infigratinib | Advanced Solid Tumor | predicted - sensitive | detail... |
FGFR2 A371V | AZD4547 | Advanced Solid Tumor | predicted - sensitive | detail... |
FGFR2 A389T | AZD4547 | Advanced Solid Tumor | predicted - sensitive | detail... |
FGFR2 A389T | Infigratinib | Advanced Solid Tumor | predicted - sensitive | detail... |
FGFR2 A389T | E7090 | Advanced Solid Tumor | predicted - sensitive | detail... |
FGFR2 A389T | Erdafitinib | Advanced Solid Tumor | predicted - sensitive | detail... |
FGFR2 A389T | Futibatinib | Advanced Solid Tumor | predicted - sensitive | detail... |
FGFR2 A389T | Pemigatinib | Advanced Solid Tumor | predicted - sensitive | detail... |
FGFR2 V392A | Pemigatinib | Advanced Solid Tumor | predicted - sensitive | detail... |
FGFR2 V392A | Futibatinib | Advanced Solid Tumor | predicted - sensitive | detail... |
FGFR2 V392A | Erdafitinib | Advanced Solid Tumor | predicted - sensitive | detail... |
FGFR2 V392A | E7090 | Advanced Solid Tumor | predicted - sensitive | detail... |
FGFR2 V392A | Infigratinib | Advanced Solid Tumor | predicted - sensitive | detail... |
FGFR2 V392A | AZD4547 | Advanced Solid Tumor | predicted - sensitive | detail... |
FGFR2 R399Q | AZD4547 | Advanced Solid Tumor | predicted - sensitive | detail... |
FGFR2 R399Q | Infigratinib | Advanced Solid Tumor | predicted - sensitive | detail... |
FGFR2 R399Q | E7090 | Advanced Solid Tumor | predicted - sensitive | detail... |
FGFR2 R399Q | Erdafitinib | Advanced Solid Tumor | predicted - sensitive | detail... |
FGFR2 R399Q | Futibatinib | Advanced Solid Tumor | predicted - sensitive | detail... |
FGFR2 R399Q | Pemigatinib | Advanced Solid Tumor | predicted - sensitive | detail... |
FGFR2 H416R | Pemigatinib | Advanced Solid Tumor | predicted - sensitive | detail... |
FGFR2 H416R | Futibatinib | Advanced Solid Tumor | predicted - sensitive | detail... |
FGFR2 H416R | Erdafitinib | Advanced Solid Tumor | predicted - sensitive | detail... |
FGFR2 H416R | E7090 | Advanced Solid Tumor | predicted - sensitive | detail... |
FGFR2 H416R | Infigratinib | Advanced Solid Tumor | predicted - sensitive | detail... |
FGFR2 H416R | AZD4547 | Advanced Solid Tumor | predicted - sensitive | detail... |
BRAF N486_P490del BRAF R509H | Vemurafenib | Advanced Solid Tumor | resistant | detail... |
BRAF N486_P490del BRAF R509H BRAF V600E | Vemurafenib | Advanced Solid Tumor | resistant | detail... |
BRAF N486_P490del BRAF R509H BRAF V600E | GDC0879 | Advanced Solid Tumor | sensitive | detail... |
BRAF N486_P490del BRAF R509H | GDC0879 | Advanced Solid Tumor | sensitive | detail... |
BRAF R509H BRAF V600E | GDC0879 | Advanced Solid Tumor | sensitive | detail... |
BRAF R509H BRAF V600E | Vemurafenib | Advanced Solid Tumor | sensitive | detail... |
FGFR2 I422V | AZD4547 | Advanced Solid Tumor | predicted - sensitive | detail... |
FGFR2 I422V | Infigratinib | Advanced Solid Tumor | predicted - sensitive | detail... |
FGFR2 I422V | E7090 | Advanced Solid Tumor | predicted - sensitive | detail... |
FGFR2 I422V | Erdafitinib | Advanced Solid Tumor | predicted - sensitive | detail... |
FGFR2 I422V | Futibatinib | Advanced Solid Tumor | predicted - sensitive | detail... |
FGFR2 I422V | Pemigatinib | Advanced Solid Tumor | predicted - sensitive | detail... |
FGFR2 I422V | Dovitinib | Advanced Solid Tumor | predicted - sensitive | detail... |
FGFR2 E475K | AZD4547 | Advanced Solid Tumor | predicted - sensitive | detail... |
FGFR2 E475K | Infigratinib | Advanced Solid Tumor | predicted - sensitive | detail... |
FGFR2 E475K | E7090 | Advanced Solid Tumor | predicted - sensitive | detail... |
FGFR2 E475K | Erdafitinib | Advanced Solid Tumor | predicted - sensitive | detail... |
FGFR2 E475K | Futibatinib | Advanced Solid Tumor | predicted - sensitive | detail... |
FGFR2 E475K | Pemigatinib | Advanced Solid Tumor | predicted - sensitive | detail... |
FGFR2 H544Q | Pemigatinib | Advanced Solid Tumor | predicted - sensitive | detail... |
FGFR2 H544Q | Futibatinib | Advanced Solid Tumor | predicted - sensitive | detail... |
FGFR2 H544Q | Erdafitinib | Advanced Solid Tumor | predicted - sensitive | detail... |
FGFR2 H544Q | E7090 | Advanced Solid Tumor | predicted - sensitive | detail... |
FGFR2 H544Q | Infigratinib | Advanced Solid Tumor | predicted - sensitive | detail... |
FGFR2 H544Q | AZD4547 | Advanced Solid Tumor | predicted - sensitive | detail... |
FGFR2 L560F | AZD4547 | Advanced Solid Tumor | predicted - sensitive | detail... |
FGFR2 L560F | Infigratinib | Advanced Solid Tumor | predicted - sensitive | detail... |
FGFR2 L560F | E7090 | Advanced Solid Tumor | predicted - sensitive | detail... |
FGFR2 L560F | Erdafitinib | Advanced Solid Tumor | predicted - sensitive | detail... |
FGFR2 L560F | Futibatinib | Advanced Solid Tumor | predicted - sensitive | detail... |
FGFR2 L560F | Pemigatinib | Advanced Solid Tumor | predicted - sensitive | detail... |
FGFR2 H544Q | Dovitinib | Advanced Solid Tumor | predicted - resistant | detail... |
FGFR2 P582L | AZD4547 | Advanced Solid Tumor | predicted - sensitive | detail... |
FGFR2 P582L | Infigratinib | Advanced Solid Tumor | predicted - sensitive | detail... |
FGFR2 P582L | E7090 | Advanced Solid Tumor | predicted - sensitive | detail... |
FGFR2 P582L | Erdafitinib | Advanced Solid Tumor | predicted - sensitive | detail... |
FGFR2 P582L | Futibatinib | Advanced Solid Tumor | predicted - sensitive | detail... |
FGFR2 P582L | Pemigatinib | Advanced Solid Tumor | predicted - sensitive | detail... |
FGFR2 E596K | Pemigatinib | Advanced Solid Tumor | predicted - sensitive | detail... |
FGFR2 E596K | Futibatinib | Advanced Solid Tumor | predicted - sensitive | detail... |
FGFR2 E596K | Erdafitinib | Advanced Solid Tumor | predicted - sensitive | detail... |
FGFR2 E596K | E7090 | Advanced Solid Tumor | predicted - sensitive | detail... |
FGFR2 E596K | Infigratinib | Advanced Solid Tumor | predicted - sensitive | detail... |
FGFR2 E596K | AZD4547 | Advanced Solid Tumor | predicted - sensitive | detail... |
FGFR2 G613S | AZD4547 | Advanced Solid Tumor | predicted - sensitive | detail... |
FGFR2 G613S | Infigratinib | Advanced Solid Tumor | predicted - sensitive | detail... |
FGFR2 G613S | E7090 | Advanced Solid Tumor | predicted - sensitive | detail... |
FGFR2 G613S | Erdafitinib | Advanced Solid Tumor | predicted - sensitive | detail... |
FGFR2 G613S | Futibatinib | Advanced Solid Tumor | predicted - sensitive | detail... |
FGFR2 G613S | Pemigatinib | Advanced Solid Tumor | predicted - sensitive | detail... |
FGFR2 G613S | Dovitinib | Advanced Solid Tumor | predicted - resistant | detail... |
FGFR2 M640I | AZD4547 | Advanced Solid Tumor | predicted - sensitive | detail... |
FGFR2 M640I | Infigratinib | Advanced Solid Tumor | predicted - sensitive | detail... |
FGFR2 M640I | E7090 | Advanced Solid Tumor | predicted - sensitive | detail... |
FGFR2 M640I | Erdafitinib | Advanced Solid Tumor | predicted - sensitive | detail... |
FGFR2 M640I | Futibatinib | Advanced Solid Tumor | predicted - sensitive | detail... |
FGFR2 M640I | Pemigatinib | Advanced Solid Tumor | predicted - sensitive | detail... |
FGFR2 R664W | Pemigatinib | Advanced Solid Tumor | predicted - sensitive | detail... |
FGFR2 R664W | Futibatinib | Advanced Solid Tumor | predicted - sensitive | detail... |
FGFR2 R664W | Erdafitinib | Advanced Solid Tumor | predicted - sensitive | detail... |
FGFR2 R664W | E7090 | Advanced Solid Tumor | predicted - sensitive | detail... |
FGFR2 R664W | Infigratinib | Advanced Solid Tumor | predicted - sensitive | detail... |
FGFR2 R664W | AZD4547 | Advanced Solid Tumor | predicted - sensitive | detail... |
FGFR2 E718K | AZD4547 | Advanced Solid Tumor | predicted - sensitive | detail... |
FGFR2 E718K | Infigratinib | Advanced Solid Tumor | predicted - sensitive | detail... |
FGFR2 E718K | E7090 | Advanced Solid Tumor | predicted - sensitive | detail... |
FGFR2 E718K | Erdafitinib | Advanced Solid Tumor | predicted - sensitive | detail... |
FGFR2 E718K | Futibatinib | Advanced Solid Tumor | predicted - sensitive | detail... |
FGFR2 E718K | Pemigatinib | Advanced Solid Tumor | predicted - sensitive | detail... |
FGFR2 E718K | Dovitinib | Advanced Solid Tumor | predicted - sensitive | detail... |
FGFR2 S791T | AZD4547 | Advanced Solid Tumor | predicted - sensitive | detail... |
FGFR2 S791T | Infigratinib | Advanced Solid Tumor | predicted - sensitive | detail... |
FGFR2 S791T | E7090 | Advanced Solid Tumor | predicted - sensitive | detail... |
FGFR2 S791T | Erdafitinib | Advanced Solid Tumor | predicted - sensitive | detail... |
FGFR2 S791T | Futibatinib | Advanced Solid Tumor | predicted - sensitive | detail... |
FGFR2 S791T | Pemigatinib | Advanced Solid Tumor | predicted - sensitive | detail... |
FGFR2 S791T | Dovitinib | Advanced Solid Tumor | predicted - resistant | detail... |
MDM2 C308Y | Nutlin-3a | Advanced Solid Tumor | predicted - resistant | detail... |
FGFR3 G380E | Infigratinib | Advanced Solid Tumor | predicted - sensitive | detail... |
FGFR3 G380E | Erdafitinib | Advanced Solid Tumor | predicted - sensitive | detail... |
FGFR3 G380E | Pemigatinib | Advanced Solid Tumor | predicted - sensitive | detail... |
FGFR3 G380E | Dovitinib | Advanced Solid Tumor | predicted - resistant | detail... |
FGFR3 R248_S249insC | E7090 | Advanced Solid Tumor | predicted - resistant | detail... |
FGFR3 R248_S249insC | Dovitinib | Advanced Solid Tumor | predicted - resistant | detail... |
FGFR3 H284fs | Dovitinib | Advanced Solid Tumor | predicted - resistant | detail... |
FGFR3 H284fs | Pemigatinib | Advanced Solid Tumor | predicted - resistant | detail... |
FGFR3 H284fs | E7090 | Advanced Solid Tumor | predicted - resistant | detail... |
FGFR3 H284fs | Infigratinib | Advanced Solid Tumor | predicted - sensitive | detail... |
EML4 - ALK | XMU-MP-5 | Advanced Solid Tumor | sensitive | detail... |
MAP2K1 D67N | Selumetinib | Advanced Solid Tumor | sensitive | detail... |
EML4 - ALK ALK G1202R | XMU-MP-5 | Advanced Solid Tumor | sensitive | detail... |
EML4 - ALK ALK L1196M | XMU-MP-5 | Advanced Solid Tumor | sensitive | detail... |
EML4 - ALK ALK G1269A | XMU-MP-5 | Advanced Solid Tumor | sensitive | detail... |
EML4 - ALK ALK I1171T | XMU-MP-5 | Advanced Solid Tumor | sensitive | detail... |
EML4 - ALK ALK C1156Y | XMU-MP-5 | Advanced Solid Tumor | sensitive | detail... |
KIT exon 11 del KIT A829P | THE-630 | Advanced Solid Tumor | predicted - sensitive | detail... |
KIT exon 11 del KIT D816G | THE-630 | Advanced Solid Tumor | predicted - sensitive | detail... |
KIT exon 11 del KIT D816H | THE-630 | Advanced Solid Tumor | predicted - sensitive | detail... |
KIT exon 11 del KIT D820A | THE-630 | Advanced Solid Tumor | predicted - sensitive | detail... |
KIT exon 11 del KIT D820G | THE-630 | Advanced Solid Tumor | predicted - sensitive | detail... |
KIT exon 11 del KIT N822K | THE-630 | Advanced Solid Tumor | predicted - sensitive | detail... |
KIT exon 11 del KIT T670I | THE-630 | Advanced Solid Tumor | predicted - sensitive | detail... |
KIT exon 11 del KIT V654A | THE-630 | Advanced Solid Tumor | predicted - sensitive | detail... |
KIT exon 11 del KIT Y823D | THE-630 | Advanced Solid Tumor | predicted - sensitive | detail... |
KIT exon 9 ins KIT D816G | THE-630 | Advanced Solid Tumor | predicted - sensitive | detail... |
KIT exon 9 ins KIT V654A | THE-630 | Advanced Solid Tumor | predicted - sensitive | detail... |
BRAF V600X | Belvarafenib + Cobimetinib | Advanced Solid Tumor | predicted - sensitive | detail... |
PIK3CA act mut | RLY-2608 | Advanced Solid Tumor | predicted - sensitive | detail... |
FGFR1 amp | HQP1351 | Advanced Solid Tumor | predicted - sensitive | detail... |
FGFR1 K656E | HQP1351 | Advanced Solid Tumor | predicted - sensitive | detail... |
FGFR1 K656E | Futibatinib | Advanced Solid Tumor | predicted - sensitive | detail... |
FGFR1 K656N | Erdafitinib | Advanced Solid Tumor | predicted - resistant | detail... |
FGFR1 K656N | HQP1351 | Advanced Solid Tumor | predicted - sensitive | detail... |
FGFR1 K656N | Infigratinib | Advanced Solid Tumor | predicted - sensitive | detail... |
FGFR1 K656N | Futibatinib | Advanced Solid Tumor | predicted - sensitive | detail... |
FGFR1 K656N | Pemigatinib | Advanced Solid Tumor | predicted - resistant | detail... |
FGFR1 V561F | Erdafitinib | Advanced Solid Tumor | predicted - resistant | detail... |
FGFR1 V561F | HQP1351 | Advanced Solid Tumor | sensitive | detail... |
FGFR1 V561F | Infigratinib | Advanced Solid Tumor | resistant | detail... |
FGFR1 V561F | Pemigatinib | Advanced Solid Tumor | predicted - resistant | detail... |
FGFR1 V561F | Futibatinib | Advanced Solid Tumor | predicted - resistant | detail... |
FGFR1 V561M | Erdafitinib | Advanced Solid Tumor | predicted - resistant | detail... |
FGFR1 V561M | Ponatinib | Advanced Solid Tumor | predicted - resistant | detail... |
FGFR1 V561M | HQP1351 | Advanced Solid Tumor | sensitive | detail... |
FGFR1 V561M | Futibatinib | Advanced Solid Tumor | predicted - resistant | detail... |
FGFR1 V561M | Infigratinib | Advanced Solid Tumor | predicted - resistant | detail... |
FGFR1 V561M | Pemigatinib | Advanced Solid Tumor | predicted - resistant | detail... |
FGFR2 amp | HQP1351 | Advanced Solid Tumor | predicted - sensitive | detail... |
ATM inact mut | Ceralasertib + Olaparib | Advanced Solid Tumor | predicted - sensitive | detail... |
EML4 - ALK ALK F1174L | XMU-MP-5 | Advanced Solid Tumor | predicted - resistant | detail... |
KIT V559D | Nintedanib | Advanced Solid Tumor | sensitive | detail... |
KIT V559G | Nintedanib | Advanced Solid Tumor | sensitive | detail... |
KIT L576P | Nintedanib | Advanced Solid Tumor | sensitive | detail... |
KIT V654A | Nintedanib | Advanced Solid Tumor | sensitive | detail... |
KIT T670E | Nintedanib | Advanced Solid Tumor | sensitive | detail... |
KIT V559D KIT T670I | Nintedanib | Advanced Solid Tumor | sensitive | detail... |
KIT T670I | Nintedanib | Advanced Solid Tumor | sensitive | detail... |
KIT D816E | Nintedanib | Advanced Solid Tumor | sensitive | detail... |
KIT A829P | Nintedanib | Advanced Solid Tumor | sensitive | detail... |
KIT Y823D | Nintedanib | Advanced Solid Tumor | sensitive | detail... |
KIT D820E | Nintedanib | Advanced Solid Tumor | sensitive | detail... |
RET G810R | TPX-0046 | Advanced Solid Tumor | predicted - sensitive | detail... |
RET G810C | TPX-0046 | Advanced Solid Tumor | predicted - sensitive | detail... |
RET G810S | TPX-0046 | Advanced Solid Tumor | predicted - sensitive | detail... |
KIT D820G | Nintedanib | Advanced Solid Tumor | sensitive | detail... |
KIT D820Y | Nintedanib | Advanced Solid Tumor | sensitive | detail... |
KIT V559D KIT V654A | Nintedanib | Advanced Solid Tumor | predicted - sensitive | detail... |
KIT L576P | Imatinib | Advanced Solid Tumor | sensitive | detail... |
KIT L576P | Sunitinib | Advanced Solid Tumor | sensitive | detail... |
KIT V559G | Imatinib | Advanced Solid Tumor | sensitive | detail... |
KIT V559G | Sunitinib | Advanced Solid Tumor | sensitive | detail... |
KIT T670E | Sunitinib | Advanced Solid Tumor | sensitive | detail... |
KIT T670E | Avapritinib | Advanced Solid Tumor | resistant | detail... |
KIT T670E | Ripretinib | Advanced Solid Tumor | resistant | detail... |
KIT T670E | Imatinib | Advanced Solid Tumor | resistant | detail... |
KIT D816H | Imatinib | Advanced Solid Tumor | resistant | detail... |
KIT D816E | Imatinib | Advanced Solid Tumor | sensitive | detail... |
KIT D816E | Sunitinib | Advanced Solid Tumor | sensitive | detail... |
KIT V559D KIT T670I | Avapritinib | Advanced Solid Tumor | resistant | detail... |
KIT V559D KIT V654A | Avapritinib | Advanced Solid Tumor | resistant | detail... |
KIT V559D KIT T670I | Imatinib | Advanced Solid Tumor | resistant | detail... |
KIT V559D KIT V654A | Ripretinib | Advanced Solid Tumor | resistant | detail... |
KIT V559D KIT T670I | Ripretinib | Advanced Solid Tumor | resistant | detail... |
IDH1 R132H | Ceralasertib | Advanced Solid Tumor | sensitive | detail... |
IDH1 R132H | BAY1895344 | Advanced Solid Tumor | sensitive | detail... |
IDH1 R132H | Ceralasertib + Olaparib | Advanced Solid Tumor | sensitive | detail... |
IDH1 R132H | BAY1895344 + Olaparib | Advanced Solid Tumor | sensitive | detail... |
IDH1 R132H | Ceralasertib + Niraparib | Advanced Solid Tumor | sensitive | detail... |
IDH1 R132H | Ceralasertib + Talazoparib | Advanced Solid Tumor | sensitive | detail... |
EML4 - ALK ALK L1196M | TPX-0131 | Advanced Solid Tumor | sensitive | detail... |
EML4 - ALK ALK I1171N ALK L1198F | TPX-0131 | Advanced Solid Tumor | sensitive | detail... |
ALK C1156Y | TPX-0131 | Advanced Solid Tumor | predicted - sensitive | detail... |
ALK S1206C ALK E1210K | TPX-0131 | Advanced Solid Tumor | predicted - sensitive | detail... |
ALK C1156Y ALK L1198F | TPX-0131 | Advanced Solid Tumor | predicted - sensitive | detail... |
ALK L1196M ALK L1198F | TPX-0131 | Advanced Solid Tumor | predicted - sensitive | detail... |
ALK E1210K | TPX-0131 | Advanced Solid Tumor | predicted - sensitive | detail... |
ALK L1196M | TPX-0131 | Advanced Solid Tumor | predicted - sensitive | detail... |
ALK T1151M | TPX-0131 | Advanced Solid Tumor | predicted - sensitive | detail... |
ALK G1202del | TPX-0131 | Advanced Solid Tumor | predicted - sensitive | detail... |
ALK T1151dup | TPX-0131 | Advanced Solid Tumor | predicted - sensitive | detail... |
ALK V1180L | TPX-0131 | Advanced Solid Tumor | predicted - sensitive | detail... |
ALK G1269A | TPX-0131 | Advanced Solid Tumor | predicted - sensitive | detail... |
ALK F1174C | TPX-0131 | Advanced Solid Tumor | predicted - sensitive | detail... |
ALK F1174L | TPX-0131 | Advanced Solid Tumor | predicted - sensitive | detail... |
ALK I1171N | TPX-0131 | Advanced Solid Tumor | decreased response | detail... |
ALK L1152P | TPX-0131 | Advanced Solid Tumor | decreased response | detail... |
ALK D1203N | TPX-0131 | Advanced Solid Tumor | decreased response | detail... |
ALK D1203N ALK E1210K | TPX-0131 | Advanced Solid Tumor | decreased response | detail... |
ALK G1269S | TPX-0131 | Advanced Solid Tumor | decreased response | detail... |
ALK S1206R | TPX-0131 | Advanced Solid Tumor | predicted - sensitive | detail... |
ALK L1198F ALK G1202R | TPX-0131 | Advanced Solid Tumor | predicted - sensitive | detail... |
ALK F1245C | TPX-0131 | Advanced Solid Tumor | predicted - sensitive | detail... |
ALK R1275Q | TPX-0131 | Advanced Solid Tumor | predicted - sensitive | detail... |
ALK L1198F | TPX-0131 | Advanced Solid Tumor | predicted - sensitive | detail... |
ALK L1152R | TPX-0131 | Advanced Solid Tumor | predicted - sensitive | detail... |
ALK F1174S | TPX-0131 | Advanced Solid Tumor | predicted - sensitive | detail... |
EML4 - ALK ALK C1156Y ALK G1202R | Crizotinib | Advanced Solid Tumor | resistant | detail... |
EML4 - ALK ALK G1202R ALK G1269A | Crizotinib | Advanced Solid Tumor | resistant | detail... |
EML4 - ALK ALK G1202R ALK L1204V ALK G1269A | Crizotinib | Advanced Solid Tumor | resistant | detail... |
EML4 - ALK ALK L1198F ALK G1202R ALK G1269A | Crizotinib | Advanced Solid Tumor | resistant | detail... |
EML4 - ALK ALK C1156Y ALK G1202R | Alectinib | Advanced Solid Tumor | resistant | detail... |
EML4 - ALK ALK G1202R ALK G1269A | Alectinib | Advanced Solid Tumor | resistant | detail... |
EML4 - ALK ALK G1202R ALK L1204V ALK G1269A | Alectinib | Advanced Solid Tumor | resistant | detail... |
EML4 - ALK ALK L1198F ALK G1202R ALK G1269A | Alectinib | Advanced Solid Tumor | resistant | detail... |
EML4 - ALK ALK C1156Y ALK G1202R | Brigatinib | Advanced Solid Tumor | resistant | detail... |
EML4 - ALK ALK G1202R ALK G1269A | Brigatinib | Advanced Solid Tumor | resistant | detail... |
EML4 - ALK ALK G1202R ALK L1204V ALK G1269A | Brigatinib | Advanced Solid Tumor | resistant | detail... |
EML4 - ALK ALK L1198F ALK G1202R ALK G1269A | Brigatinib | Advanced Solid Tumor | resistant | detail... |
EML4 - ALK ALK C1156Y ALK G1202R | Ceritinib | Advanced Solid Tumor | resistant | detail... |
EML4 - ALK ALK G1202R ALK G1269A | Ceritinib | Advanced Solid Tumor | resistant | detail... |
EML4 - ALK ALK G1202R ALK L1204V ALK G1269A | Ceritinib | Advanced Solid Tumor | resistant | detail... |
EML4 - ALK ALK L1198F ALK G1202R ALK G1269A | Ceritinib | Advanced Solid Tumor | resistant | detail... |
EML4 - ALK ALK C1156Y ALK G1202R | Lorlatinib | Advanced Solid Tumor | resistant | detail... |
EML4 - ALK ALK G1202R ALK G1269A | Lorlatinib | Advanced Solid Tumor | resistant | detail... |
EML4 - ALK ALK G1202R ALK L1204V ALK G1269A | Lorlatinib | Advanced Solid Tumor | resistant | detail... |
EML4 - ALK ALK L1198F ALK G1202R ALK G1269A | Lorlatinib | Advanced Solid Tumor | resistant | detail... |
ROS1 G2032R | SAF-189s | Advanced Solid Tumor | predicted - sensitive | detail... |
ROS1 L2026M | SAF-189s | Advanced Solid Tumor | predicted - sensitive | detail... |
ROS1 S1986F | SAF-189s | Advanced Solid Tumor | predicted - sensitive | detail... |
ROS1 S1986Y | SAF-189s | Advanced Solid Tumor | predicted - sensitive | detail... |
ROS1 D2033N | SAF-189s | Advanced Solid Tumor | predicted - sensitive | detail... |
FGFR2 fusion | Pemigatinib | Advanced Solid Tumor | predicted - sensitive | detail... |
ROS1 fusion | Entrectinib | Advanced Solid Tumor | predicted - sensitive | detail... |
EML4 - ALK ALK F1174L | Iruplinalkib | Advanced Solid Tumor | sensitive | detail... |
EML4 - ALK ALK G1202R | Iruplinalkib | Advanced Solid Tumor | sensitive | detail... |
EML4 - ALK ALK F1174C | Iruplinalkib | Advanced Solid Tumor | sensitive | detail... |
EML4 - ALK ALK G1269A | Iruplinalkib | Advanced Solid Tumor | sensitive | detail... |
EML4 - ALK ALK I1171S | Iruplinalkib | Advanced Solid Tumor | sensitive | detail... |
EML4 - ALK ALK T1151dup | Iruplinalkib | Advanced Solid Tumor | sensitive | detail... |
EML4 - ALK ALK F1174V | Iruplinalkib | Advanced Solid Tumor | sensitive | detail... |
EML4 - ALK ALK V1180L | Iruplinalkib | Advanced Solid Tumor | sensitive | detail... |
EML4 - ALK ALK L1152R | Iruplinalkib | Advanced Solid Tumor | sensitive | detail... |
EML4 - ALK ALK L1152P | Iruplinalkib | Advanced Solid Tumor | sensitive | detail... |
EML4 - ALK ALK I1171T | Iruplinalkib | Advanced Solid Tumor | sensitive | detail... |
EML4 - ALK ALK I1171N | Iruplinalkib | Advanced Solid Tumor | sensitive | detail... |
ROS1 G2032R | Lorlatinib | Advanced Solid Tumor | predicted - sensitive | detail... |
ROS1 L2026M | Lorlatinib | Advanced Solid Tumor | predicted - sensitive | detail... |
ROS1 S1986F | Lorlatinib | Advanced Solid Tumor | predicted - sensitive | detail... |
ROS1 S1986Y | Lorlatinib | Advanced Solid Tumor | predicted - sensitive | detail... |
ROS1 D2033N | Lorlatinib | Advanced Solid Tumor | predicted - sensitive | detail... |
RET V804M RET Y806C | Selpercatinib | Advanced Solid Tumor | decreased response | detail... |
RET V804M RET Y806C RET M918T | Selpercatinib | Advanced Solid Tumor | predicted - resistant | detail... |
ROS1 G2032R | Ceritinib | Advanced Solid Tumor | predicted - resistant | detail... |
ROS1 G2032R | Crizotinib | Advanced Solid Tumor | predicted - resistant | detail... |
BRAF V600E | Dabrafenib + Trametinib | Advanced Solid Tumor | sensitive | detail... |
RET G810R | APS03118 | Advanced Solid Tumor | predicted - sensitive | detail... |
RET V804M | APS03118 | Advanced Solid Tumor | predicted - sensitive | detail... |
RET M918T | APS03118 | Advanced Solid Tumor | predicted - sensitive | detail... |
RET G810S | APS03118 | Advanced Solid Tumor | predicted - sensitive | detail... |
KIT D419del | Imatinib | Advanced Solid Tumor | predicted - sensitive | detail... |
RET G810C | APS03118 | Advanced Solid Tumor | predicted - sensitive | detail... |
RET V804L | APS03118 | Advanced Solid Tumor | predicted - sensitive | detail... |
RET V804E | APS03118 | Advanced Solid Tumor | predicted - sensitive | detail... |
RET M918T | Pralsetinib | Advanced Solid Tumor | sensitive | detail... |
RET T930K | Selpercatinib | Advanced Solid Tumor | sensitive | detail... |
RET T930K | Pralsetinib | Advanced Solid Tumor | sensitive | detail... |
RET T930P | Selpercatinib | Advanced Solid Tumor | sensitive | detail... |
RET T930P | Pralsetinib | Advanced Solid Tumor | sensitive | detail... |
RET D898_E901del | Selpercatinib | Advanced Solid Tumor | sensitive | detail... |
RET D898_E901del | Pralsetinib | Advanced Solid Tumor | sensitive | detail... |
BRAF V600E | Cobimetinib + Vemurafenib | Advanced Solid Tumor | sensitive | detail... |
ALK C1156Y ALK L1198F | Crizotinib | Advanced Solid Tumor | sensitive | detail... |
EML4 - ALK ALK I1171N ALK D1203N | Crizotinib | Advanced Solid Tumor | resistant | detail... |
EML4 - ALK ALK G1202R ALK S1206F | Crizotinib | Advanced Solid Tumor | resistant | detail... |
EML4 - ALK ALK G1202R ALK S1206F ALK G1269A | Crizotinib | Advanced Solid Tumor | resistant | detail... |
EML4 - ALK ALK G1202R ALK S1206F | Ceritinib | Advanced Solid Tumor | resistant | detail... |
EML4 - ALK ALK G1202R ALK S1206F ALK G1269A | Ceritinib | Advanced Solid Tumor | resistant | detail... |
EML4 - ALK ALK I1171N ALK D1203N | Alectinib | Advanced Solid Tumor | resistant | detail... |
EML4 - ALK ALK G1202R ALK S1206F | Alectinib | Advanced Solid Tumor | resistant | detail... |
EML4 - ALK ALK G1202R ALK S1206F ALK G1269A | Alectinib | Advanced Solid Tumor | resistant | detail... |
EML4 - ALK ALK G1202R ALK S1206F | Brigatinib | Advanced Solid Tumor | resistant | detail... |
EML4 - ALK ALK G1202R ALK S1206F ALK G1269A | Brigatinib | Advanced Solid Tumor | resistant | detail... |
EML4 - ALK ALK I1171N ALK D1203N | Lorlatinib | Advanced Solid Tumor | resistant | detail... |
EML4 - ALK ALK G1202R ALK S1206F | Lorlatinib | Advanced Solid Tumor | resistant | detail... |
EML4 - ALK ALK G1202R ALK S1206F ALK G1269A | Lorlatinib | Advanced Solid Tumor | resistant | detail... |
ALK rearrange | TQ-B3101 | Advanced Solid Tumor | predicted - sensitive | detail... |
ROS1 rearrange | TQ-B3101 | Advanced Solid Tumor | predicted - sensitive | detail... |
RET fusion | Selpercatinib | Advanced Solid Tumor | sensitive | detail... |
BRAF act mut | CC-91516 | Advanced Solid Tumor | predicted - sensitive | detail... |
CTNNB1 act mut | CC-91516 | Advanced Solid Tumor | predicted - sensitive | detail... |
EML4 - ALK | TQ-B3139 | Advanced Solid Tumor | sensitive | detail... |
EML4 - ALK ALK R1275Q | TQ-B3139 | Advanced Solid Tumor | sensitive | detail... |
EML4 - ALK ALK L1152R | TQ-B3139 | Advanced Solid Tumor | sensitive | detail... |
EML4 - ALK ALK C1156Y | TQ-B3139 | Advanced Solid Tumor | sensitive | detail... |
EML4 - ALK ALK L1196M | TQ-B3139 | Advanced Solid Tumor | sensitive | detail... |
CD274 positive | MT-6402 | Advanced Solid Tumor | predicted - resistant | detail... |
ALK L1196M | APG-2449 | Advanced Solid Tumor | predicted - sensitive | detail... |
ALK G1269A | APG-2449 | Advanced Solid Tumor | predicted - sensitive | detail... |
ALK S1206Y | APG-2449 | Advanced Solid Tumor | predicted - sensitive | detail... |
ALK G1202R | APG-2449 | Advanced Solid Tumor | predicted - sensitive | detail... |
EML4 - ALK | APG-2449 | Advanced Solid Tumor | sensitive | detail... |
EML4 - ALK ALK I1171T | APG-2449 | Advanced Solid Tumor | sensitive | detail... |
EML4 - ALK ALK R1275Q | APG-2449 | Advanced Solid Tumor | sensitive | detail... |
EML4 - ALK ALK F1174L | APG-2449 | Advanced Solid Tumor | sensitive | detail... |
EML4 - ALK ALK L1196M | APG-2449 | Advanced Solid Tumor | sensitive | detail... |
EML4 - ALK ALK G1202R | APG-2449 | Advanced Solid Tumor | sensitive | detail... |
POLE inact mut | Nivolumab | Advanced Solid Tumor | predicted - sensitive | detail... |
RET C630del | Pralsetinib | Advanced Solid Tumor | sensitive | detail... |
NRAS mutant | FCN-159 | Advanced Solid Tumor | predicted - sensitive | detail... |
ATM inact mut | RP-3500 | Advanced Solid Tumor | predicted - sensitive | detail... |
CDK12 inact mut | RP-3500 | Advanced Solid Tumor | predicted - sensitive | detail... |
ATM mutant | Olaparib | Advanced Solid Tumor | conflicting | detail... |
TP53 wild-type | BI 907828 + Ezabenlimab | Advanced Solid Tumor | predicted - sensitive | detail... |
HRAS G13R PTEN inact mut | AZD8186 + Tipifarnib | Advanced Solid Tumor | predicted - sensitive | detail... |
HRAS G13R PTEN inact mut | Tipifarnib | Advanced Solid Tumor | predicted - sensitive | detail... |
CD274 positive | GEN1046 | Advanced Solid Tumor | sensitive | detail... |
FGFR2 N549H | 3D185 | Advanced Solid Tumor | predicted - sensitive | detail... |
FGFR1 V561M | 3D185 | Advanced Solid Tumor | predicted - sensitive | detail... |
BRAF R506_K507insLLR | Vemurafenib | Advanced Solid Tumor | resistant | detail... |
BRAF R506_K507insLLR | Dabrafenib | Advanced Solid Tumor | resistant | detail... |
BRAF V504_R506dup | Dabrafenib | Advanced Solid Tumor | resistant | detail... |
BRAF R506_K507insLLR | PLX8394 | Advanced Solid Tumor | resistant | detail... |
BRAF V504_R506dup | PLX8394 | Advanced Solid Tumor | resistant | detail... |
BRAF R506_K507insLLR | LY3009120 | Advanced Solid Tumor | predicted - resistant | detail... |
BRAF V504_R506dup | LY3009120 | Advanced Solid Tumor | predicted - resistant | detail... |
BRAF R506_K507insLLR | Trametinib | Advanced Solid Tumor | sensitive | detail... |
BRAF R506_K507insLLR | Sorafenib | Advanced Solid Tumor | predicted - resistant | detail... |
BRAF R506_K507insLLR | Cobimetinib | Advanced Solid Tumor | predicted - sensitive | detail... |
BRAF R506_K507insLLR | Selumetinib | Advanced Solid Tumor | predicted - sensitive | detail... |
BRAF R506_K507insLLR | Binimetinib | Advanced Solid Tumor | predicted - sensitive | detail... |
BRAF L505H | Vemurafenib | Advanced Solid Tumor | predicted - resistant | detail... |
BRAF L485F | Vemurafenib | Advanced Solid Tumor | predicted - resistant | detail... |
BRAF L505H | PLX8394 | Advanced Solid Tumor | predicted - resistant | detail... |
BRAF L485F | PLX8394 | Advanced Solid Tumor | predicted - resistant | detail... |
BRAF L505H | Dabrafenib | Advanced Solid Tumor | predicted - resistant | detail... |
BRAF L485F | Dabrafenib | Advanced Solid Tumor | predicted - resistant | detail... |
BRAF L505H | LY3009120 | Advanced Solid Tumor | predicted - resistant | detail... |
BRAF L485F | LY3009120 | Advanced Solid Tumor | predicted - sensitive | detail... |
BRAF V600X | PLX8394 | Advanced Solid Tumor | predicted - sensitive | detail... |
ALK G1128A | Repotrectinib | Advanced Solid Tumor | sensitive | detail... |
ALK I1171N | Repotrectinib | Advanced Solid Tumor | sensitive | detail... |
ALK F1174L | Repotrectinib | Advanced Solid Tumor | sensitive | detail... |
ALK R1192P | Repotrectinib | Advanced Solid Tumor | sensitive | detail... |
ALK F1245C | Repotrectinib | Advanced Solid Tumor | sensitive | detail... |
ALK Y1278S | Repotrectinib | Advanced Solid Tumor | sensitive | detail... |
ALK R1275Q | Repotrectinib | Advanced Solid Tumor | sensitive | detail... |
EML4 - ALK ALK I1171N | Repotrectinib | Advanced Solid Tumor | resistant | detail... |
EML4 - ALK ALK G1202R | Ensartinib | Advanced Solid Tumor | resistant | detail... |
EML4 - ALK ALK I1171N | Ensartinib | Advanced Solid Tumor | sensitive | detail... |
EML4 - ALK ALK E1129V ALK G1202R | Lorlatinib | Advanced Solid Tumor | resistant | detail... |
EML4 - ALK ALK F1174C ALK G1202R | Lorlatinib | Advanced Solid Tumor | resistant | detail... |
EML4 - ALK ALK F1174I ALK G1202R | Lorlatinib | Advanced Solid Tumor | resistant | detail... |
EML4 - ALK ALK E1129V ALK I1171N | Lorlatinib | Advanced Solid Tumor | resistant | detail... |
EML4 - ALK ALK C1156Y ALK I1171N | Lorlatinib | Advanced Solid Tumor | resistant | detail... |
EML4 - ALK ALK E1129V ALK G1202R | Crizotinib | Advanced Solid Tumor | resistant | detail... |
EML4 - ALK ALK F1174C ALK G1202R | Crizotinib | Advanced Solid Tumor | resistant | detail... |
EML4 - ALK ALK F1174I ALK G1202R | Crizotinib | Advanced Solid Tumor | resistant | detail... |
EML4 - ALK ALK E1129V ALK I1171N | Crizotinib | Advanced Solid Tumor | resistant | detail... |
EML4 - ALK ALK C1156Y ALK I1171N | Crizotinib | Advanced Solid Tumor | resistant | detail... |
EML4 - ALK ALK E1129V ALK G1202R | Alectinib | Advanced Solid Tumor | resistant | detail... |
EML4 - ALK ALK F1174C ALK G1202R | Alectinib | Advanced Solid Tumor | resistant | detail... |
EML4 - ALK ALK F1174I ALK G1202R | Alectinib | Advanced Solid Tumor | resistant | detail... |
EML4 - ALK ALK E1129V ALK I1171N | Alectinib | Advanced Solid Tumor | resistant | detail... |
EML4 - ALK ALK C1156Y ALK I1171N | Alectinib | Advanced Solid Tumor | resistant | detail... |
ATM inact mut | Avelumab + Talazoparib | Advanced Solid Tumor | no benefit | detail... |
EML4 - ALK ALK E1129V ALK G1202R | TPX-0131 | Advanced Solid Tumor | sensitive | detail... |
ALK R753Q | Crizotinib | Advanced Solid Tumor | sensitive | detail... |
ALK F856S | Crizotinib | Advanced Solid Tumor | sensitive | detail... |
EML4 - ALK ALK F1174I ALK G1202R | TPX-0131 | Advanced Solid Tumor | resistant | detail... |
EML4 - ALK ALK F1174C ALK G1202R | TPX-0131 | Advanced Solid Tumor | resistant | detail... |
EML4 - ALK ALK E1129V ALK I1171N | TPX-0131 | Advanced Solid Tumor | resistant | detail... |
EML4 - ALK ALK C1156Y ALK I1171N | TPX-0131 | Advanced Solid Tumor | resistant | detail... |
EML4 - ALK ALK I1171N ALK L1256F | TPX-0131 | Advanced Solid Tumor | resistant | detail... |
EML4 - ALK ALK E1129V ALK G1202R | Gilteritinib | Advanced Solid Tumor | resistant | detail... |
EML4 - ALK ALK C1156Y ALK G1202R | Gilteritinib | Advanced Solid Tumor | sensitive | detail... |
EML4 - ALK ALK F1174C ALK G1202R | Gilteritinib | Advanced Solid Tumor | resistant | detail... |
EML4 - ALK ALK F1174I ALK G1202R | Gilteritinib | Advanced Solid Tumor | resistant | detail... |
EML4 - ALK ALK C1156Y ALK I1171N | Gilteritinib | Advanced Solid Tumor | sensitive | detail... |
MAP2K1 I99_K104del | Trametinib | Advanced Solid Tumor | resistant | detail... |
MAP2K1 E102_I103del | Trametinib | Advanced Solid Tumor | resistant | detail... |
MAP2K1 P105_A106del | Trametinib | Advanced Solid Tumor | resistant | detail... |
MAP2K1 L115P | Trametinib | Advanced Solid Tumor | resistant | detail... |
MAP2K1 R49L | Trametinib | Advanced Solid Tumor | sensitive | detail... |
MAP2K1 F53_Q58delinsL | Trametinib | Advanced Solid Tumor | sensitive | detail... |
MAP2K1 F53C | Trametinib | Advanced Solid Tumor | sensitive | detail... |
MAP2K1 F53I | Trametinib | Advanced Solid Tumor | sensitive | detail... |
MAP2K1 F53L | Trametinib | Advanced Solid Tumor | sensitive | detail... |
MAP2K1 L42_K57del | Trametinib | Advanced Solid Tumor | sensitive | detail... |
MAP2K1 F53V | Trametinib | Advanced Solid Tumor | sensitive | detail... |
MAP2K1 Q56P | Trametinib | Advanced Solid Tumor | sensitive | detail... |
MAP2K1 K57_G61del | Trametinib | Advanced Solid Tumor | sensitive | detail... |
MAP2K1 K57E | Trametinib | Advanced Solid Tumor | sensitive | detail... |
MAP2K1 K57N | Trametinib | Advanced Solid Tumor | sensitive | detail... |
MAP2K1 K57T | Trametinib | Advanced Solid Tumor | sensitive | detail... |
MAP2K1 Q58_E62del | Trametinib | Advanced Solid Tumor | sensitive | detail... |
MAP2K1 K59del | Trametinib | Advanced Solid Tumor | sensitive | detail... |
MAP2K1 V60E | Trametinib | Advanced Solid Tumor | sensitive | detail... |
MAP2K1 G61_D65del | Trametinib | Advanced Solid Tumor | sensitive | detail... |
MAP2K1 L63_D67del | Trametinib | Advanced Solid Tumor | sensitive | detail... |
MAP2K1 C121S | Trametinib | Advanced Solid Tumor | sensitive | detail... |
MAP2K1 G128D | Trametinib | Advanced Solid Tumor | sensitive | detail... |
MAP2K1 F129L | Trametinib | Advanced Solid Tumor | sensitive | detail... |
MAP2K1 E203K | Trametinib | Advanced Solid Tumor | sensitive | detail... |
FGFR2 V565L | TYRA-200 | Advanced Solid Tumor | predicted - sensitive | detail... |
FGFR2 V565F | TYRA-200 | Advanced Solid Tumor | predicted - sensitive | detail... |
FGFR2 V565I | TYRA-200 | Advanced Solid Tumor | predicted - sensitive | detail... |
FGFR2 K660E | TYRA-200 | Advanced Solid Tumor | predicted - sensitive | detail... |
FGFR2 K660N | TYRA-200 | Advanced Solid Tumor | predicted - sensitive | detail... |
FGFR2 E566A | TYRA-200 | Advanced Solid Tumor | predicted - sensitive | detail... |
FGFR2 N550H | TYRA-200 | Advanced Solid Tumor | predicted - sensitive | detail... |
FGFR2 N550K | TYRA-200 | Advanced Solid Tumor | predicted - sensitive | detail... |
ALK L1196M | Conteltinib | Advanced Solid Tumor | predicted - sensitive | detail... |
ALK F1174L | Conteltinib | Advanced Solid Tumor | predicted - sensitive | detail... |
ALK G1202R | Conteltinib | Advanced Solid Tumor | predicted - sensitive | detail... |
ALK G1269S | Conteltinib | Advanced Solid Tumor | predicted - sensitive | detail... |
ALK R1275Q | Conteltinib | Advanced Solid Tumor | predicted - sensitive | detail... |
RET E632_L633del | Selpercatinib | Advanced Solid Tumor | conflicting | detail... |
RET E632_L633del | Pralsetinib | Advanced Solid Tumor | conflicting | detail... |
BRAF V600E | Erlotinib + Vemurafenib | Advanced Solid Tumor | predicted - sensitive | detail... |
BRAF L525R | Selumetinib | Advanced Solid Tumor | sensitive | detail... |
BRAF L525R | Dactolisib + Selumetinib | Advanced Solid Tumor | predicted - sensitive | detail... |
BRAF L525R | Dactolisib | Advanced Solid Tumor | sensitive | detail... |
MAP2K1 L42F | Trametinib | Advanced Solid Tumor | predicted - sensitive | detail... |
MAP2K1 N109_R113del | Trametinib | Advanced Solid Tumor | predicted - sensitive | detail... |
MAP2K1 T55P | Trametinib | Advanced Solid Tumor | predicted - sensitive | detail... |
MAP2K1 H119Q | Trametinib | Advanced Solid Tumor | predicted - sensitive | detail... |
MAP2K1 H119Y | Trametinib | Advanced Solid Tumor | predicted - sensitive | detail... |
MAP2K1 L177M | Trametinib | Advanced Solid Tumor | predicted - sensitive | detail... |
MAP2K1 K57N | SCH772984 | Advanced Solid Tumor | predicted - sensitive | detail... |
MAP2K1 I103N | SCH772984 | Advanced Solid Tumor | predicted - sensitive | detail... |
MAP2K1 H119Q | SCH772984 | Advanced Solid Tumor | predicted - sensitive | detail... |
MAP2K1 N122D | SCH772984 | Advanced Solid Tumor | predicted - sensitive | detail... |
MAP2K1 L177M | SCH772984 | Advanced Solid Tumor | predicted - sensitive | detail... |
MAP2K1 E203K | SCH772984 | Advanced Solid Tumor | predicted - sensitive | detail... |
MAP2K1 E102_I103del | SCH772984 | Advanced Solid Tumor | predicted - sensitive | detail... |
MAP2K1 N109_R113del | SCH772984 | Advanced Solid Tumor | predicted - sensitive | detail... |
MAP2K1 I103_K104del | SCH772984 | Advanced Solid Tumor | predicted - sensitive | detail... |
MAP2K1 P105_A106del | SCH772984 | Advanced Solid Tumor | predicted - sensitive | detail... |
MAP2K1 P105_I107delinsL | SCH772984 | Advanced Solid Tumor | predicted - sensitive | detail... |
MAP2K1 I103_K104del | Trametinib | Advanced Solid Tumor | decreased response | detail... |
MAP2K1 P105_I107delinsL | Trametinib | Advanced Solid Tumor | decreased response | detail... |
ALK rearrange | Entrectinib | Advanced Solid Tumor | predicted - sensitive | detail... |
BRAF class 1 | BDTX-4933 | Advanced Solid Tumor | predicted - sensitive | detail... |
BRAF class 2 | BDTX-4933 | Advanced Solid Tumor | predicted - sensitive | detail... |
BRAF class 3 | BDTX-4933 | Advanced Solid Tumor | predicted - sensitive | detail... |
MAP2K1 Q56_G61delinsR | Trametinib | Advanced Solid Tumor | sensitive | detail... |
RET V804M | TY-1091 | Advanced Solid Tumor | predicted - sensitive | detail... |
RET V804L | TY-1091 | Advanced Solid Tumor | predicted - sensitive | detail... |
RET V804E | TY-1091 | Advanced Solid Tumor | predicted - sensitive | detail... |
RET G810S | TY-1091 | Advanced Solid Tumor | predicted - sensitive | detail... |
RET V804M RET G810S | TY-1091 | Advanced Solid Tumor | predicted - sensitive | detail... |
RET G810S RET M918T | TY-1091 | Advanced Solid Tumor | predicted - sensitive | detail... |
PTEN inact mut | Temsirolimus | Advanced Solid Tumor | predicted - sensitive | detail... |
BRAF class 1 | Exarafenib | Advanced Solid Tumor | predicted - sensitive | detail... |
BRAF class 2 | Exarafenib | Advanced Solid Tumor | predicted - sensitive | detail... |
BRAF class 3 | Exarafenib | Advanced Solid Tumor | predicted - sensitive | detail... |
BRAF class 1 | DCC-3084 | Advanced Solid Tumor | predicted - sensitive | detail... |
BRAF class 2 | DCC-3084 | Advanced Solid Tumor | predicted - sensitive | detail... |
BRAF class 3 | DCC-3084 | Advanced Solid Tumor | predicted - sensitive | detail... |
BRAF fusion | DCC-3084 | Advanced Solid Tumor | predicted - sensitive | detail... |
ALK F1174L | CCC-003 | Advanced Solid Tumor | sensitive | detail... |
BRAF fusion | PLX8394 | Advanced Solid Tumor | predicted - sensitive | detail... |
PIK3CA mutant | TOS-358 | Advanced Solid Tumor | predicted - sensitive | detail... |
FGFR2 V564F | RLY-4008 | Advanced Solid Tumor | predicted - sensitive | detail... |
FGFR2 N549D | RLY-4008 | Advanced Solid Tumor | predicted - sensitive | detail... |
FGFR2 V564L | RLY-4008 | Advanced Solid Tumor | predicted - sensitive | detail... |
FGFR2 E565A | RLY-4008 | Advanced Solid Tumor | predicted - sensitive | detail... |
FGFR2 L617V | RLY-4008 | Advanced Solid Tumor | predicted - sensitive | detail... |
FGFR2 N549H | RLY-4008 | Advanced Solid Tumor | predicted - sensitive | detail... |
FGFR2 K641N | RLY-4008 | Advanced Solid Tumor | predicted - sensitive | detail... |
FGFR2 K659M | RLY-4008 | Advanced Solid Tumor | predicted - sensitive | detail... |
FGFR2 V564F | Futibatinib | Advanced Solid Tumor | predicted - resistant | detail... |
FGFR2 V564F | Pemigatinib | Advanced Solid Tumor | resistant | detail... |
FGFR2 V564F | Erdafitinib | Advanced Solid Tumor | predicted - resistant | detail... |
FGFR2 V564L | Pemigatinib | Advanced Solid Tumor | predicted - sensitive | detail... |
FGFR2 V564L | Infigratinib | Advanced Solid Tumor | predicted - sensitive | detail... |
FGFR2 V564I | Infigratinib | Advanced Solid Tumor | predicted - sensitive | detail... |
FGFR3 K652E | Infigratinib | Advanced Solid Tumor | sensitive | detail... |
FGFR3 N542K | Infigratinib | Advanced Solid Tumor | sensitive | detail... |
FGFR3 S249C | Dasatinib | Advanced Solid Tumor | resistant | detail... |
FGFR3 S249C | Dasatinib + Infigratinib | Advanced Solid Tumor | sensitive | detail... |
FGFR3 N542K | Dasatinib + Infigratinib | Advanced Solid Tumor | sensitive | detail... |
FGFR3 K652E | Dasatinib + Infigratinib | Advanced Solid Tumor | sensitive | detail... |
CD274 positive | PF-07257876 | Advanced Solid Tumor | predicted - sensitive | detail... |
CD274 positive | KN046 | Advanced Solid Tumor | predicted - sensitive | detail... |
PIK3CA act mut | Temsirolimus | Advanced Solid Tumor | predicted - sensitive | detail... |
BRAF V600X | ABM-1310 | Advanced Solid Tumor | predicted - sensitive | detail... |
NRAS G12D | IHMT-RAF-128 | Advanced Solid Tumor | sensitive | detail... |
BRAF V600E | IHMT-RAF-128 | Advanced Solid Tumor | sensitive | detail... |
BRAF K601E | IHMT-RAF-128 | Advanced Solid Tumor | sensitive | detail... |
BRAF G469A | IHMT-RAF-128 | Advanced Solid Tumor | sensitive | detail... |
HRAS G12D | MRTX-1133 | Advanced Solid Tumor | no benefit | detail... |
NRAS G12D | MRTX-1133 | Advanced Solid Tumor | no benefit | detail... |
HRAS G12D HRAS Q95H | MRTX-1133 | Advanced Solid Tumor | sensitive | detail... |
NRAS G12D NRAS L95H | MRTX-1133 | Advanced Solid Tumor | sensitive | detail... |
CDKN2A loss | Palbociclib | Advanced Solid Tumor | no benefit | detail... |
CDKN2A loss | Ribociclib | Advanced Solid Tumor | no benefit | detail... |
RET C634R | Selpercatinib | Advanced Solid Tumor | sensitive | detail... |
RET C634R | Pralsetinib | Advanced Solid Tumor | sensitive | detail... |
RET C620R | Selpercatinib | Advanced Solid Tumor | sensitive | detail... |
RET C620R | Pralsetinib | Advanced Solid Tumor | sensitive | detail... |
RET D631Y | Selpercatinib | Advanced Solid Tumor | sensitive | detail... |
RET D631Y | Pralsetinib | Advanced Solid Tumor | sensitive | detail... |
RET D631_L633delinsE | Selpercatinib | Advanced Solid Tumor | sensitive | detail... |
RET D631_L633delinsE | Pralsetinib | Advanced Solid Tumor | sensitive | detail... |
RET D567N | Selpercatinib | Advanced Solid Tumor | sensitive | detail... |
RET D567N | Pralsetinib | Advanced Solid Tumor | sensitive | detail... |
RET D567Y | Selpercatinib | Advanced Solid Tumor | sensitive | detail... |
RET D567Y | Pralsetinib | Advanced Solid Tumor | sensitive | detail... |
RET G607C | Selpercatinib | Advanced Solid Tumor | sensitive | detail... |
RET G607C | Pralsetinib | Advanced Solid Tumor | sensitive | detail... |
RET D571N | Selpercatinib | Advanced Solid Tumor | sensitive | detail... |
RET D571N | Pralsetinib | Advanced Solid Tumor | sensitive | detail... |
RET E574D | Selpercatinib | Advanced Solid Tumor | sensitive | detail... |
RET E574D | Pralsetinib | Advanced Solid Tumor | sensitive | detail... |
RET D584N | Selpercatinib | Advanced Solid Tumor | sensitive | detail... |
RET D584N | Pralsetinib | Advanced Solid Tumor | sensitive | detail... |
IDH1 R132H | HMPL-306 | Advanced Solid Tumor | predicted - sensitive | detail... |
IDH2 R140Q | HMPL-306 | Advanced Solid Tumor | predicted - sensitive | detail... |
IDH2 R172K | HMPL-306 | Advanced Solid Tumor | predicted - sensitive | detail... |
RET D898_E901del | Cabozantinib | Advanced Solid Tumor | resistant | detail... |
RET D898_E901del | Vandetanib | Advanced Solid Tumor | predicted - sensitive | detail... |
PIK3CA act mut | Copanlisib | Advanced Solid Tumor | predicted - sensitive | detail... |
FGFR1 fusion | Erdafitinib | Advanced Solid Tumor | predicted - sensitive | detail... |
FGFR2 fusion | Erdafitinib | Advanced Solid Tumor | predicted - sensitive | detail... |
FGFR3 fusion | Erdafitinib | Advanced Solid Tumor | predicted - sensitive | detail... |
ROS1 D2113N | Crizotinib | Advanced Solid Tumor | sensitive | detail... |
ROS1 D2113N | Lorlatinib | Advanced Solid Tumor | sensitive | detail... |
ROS1 D2113N | NUV-520 | Advanced Solid Tumor | sensitive | detail... |
ROS1 D2113N | Repotrectinib | Advanced Solid Tumor | sensitive | detail... |
ROS1 D2113G | Crizotinib | Advanced Solid Tumor | sensitive | detail... |
ROS1 D2113G | Lorlatinib | Advanced Solid Tumor | sensitive | detail... |
ROS1 D2113G | NUV-520 | Advanced Solid Tumor | sensitive | detail... |
ROS1 D2113G | Repotrectinib | Advanced Solid Tumor | sensitive | detail... |
ROS1 D2113N | TNO155 | Advanced Solid Tumor | sensitive | detail... |
ROS1 D2113N | RMC-4550 | Advanced Solid Tumor | sensitive | detail... |
ROS1 D2113N | Selumetinib | Advanced Solid Tumor | sensitive | detail... |
ROS1 D2113G | TNO155 | Advanced Solid Tumor | sensitive | detail... |
ROS1 D2113G | RMC-4550 | Advanced Solid Tumor | sensitive | detail... |
ROS1 D2113G | Selumetinib | Advanced Solid Tumor | sensitive | detail... |
RET V804M | FHND5071 | Advanced Solid Tumor | predicted - sensitive | detail... |
RET M918T | FHND5071 | Advanced Solid Tumor | predicted - sensitive | detail... |
BRAF L485_T488delinsF | Sorafenib | Advanced Solid Tumor | predicted - sensitive | detail... |
BRAF L485_T488delinsF | LXH 254 | Advanced Solid Tumor | predicted - sensitive | detail... |
BRAF L485_T488delinsF | Dabrafenib | Advanced Solid Tumor | predicted - resistant | detail... |
RET M918T | Vepafestinib | Advanced Solid Tumor | sensitive | detail... |
MDM2 amp TP53 wild-type | BI 907828 | Advanced Solid Tumor | predicted - sensitive | detail... |
PTEN del | Atezolizumab + Ipatasertib | Advanced Solid Tumor | no benefit | detail... |
PTEN inact mut | Atezolizumab + Ipatasertib | Advanced Solid Tumor | no benefit | detail... |
PIK3CA act mut | Atezolizumab + Ipatasertib | Advanced Solid Tumor | no benefit | detail... |
BRAF fusion | Belvarafenib + Cobimetinib | Advanced Solid Tumor | predicted - sensitive | detail... |
PIK3CA act mut | Copanlisib + Nivolumab | Advanced Solid Tumor | predicted - sensitive | detail... |
PTEN inact mut | Copanlisib + Nivolumab | Advanced Solid Tumor | predicted - sensitive | detail... |
FGFR2 V564I | Pemigatinib | Advanced Solid Tumor | predicted - sensitive | detail... |
FGFR3 V555M | Pemigatinib | Advanced Solid Tumor | resistant | detail... |
PIK3CA P539R PIK3CA H1047R | STX-478 | Advanced Solid Tumor | sensitive | detail... |
PIK3CA D350N PIK3CA H1047R | STX-478 | Advanced Solid Tumor | sensitive | detail... |
RET mutant | EP0031 | Advanced Solid Tumor | predicted - sensitive | detail... |
FBXW7 del | Ceralasertib | Advanced Solid Tumor | sensitive | detail... |
FBXW7 del | Adavosertib | Advanced Solid Tumor | sensitive | detail... |
FBXW7 del | AZD7762 | Advanced Solid Tumor | sensitive | detail... |
FBXW7 del | RP-6306 | Advanced Solid Tumor | sensitive | detail... |
ATM inact mut | Ipilimumab + Nivolumab | Advanced Solid Tumor | no benefit | detail... |
EML4 - ALK ALK E1210K | Ensartinib | Advanced Solid Tumor | resistant | detail... |
EML4 - ALK ALK G1123S | Ensartinib | Advanced Solid Tumor | sensitive | detail... |
EML4 - ALK ALK L1198F | Ensartinib | Advanced Solid Tumor | sensitive | detail... |
EML4 - ALK ALK G1269A | Ensartinib | Advanced Solid Tumor | resistant | detail... |
EML4 - ALK ALK L1152R | Ensartinib | Advanced Solid Tumor | sensitive | detail... |
EML4 - ALK ALK F1174V | Ensartinib | Advanced Solid Tumor | sensitive | detail... |
EML4 - ALK ALK V1180L | Ensartinib | Advanced Solid Tumor | sensitive | detail... |
EML4 - ALK ALK G1123S | Crizotinib | Advanced Solid Tumor | sensitive | detail... |
EML4 - ALK ALK G1123S | Ceritinib | Advanced Solid Tumor | resistant | detail... |
EML4 - ALK ALK G1123S | Alectinib | Advanced Solid Tumor | sensitive | detail... |
EML4 - ALK ALK G1123S | Brigatinib | Advanced Solid Tumor | sensitive | detail... |
EML4 - ALK ALK F1245C | Brigatinib | Advanced Solid Tumor | sensitive | detail... |
EML4 - ALK ALK G1123S | Lorlatinib | Advanced Solid Tumor | sensitive | detail... |
EML4 - ALK ALK F1245C | Lorlatinib | Advanced Solid Tumor | sensitive | detail... |
BRAF N486_P490del | Trametinib | Advanced Solid Tumor | predicted - sensitive | detail... |
BRAF L485_P490delinsF | Trametinib | Advanced Solid Tumor | predicted - sensitive | detail... |
BRAF L485_P490delinsY | Trametinib | Advanced Solid Tumor | predicted - sensitive | detail... |
BRAF V487_P492delinsA | Trametinib | Advanced Solid Tumor | predicted - sensitive | detail... |
BRAF L485_P490delinsFS | Trametinib | Advanced Solid Tumor | predicted - sensitive | detail... |
BRAF N486_P490del | Vemurafenib | Advanced Solid Tumor | predicted - resistant | detail... |
BRAF L485_P490delinsF | Vemurafenib | Advanced Solid Tumor | predicted - resistant | detail... |
BRAF L485_P490delinsY | Vemurafenib | Advanced Solid Tumor | predicted - resistant | detail... |
BRAF V487_P492delinsA | Vemurafenib | Advanced Solid Tumor | predicted - resistant | detail... |
BRAF L485_P490delinsFS | Vemurafenib | Advanced Solid Tumor | predicted - resistant | detail... |
BRAF L485_P490delinsF | Encorafenib | Advanced Solid Tumor | predicted - resistant | detail... |
BRAF L485_P490delinsY | Encorafenib | Advanced Solid Tumor | predicted - resistant | detail... |
BRAF L485_P490delinsFS | Encorafenib | Advanced Solid Tumor | predicted - resistant | detail... |
BRAF L485_P490delinsFS | GDC0879 | Advanced Solid Tumor | predicted - sensitive | detail... |
BRAF L485_P490delinsFS | Sorafenib | Advanced Solid Tumor | predicted - sensitive | detail... |
BRAF L485_P490delinsFS | Belvarafenib | Advanced Solid Tumor | predicted - sensitive | detail... |
BRAF L485_P490delinsFS | Lifirafenib | Advanced Solid Tumor | predicted - sensitive | detail... |
BRAF L485_P490delinsFS | Tovorafenib | Advanced Solid Tumor | predicted - sensitive | detail... |
BRAF L485_P490delinsFS | TAK-632 | Advanced Solid Tumor | predicted - sensitive | detail... |
BRAF N486_P490del | Dabrafenib | Advanced Solid Tumor | predicted - sensitive | detail... |
BRAF L485_P490delinsF | Dabrafenib | Advanced Solid Tumor | predicted - resistant | detail... |
BRAF L485_P490delinsY | Dabrafenib | Advanced Solid Tumor | predicted - resistant | detail... |
BRAF V487_P492delinsA | Dabrafenib | Advanced Solid Tumor | predicted - sensitive | detail... |
BRAF L485_P490delinsFS | Dabrafenib | Advanced Solid Tumor | predicted - resistant | detail... |
BRAF N486_P490del | LXH 254 | Advanced Solid Tumor | predicted - sensitive | detail... |
BRAF L485_P490delinsF | LXH 254 | Advanced Solid Tumor | predicted - sensitive | detail... |
BRAF L485_P490delinsY | LXH 254 | Advanced Solid Tumor | predicted - sensitive | detail... |
BRAF V487_P492delinsA | LXH 254 | Advanced Solid Tumor | predicted - sensitive | detail... |
BRAF L485_P490delinsFS | LXH 254 | Advanced Solid Tumor | predicted - sensitive | detail... |
ALK F1174I | Lorlatinib | Advanced Solid Tumor | sensitive | detail... |
ALK R1192P | Lorlatinib | Advanced Solid Tumor | sensitive | detail... |
ALK Y1278S | Lorlatinib | Advanced Solid Tumor | sensitive | detail... |
ALK G1269A | Lorlatinib | Advanced Solid Tumor | sensitive | detail... |
NRAS G12C | JDQ443 | Advanced Solid Tumor | sensitive | detail... |
HRAS G12C | JDQ443 | Advanced Solid Tumor | sensitive | detail... |
HRAS G12C | Sotorasib | Advanced Solid Tumor | sensitive | detail... |
NRAS G12C | Sotorasib | Advanced Solid Tumor | sensitive | detail... |
NRAS G12C | RM-018 | Advanced Solid Tumor | sensitive | detail... |
HRAS G12C | RM-018 | Advanced Solid Tumor | sensitive | detail... |
ATM inact mut | Radiotherapy + RP-3500 | Advanced Solid Tumor | predicted - sensitive | detail... |
NRAS mutant | IK-595 | Advanced Solid Tumor | predicted - sensitive | detail... |
MLH1 negative | Nivolumab | Advanced Solid Tumor | predicted - sensitive | detail... |
MSH2 negative | Nivolumab | Advanced Solid Tumor | predicted - sensitive | detail... |
Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
---|---|---|---|---|---|---|
NCT00006199 | Phase I | Tipifarnib Topotecan | Study of the Farnesyl Transferase Inhibitor, R115777, in Combination With Topotecan (NYU 99-32) | Unknown status | USA | 0 |
NCT00084695 | Phase II | Fludarabine Busulfan + Melphalan anti-thymocyte globulin Cyclophosphamide Prednisone | Umbilical Cord Blood for Stem Cell Transplantation in Treating Young Patients With Malignant or Nonmalignant Diseases | Unknown status | USA | 0 |
NCT00089245 | Phase I | Omburtamab I-131 | Radiolabeled Monoclonal Antibody Therapy in Treating Patients With Refractory, Recurrent, or Advanced CNS or Leptomeningeal Cancer | Terminated | USA | 0 |
NCT00313599 | Phase I | Lapatinib + Paclitaxel | Lapatinib and Paclitaxel in Treating Patients With Advanced Solid Tumors | Completed | USA | 0 |
NCT00463060 | Phase Ib/II | Sunitinib | Sutent and Radiation as Treatment for Limited Extent Metastatic Cancer | Completed | USA | 0 |
NCT00576654 | Phase I | Irinotecan Veliparib | Veliparib and Irinotecan Hydrochloride in Treating Patients With Cancer That Is Metastatic or Cannot Be Removed by Surgery | Active, not recruiting | USA | 0 |
NCT00585195 | Phase I | Crizotinib + Itraconazole Crizotinib + Rifampin | A Study Of Oral PF-02341066, A C-Met/Hepatocyte Growth Factor Tyrosine Kinase Inhibitor, In Patients With Advanced Cancer (PROFILE 1001) | Completed | USA | AUS | 2 |
NCT00608361 | Phase I | Dasatinib | Dasatinib in Treating Patients With Solid Tumors or Lymphomas That Are Metastatic or Cannot Be Removed By Surgery | Completed | USA | 0 |
NCT00610948 | Phase I | Everolimus Panitumumab | Everolimus, Fluorouracil, Leucovorin, Panitumumab, and Oxaliplatin in Treating Patients With Solid Tumors That Did Not Respond to Treatment | Completed | USA | 0 |
NCT00625378 | Phase III | Sorafenib | Sorafenib Long Term Extension Program (STEP) | Completed | USA | ITA | GBR | FRA | ESP | DEU | CAN | BEL | AUS | 10 |
NCT00658658 | Phase I | Panitumumab | Panitumumab Pediatric Study | Completed | USA | 0 |
NCT00665990 | Phase I | Bevacizumab + Cyclophosphamide + Sorafenib | Phase I Study of Bevacizumab and Sorafenib Combined With Low Dose Cyclophosphamide in Patients With Refractory Solid Tumors and Leukemia | Completed | USA | 0 |
NCT00697632 | Phase I | Glesatinib | Safety Study of Oral MGCD265 Administered Without Interruption to Subjects With Advanced Malignancies | Completed | USA | CAN | 1 |
NCT00740805 | Phase I | Aldoxorubicin + Cyclophosphamide + Veliparib | Veliparib, Cyclophosphamide, and Doxorubicin Hydrochloride in Treating Patients With Metastatic or Unresectable Solid Tumors or Non-Hodgkin Lymphoma | Active, not recruiting | USA | 0 |
NCT00756340 | Phase I | Bevacizumab + Everolimus | A Trial of Everolimus and Bevacizumab in Children With Recurrent Solid Tumors | Completed | USA | 0 |
NCT00761644 | Phase I | Bevacizumab + Pegylated liposomal doxorubicin + Temsirolimus | Doxil, Bevacizumab and Temsirolimus Trial | Completed | USA | 0 |
NCT00770263 | Phase I | Erlotinib + Temsirolimus | Erlotinib and Temsirolimus for Solid Tumors | Completed | USA | 0 |
NCT00776867 | Phase I | Perifosine | Study of Single Agent Perifosine for Recurrent Pediatric Solid Tumors | Completed | USA | 0 |
NCT00781612 | Phase II | Ado-trastuzumab emtansine + Trastuzumab Ado-trastuzumab emtansine + Paclitaxel Ado-trastuzumab emtansine Ado-trastuzumab emtansine + Docetaxel Ado-trastuzumab emtansine + Capecitabine Ado-trastuzumab emtansine + Pertuzumab | A Safety Extension Study of Trastuzumab Emtansine in Participants Previously Treated With Trastuzumab Emtansine Alone or in Combination With Other Anti-Cancer Therapy in One of the Parent Studies | Recruiting | USA | ITA | GBR | FRA | ESP | DEU | CAN | BEL | AUT | AUS | 29 |
NCT00790816 | Phase I | Lapatinib + Paclitaxel Lapatinib Lapatinib + Trastuzumab Capecitabine + Lapatinib Lapatinib + Letrozole Capecitabine + Lapatinib + Oxaliplatin Gemcitabine + Lapatinib Docetaxel + Lapatinib Fluorouracil + Lapatinib + Leucovorin + Oxaliplatin Fluorouracil + Irinotecan + Lapatinib + Leucovorin | Continuation Study of Lapatinib Monotherapy or Lapatinib in Combination With Other Anti-cancer Agents | Completed | USA | ESP | CAN | 2 |
NCT00854152 | Phase I | Apitolisib | A Study Evaluating GDC-0980 Administered Once Daily in Patients With Refractory Solid Tumors or Non-Hodgkin's Lymphoma | Completed | USA | GBR | 0 |
NCT00858377 | Phase I | AMG 900 | A Phase 1 First-in-Human Study Evaluating AMG 900 in Advanced Solid Tumors | Completed | USA | AUS | 0 |
NCT00889954 | Phase I | Autologous TGF beta resistant HER2 EBV CTLs | Her2 and TGFBeta CTLs in Treatment of Her2 Positive Malignancy | Completed | USA | 0 |
NCT00909831 | Phase I | Hydroxychloroquine + Temsirolimus | Hydroxychloroquine and Temsirolimus in Treating Patients With Metastatic Solid Tumors That Have Not Responded to Treatment | Completed | USA | 0 |
NCT00926640 | Phase I | Belinostat + Cisplatin + Etoposide | A Phase I Study of Belinostat in Combination With Cisplatin and Etoposide in Adults With Small Cell Lung Carcinoma and Other Advanced Cancers | Completed | USA | 0 |
NCT00939770 | Phase Ib/II | Crizotinib | Crizotinib in Treating Young Patients With Relapsed or Refractory Solid Tumors or Anaplastic Large Cell Lymphoma | Completed | USA | CAN | 0 |
NCT00940381 | Phase I | Cetuximab + Sirolimus | Sirolimus and Cetuximab in Advanced Malignancies | Completed | USA | 0 |
NCT00981890 | Phase I | Sunitinib | Stereotactic Radiosurgery With Sunitinib for Brain Metastases | Completed | CAN | 0 |
NCT00996892 | Phase I | Cobimetinib + Pictilisib | Safety, Tolerability and Pharmacokinetics of Cobimetinib in Combination With Pictilisib in Patients With Locally Advanced or Metastatic Solid Tumors | Terminated | USA | 0 |
NCT00999401 | Phase I | Sapacitabine + Seliciclib | A Study of Oral Sapacitabine and Oral Seliciclib in Patients With Advanced Solid Tumors | Completed | USA | 0 |
NCT01004224 | Phase I | Infigratinib | A Dose Escalation Study in Adult Patients With Advanced Solid Malignancies | Completed | USA | ITA | FRA | ESP | DEU | AUT | AUS | 7 |
NCT01004861 | Phase I | Pexidartinib | Safety Study of PLX108-01 in Patients With Solid Tumors | Completed | USA | 0 |
NCT01012817 | Phase Ib/II | Topotecan + Veliparib | Veliparib and Topotecan Hydrochloride in Treating Patients With Solid Tumors, Relapsed or Refractory Ovarian Cancer, or Primary Peritoneal Cancer | Active, not recruiting | USA | 0 |
NCT01014936 | Phase I | Tepotinib | First-in-Man, Dose-escalation Trial of C-met Kinase Inhibitor MSC2156119J in Subjects With Advanced Solid Tumors | Completed | USA | 0 |
NCT01015222 | Phase I | Methylnaltrexone Bromide Dasatinib Paclitaxel Bevacizumab | Dasatinib, Bevacizumab, Paclitaxel in Patients With Advanced Malignancies | Completed | USA | 0 |
NCT01017640 | Phase I | Veliparib Mitomycin C + Veliparib | Veliparib With or Without Mitomycin C in Treating Patients With Metastatic, Unresectable, or Recurrent Solid Tumors | Completed | USA | 0 |
NCT01023737 | Phase I | Hydroxychloroquine + Vorinostat | Hydroxychloroquine + Vorinostat in Advanced Solid Tumors | Completed | USA | 0 |
NCT01037790 | Phase II | Palbociclib | PHASE II TRIAL OF THE CYCLIN-DEPEDENT KINASE INHIBITOR PD 0332991 IN PATIENTS WITH CANCER | Completed | USA | 0 |
NCT01042535 | Phase Ib/II | Ad.p53-DC vaccine + Indoximod | Vaccine Therapy and 1-MT in Treating Patients With Metastatic Breast Cancer | Completed | USA | 0 |
NCT01058707 | Phase I | Sapanisertib | Dose Escalation Study of MLN0128 in Subjects With Advanced Malignancies | Completed | USA | ESP | 0 |
NCT01061788 | Phase I | Everolimus + Ganitumab + Panitumumab | A Trial of AMG 479, Everolimus (RAD001) and Panitumumab in Patients With Advanced Cancer | Completed | USA | 0 |
NCT01063075 | Phase II | Carboplatin + Cetuximab + Fluorouracil | A Study in Advanced Solid Tumors | Completed | USA | CAN | 0 |
NCT01071941 | Phase I | Oncolytic HSV-1 rRp450 | rRp450-Phase I Trial in Liver Metastases and Primary Liver Tumors | Recruiting | USA | 0 |
NCT01081808 | Phase I | EGFRBi-armed autologous activated T cells | Laboratory-Treated Autologous Lymphocytes, Aldesleukin, and Sargramostim (GM-CSF) in Treating Advanced Solid Tumors | Terminated | USA | 0 |
NCT01087554 | Phase I | Temsirolimus Everolimus Sirolimus Vorinostat | Sirolimus or Everolimus or Temsirolimus and Vorinostat in Advanced Cancer | Active, not recruiting | USA | 0 |
NCT01087983 | Phase I | Lapatinib + Sirolimus Lapatinib + Metformin | Lapatinib With Sirolimus or Metformin | Completed | USA | 0 |
NCT01099358 | Phase II | Cetuximab + Cisplatin Fluorouracil | Study in Advanced Solid Tumors | Completed | USA | CAN | 0 |
NCT01106599 | Phase I | GDC-0623 | A Study Evaluating the Safety, Tolerability, and Pharmacokinetics of GDC-0623 in Patients With Locally Advanced or Metastatic Solid Tumors | Completed | USA | 0 |
NCT01107522 | Phase I | Carboxyamidotriazole Orotate + Temozolomide Carboxyamidotriazole Orotate | Safety and Tolerability of Carboxyamidotriazole Orotate (CTO) in Solid Tumors or With Temodar® in Glioblastoma or Other Recurrent Malignant Gliomas or in Combination With Temodar® and Radiation Therapy for Patients With Newly Diagnosed Glioblastoma and Malignant Gliomas | Active, not recruiting | USA | 0 |
NCT01113476 | Phase I | Bevacizumab + Gemcitabine + Nab-paclitaxel | Nab-paclitaxel, Gemcitabine, and Bevacizumab in Advanced Malignancies | Completed | USA | 0 |
NCT01121588 | Phase I | Crizotinib | An Investigational Drug, Crizotinib (PF-02341066), Is Being Studied In Tumors, Except Non-Small Cell Lung Cancer, That Are Positive For Anaplastic Lymphoma Kinase (ALK) | Terminated | USA | ITA | 5 |
NCT01122199 | Phase I | Everolimus + Ganitumab | Study of RAD001 + AMG479 for Patients With Advanced Solid Tumors | Completed | USA | 0 |
NCT01138085 | Phase I | Trametinib + Uprosertib | Safety, Pharmacokinetics (PK) of AKT and MEK Combination | Completed | USA | 0 |
NCT01139723 | Phase I | Bevacizumab MINT1526A | A Study of the Safety and Pharmacokinetics of MINT1526A, Administered Intravenously As a Single Agent and in Combination With Bevacizumab to Patients With Advanced Solid Tumors | Completed | USA | 0 |
NCT01164163 | Phase I | Ruxolitinib | INCB18424 in Treating Young Patients With Relapsed or Refractory Solid Tumor, Leukemia, or Myeloproliferative Disease | Completed | USA | 0 |
NCT01177397 | Phase Ib/II | Onatasertib | Study to Assess Safety, Pharmacokinetics, and Efficacy of Oral CC-223 for Patients With Advanced Solid Tumors, Non-Hodgkin Lymphoma or Multiple Myeloma | Completed | USA | GBR | FRA | ESP | 0 |
NCT01184326 | Phase I | Everolimus + Pazopanib | An Expanded Phase I Study of Pazopanib and Everolimus in Patients With Advanced Solid Tumors and Previously Treated Advanced Urothelial Cancer | Completed | USA | 0 |
NCT01187199 | Phase I | Bevacizumab Paclitaxel Carboplatin Sorafenib Temsirolimus | Phase I Trial of Bevacizumab and Temsirolimus in Combination With 1) Carboplatin, 2) Paclitaxel, 3) Sorafenib for the Treatment of Advanced Cancer | Active, not recruiting | USA | 0 |
NCT01197170 | Phase I | Erlotinib Everolimus Sorafenib Anastrozole Bevacizumab | Hormone Receptor Positive Disease Across Solid Tumor Types: A Phase I Study of Single-Agent Hormone Blockade and Combination Approaches With Targeted Agents to Provide Synergy and Overcome Resistance | Completed | USA | 0 |
NCT01213238 | Phase I | Oxaliplatin Capecitabine Bevacizumab | Hepatic Arterial Infusion Oxaliplatin, Capecitabine With or Without Bevacizumab | Completed | USA | 0 |
NCT01218555 | Phase I | Lenalidomide Everolimus | Study of Everolimus (RAD001)in Combination With Lenalidomide | Completed | USA | 0 |
NCT01218867 | Phase Ib/II | Anti-VEGFR2 CAR CD8 lymphocytes Cyclophosphamide Fludarabine Aldesleukin | Treating Metastatic Cancer With Anti-VEGFR2 Gene Engineered CD8+ Lymphocytes | Terminated | USA | 0 |
NCT01219699 | Phase I | Alpelisib Alpelisib + Fulvestrant | A Study of BYL719 in Adult Patients With Advanced Solid Malignancies, Whose Tumors Have an Alteration of the PIK3CA Gene | Completed | USA | GBR | ESP | DEU | 1 |
NCT01226316 | Phase I | Capivasertib | Safety, Tolerability & Potential Anti-cancer Activity of Increasing Doses of AZD5363 in Different Treatment Schedules | Active, not recruiting | USA | ITA | GBR | FRA | ESP | CAN | 4 |
NCT01231594 | Phase I | Dabrafenib Trametinib | A Rollover Study to Provide Continued Treatment With GSK2118436 to Subjects With BRAF Mutation-Positive Tumors | Completed | USA | ITA | GBR | FRA | ESP | DEU | CAN | AUS | 1 |
NCT01237236 | Phase I | Ribociclib | A Trial of LEE011 in Patients With Advanced Solid Tumors or Lymphoma. | Completed | USA | FRA | 1 |
NCT01239134 | Phase I | TRX518 | Trial of TRX518 (Anti-GITR mAb) in Stage III or IV Malignant Melanoma or Other Solid Tumors | Completed | USA | 0 |
NCT01240590 | Phase Ib/II | Cisplatin + Crolibulin Cisplatin | A Phase I/II Trial of Crolibulin (EPC2407) Plus Cisplatin in Adults With Solid Tumors With a Focus on Anaplastic Thyroid Cancer (ATC) | Completed | USA | 0 |
NCT01248949 | Phase I | Bevacizumab MEDI3617 Gemcitabine Carboplatin Paclitaxel | A Study to Evaluate the Safety and Antitumor Activity in Subjects With Advanced Solid Tumors | Completed | USA | 0 |
NCT01249443 | Phase I | Carboplatin Vorinostat Paclitaxel | Vorinostat in Combination With Paclitaxel and Carboplatin in Treating Patients With Metastatic or Recurrent Solid Tumors and HIV Infection | Terminated | USA | 0 |
NCT01253707 | Phase I | AMG 337 | A Study of AMG 337 in Subjects With Advanced Solid Tumors | Completed | USA | 0 |
NCT01264432 | Phase I | Veliparib | Veliparib and Radiation Therapy in Treating Patients With Advanced Solid Malignancies With Peritoneal Carcinomatosis, Epithelial Ovarian, Fallopian, or Primary Peritoneal Cancer | Completed | USA | CAN | 0 |
NCT01266057 | Phase I | Hydroxychloroquine + Vorinostat Hydroxychloroquine + Sirolimus | Sirolimus or Vorinostat and Hydroxychloroquine in Advanced Cancer | Completed | USA | 0 |
NCT01273155 | Phase I | Belinostat | Belinostat for Solid Tumors and Lymphomas in Patients With Varying Degrees of Hepatic Dysfunction | Completed | USA | 0 |
NCT01276210 | Phase I | Sorafenib | Sorafenib Tosylate and Stereotactic Radiosurgery in Treating Patients With Brain Metastases | Completed | USA | 0 |
NCT01281150 | Phase I | Veliparib Paclitaxel Carboplatin | Veliparib in Combination With Carboplatin and Paclitaxel in Treating Patients With Locally Advanced or Metastatic Solid Tumors | Completed | USA | 0 |
NCT01281176 | Phase I | Carboplatin + Vorinostat Paclitaxel + Vorinostat | High-Dose or Low-Dose Vorinostat in Combination With Carboplatin or Paclitaxel in Treating Patients With Advanced Solid Tumors | Active, not recruiting | USA | 0 |
NCT01283945 | Phase Ib/II | Lucitanib | Study of Oral Lucitanib (E-3810), a Dual VEGFR-FGFR Tyrosine Kinase Inhibitor, in Patients With Solid Tumors | Completed | ITA | FRA | ESP | 0 |
NCT01285037 | Phase I | Cisplatin Cetuximab Merestinib | A Study of LY2801653 in Advanced Cancer | Completed | USA | 0 |
NCT01286987 | Phase I | Talazoparib | Study of BMN 673, a PARP Inhibitor, in Patients With Advanced or Recurrent Solid Tumors | Completed | USA | GBR | 0 |
NCT01287546 | Phase I | Emibetuzumab + Erlotinib Emibetuzumab + Trametinib Emibetuzumab | A Study of LY2875358 in Participants With Advanced Cancer | Completed | USA | 0 |
NCT01288430 | Phase I | DS-2248 | A Study of DS-2248, in Subjects With Advanced Solid Tumors | Terminated | USA | 0 |
NCT01292655 | Phase I | BMS-906024 | Study to Evaluate the Safety and Tolerability of IV Doses of BMS-906024 in Subjects With Advanced or Metastatic Solid Tumors | Completed | USA | CAN | AUS | 0 |
NCT01294670 | Phase Ib/II | Etoposide + Vorinostat | Clinical Study of Vorinostat in Combination With Etoposide in Pediatric Patients < 21 Years at Diagnosis With Refractory Solid Tumors | Completed | USA | CAN | 0 |
NCT01296555 | Phase I | Fulvestrant Taselisib Letrozole | A Dose Escalation Study Evaluating the Safety and Tolerability of GDC-0032 in Patients With Locally Advanced or Metastatic Solid Tumors And in Combination With Endocrine Therapy in Patients With Locally Advanced or Metastatic Hormone Receptor-Positive Breast Cancer | Completed | USA | FRA | ESP | CAN | 0 |
NCT01296581 | Phase I | Vorolanib | Safety Study of X-82 in Patients With Advanced Solid Tumors | Completed | USA | 0 |
NCT01297452 | Phase I | Buparlisib + Carboplatin + Paclitaxel | BKM120 + Carboplatin + Paclitaxel for Patients With Advanced Solid Tumors | Completed | USA | 0 |
NCT01299636 | Phase I | PM060184 | Study of PM060184 in Patients With Advanced Solid Tumors | Completed | USA | 0 |
NCT01302405 | Phase I | PRI-724 | Safety and Efficacy Study of PRI-724 in Subjects With Advanced Solid Tumors | Terminated | USA | 0 |
NCT01303341 | Phase I | Riluzole + Sorafenib | Riluzole and Sorafenib Tosylate in Treating Patients With Advanced Solid Tumors or Melanoma | Active, not recruiting | USA | 0 |
NCT01307267 | Phase I | Rituximab + Utomilumab Utomilumab | A Study Of PF-05082566 As A Single Agent And In Combination With Rituximab | Completed | USA | ITA | FRA | AUS | 1 |
NCT01324479 | Phase I | Capmatinib | Study of INC280 in Patients With c-MET Dependent Advanced Solid Tumors | Completed | USA | ITA | FRA | ESP | DEU | CAN | AUS | 8 |
NCT01325441 | Phase Ib/II | Napabucasin + Paclitaxel | A Study of BBI608 Administered With Paclitaxel in Adult Patients With Advanced Malignancies | Completed | USA | CAN | 0 |
NCT01326702 | Phase Ib/II | Veliparib Rituximab Bendamustine | Veliparib, Bendamustine Hydrochloride, and Rituximab in Treating Patients With Relapsed or Refractory Lymphoma, Multiple Myeloma, or Solid Tumors | Completed | USA | 0 |
NCT01327612 | Phase II | Fluorouracil + Leucovorin + Oxaliplatin + Pembrolizumab Ganitumab Bevacizumab Conatumumab | Open Label Extension Study of Conatumumab and AMG 479 | Completed | USA | ESP | 1 |
NCT01336842 | Phase I | Cisplatin Panobinostat Pemetrexed Disodium | Study of Cisplatin and Pemetrexed in Combination With Panobinostat in Solid Tumors | Completed | USA | 0 |
NCT01339871 | Phase I | Vorinostat Pazopanib | Phase I Study of Pazopanib and Vorinostat | Completed | USA | 0 |
NCT01346358 | Phase I | LY3022855 | A Study of IMC-CS4 in Subjects With Advanced Solid Tumors | Completed | USA | 0 |
NCT01347866 | Phase I | Gedatolisib PD-0325901 Irinotecan | Clinical Study Of PI3K/mTOR Inhibitors In Combination With An Oral MEK Inhibitor Or Irinotecan In Patients With Advanced Cancer | Terminated | USA | ITA | ESP | CAN | 0 |
NCT01349660 | Phase Ib/II | Bevacizumab + Buparlisib | Combination of BKM120 and Bevacizumab in Refractory Solid Tumors and Relapsed/Refractory Glioblastoma Multiforme | Completed | USA | 0 |
NCT01351103 | Phase I | LGK974 LGK974 + Spartalizumab | A Study of LGK974 in Patients With Malignancies Dependent on Wnt Ligands | Active, not recruiting | USA | ITA | FRA | ESP | DEU | CAN | 1 |
NCT01353625 | Phase I | CC-115 | Study to Assess Safety and Tolerability of Oral CC-115 for Patients With Advanced Solid Tumors, and Hematologic Malignancies. | Completed | USA | FRA | ESP | DEU | 0 |
NCT01358331 | Phase I | MK-8353 | A Study of the Safety, Tolerability, and Efficacy of MK-8353 in Participants With Advanced Solid Tumors (MK-8353-001) | Terminated | 0 | |
NCT01362374 | Phase I | Enzalutamide Paclitaxel Docetaxel Ipatasertib Fluorouracil + Leucovorin + Oxaliplatin + Pembrolizumab | Safety and Pharmacology Of GDC-0068 in Combination With Docetaxel, Fluoropyrimidine Plus Oxaliplatin, Paclitaxel, or Enzalutamide in Patients With Advanced Solid Tumors | Completed | USA | GBR | FRA | ESP | 0 |
NCT01366144 | Phase I | Paclitaxel Veliparib Carboplatin | Veliparib, Paclitaxel, and Carboplatin in Treating Patients With Solid Tumors That Are Metastatic or Cannot Be Removed by Surgery and Liver or Kidney Dysfunction | Active, not recruiting | USA | 0 |
NCT01375699 | Phase I | Doxorubicin | Doxorubicin With or Without Sildenafil, With Analysis of Cardiac Markers | Completed | USA | 0 |
NCT01375829 | Phase I | Ixabepilone + Temsirolimus | Ixabepilone and Temsirolimus in Treating Patients With Solid Tumors That Are Metastatic or Cannot Be Removed by Surgery | Active, not recruiting | USA | 0 |
NCT01375842 | Phase I | Atezolizumab | A Phase 1 Study of MPDL3280A (an Engineered Anti-PDL1 Antibody) in Patients With Locally Advanced or Metastatic Solid Tumors | Completed | USA | GBR | FRA | ESP | 0 |
NCT01376310 | Phase II | Docetaxel + Trametinib Erlotinib + Trametinib Trametinib Pemetrexed Disodium + Trametinib Carboplatin + Trametinib Nab-paclitaxel + Trametinib Gemcitabine + Trametinib Everolimus + Trametinib | GSK1120212 Rollover Study | Terminated | USA | FRA | CAN | 3 |
NCT01376505 | Phase I | HER2 Vaccine | Vaccine Therapy in Treating Patients With Metastatic Solid Tumors | Completed | USA | 0 |
NCT01391533 | Phase I | SAR125844 | Study of SAR125844 Single Agent Administered as Slow Intravenous Infusion in Adult Patients With Advanced Malignant Solid Tumors | Completed | USA | ITA | FRA | ESP | 0 |
NCT01392521 | Phase I | Copanlisib + Refametinib | Phase Ib Study of PI3(Phosphoinositol 3)-Kinase Inhibitor Copanlisib With MEK (Mitogen-activated Protein Kinase) Inhibitor Refametinib (BAY86-9766) in Patients With Advanced Cancer | Completed | USA | DEU | 1 |
NCT01393509 | Phase I | PU-H71 | The First-in-human Phase I Trial of PU-H71 in Patients With Advanced Malignancies | Completed | USA | 0 |
NCT01405391 | Phase I | Lurbinectedin | Study of PM01183 in Non-Colorectal Cancer Patients as a Days 1 and 8 Intravenous Short Infusion Every 3 Weeks | Completed | USA | 0 |
NCT01407562 | Phase I | Carboplatin Paclitaxel Pazopanib | Study of Pazopanib, Paclitaxel, and Carboplatin in Patients With Advanced Solid Tumors | Terminated | USA | 0 |
NCT01411410 | Phase I | Copanlisib + Paclitaxel | Phase I Study of PI3(Phosphoinositol 3)-Kinase Inhibitor BAY80-6946 With Paclitaxel in Patients With Advanced Cancer | Completed | USA | 0 |
NCT01417546 | Phase I | NHS-IL12 | NHS-IL12 for Solid Tumors | Completed | USA | 0 |
NCT01425008 | Phase I | Tovorafenib | Study of MLN2480 in Patients With Relapsed or Refractory Solid Tumors Followed by a Dose Expansion in Patients With Metastatic Melanoma | Completed | USA | GBR | 0 |
NCT01433991 | Phase Ib/II | Golvatinib Lenvatinib | E7050 in Combination With E7080 in Subjects With Advanced Solid Tumors (Dose Escalation) and in Subjects With Recurrent Glioblastoma or Unresectable Stage III or Stage IV Melanoma After Prior Systemic Therapy (Expansion Cohort and Phase 2) | Terminated | USA | 0 |
NCT01434316 | Phase I | Dinaciclib + Veliparib Veliparib | Veliparib and Dinaciclib in Treating Patients With Advanced Solid Tumors | Active, not recruiting | USA | 0 |
NCT01438554 | Phase I | Pazopanib + Trametinib | Phase 1 Study of Pazopanib With GSK1120212 in Advanced Solid Tumors, Enriched With Patients With Differentiated Thyroid Cancer, Soft-tissue Sarcoma, and Cholangiocarcinoma | Completed | USA | 0 |
NCT01443481 | Phase I | Dovitinib | Pharmacokinetics (PK) of TKI258 in Cancer Patients With Normal and Impaired Hepatic Function | Completed | USA | ITA | DEU | BEL | 2 |
NCT01445509 | Phase I | Bevacizumab Dasatinib | Dasatinib in Combination With Bevacizumab to Treat Advanced Solid Tumors | Completed | USA | 0 |
NCT01449058 | Phase Ib/II | Alpelisib + Binimetinib | A Phase Ib Study of MEK162 Plus BYL719 in Adult Patients With Selected Advanced Solid Tumors | Completed | USA | ITA | GBR | FRA | ESP | AUS | 1 |
NCT01449370 | Phase I | Serabelisib | Dose Escalation Study of MLN1117 in Subjects With Advanced Cancer | Completed | USA | GBR | ESP | 0 |
NCT01449461 | Phase Ib/II | Brigatinib | A Phase 1/2 Study of the Oral ALK/EGFR Inhibitor AP26113 | Completed | 0 | |
NCT01450384 | Phase I | Pemetrexed Disodium + Sorafenib | Pemetrexed Disodium and Sorafenib Tosylate in Treating Patients With Advanced Solid Tumors | Completed | USA | 0 |
NCT01458067 | Phase I | GSK2636771 | A Phase I/IIa, First Time in Human, Study of GSK2636771 in Subjects With Advanced Solid Tumors With Phosphatase and Tensin Homolog (PTEN) Deficiency | Completed | USA | GBR | 1 |
NCT01468922 | Phase I | Tivantinib Pazopanib | Pazopanib and ARQ 197 for Advanced Solid Tumors | Completed | USA | 0 |
NCT01470209 | Phase I | Buparlisib + Everolimus | A Phase I Study of BKM120 and Everolimus in Advanced Solid Malignancies | Completed | USA | 0 |
NCT01472016 | Phase I | Docetaxel ABT-700 Cetuximab Erlotinib Fluorouracil + Irinotecan + Leucovorin | Study of ABT-700 in Subjects With Advanced Solid Tumors | Completed | 0 | |
NCT01473095 | Phase I | Miransertib | Phase 1 Dose Escalation Study of ARQ 092 in Adult Subjects With Advanced Solid Tumors and Recurrent Malignant Lymphoma | Completed | USA | 0 |
NCT01480154 | Phase I | Hydroxychloroquine + MK2206 | Akt Inhibitor MK2206 and Hydroxychloroquine in Treating Patients With Advanced Solid Tumors, Melanoma, Prostate or Kidney Cancer | Active, not recruiting | USA | 0 |
NCT01485042 | Phase I | Evofosfamide + Pazopanib | Dose Escalation Study of Pazopanib Plus TH-302 | Completed | USA | 0 |
NCT01494688 | Phase I | Emactuzumab Emactuzumab + Paclitaxel | A Study of RO5509554 as Monotherapy and in Combination With Paclitaxel in Patients With Advanced Solid Tumors | Completed | USA | FRA | 0 |
NCT01497392 | Phase I | Gemcitabine Dovitinib Capecitabine | Dovitinib Lactate, Gemcitabine Hydrochloride, and Capecitabine in Treating Patients With Advanced or Metastatic Solid Tumors, Pancreatic Cancer and Biliary Cancers | Completed | USA | 0 |
NCT01497626 | Phase I | Bortezomib + Lapatinib | Lapatinib and Bortezomib in Patients With Advanced Malignancies | Terminated | USA | 0 |
NCT01497704 | Phase Ib/II | Rivoceranib | Dose-Escalation and Safety Trial of YN968D1 | Completed | USA | 1 |
NCT01498484 | Phase II | EB-VST cells | Therapeutic Effects of Epstein-Barr Virus Immune T-Lymphocytes Derived From a Normal HLA-Compatible Or Partially-Matched Third-Party Donor in the Treatment of EBV Lymphoproliferative Disorders and EBV-Associated Malignancies | Completed | USA | 0 |
NCT01505569 | Phase I | Filgrastim Busulfan + Melphalan Etoposide + Ifosfamide Thiotepa Carboplatin | Auto Transplant for High Risk or Relapsed Solid or CNS Tumors | Completed | USA | 0 |
NCT01508104 | Phase Ib/II | Dactolisib + Everolimus Everolimus | Safety Study of BEZ235 With Everolimus in Subjects With Advanced Solid Tumors | Terminated | USA | 0 |
NCT01518413 | Phase I | Irinotecan + Sorafenib | Dose Escalation Study of Sorafenib and Irinotecan Combination Therapy in Pediatric Patients With Solid Tumors | Completed | USA | 0 |
NCT01520389 | Phase I | MM-151 Irinotecan | Safety Study of the Drug MM-151 in Patients With Advanced Solid Tumors Resisting Ordinary Treatment | Completed | USA | 0 |
NCT01522820 | Phase I | Rasdegafusp alfa Sirolimus | Vaccine Therapy With or Without Sirolimus in Treating Patients With NY-ESO-1 Expressing Solid Tumors | Completed | USA | 0 |
NCT01522989 | Phase I | Fluorouracil + Oxaliplatin + Palbociclib | PD-0332991, 5-FU, and Oxaliplatin for Advanced Solid Tumor Malignancies | Unknown status | USA | 0 |
NCT01524978 | Phase II | Vemurafenib Cetuximab | A Study of Zelboraf (Vemurafenib) in Patients With BRAF V600 Mutation-Positive Cancers | Completed | USA | GBR | FRA | ESP | DEU | 1 |
NCT01525602 | Phase I | Paclitaxel + Pexidartinib | Safety Study of PLX3397 and Paclitaxel in Patients With Advanced Solid Tumors | Completed | USA | 0 |
NCT01526473 | Phase I | AVX901 | A Phase I Study To Evaluate The Antitumor Activity And Safety Of AVX901 | Completed | USA | 0 |
NCT01528046 | Phase I | Metformin Irinotecan + Temozolomide + Vincristine Sulfate | Metformin in Children With Relapsed or Refractory Solid Tumors | Completed | USA | 0 |
NCT01529593 | Phase I | Metformin + Temsirolimus | Temsirolimus in Combination With Metformin in Patients With Advanced Cancers | Active, not recruiting | USA | 0 |
NCT01531361 | Phase I | Sorafenib + Vemurafenib Crizotinib + Vemurafenib | Vemurafenib With Sorafenib Tosylate or Crizotinib in Treating Patients With Advanced Malignancies With BRAF Mutations | Completed | USA | 0 |
NCT01531894 | Phase II | Afuresertib | Continuation Study of the Oral AKT Inhibitor GSK2110183 | Completed | USA | CAN | AUS | 2 |
NCT01532011 | Phase I | Erlotinib + Pralatrexate | Erlotinib in Combination With Pralatrexate in Advanced Malignancies | Completed | USA | 0 |
NCT01534598 | Phase I | 5-Fluoro-2-deoxycytidine + Tetrahydrouridine | FdCyd and THU for Advanced Solid Tumors | Completed | USA | 0 |
NCT01537107 | Phase I | Sirolimus + Vismodegib | Sirolimus and Vismodegib in Treating Patients With Solid Tumors or Pancreatic Cancer That is Metastatic or Cannot Be Removed By Surgery | Completed | USA | 0 |
NCT01537744 | Phase I | Azacitidine + Romidepsin | A Trial of Oral 5-azacitidine in Combination With Romidepsin in Advanced Solid Tumors, With an Expansion Cohort in Non-small Cell Lung Cancer | Completed | USA | 0 |
NCT01540253 | Phase I | Buparlisib + Docetaxel | PI3K Inhibitor BKM120 and Docetaxel in Treating Patients With Advanced Solid Tumor That is Locally Advanced, Cannot Be Removed By Surgery, or Metastatic | Completed | USA | 0 |
NCT01540526 | Phase I | Axitinib | Pharmacodynamic Study With FLT-PET/CT in Patients With Prostate/Other Solid Malignancies Treated With High Dose Axitinib | Completed | USA | 0 |
NCT01548144 | Phase I | Crizotinib + Pazopanib Crizotinib + Pemetrexed Disodium Pazopanib + Pemetrexed Disodium Crizotinib + Pazopanib + Pemetrexed Disodium | Pazopanib or Pemetrexed and Crizotinib in Advanced Cancer | Terminated | USA | 0 |
NCT01552356 | Phase I | Pazopanib | Pazopanib Hydrochloride in Treating Patients With Advanced or Refractory Solid Tumors | Active, not recruiting | USA | 0 |
NCT01552434 | Phase I | Bevacizumab + Cetuximab + Temsirolimus + Valproic acid | Bevacizumab, Temsirolimus, Valproic Acid, Cetuximab | Active, not recruiting | USA | 0 |
NCT01553071 | Phase I | Safingol Fenretinide | Phase I Trial of IV Fenretinide (4-HPR) Plus IV Safingol for Patients With Relapsed Malignancies | Terminated | USA | 0 |
NCT01562275 | Phase I | Cobimetinib + Ipatasertib | A Study Evaluating the Safety, Tolerability, and Pharmacokinetics of GDC-0973 in Combination With GDC-0068 When Administered in Patients With Locally Advanced or Metastatic Solid Tumors | Completed | USA | ESP | 0 |
NCT01562899 | Phase II | Binimetinib + Ganitumab | A Study of MEK162 and AMG 479 in Patients With Selected Solid Tumors | Terminated | USA | ITA | GBR | FRA | ESP | CAN | BEL | AUS | 0 |
NCT01564251 | Phase I | GDC-0575 + Gemcitabine GDC-0575 | A Study of GDC-0575 Alone And in Combination With Gemcitabine in Patients With Refractory Solid Tumors or Lymphoma | Completed | USA | FRA | 0 |
NCT01571024 | Phase I | Fluorouracil + Leucovorin + Oxaliplatin + Pembrolizumab Buparlisib | BKM120 + mFOLFOX6 in Advanced Solid Tumors With Expansion Cohort Pancreatic Cancer | Completed | USA | 0 |
NCT01576406 | Phase I | Crizotinib | Hepatic Impairment Study For Crizotinib In Advanced Cancer Patients | Completed | USA | 0 |
NCT01576666 | Phase Ib/II | Buparlisib + Sonidegib | Phase Ib, Dose Escalation Study of Oral LDE225 in Combination With BKM120 in Patients With Advanced Solid Tumors | Completed | USA | ITA | GBR | ESP | DEU | CAN | BEL | AUS | 0 |
NCT01577745 | Phase I | MEDI0639 | A Phase 1 Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of MEDI0639 in Advanced Solid Tumors | Completed | USA | 0 |
NCT01581541 | Phase I | PU-H71 | PU-H71 in Patients With Solid Tumors and Low-Grade Non-Hodgkin s Lymphoma That Have Not Responded to Standard Treatment | Terminated | USA | 0 |
NCT01582191 | Phase I | Everolimus + Vandetanib | Vandetanib and Everolimus in Treating Patients With Advanced or Metastatic Cancer | Active, not recruiting | USA | 0 |
NCT01587040 | Phase Ib/II | XL147 Voxtalisib | Open Label Treatment Extension Study With SAR245408 or SAR245409 as a Monotherapy or as a Combination Regimen | Completed | USA | FRA | ESP | BEL | 0 |
NCT01587703 | Phase I | Molibresib | A Study to Investigate the Safety, Pharmacokinetics, Pharmacodynamics, and Clinical Activity of GSK525762 in Subjects With NUT Midline Carcinoma (NMC) and Other Cancers | Completed | USA | GBR | FRA | ESP | AUS | 2 |
NCT01588184 | Phase III | Bevacizumab | An Extension Study to Provide Continued Avastin Therapy to Patients With Solid Tumours Who Were Previously Enrolled in a Roche/Genentech Sponsored Study | Completed | ITA | GBR | FRA | ESP | DEU | CAN | AUT | 14 |
NCT01588678 | Phase I | DS-3078a | A Open-Label, Multiple Ascending Dose Study of DS-3078a, an Oral TORC1/2 Kinase Inhibitor, in Subjects With Advanced Solid Tumors or Lymphomas | Completed | USA | 0 |
NCT01588821 | Phase II | Cabozantinib | Cabozantinib in Advanced Solid Malignancies | Completed | USA | 0 |
NCT01591356 | Phase I | siRNA-EphA2-DOPC | EphA2 siRNA in Treating Patients With Advanced or Recurrent Solid Tumors | Recruiting | USA | 0 |
NCT01593228 | Phase III | Carboplatin + Doxorubicin + Iniparib Iniparib + Paclitaxel Iniparib + Irinotecan Iniparib + Topotecan Carboplatin + Gemcitabine + Iniparib Iniparib | Treatment Extension Study for Patients Who Have Previously Participated and Have Benefited From Iniparib in a Clinical Trial | Completed | USA | ITA | ESP | BEL | 0 |
NCT01596140 | Phase I | Temsirolimus + Vemurafenib Everolimus + Vemurafenib | Vemurafenib in Combination With Everolimus or Temsirolimus With Advanced Cancer | Completed | USA | 0 |
NCT01596270 | Phase I | Voxtalisib | A Study of the Safety and Pharmacokinetics of SAR245409 Tablets in Patients With Solid Tumors or Lymphoma | Completed | USA | 0 |
NCT01606878 | Phase I | Dexamethasone + Doxorubicin + Vincristine Sulfate Cyclophosphamide + Topotecan Crizotinib | Crizotinib and Combination Chemotherapy in Treating Younger Patients With Relapsed or Refractory Solid Tumors or Anaplastic Large Cell Lymphoma | Completed | USA | CAN | 0 |
NCT01607905 | Phase I | Selinexor | Safety Study of the Selective Inhibitor of Nuclear Export (SINE) KPT-330 in Patients With Advanced or Metastatic Solid Tumor Cancer | Completed | USA | CAN | 1 |
NCT01609556 | Phase I | Mirvetuximab Soravtansine | First-in-Human Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of IMGN853 in Adults With Ovarian Cancer and Other FOLR1-Positive Solid Tumors | Completed | USA | CAN | 0 |
NCT01610570 | Phase Ib/II | Plicamycin | Mithramycin for Children and Adults With Solid Tumors or Ewing Sarcoma | Terminated | USA | 0 |
NCT01624467 | Phase II | Necitumumab | A Study of Necitumumab Monotherapy and the QT/QTc Interval in Patient With Advanced Solid Tumors | Completed | USA | 0 |
NCT01624766 | Phase I | Denosumab + Everolimus Anakinra + Everolimus | Anakinra or Denosumab and Everolimus in Advanced Cancer | Completed | USA | 0 |
NCT01625156 | Phase I | Temsirolimus + Tivantinib | Tivantinib and Temsirolimus in Treating Patients With Solid Tumors That is Metastatic or Cannot be Removed By Surgery | Completed | USA | 0 |
NCT01625234 | Phase Ib/II | Ensartinib | Phase 1/2 Study of X-396, an Oral ALK Inhibitor, in Patients With ALK-positive Non-Small Cell Lung Cancer | Completed | USA | 0 |
NCT01631279 | Phase Ib/II | TH-4000 | A Dose Escalation Trial of PR610 Treating Patients With Solid Tumors | Terminated | USA | 1 |
NCT01633970 | Phase I | Atezolizumab + Carboplatin + Paclitaxel Atezolizumab + Carboplatin + Pemetrexed Disodium Atezolizumab + Bevacizumab + Capecitabine | A Phase 1b Study of MPDL3280A (an Engineered Anti-PDL1 Antibody) in Combination With Avastin (Bevacizumab) and/or With Chemotherapy in Patients With Locally Advanced or Metastatic Solid Tumors | Completed | USA | 0 |
NCT01634893 | Phase I | Hydroxychloroquine + Sorafenib | Oral Hydroxychloroquine Plus Oral Sorafenib to Treat Patients With Refractory or Relapsed Solid Tumors | Completed | USA | 0 |
NCT01636479 | Phase I | SAR405838 | Phase 1 Safety Testing of SAR405838 | Completed | USA | FRA | 1 |
NCT01636622 | Phase I | Carboplatin + Paclitaxel + Vemurafenib | Study of Vemurafenib, Carboplatin, and Paclitaxel | Completed | USA | 0 |
NCT01638533 | Phase I | Romidepsin | Romidepsin in Treating Patients With Lymphoma, Chronic Lymphocytic Leukemia, or Solid Tumors With Liver Dysfunction | Active, not recruiting | USA | CAN | 0 |
NCT01639911 | Phase I | Alisertib + Pazopanib | MLN8237 and Pazopanib in Combination for Solid Tumors | Completed | USA | 0 |
NCT01642342 | Phase I | sEphB4-HSA | Recombinant Albumin Fusion Protein sEphB4-HSA in Treating Patients With Metastatic or Recurrent Solid Tumors | Terminated | USA | 0 |
NCT01653470 | Phase I | Carboplatin Fluorouracil + Irinotecan + Leucovorin BMS-906024 Paclitaxel | Study to Evaluate Safety & Tolerability of BMS-906024 in Combination With Chemotherapy & to Define DLTs & MTD of BMS-906024 in Combination With One of the Following Chemotherapy Regimens; Weekly Paclitaxel, 5FU+Irinotecan or Carboplatin+Paclitaxel in Subjects With Advanced / Metastatic Solid Tumors | Completed | USA | CAN | BEL | 0 |
NCT01654965 | Phase I | Pegfilgrastim + Tivantinib + Topotecan | Tivantinib and Topotecan Hydrochloride in Treating Patients With Advanced or Metastatic Solid Tumors | Completed | USA | 0 |
NCT01655225 | Phase I | LY3023414 + Midazolam Letrozole + LY3023414 LY3023414 | A Study of LY3023414 in Participants With Advanced Cancer | Completed | USA | ITA | 1 |
NCT01661400 | Phase I | Cyclophosphamide Thalidomide | Anti-Angiogenic Therapy Post Transplant (ASCR) for Relapsed and Refractory Pediatric Solid Tumors | Completed | USA | 0 |
NCT01661972 | Phase Ib/II | Aflibercept + Capecitabine | Phase I/II Study of Capecitabine Plus Aflibercept to Treat Metastatic Colorectal Cancer | Completed | USA | 0 |
NCT01664000 | Phase I | thioureidobutyronitrile | A Safety, Pharmacokinetic and Pharmacodynamic Study of Kevetrin in Patients With Advanced Solid Tumors | Completed | USA | 0 |
NCT01670175 | Phase I | Cyclophosphamide + Sirolimus + Topotecan | Sirolimus With Cyclophosphamide and Topotecan for Pediatric/Adolescent Relapsed and Refractory Solid Tumors | Completed | USA | 0 |
NCT01673737 | Phase I | SAR260301 SAR260301 + Vemurafenib | A Phase I/Ib Trial for the Evaluation of SAR260301 in Monotherapy or in Combination With Vemurafenib in Patients With Various Advanced Cancer | Completed | USA | CAN | 0 |
NCT01677559 | Phase I | Alisertib + Nab-paclitaxel | Combining MLN8237 With Nab-Paclitaxel in Patients With Advanced Solid Malignancies | Completed | USA | 0 |
NCT01677741 | Phase I | Dabrafenib | A Study to Determine Safety, Tolerability and Pharmacokinetics of Oral Dabrafenib In Children and Adolescent Subjects | Completed | USA | ITA | GBR | FRA | ESP | DEU | CAN | AUS | 2 |
NCT01683149 | Phase I | Sorafenib + Topotecan | Sorafenib and Topotecan in Refractory/Recurrent Pediatric Malignancies | Completed | USA | 0 |
NCT01693562 | Phase Ib/II | Durvalumab | A Phase 1/2 Study to Evaluate MEDI4736 | Completed | USA | ITA | GBR | FRA | DEU | CAN | BEL | 2 |
NCT01695005 | Phase I | LY3039478 | A Study of LY3039478 in Participants With Advanced Cancer | Completed | USA | GBR | FRA | ESP | DEU | 1 |
NCT01697527 | Phase II | Aldesleukin + Anti-NY ESO-1 mTCR PBL + Cyclophosphamide + Fludarabine + NY-ESO-1 peptide vaccine | Gene and Vaccine Therapy in Treating Patients With Advanced Malignancies | Active, not recruiting | USA | 0 |
NCT01700270 | Phase I | Dovitinib + Fluvoxamine | Pharmacokinetic Drug-drug Interaction Study of Dovitinib (TKI258) in Patients With Advanced Solid Tumors. | Completed | USA | 3 |
NCT01703481 | Phase I | Erdafitinib | A Study to Evaluate the Safety, Pharmacokinetics, and Pharmacodynamics of JNJ-42756493 in Adult Patients With Advanced or Refractory Solid Tumors or Lymphoma | Completed | USA | FRA | ESP | 0 |
NCT01708161 | Phase I | Alpelisib + Ganitumab | A Phase Ib/II Study of the Combination of BYL719 Plus AMG 479 in Adult Patients With Selected Solid Tumors | Terminated | USA | ESP | CAN | BEL | 0 |
NCT01709435 | Phase I | Cabozantinib | Cabozantinib in Treating Younger Patients With Recurrent or Refractory Solid Tumors | Completed | USA | CAN | 0 |
NCT01713972 | Phase I | Dabrafenib + Pazopanib | Dabrafenib and Pazopanib Hydrochloride in Treating Patients With Advanced Malignant Tumors | Completed | USA | 0 |
NCT01714739 | Phase I | Lirilumab + Nivolumab | A Phase I Study of an Anti-KIR Antibody in Combination With an Anti-PD1 Antibody in Patients With Advanced Solid Tumors | Completed | USA | ITA | FRA | ESP | CAN | 1 |
NCT01723020 | Phase I | KRT-232 | A Phase 1 Study Evaluating AMG 232 in Advanced Solid Tumors or Multiple Myeloma | Completed | USA | FRA | 1 |
NCT01725100 | Phase I | Trametinib | A Study to Determine the Relative Bioavailability of the MEK Inhibitor, Trametinib, in Subjects With Solid Tumor Malignancies | Completed | USA | 0 |
NCT01727869 | Phase I | Erlotinib + REGN1400 Cetuximab + REGN1400 REGN1400 | Study of REGN1400 Alone and in Combination With Erlotinib or Cetuximab in Patients With Certain Types of Cancer | Completed | USA | 0 |
NCT01728311 | Phase I | BAY1082439 | Open Label Study of BAY1082439 in Patients With Advanced Cancer | Completed | 3 | |
NCT01730118 | Phase I | HER2 Vaccine | Ad/HER2/Neu Dendritic Cell Cancer Vaccine Testing | Completed | USA | 0 |
NCT01733004 | Phase I | Everolimus + MM-141 MM-141 Gemcitabine + MM-141 + Nab-paclitaxel | A Phase 1 Study of MM-141 in Patients With Advanced Solid Tumors | Completed | USA | FRA | 0 |
NCT01738139 | Phase I | Imatinib + Ipilimumab | Ipilimumab and Imatinib Mesylate in Advanced Cancer | Active, not recruiting | USA | 0 |
NCT01738451 | Phase I | Dabrafenib | A Study to Evaluate the Effect of Repeat Oral Dosing of GSK2118436 on Cardiac Repolarization in Subjects With V600 BRAF Mutation-Positive Tumors | Completed | USA | GBR | AUS | 0 |
NCT01739764 | Phase III | Vemurafenib | An Extension (Rollover) Study of Vemurafenib in Patients With BRAF V600 Mutation-Positive Malignancies Previously Enrolled in an Antecedent Vemurafenib Protocol | Completed | USA | ITA | GBR | FRA | ESP | DEU | CAN | BEL | 17 |
NCT01741727 | Phase II | Depatuxizumab mafodotin | A Study of ABT-414 in Subjects With Solid Tumors | Completed | USA | CAN | 0 |
NCT01742286 | Phase I | Ceritinib | Phase I Study of LDK378 in Pediatric, Malignancies With a Genetic Alteration in Anaplastic Lymphoma Kinase (ALK) | Completed | USA | ITA | GBR | FRA | ESP | DEU | CAN | AUS | 2 |
NCT01744652 | Phase I | Crizotinib + Dasatinib | Dasatinib and Crizotinib in Advanced Cancer | Completed | USA | 0 |
NCT01748825 | Phase I | Adavosertib | MK-1775 for Advanced Solid Tumors | Completed | USA | 0 |
NCT01749384 | Phase I | Bevacizumab + Tivantinib | Tivantinib and Bevacizumab in Treating Patients With Solid Tumors That Are Metastatic or Cannot Be Removed By Surgery | Completed | USA | 0 |
NCT01750983 | Phase I | Ipilimumab + Lenalidomide | Ipilimumab and Lenalidomide in Advanced Cancer | Completed | USA | 0 |
NCT01752920 | Phase I | Derazantinib | Phase 1 Dose Escalation Study of ARQ 087 in Adult Subjects With Advanced Solid Tumors | Completed | USA | ITA | 0 |
NCT01760525 | Phase I | CGM097 | A Phase I Dose Escalation Study of CGM097 in Adult Patients With Selected Advanced Solid Tumors | Completed | USA | FRA | DEU | 2 |
NCT01765543 | Phase I | Rifampin + Vemurafenib | A Pharmacokinetics Study to Investigate the Effect of Rifampin on Vemurafenib in Patients With BRAFV600 Mutation-Positive Metastatic Malignancy | Completed | USA | 4 |
NCT01767623 | Phase I | Vemurafenib | A Study of The Impact of Severe Hepatic Impairment on the Pharmacokinetics and Safety of Vemurafenib in BRAF V600 Mutation-Positive Cancer Patients | Completed | USA | GBR | AUS | 4 |
NCT01769768 | Phase I | Sonidegib Warfarin Bupropion | Phase I Study to Evaluate the Effect of LDE225 on the Pharmacokinetics of Bupropion and Warfarin in Patients | Completed | USA | 0 |
NCT01772004 | Phase I | Avelumab | Avelumab in Metastatic or Locally Advanced Solid Tumors (JAVELIN Solid Tumor) | Completed | USA | GBR | FRA | DEU | BEL | 4 |
NCT01775423 | Phase Ib/II | Napabucasin | A Study of BBI608 in Adult Patients With Advanced Malignancies | Completed | USA | CAN | 0 |
NCT01778439 | Phase I | Brontictuzumab | A Dose Escalation Study of OMP-52M51 in Subjects With Solid Tumors | Completed | USA | 0 |
NCT01781429 | Phase Ib/II | Ulixertinib | Phase I Dose-Escalation, Safety, Pharmacokinetic and Pharmacodynamic Study of BVD-523 in Patients With Advanced Malignancies | Completed | USA | 0 |
NCT01781455 | Phase Ib/II | Amcasertib | A Study of BBI503 in Adult Patients With Advanced Solid Tumors | Completed | USA | CAN | 0 |
NCT01784861 | Phase Ib/II | Everolimus + Vorolanib | VEGFR/PDGFR Dual Kinase Inhibitor X-82 and Everolimus for Treating Patients With Pancreatic Neuroendocrine Tumors | Terminated | USA | 0 |
NCT01787500 | Phase I | Cetuximab + Irinotecan + Vemurafenib | Vemurafenib, Cetuximab, and Irinotecan Hydrochloride in Treating Patients With Solid Tumors That Are Metastatic or That Cannot Be Removed by Surgery | Active, not recruiting | USA | 0 |
NCT01789281 | Phase III | Everolimus + Octreotide acetate | Everolimus Roll-over Protocol for Patients Who Have Completed a Previous Novartis-sponsored Everolimus Study. | Completed | USA | ITA | ESP | 6 |
NCT01791088 | Phase I | Sirolimus | Sirolimus in Treating Patients With Solid Tumors That Are Metastatic or Cannot Be Removed By Surgery | Completed | USA | 0 |
NCT01803282 | Phase I | Andecaliximab Fluorouracil + Leucovorin + Oxaliplatin + Pembrolizumab Carboplatin + Pemetrexed Disodium Fluorouracil + Irinotecan + Leucovorin Gemcitabine + Nab-paclitaxel Carboplatin + Paclitaxel Paclitaxel Bevacizumab | Safety and Tolerability Study in Solid Tumors | Completed | USA | 0 |
NCT01804530 | Phase I | PLX7486 Gemcitabine + Nab-paclitaxel | Phase 1 Study of PLX7486 as Single Agent and With Gemcitabine Plus Nab-Paclitaxel in Patients With Advanced Solid Tumors | Terminated | USA | 0 |
NCT01804634 | Phase II | Cyclophosphamide + Fludarabine + Melphalan + Sirolimus | A Phase II Trial of Reduced Intensity Conditioning and Haploidentical BMT for High-risk Solid Tumors | Recruiting | USA | 0 |
NCT01815294 | Phase I | Doxorubicin Pegylated liposomal doxorubicin | A Pivotal Bioequivalence Study of DOXIL/CAELYX (Doxorubicin HCL) in Patients With Advanced or Refractory Solid Malignancies Including Patients With Ovarian Cancer | Completed | USA | GBR | ESP | BEL | 0 |
NCT01822522 | Phase I | Cabozantinib | Cabozantinib-S-Malate in Treating Patients With Advanced Solid Tumors and Human Immunodeficiency Virus | Completed | USA | 0 |
NCT01822756 | Phase I | Ruxolitinib | An Open-Label Study of Ruxolitinib Given With Chemotherapy in Patients With Advanced Solid Tumors | Terminated | USA | 0 |
NCT01827384 | Phase II | Adavosertib + Carboplatin Temozolomide + Veliparib Everolimus Trametinib | Molecular Profiling-Based Targeted Therapy in Treating Patients With Advanced Solid Tumors | Completed | USA | 0 |
NCT01828554 | Phase III | Capecitabine | Capecitabine Pharmacokinetics(PK)-Actual Versus Ideal Body Weight | Completed | USA | 0 |
NCT01829971 | Phase I | MRX34 | A Multicenter Phase I Study of MRX34, MicroRNA miR-RX34 Liposomal Injection | Terminated | USA | 1 |
NCT01831726 | Phase II | Dovitinib | Dovitinib for Patients With Tumor Pathway Activations Inhibited by Dovitinib | Completed | USA | 0 |
NCT01833169 | Phase II | Buparlisib | BKM120 for Patients With PI3K-activated Tumors | Completed | USA | 0 |
NCT01835184 | Phase I | Cabozantinib + Vemurafenib | Cabozantinib-S-Malate and Vemurafenib in Treating Patients With Solid Tumors or Melanoma That is Metastatic or That Cannot Be Removed By Surgery | Terminated | USA | 0 |
NCT01837667 | Phase I | Docetaxel + LB-100 | Phase I Study of LB-100 With Docetaxel in Solid Tumors | Completed | USA | 0 |
NCT01844583 | Phase I | Alisertib + Esomeprazole Alisertib + Rifampin Alisertib | Safety, Tolerability and PK of Concomitant Esomeprazole and Rifampin, and QT Study on Single and Multiple-doses of Alisertib | Completed | USA | 0 |
NCT01844674 | Phase I | Tizanidine + Vemurafenib | A Study on the Effect of Vemurafenib on the Pharmacokinetics of a Single Dose of Tizanidine in Patients With BRAFV600 Mutation-Positive Metastatic Malignancies | Completed | USA | CAN | 3 |
NCT01849744 | Phase I | VS-4718 | Phase I Dose Escalation Study of VS-4718 in Subjects With Metastatic Non-Hematologic Malignancies | Terminated | USA | 0 |
NCT01851369 | Phase Ib/II | Temozolomide + TRC102 | TRC102 and Temozolomide for Relapsed Solid Tumors and Lymphomas | Completed | USA | 0 |
NCT01853046 | Phase I | Regorafenib | Pharmacokinetics and Safety of Regorafenib (BAY73-4506) in Cancer Subjects With Severe Renal Impairment | Completed | USA | CAN | 0 |
NCT01858883 | Phase I | Nab-paclitaxel Filgrastim Itacitinib Gemcitabine | Safety Study of INCB039110 in Combination With Gemcitabine and Nab-Paclitaxel in Subjects With Advanced Solid Tumors | Completed | USA | 0 |
NCT01875705 | Phase I | Ravoxertinib | A Dose-Escalation Study of GDC-0994 in Patients With Locally Advanced or Metastatic Solid Tumors | Completed | USA | FRA | 0 |
NCT01876511 | Phase II | Pembrolizumab | Phase 2 Study of MK-3475 in Patients With Microsatellite Unstable (MSI) Tumors | Completed | USA | 0 |
NCT01877382 | Phase I | Milademetan | A Phase 1 Multiple Ascending Dose Study of DS-3032b, an Oral Murine Double Minute 2 (MDM2) Inhibitor, in Subjects With Advanced Solid Tumors or Lymphomas | Completed | USA | 0 |
NCT01877811 | Phase Ib/II | RXDX-105 | CEP-32496 in Patients With Advanced Solid Tumors in Phase 1 and Advanced Melanoma and Metastatic Colorectal Cancer in Phase 2 | Completed | USA | 0 |
NCT01884285 | Phase I | AZD8186 Abiraterone + AZD8186 AZD8186 + Vistusertib | AZD8186 First Time In Patient Ascending Dose Study | Completed | USA | GBR | ESP | CAN | 0 |
NCT01885195 | Phase II | Binimetinib | MEK162 for Patients With RAS/RAF/MEK Activated Tumors | Completed | USA | 0 |
NCT01898078 | Phase I | Alisertib | Food Effect Study of Alisertib (MLN8237) in Patients With Advanced Solid Tumors or Lymphomas | Completed | USA | 0 |
NCT01898130 | Phase II | Bevacizumab | Bevacizumab in Pats w/ Recurrent ST Brain Metas Who Have Failed Whole Brain Radiation Therapy | Completed | USA | 0 |
NCT01899053 | Phase I | Sapanisertib + Serabelisib | Phase 1b Study of MLN0128 in Combination With MLN1117 in Adult Patients With Advanced Nonhematologic Malignancies | Completed | USA | GBR | ESP | 0 |
NCT01902173 | Phase Ib/II | Dabrafenib + Trametinib + Uprosertib Dabrafenib + Uprosertib | Uprosertib, Dabrafenib, and Trametinib in Treating Patients With Stage IIIC-IV Cancer | Active, not recruiting | USA | 0 |
NCT01905228 | Phase I | CBL0137 | A Phase 1 Trial of CBL0137 in Patients With Metastatic or Unresectable Advanced Solid Neoplasm or Refractory Lymphomas | Completed | USA | 0 |
NCT01907802 | Phase I | Dabrafenib | Dabrafenib in Treating Patients With Solid Tumors and Kidney or Liver Dysfunction | Terminated | USA | CAN | 0 |
NCT01908413 | Phase I | GDC-0917 | Phase I Study to Assess the Safety, Tolerability and Pharmacokinetics of CUDC-427 When Given to Patients With Advanced and Refractory Solid Tumors or Lymphoma | Terminated | USA | 0 |
NCT01910545 | Phase I | OTS167 | Phase 1 Study of OTS167 in Patients With Solid Tumors | Completed | USA | 0 |
NCT01915576 | Phase I | BAY1125976 | Phase I Dose Escalation Study With an Allosteric AKT 1/2 Inhibitor in Patients | Completed | USA | FRA | DEU | 1 |
NCT01922752 | Phase I | CEP-37440 | To Determine the Maximum Tolerated Dose of Oral CEP-37440 in Patients With Advanced or Metastatic Solid Tumors | Completed | USA | 0 |
NCT01923337 | Phase I | Alisertib + Irinotecan | Irinotecan and Alisertib in Treating Patients With Advanced Solid Tumors or Colorectal Cancer | Completed | USA | 0 |
NCT01924260 | Phase I | Alisertib + Gemcitabine | Alisertib and Gemcitabine Hydrochloride in Treating Patients With Solid Tumors or Pancreatic Cancer | Completed | USA | 0 |
NCT01928459 | Phase I | Alpelisib + Infigratinib | Phase 1b Trial of BGJ398/BYL719 in Solid Tumors | Completed | USA | ITA | FRA | ESP | DEU | CAN | BEL | AUS | 4 |
NCT01946074 | Phase I | ABT-165 ABT-165 + Budigalimab + Paclitaxel ABT-165 + Budigalimab ABT-165 + Paclitaxel ABT-165 + Fluorouracil + Irinotecan + Leucovorin | A Study of ABT-165 in Subjects With Solid Tumors | Completed | USA | 0 |
NCT01948297 | Phase I | Debio 1347 | Debio 1347-101 Phase I Trial in Advanced Solid Tumours With Fibroblast Growth Factor Receptor (FGFR) Alterations | Terminated | USA | ESP | 3 |
NCT01953926 | Phase II | Neratinib + Trastuzumab Fulvestrant + Neratinib + Trastuzumab Neratinib Neratinib + Paclitaxel | Basket Study of Neratinib in Participants With Solid Tumors Harboring Somatic HER2 or EGFR Exon 18 Mutations | Terminated | USA | ITA | GBR | FRA | ESP | CAN | BEL | AUS | 5 |
NCT01954043 | Phase I | Dabrafenib + Rabeprazole + Rifampin | A Pharmacokinetics (PK) Study of the Effects Rabeprazole and Rifampin on Dabrafenib in Subjects With BRAF V600 Mutation Positive Tumors | Completed | USA | GBR | AUS | 0 |
NCT01954316 | Phase I | CFI-400945 | A Study of CFI-400945 Fumarate in Patients With Advanced Cancer | Completed | USA | CAN | 0 |
NCT01967823 | Phase II | Aldesleukin + Anti-NY ESO-1 mTCR PBL + Cyclophosphamide + Fludarabine | T Cell Receptor Immunotherapy Targeting NY-ESO-1 for Patients With NY-ESO-1 Expressing Cancer | Completed | USA | 0 |
NCT01971489 | Phase I | Buparlisib + Cisplatin + Gemcitabine | PI3K Inhibitor BKM120, Gemcitabine Hydrochloride, and Cisplatin in Treating Patients With Advanced Solid Tumors | Withdrawn | USA | 0 |
NCT01971515 | Phase I | M2698 | First-in-Human Dose Escalation Trial in Subjects With Advanced Malignancies | Completed | USA | 0 |
NCT01973868 | Phase I | Cetuximab + Regorafenib | Safety and Pharmacokinetics of Regorafenib and Cetuximab in Combination | Completed | USA | 0 |
NCT01974258 | Phase I | Onartuzumab + Vemurafenib Cobimetinib + Onartuzumab Cobimetinib + Onartuzumab + Vemurafenib | Safety, Tolerability, and Pharmacokinetics of Onartuzumab Combined With Vemurafenib and/or Cobimetinib in Cancer Patients | Withdrawn | USA | 0 |
NCT01975831 | Phase I | Durvalumab + Tremelimumab | A Phase 1 Study to Evaluate MEDI4736 in Combination With Tremelimumab | Completed | USA | 0 |
NCT01976741 | Phase I | Rogaratinib | Phase I Dose Escalation Pan-FGFR (Fibroblast Growth Factor Receptor) Inhibitor | Completed | USA | FRA | ESP | DEU | 3 |
NCT01981187 | Phase II | Encorafenib | LGX818 for Patients With BRAFV600 Mutated Tumors | Terminated | USA | 0 |
NCT01986166 | Phase I | Cobimetinib + Duligotuzumab | A Study of MEHD7945A and Cobimetinib (GDC-0973) in Patients With Locally Advanced or Metastatic Cancers With Mutant KRAS | Completed | USA | ESP | 0 |
NCT01987362 | Phase I | TEN-010 | A Two Part, Multicenter, Open-label Study of TEN-010 Given Subcutaneously | Completed | USA | 0 |
NCT01988896 | Phase I | Atezolizumab + Cobimetinib | A Phase 1b Study of MPDL3280A (an Engineered Anti-PDL1 Antibody) in Combination With Cobimetinib in Patients With Locally Advanced or Metastatic Solid Tumors | Completed | USA | DEU | CAN | AUS | 2 |
NCT01989546 | Phase Ib/II | Talazoparib | Pilot Trial of BMN 673, an Oral PARP Inhibitor, in Patients With Advanced Solid Tumors and Deleterious BRCA Mutations | Completed | USA | 0 |
NCT01989585 | Phase Ib/II | Dabrafenib + Navitoclax + Trametinib Dabrafenib + Trametinib | Testing the Addition of Navitoclax to the Combination of Dabrafenib and Trametinib in People Who Have BRAF Mutant Melanoma | Active, not recruiting | USA | 0 |
NCT01991938 | Phase I | VS-5584 | Phase I Dose Escalation Study of VS-5584 in Subjects With Advanced Non-Hematologic Malignancies or Lymphoma | Terminated | USA | GBR | 0 |
NCT01992874 | Phase I | Pimasertib | Relative Bioavailability of Pimasertib in Cancer Patients | Completed | USA | 0 |
NCT01999738 | Phase I | EC1456 | Folic Acid-Tubulysin Conjugate EC1456 In Patients With Advanced Solid Tumors | Completed | USA | 0 |
NCT01999972 | Phase I | Axitinib + Crizotinib | A Phase 1b Study Of Axitinib In Combination With Crizotinib In Patients With Advanced Solid Tumors | Completed | USA | GBR | 0 |
NCT02000934 | Phase I | Mivavotinib | A Study of TAK-659 in Adult Patients With Advanced Solid Tumor and Lymphoma Malignancies | Completed | USA | ITA | GBR | ESP | 0 |
NCT02002689 | Phase II | Sonidegib | LDE225 for Patients With PTCH1 or SMO Mutated Tumors | Terminated | USA | 0 |
NCT02004106 | Phase I | Cergutuzumab amunaleukin | A Study of RO6895882 in Patients With Advanced and/or Metastatic Solid Tumors | Completed | USA | GBR | FRA | ESP | 4 |
NCT02009631 | Phase I | Veliparib | A Study to Evaluate the Effects of Veliparib on Heart Rhythms in Patients With Solid Tumors | Completed | USA | ESP | 1 |
NCT02012231 | Phase Ib/II | PLX8394 | Phase I/IIa Study to Evaluate the Safety, PK, PD, and Preliminary Efficacy of PLX8394 in Patients With Advanced Cancers. | Terminated | USA | 0 |
NCT02014116 | Phase I | LY3009120 | A Study of LY3009120 in Participants With Advanced Cancer or Cancer That Has Spread to Other Parts of Their Body | Terminated | USA | FRA | ESP | AUS | 0 |
NCT02014909 | Phase I | CDX-3379 CDX-3379 + Vemurafenib CDX-3379 + Trastuzumab CDX-3379 + Cetuximab CDX-3379 + Erlotinib | A Phase 1 Study to Evaluate the Safety and Pharmacokinetics of KTN3379 in Adult Subjects With Advanced Tumors | Completed | USA | 0 |
NCT02015117 | Phase I | Trametinib | Trametinib With or Without Whole Brain Radiation Therapy in Treating Patients With Brain Metastases | Active, not recruiting | USA | 0 |
NCT02022982 | Phase Ib/II | Palbociclib + PD-0325901 | PALBOCICLIB + PD-0325901 for NSCLC & Solid Tumors | Active, not recruiting | USA | 0 |
NCT02025803 | Phase I | Capecitabine + TAS-114 | A Safety, Tolerability and Pharmacokinetic Study of TAS-114 in Combination With Capecitabine in Patients With Advanced Solid Tumors | Completed | USA | 0 |
NCT02029001 | Phase II | Durvalumab + Tremelimumab Olaparib Pazopanib Nilotinib | Adapting Treatment to the Tumor Molecular Alterations for Patients With Advanced Solid Tumors: MyOwnSpecificTreatment (MOST plus) | Recruiting | FRA | 0 |
NCT02033148 | Phase I | Icotinib | Icotinib Hydrochloride in Treating Patients With Advanced Cancers | Withdrawn | 0 | |
NCT02038673 | Phase I | ASP5878 | An Open-label Phase I Study of Oral ASP5878 at Single and Multiple Doses in Patients With Solid Tumors | Completed | USA | 3 |
NCT02042989 | Phase I | Ixazomib + Vorinostat | MLN9708 and Vorinostat in Patients With Advanced p53 Mutant Malignancies | Completed | USA | 0 |
NCT02048488 | Phase Ib/II | Belizatinib | A Phase I/IIa Open-Label, Dose Escalation and Cohort Expansion Trial of Oral TSR-011 in Patients With Advanced Solid Tumors and Lymphomas | Completed | USA | GBR | ESP | 2 |
NCT02048709 | Phase I | Navoximod | IDO Inhibitor in Advanced Solid Tumors | Completed | USA | 0 |
NCT02048943 | Phase I | Dovitinib + Gemcitabine + Nab-paclitaxel Nab-paclitaxel Dovitinib | Dovitinib Lactate, Gemcitabine Hydrochloride, and Paclitaxel Albumin-Stabilized Nanoparticle Formulation in Treating Patients With Advanced Solid Tumors or Pancreatic Cancer | Withdrawn | USA | 0 |
NCT02049593 | Phase I | Talazoparib + Temozolomide Irinotecan + Talazoparib | PARP Inhibitor BMN-673 and Temozolomide or Irinotecan Hydrochloride in Treating Patients With Locally Advanced or Metastatic Solid Tumors | Completed | USA | 0 |
NCT02051751 | Phase I | Alpelisib + Paclitaxel | A Study to Evaluate the Potential Benefit of the Addition of BYL719 to Paclitaxel in the Treatment of Breast Cancer and Head-and-neck Cancer | Completed | USA | ITA | FRA | ESP | 0 |
NCT02052778 | Phase Ib/II | Futibatinib | A Study of TAS-120 in Patients With Advanced Solid Tumors | Unknown status | USA | ITA | GBR | FRA | ESP | DEU | CAN | AUS | 5 |
NCT02054806 | Phase I | Pembrolizumab | Study of Pembrolizumab (MK-3475) in Participants With Advanced Solid Tumors (MK-3475-028/KEYNOTE-28) | Completed | 0 | |
NCT02065063 | Phase I | Palbociclib + Trametinib | A Study to Investigate the Safety, Pharmacokinetics, Pharmacodynamics, and Anti-Cancer Activity of Trametinib in Combination With Palbociclib in Subjects With Solid Tumors | Completed | USA | 0 |
NCT02069730 | Phase I | Selinexor | A Study of Drug Therapies for Salivary Gland Cancers Based on Testing of Genes | Active, not recruiting | CAN | 0 |
NCT02070406 | Phase I | Aldesleukin + Cyclophosphamide + Fludarabine NY-ESO-1 peptide vaccine | Gene-Modified T Cells, Vaccine Therapy, and Ipilimumab in Treating Patients With Locally Advanced or Metastatic Malignancies | Terminated | USA | 0 |
NCT02070549 | Phase I | Trametinib | Trametinib in Treating Patients With Advanced Cancer With or Without Hepatic Dysfunction | Active, not recruiting | USA | CAN | 0 |
NCT02071862 | Phase I | Everolimus + Telaglenastat Erlotinib + Telaglenastat Docetaxel + Telaglenastat Telaglenastat Paclitaxel + Telaglenastat Cabozantinib + Telaglenastat | Study of the Glutaminase Inhibitor CB-839 in Solid Tumors | Completed | USA | 0 |
NCT02073994 | Phase I | Ivosidenib | Study of Orally Administered AG-120 in Subjects With Advanced Solid Tumors, Including Glioma, With an IDH1 Mutation | Completed | USA | FRA | 0 |
NCT02076997 | Phase I | Methotrexate | Individualized High Dose Methotrexate to Treat Cancer in Children Who Have a Significant Risk for Side Effects to Methotrexate | Completed | USA | 0 |
NCT02077933 | Phase I | Alpelisib + Everolimus Alpelisib + Everolimus + Exemestane | Study of Safety and Efficacy of BYL719 With Everolimus or BYL719 With Everolimus and Exemestane in Advanced Breast Cancer Patients, Renal Cell Cancer and Pancreatic Tumors | Completed | USA | ITA | GBR | FRA | ESP | DEU | 3 |
NCT02078752 | Phase I | PF-06647263 | A Study Of PF-06647263 In Patients With Advanced Solid Tumors | Terminated | USA | 0 |
NCT02079740 | Phase Ib/II | Navitoclax + Trametinib | Trametinib and Navitoclax in Treating Patients With Advanced or Metastatic Solid Tumors | Active, not recruiting | USA | 0 |
NCT02080078 | Phase I | Erlotinib + Theophylline | A Phase I Dose Escalation Study of Erlotinib in Combination With Theophylline | Terminated | CAN | 0 |
NCT02081495 | Phase I | Pegylated liposomal doxorubicin | A Study of DOXIL/CAELYX in Patients With Advanced or Refractory Solid Malignancies Including Patients With Ovarian Cancer | Completed | USA | ESP | CAN | BEL | 0 |
NCT02082210 | Phase Ib/II | Emibetuzumab + Ramucirumab | A Study of LY2875358 in Combination With Ramucirumab (LY3009806) in Participants With Advanced Cancer | Completed | USA | 0 |
NCT02082665 | Phase I | Dabrafenib + Midazolam + Rosuvastatin | Effects of Dabrafenib on the Single Dose Pharmacokinetics (PK) of Rosuvastatin and Midazolam | Completed | USA | ESP | 0 |
NCT02091141 | Phase II | Erlotinib Alectinib Cobimetinib + Vemurafenib Pertuzumab + Trastuzumab Vismodegib Atezolizumab | My Pathway: A Study Evaluating Herceptin/Perjeta, Tarceva, Zelboraf/Cotellic, Erivedge, Alecensa, and Tecentriq Treatment Targeted Against Certain Molecular Alterations in Participants With Advanced Solid Tumors | Completed | USA | 0 |
NCT02095054 | Phase I | Cetuximab + Regorafenib | Regorafenib and Cetuximab in Patients With Advanced Malignancy | Completed | USA | 0 |
NCT02095132 | Phase Ib/II | Adavosertib + Irinotecan | Adavosertib and Irinotecan Hydrochloride in Treating Younger Patients With Relapsed or Refractory Solid Tumors | Completed | USA | CAN | 0 |
NCT02097225 | Phase I | Dabrafenib + Onalespib + Trametinib | Onalespib, Dabrafenib, and Trametinib in Treating Patients With BRAF-Mutant Melanoma or Solid Tumors That Are Metastatic or Cannot Be Removed by Surgery | Unknown status | USA | 0 |
NCT02097810 | Phase I | Entrectinib | Study of Oral RXDX-101 in Adult Patients With Locally Advanced or Metastatic Cancer Targeting NTRK1, NTRK2, NTRK3, ROS1, or ALK Molecular Alterations. (STARTRK-1) | Completed | USA | 1 |
NCT02098967 | Phase I | RO6839921 | A Study of the Safety and Pharmacokinetics of RO6839921, An MDM2 Antagonist, in Patients With Advanced Cancers, Including Acute Myeloid Leukemia. | Completed | USA | CAN | 0 |
NCT02099058 | Phase I | Carboplatin + Telisotuzumab vedotin Erlotinib + Telisotuzumab vedotin Telisotuzumab vedotin Bevacizumab + Telisotuzumab vedotin Cetuximab + Telisotuzumab vedotin | A Phase 1/1b Study With ABBV-399, an Antibody Drug Conjugate, in Subjects With Advanced Solid Cancer Tumors | Active, not recruiting | USA | ITA | FRA | BEL | 5 |
NCT02110563 | Phase I | DCR-MYC | Phase I, Multicenter, Dose Escalation Study of DCR-MYC in Patients With Solid Tumors, Multiple Myeloma, or Lymphoma | Terminated | USA | 0 |
NCT02111850 | Phase Ib/II | Aldesleukin + Anti-MAGE-A3-DP4 TCR T-cells + Cyclophosphamide + Fludarabine | T Cell Receptor Immunotherapy Targeting MAGE-A3 for Patients With Metastatic Cancer Who Are HLA-DP0401 Positive | Completed | USA | 0 |
NCT02112565 | Phase I | COH29 | RNR Inhibitor COH29 in Treating Patients With Solid Tumors That Are Refractory to Standard Therapy or For Which No Standard Therapy Exists | Active, not recruiting | USA | 0 |
NCT02116777 | Phase Ib/II | Talazoparib + Temozolomide | BMN-673 and Temozolomide in Treating Younger Patients With Refractory or Recurrent Malignancies | Completed | USA | 0 |
NCT02116803 | Phase III | Dovitinib | An Open Label Multi-center Extension Study to Evaluate Long-term Safety/ Tolerability of Dovitinib in Patients With Solid Tumors Who Continue to Receive Treatment With Dovitinib (TKI258) in Novartis-sponsored Single Agent Dovitinib Studies Which Fulfilled the Requirements for the Primary Objective | Completed | USA | ITA | ESP | BEL | AUT | 2 |
NCT02117648 | Phase I | Abemaciclib + Clarithromycin Abemaciclib | A Study of LY2835219 in Participants With Cancer | Completed | USA | 0 |
NCT02118337 | Phase I | Durvalumab + MEDI0680 | A Phase 1, Open-label Study to Evaluate the Safety and Tolerability of MEDI0680 (AMP-514) in Combination With MEDI4736 in Subjects With Advanced Malignancies | Completed | USA | GBR | FRA | CAN | AUS | 1 |
NCT02122770 | Phase I | Paclitaxel Docetaxel Itraconazole Carboplatin MLN4924 Fluconazole | Effects of Fluconazole and Itraconazole CYP3A-Mediated Inhibition on the Pharmacokinetics, Safety, and Tolerability of MLN4924 in Patients With Advanced Solid Tumors | Completed | USA | 0 |
NCT02122809 | Phase I | Chiauranib | Phase I Study of Chiauranib in Patients With Advanced Solid Tumors | Completed | 1 | |
NCT02122913 | Phase I | Larotrectinib | A Study to Test the Safety of the Investigational Drug Larotrectinib in Adults That May Treat Cancer | Completed | USA | 0 |
NCT02124148 | Phase I | Cisplatin + Prexasertib Cetuximab + Prexasertib Pemetrexed Disodium + Prexasertib LY3023414 + Prexasertib Fluorouracil + Leucovorin + Prexasertib | A Study of Prexasertib (LY2606368) With Chemotherapy or Targeted Agents in Participants With Advanced Cancer | Completed | USA | 0 |
NCT02124772 | Phase I | Trametinib Dabrafenib + Trametinib | Study to Investigate Safety, Pharmacokinetic (PK), Pharmacodynamic (PD) and Clinical Activity of Trametinib in Subjects With Cancer or Plexiform Neurofibromas and Trametinib in Combination With Dabrafenib in Subjects With Cancers Harboring V600 Mutations | Completed | USA | GBR | FRA | CAN | AUS | 0 |
NCT02130466 | Phase Ib/II | Dabrafenib + Trametinib Pembrolizumab + Trametinib Dabrafenib + Pembrolizumab Dabrafenib + Pembrolizumab + Trametinib | A Study of the Safety and Efficacy of Pembrolizumab (MK-3475) in Combination With Trametinib and Dabrafenib in Participants With Advanced Melanoma (MK-3475-022/KEYNOTE-022) | Completed | 0 | |
NCT02132754 | Phase I | Pembrolizumab MK-4166 | Study of MK-4166 and MK-4166 in Combination With Pembrolizumab (MK-3475) in Participants With Advanced Solid Tumors (MK-4166-001) | Completed | 0 | |
NCT02134067 | Phase I | VIC-1911 Paclitaxel | Dose-escalating, Safety, Tolerability and PK Study of TAS-119 in Combination With Paclitaxel in Patients With Advanced Solid Tumors | Terminated | USA | 0 |
NCT02138812 | Phase I | BAY1161909 + Paclitaxel | Phase I Dose Escalation of Oral BAY1161909 in Combination With Intravenous Paclitaxel | Terminated | USA | 0 |
NCT02142803 | Phase I | Bevacizumab + Sapanisertib | MLN0128 and Bevacizumab in Treating Patients With Recurrent Glioblastoma or Advanced Solid Tumors | Active, not recruiting | USA | 0 |
NCT02143401 | Phase I | Navitoclax + Sorafenib | Navitoclax and Sorafenib Tosylate in Treating Patients With Relapsed or Refractory Solid Tumors | Active, not recruiting | USA | 0 |
NCT02143635 | Phase I | Siremadlin | Study to Determine and Evaluate a Safe and Tolerated Dose of HDM201 in Patients With Selected Advanced Tumors That Are TP53wt | Completed | USA | FRA | ESP | DEU | 4 |
NCT02145559 | Phase I | Metformin + Sirolimus Sirolimus | A Pharmacodynamic Study of Sirolimus and Metformin in Patients With Advanced Solid Tumors | Completed | USA | 0 |
NCT02146222 | Phase I | Docetaxel + Vorolanib | VEGFR/PDGFR Dual Kinase Inhibitor X-82 and Docetaxel in Treating Patients With Solid Tumors | Completed | USA | 0 |
NCT02150733 | Phase I | Tivantinib | Pharmacokinetics of Tivantinib in Subjects With Advanced Solid Tumors and Hepatic Impairment | Completed | USA | 0 |
NCT02152943 | Phase I | Everolimus + Letrozole + Trastuzumab | Everolimus, Letrozole and Trastuzumab in HR- and HER2/Neu-positive Patients | Completed | USA | 0 |
NCT02155582 | Phase I | Copanlisib | Copanlisib Pharmacodynamic Study | Completed | GBR | FRA | BEL | 0 |
NCT02157792 | Phase I | Berzosertib + Irinotecan Berzosertib + Cisplatin + Gemcitabine Berzosertib + Cisplatin + Etoposide Berzosertib + Cisplatin Berzosertib + Carboplatin + Cisplatin Berzosertib + Gemcitabine | M6620 First in Human Study | Completed | USA | GBR | 0 |
NCT02159989 | Phase I | Aflibercept + Sapanisertib | MLN0128 and Ziv-Aflibercept in Treating Recurrent Solid Tumors That Are Metastatic or Cannot Be Removed By Surgery | Completed | USA | 0 |
NCT02160041 | Phase II | Infigratinib | BGJ398 for Patients With Tumors With FGFR Genetic Alterations | Terminated | USA | 0 |
NCT02160106 | Phase I | Vactosertib | First in Human Dose Escalation Study of TEW-7197 in Subjects With Advanced Stage Solid Tumors | Completed | USA | 0 |
NCT02161770 | Phase I | Osimertinib | Study to Assess the Blood Levels and Safety of AZD9291 in Patients With Advanced Solid Tumours and Normal Liver Function or Mild or Moderate Liver Impairment | Completed | USA | GBR | FRA | ESP | BEL | 1 |
NCT02162888 | Phase I | Bendamustine | A Phase I, Bioequivalence Study to Evaluate Two Formulations of Bendamustine (BDM) Hydrochloride (HCl) Administered to Cancer Patients | Completed | USA | 0 |
NCT02164838 | Phase I | Axitinib | VEGF Receptor Tyrosine Kinase Inhibitor Axitinib in Children With Recurrent or Refractory Solid Tumors | Completed | USA | CAN | 0 |
NCT02168777 | Phase Ib/II | Refametinib + Regorafenib Refametinib | Refametinib (BAY86-9766) in Combination With Regorafenib (Stivarga, BAY73-4506) in Patients With Advanced or Metastatic Cancer | Terminated | USA | 0 |
NCT02173093 | Phase Ib/II | Aldesleukin + GD2Bi-aATC + Sargramostim | Activated T Cells Armed With GD2 Bispecific Antibody in Children and Young Adults With Neuroblastoma and Osteosarcoma | Unknown status | USA | 0 |
NCT02174172 | Phase I | Atezolizumab + Bevacizumab + Peg-interferon alfa-2a Atezolizumab + Interferon alpha-2b Atezolizumab + Peg-interferon alfa-2a Atezolizumab + Ipilimumab Atezolizumab + Obinutuzumab | A Study to Assess the Safety and Tolerability of MPDL3280A in Combination With Other Immune-modulating Therapies in Patients With Locally Advanced or Metastatic Solid Tumors | Completed | USA | 1 |
NCT02179918 | Phase I | Utomilumab Pembrolizumab | A Study Of 4-1BB Agonist PF-05082566 Plus PD-1 Inhibitor MK-3475 In Patients With Solid Tumors (B1641003/KEYNOTE-0036) | Completed | USA | 0 |
NCT02186821 | Phase II | Ceritinib | Ceritinib (LDK378) for Patients Whose Tumors Have Aberrations in ALK or ROS1 (SIGNATURE) | Terminated | USA | 0 |
NCT02187783 | Phase II | Ribociclib | LEE011 for Patients With CDK4/6 Pathway Activated Tumors (SIGNATURE) | Completed | USA | 0 |
NCT02187848 | Phase Ib/II | SAR408701 | Evaluation of SAR408701 in Patients With Advanced Solid Tumors | Active, not recruiting | USA | FRA | ESP | CAN | 1 |
NCT02188264 | Phase I | Cyclosporine Selumetinib | Selumetinib and Cyclosporine in Treating Patients With Advanced Solid Tumors or Advanced or Metastatic Colorectal Cancer | Active, not recruiting | USA | CAN | 0 |
NCT02189174 | Phase Ib/II | CLR457 | Study of CLR457 Administered Orally in Adult Patients With Advanced Solid Malignancies | Terminated | USA | ESP | CAN | 2 |
NCT02194049 | Phase I | Buparlisib + Cisplatin + Etoposide | Cisplatin, Etoposide and PI3K Inhibitor BKM120 in Treating Patients With Advanced Solid Tumors or Small Cell Lung Cancer | Completed | USA | 0 |
NCT02197572 | Phase I | Sapanisertib | Effect of MLN0128 on the QTc Interval in Participants With Advanced Solid Tumors | Completed | USA | 0 |
NCT02201212 | Phase II | Everolimus | Everolimus for Cancer With TSC1 or TSC2 Mutation | Completed | USA | 0 |
NCT02205333 | Phase Ib/II | Rituximab MEDI6469 Tremelimumab Durvalumab | A Phase 1b/2 Safety and Tolerability of MEDI6469 in Combination With Therapeutic Immune Agents or Monoclonal Antibodies | Terminated | USA | 0 |
NCT02211755 | Phase I | Bortezomib + Clofarabine | Trial of the Combination of Bortezomib and Clofarabine in Adults With Relapsed Solid Tumors | Recruiting | USA | 0 |
NCT02214147 | Phase I | Alisertib | Pharmacokinetics of Alisertib in Adults With Advanced Solid Tumors or Relapsed/Refractory Lymphoma With Varying Degrees of Hepatic Function | Completed | USA | 0 |
NCT02216409 | Phase I | Hu5F9-G4 | Phase 1 Trial of Hu5F9-G4, a CD47-targeting Antibody | Completed | USA | 0 |
NCT02219711 | Phase I | Sitravatinib | Phase 1/1b Study of MGCD516 in Patients With Advanced Cancer | Completed | USA | 1 |
NCT02219724 | Phase I | Vonlerolizumab | A Phase I, Open-Label Study of MOXR0916 in Patients With Locally Advanced or Metastatic Solid Tumors | Completed | USA | ESP | CAN | BEL | AUS | 1 |
NCT02221882 | Phase I | LY3164530 | A Study of LY3164530 in Participants With Cancer | Completed | USA | 0 |
NCT02221960 | Phase I | Durvalumab Efizonerimod | A Phase 1 Study to Evaluate MEDI6383 Alone and in Combination With MEDI4736 in Adult Subjects With Select Advanced Solid Tumors | Completed | USA | AUS | 0 |
NCT02222922 | Phase I | Avelumab + Cofetuzumab pelidotin Fluconazole Cofetuzumab pelidotin | A Study Of PF-06647020 For Adult Patients With Advanced Solid Tumors | Completed | USA | ESP | 0 |
NCT02223247 | Phase I | TVB-2640 | A Phase 1, First-In-Human Study of Escalating Doses of Oral TVB-2640 in Patients With Solid Tumors | Completed | USA | GBR | 0 |
NCT02224599 | Phase Ib/II | Autologous TAPA-pulsed dendritic cell vaccine + Cyclophosphamide | Cyclophosphamide, TAPA-Pulsed Dendritic Cell Therapy and Imiquimod in Progressive and/or Refractory Solid Malignancies | Terminated | USA | 0 |
NCT02227940 | Phase I | Ceritinib + Gemcitabine + Nab-paclitaxel Ceritinib + Cisplatin + Gemcitabine Ceritinib + Gemcitabine | Ceritinib and Combination Chemotherapy in Treating Patients With Advanced Solid Tumors or Locally Advanced or Metastatic Pancreatic Cancer | Completed | USA | 0 |
NCT02228811 | Phase I | Altiratinib | A Study of DCC-2701 in Participants With Advanced Solid Tumors | Terminated | USA | 0 |
NCT02232243 | Phase I | Hydroxychloroquine | HCQ on PAR-4 Levels in Patients With Resectable Solid Tumors | Completed | USA | 0 |
NCT02239900 | Phase Ib/II | Ipilimumab | Ipilimumab and Stereotactic Body Radiation Therapy (SBRT) in Advanced Solid Tumors | Completed | USA | 0 |
NCT02240238 | Phase Ib/II | Gemcitabine + NC-6004 | Combination Therapy With NC-6004 and Gemcitabine in Advanced Solid Tumors or Non-Small Cell Lung, Biliary and Bladder Cancer | Completed | USA | ITA | 3 |
NCT02243917 | Phase I | CB-5083 | A Phase 1 Study Evaluating CB-5083 in Patients With Advanced Solid Tumors | Terminated | USA | 0 |
NCT02250157 | Phase I | Oratecan | A Dose-regimen Finding Study to Evaluate Safety, Tolerability, Pharmacokinetics and Activity of Oratecan in Subjects With Advanced Malignancies | Completed | USA | 0 |
NCT02250781 | Phase I | ONC201 | Akt/ERK Inhibitor ONC201 in Treating Patients With Advanced Solid Tumors | Completed | USA | 0 |
NCT02253420 | Phase I | Copanlisib Itraconazole | COPANLISIB (BAY80-6946) Drug-drug Interaction Study in Advanced Solid Tumor Patients | Completed | USA | CAN | 0 |
NCT02253992 | Phase Ib/II | Nivolumab + Urelumab | Study of the Safety and Tolerability of Urelumab Administered in Combination With Nivolumab in Solid Tumors and B-cell Non-Hodgkins Lymphoma | Terminated | USA | FRA | ESP | DEU | 0 |
NCT02259010 | Phase I | Alisertib Itraconazole | A Study to Evaluate the Effect of Itraconazole on the Pharmacokinetics of Alisertib in Patients With Advanced Solid Tumors or Relapsed/Refractory Lymphoma | Completed | USA | 0 |
NCT02260661 | Phase I | Fulvestrant AZD8835 | Phase I, Dose Study to Look at the Safety and Pharmacokinetics of AZD8835 in Patients With Advanced Solid Tumours | Completed | USA | GBR | 0 |
NCT02261220 | Phase I | Durvalumab + Tremelimumab | A Phase 1 Study of MEDI4736 in Combination With Tremelimumab in Subjects With Advanced Solid Tumors | Completed | USA | GBR | FRA | ESP | DEU | CAN | 3 |
NCT02264613 | Phase Ib/II | ALRN-6924 | Safety Study of ALRN-6924 in Patients With Advanced Solid Tumors | Completed | USA | 0 |
NCT02264678 | Phase Ib/II | Ceralasertib Carboplatin + Ceralasertib Ceralasertib + Durvalumab Ceralasertib + Olaparib | Ascending Doses of Ceralasertib in Combination With Chemotherapy and/or Novel Anti Cancer Agents | Recruiting | USA | GBR | FRA | ESP | CAN | BEL | AUS | 2 |
NCT02265510 | Phase I | Gemcitabine Carfilzomib Dexamethasone Lenalidomide Nab-paclitaxel Azacitidine INCB052793 Bortezomib | An Open-Label Study of a Novel JAK-inhibitor, INCB052793, Given to Patients With Advanced Malignancies | Terminated | USA | 0 |
NCT02266745 | Phase I | Imifoplatin | A Phase 1 Study of PT-112 Injection in Subjects With Advanced Solid Tumors | Recruiting | USA | FRA | 0 |
NCT02272998 | Phase II | Ponatinib | Ponatinib for Patients Whose Advanced Solid Tumor Cancer Has Activating Mutations Involving the Following Genes: FGFR1, FGFR2, FGFR3, FGFR4, RET, KIT. | Active, not recruiting | USA | 0 |
NCT02273739 | Phase Ib/II | Enasidenib | Study of Orally Administered AG-221 in Subjects With Advanced Solid Tumors, Including Glioma, and With Angioimmunoblastic T-cell Lymphoma, With an IDH2 Mutation | Completed | USA | FRA | 0 |
NCT02278250 | Phase I | VX-803 Carboplatin + VX-803 | An Open-Label Study of the Safety, Tolerability, and Pharmacokinetic/Pharmacodynamic Profile of M4344 (Formerly VX-803) as a Single Agent and in Combination With Cytotoxic Chemotherapy in Participants With Advanced Solid Tumors | Completed | USA | GBR | ESP | 1 |
NCT02279433 | Phase I | Taletrectinib | A First-in-human Study to Evaluate the Safety, Tolerability and Pharmacokinetics of DS-6051b | Completed | USA | 0 |
NCT02281409 | Phase Ib/II | Mogamulizumab | Safety, Tolerability, and Immunoregulatory Activity of Mogamulizumab (KW-0761) in Subjects With Advanced and/or Metastatic Solid Tumors | Completed | USA | 0 |
NCT02285439 | Phase Ib/II | Binimetinib | Study of MEK162 for Children With Low-Grade Gliomas | Active, not recruiting | USA | 0 |
NCT02286687 | Phase II | Talazoparib | Talazoparib in Treating Patients With Recurrent, Refractory, Advanced, or Metastatic Cancers and Alterations in the BRCA Genes | Active, not recruiting | USA | 0 |
NCT02287311 | Phase I | LMP/BARF1/EBNA1-specific cytotoxic T lymphocytes Cyclophosphamide + Fludarabine | Most Closely Matched 3rd Party Rapidly Generated LMP, BARF1 And EBNA1 Specific CTL, EBV-Positive Lymphoma (MABEL) | Recruiting | USA | 0 |
NCT02298387 | Phase I | Navicixizumab | A Phase 1 Study of OMP-305B83 in Subjects With Solid Tumors | Completed | USA | 0 |
NCT02298959 | Phase I | Aflibercept + Pembrolizumab | Pembrolizumab and Ziv-aflibercept in Treating Patients With Advanced Solid Tumors | Active, not recruiting | USA | CAN | 0 |
NCT02301117 | Phase I | Trifluridine-tipiracil hydrochloride | A Phase I Study of TAS-102 in Patients With Advanced Solid Tumors With Renal Impairment | Completed | USA | 2 |
NCT02301130 | Phase I | Mogamulizumab Durvalumab Tremelimumab | Study of Mogamulizumab + MEDI4736 and Mogamulizumab + Tremelimumab in Subjects w/ Advanced Solid Tumors | Completed | USA | 0 |
NCT02303028 | Phase Ib/II | Pazopanib + Topotecan | Phase I Dose Escalation Study of Topotecan and Pazopanib in Children With Recurrent/Refractory Solid and CNS Tumours | Completed | CAN | 0 |
NCT02303990 | Phase I | Pembrolizumab | RADVAX A Stratified Phase I Trial of Pembrolizumab With Hypofractionated Radiotherapy in Patients With Advanced and Metastatic Cancers | Completed | USA | 0 |
NCT02304393 | Phase I | Selicrelumab Atezolizumab | A Study of RO7009789 in Combination With MPDL3280A in Patients With Locally Advanced and Metastatic Solid Tumors | Completed | USA | FRA | ESP | CAN | 2 |
NCT02304419 | Phase I | Galunisertib | A Study of Galunisertib on the Immune System in Participants With Cancer | Completed | USA | 0 |
NCT02304458 | Phase Ib/II | Ipilimumab + Nivolumab | Nivolumab With or Without Ipilimumab in Treating Younger Patients With Recurrent or Refractory Solid Tumors or Sarcomas | Completed | USA | CAN | 0 |
NCT02307240 | Phase I | CUDC-907 | Open Label, Multi-center Study to Assess the Safety, Tolerability and Pharmacokinetics of CUDC-907 in Subjects With Advanced/Relapsed Solid Tumors | Completed | USA | 0 |
NCT02312804 | Phase I | Paclitaxel Carboplatin Infigratinib | Ph Ib/BGJ398/Cervix and Other Solid Tumors | Withdrawn | 0 | |
NCT02313012 | Phase I | CC-90003 | Safety and PK Study of CC-90003 in Relapsed/Refractory Solid Tumors | Terminated | USA | AUS | 0 |
NCT02317874 | Phase I | Carboplatin + Paclitaxel + Talazoparib | Testing the Addition of the Anti-Cancer Drug Talazoparib to the Combination of Carboplatin and Paclitaxel for the Treatment of Advanced Cancer | Completed | USA | 0 |
NCT02318277 | Phase Ib/II | Durvalumab + Epacadostat | A Study of INCB024360 in Combination With MEDI4736 in Subjects With Selected Advanced Solid Tumors | Completed | USA | 0 |
NCT02318329 | Phase I | Bemarituzumab | Open-Label, Dose-Finding Study Evaluating Safety and PK of FPA144 in Patients With Advanced Solid Tumors | Completed | USA | 2 |
NCT02318394 | Phase I | Tavolimab | A Phase 1 Study of MEDI0562 in Adult Subjects With Selected Advanced Solid Tumors | Completed | USA | 1 |
NCT02318901 | Phase Ib/II | Ado-trastuzumab emtansine + Pembrolizumab Pembrolizumab + Trastuzumab Cetuximab + Pembrolizumab | Pembrolizumab and Monoclonal Antibody Therapy in Advanced Cancer | Terminated | USA | 0 |
NCT02321501 | Phase I | Ceritinib + Everolimus | Ceritinib and Everolimus in Treating Patients With Locally Advanced or Metastatic Solid Tumors or Stage IIIB-IV Non-small Cell Lung Cancer | Active, not recruiting | USA | 0 |
NCT02323880 | Phase I | Selinexor | Study of Selinexor in Pediatric Solid Tumors | Active, not recruiting | USA | 0 |
NCT02324621 | Phase I | ONC201 | Continuation of Oral ONC201 in Treating Patients With Advanced Solid Tumors | Completed | USA | 0 |
NCT02325739 | Phase Ib/II | FGF401 | Safety and Efficacy of FGF401 in Patients With Solid Malignancies | Completed | USA | ITA | FRA | ESP | DEU | 6 |
NCT02327169 | Phase I | Sapanisertib + Tovorafenib Alisertib + Tovorafenib Paclitaxel + Tovorafenib | A Phase 1B Study of MLN2480 in Combination With MLN0128 or Alisertib or Paclitaxel in Adult Patients With Advanced Nonhematologic Malignancies | Completed | USA | GBR | FRA | ESP | 0 |
NCT02331251 | Phase Ib/II | Vinorelbine Pembrolizumab Irinotecan Doxorubicin Gemcitabine Docetaxel Nab-paclitaxel | Study of Pembrolizumab Plus Chemotherapy in Patients With Advanced Cancer (PembroPlus) | Terminated | USA | 0 |
NCT02332668 | Phase Ib/II | Pembrolizumab | A Study of Pembrolizumab (MK-3475) in Pediatric Participants With an Advanced Solid Tumor or Lymphoma (MK-3475-051/KEYNOTE-051) | Recruiting | USA | ITA | GBR | FRA | DEU | 5 |
NCT02341456 | Phase I | Adavosertib Carboplatin Paclitaxel | Phase Ib Study AZD1775 in Combination With Carboplatin and Paclitaxel in Adult Asian Patients With Solid Tumours | Completed | AUS | 2 |
NCT02343718 | Phase I | Temsirolimus + Vinblastine | Vinblastine and Temsirolimus in Pediatric Patients With Recurrent or Refractory Lymphoma or Solid Tumours Including CNS Tumours | Completed | CAN | 0 |
NCT02350673 | Phase I | Cergutuzumab amunaleukin Atezolizumab | A Study of Intravenous RO6895882 and MPDL3280A Combination in Patients With Locally Advanced and/or Metastatic Solid Tumors | Completed | USA | ESP | CAN | 3 |
NCT02352844 | Phase II | Everolimus | Everolimus in Patients With Advanced Solid Malignancies With TSC1, TSC2, NF1, NF2, or STK11 Mutations | Completed | USA | 0 |
NCT02354547 | Phase I | Cyclophosphamide + SGT-53 + Topotecan | A Study of SGT-53 in Children With Refractory or Recurrent Solid Tumors | Suspended | USA | 0 |
NCT02354612 | Phase Ib/II | Axitinib + Carotuximab Carotuximab + Pazopanib Capecitabine + Carotuximab Carotuximab Bevacizumab + Carotuximab | An Open Label Continuation Study of TRC105 Therapy for Patients Who Have Completed a Prior TRC105 Trial and Are Judged by the Investigator to Have the Potential to Benefit From Continued TRC105 Therapy | No longer available | USA | 0 |
NCT02355535 | Phase I | PAC-1 | Procaspase Activating Compound-1 (PAC-1) in the Treatment of Advanced Malignancies | Completed | USA | 0 |
NCT02358200 | Phase I | Carboplatin + Paclitaxel + Talazoparib | Study of BMN-673 With Carboplatin and Paclitaxel in Patients With Advanced BRCA-mutated Solid Tumor or Triple Negative Metastatic Breast Cancer | Terminated | USA | 0 |
NCT02365662 | Phase I | ABBV-221 | A Study Evaluating Safety and Pharmacokinetics of ABBV-221 in Subjects With Advanced Solid Tumor Types Likely to Exhibit Elevated Levels of Epidermal Growth Factor Receptor | Terminated | USA | ESP | 0 |
NCT02366949 | Phase I | BAY1217389 + Paclitaxel Paclitaxel | Phase I Study of Oral BAY 1217389 in Combination With Intravenous Paclitaxel | Completed | USA | 1 |
NCT02367196 | Phase I | CC-90002 + Rituximab CC-90002 | A Phase 1, Dose Finding Study of CC-90002 in Subjects With Advanced Solid and Hematologic Cancers | Completed | USA | ESP | 0 |
NCT02368951 | Phase I | Aprutumab ixadotin | Phase I, Dose-escalation Trial of BAY1187982 in Subjects With Advanced Solid Tumors Known to Express Fibroblast Growth Factor Receptor 2 (FGFR2) | Terminated | USA | 2 |
NCT02369029 | Phase I | BAY 1238097 | BAY1238097, First in Man | Terminated | USA | GBR | FRA | DEU | 2 |
NCT02376699 | Phase I | Pembrolizumab + SEA-CD40 SEA-CD40 | Safety Study of SEA-CD40 in Cancer Patients | Terminated | USA | 0 |
NCT02379416 | Phase I | Nab-paclitaxel + Nilotinib | Combination Nilotinib and Paclitaxel in Adults With Relapsed Solid Tumors | Recruiting | USA | 0 |
NCT02379520 | Phase I | Cyclophosphamide + Fludarabine + HPVST cells + Nivolumab HPVST cells | HPV-16/18 E6/E7-Specific T Lymphocytes, Relapsed HPV-Associated Cancers, HESTIA (HESTIA) | Active, not recruiting | USA | 0 |
NCT02381886 | Phase I | IDH305 | A Study of IDH305 in Patients With Advanced Malignancies That Harbor IDH1R132 Mutations | Active, not recruiting | USA | ESP | DEU | CAN | BEL | AUS | 2 |
NCT02383212 | Phase I | Carboplatin + Cemiplimab + Docetaxel Carboplatin + Cemiplimab + Pemetrexed Disodium Cemiplimab + Cyclophosphamide + Sargramostim Cemiplimab + Cyclophosphamide Cemiplimab Carboplatin + Cemiplimab + Paclitaxel Cemiplimab + Docetaxel | Study of REGN2810 (Anti-PD-1) in Patients With Advanced Malignancies | Completed | USA | ESP | AUS | 0 |
NCT02386501 | Phase Ib/II | ADXS31-164 | Dose Escalation Study of ADXS31-164 in Subjects With HER2 Expressing Solid Tumors | Completed | USA | 0 |
NCT02387125 | Phase I | CMB305 | A Phase 1b Safety Study of CMB305 (Sequentially Administered LV305 and G305) in Patients With Locally Advanced, Relapsed, or Metastatic Cancer Expressing NY-ESO-1 | Terminated | USA | 0 |
NCT02389309 | Phase I | Cyclophosphamide + Dasatinib + Temsirolimus | A Trial of Dasatinib (PDGFR and SRC Inhibitor), Temsirolimus and Cyclophosphamide in Patients With Advanced Solid Tumors | Active, not recruiting | USA | 0 |
NCT02390752 | Phase Ib/II | Pexidartinib | PLX3397 in Children and Young Adults With Refractory Leukemias and Refractory Solid Tumors Including Neurofibromatosis Type 1 (NF1) Associated Plexiform Neurofibromas (PN) | Recruiting | USA | 0 |
NCT02390843 | Phase I | Cyclophosphamide + Filgrastim + Simvastatin + Topotecan | Simvastatin With Topotecan and Cyclophosphamide in Relapsed and/or Refractory Pediatric Solid and CNS Tumors (AflacST1402) | Completed | USA | 0 |
NCT02391480 | Phase I | Mivebresib | A Study Evaluating the Safety and Pharmacokinetics of ABBV-075 in Subjects With Cancer | Completed | USA | 0 |
NCT02391727 | Phase I | SYN004 | Safety, Immunogenicity and Pharmacokinetics of SYN004 in Patients With Solid Tumors (SYN004_Ph_1) | Completed | USA | 0 |
NCT02392611 | Phase I | Exemestane + GS-5829 | Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of GS-5829 in Adults With Advanced Solid Tumors and Lymphomas | Completed | USA | 0 |
NCT02392793 | Phase I | Irinotecan + Talazoparib Temozolomide | Talazoparib Plus Irinotecan With or Without Temozolomide in Children With Refractory or Recurrent Solid Malignancies | Completed | USA | 0 |
NCT02393248 | Phase Ib/II | Cisplatin + Gemcitabine + Pemigatinib Docetaxel + Pemigatinib Pemigatinib + Retifanlimab Pemigatinib + Trastuzumab Epacadostat + Pembrolizumab | Open-Label, Dose-Escalation Study of Pemigatinib in Subjects With Advanced Malignancies - (FIGHT-101) | Terminated | USA | 1 |
NCT02401815 | Phase Ib/II | PLX9486 + Sunitinib Pexidartinib + PLX9486 PLX9486 | PLX9486 as a Single Agent and in Combination With PLX3397 or PLX9486 With Sunitinib in Patients With Advanced Solid Tumors | Completed | USA | 0 |
NCT02404441 | Phase Ib/II | Spartalizumab | Phase I/II Study of PDR001 in Patients With Advanced Malignancies | Completed | USA | ITA | FRA | ESP | DEU | CAN | 8 |
NCT02404480 | Phase I | PTC596 | PTC596 in Patients With Advanced Solid Tumors | Completed | USA | CAN | 0 |
NCT02407509 | Phase I | RO5126766 Everolimus + RO5126766 | Phase I Trial of VS-6766 Alone and in Combination With Everolimus (RAF/MEK) | Recruiting | GBR | 0 |
NCT02407990 | Phase I | Tislelizumab | Study of the Safety, Pharmacokinetics and Antitumor Activities of BGB-A317 in Subjects With Advanced Tumors | Completed | USA | AUS | 3 |
NCT02408861 | Phase I | Ipilimumab + Nivolumab | Nivolumab and Ipilimumab in Treating Patients With Advanced HIV Associated Solid Tumors | Recruiting | USA | AUS | 0 |
NCT02410512 | Phase I | Vonlerolizumab Atezolizumab | A Dose-Escalation Study of the Safety and Pharmacokinetics of MOXR0916 and MPDL3280A in Patients With Locally Advanced or Metastatic Solid Tumors | Completed | USA | FRA | ESP | CAN | BEL | AUS | 1 |
NCT02412462 | Phase I | AB-16B5 | Phase I Dose Escalation Study of AB-16B5 in Subjects With an Advanced Solid Malignancy | Completed | CAN | 0 |
NCT02412722 | Phase I | Sapanisertib Paclitaxel | Safety, Tolerability, and Pharmacokinetics of MLN0128 as a Single Agent and in Combination With Paclitaxel in Adults With Advanced Nonhematologic Malignancies | Completed | USA | 0 |
NCT02414516 | Phase I | OBP-801 | A Dose-Escalation Study of OBP-801 in Patients With Advanced Solid Tumors | Unknown status | USA | 0 |
NCT02414724 | Phase I | Gemcitabine + Ribociclib | Ribociclib and Gemcitabine Hydrochloride in Treating Patients With Advanced Solid Tumors or Lymphoma | Terminated | USA | 0 |
NCT02419417 | Phase Ib/II | BMS986158 Paclitaxel | Study of BMS-986158 in Subjects With Select Advanced Solid Tumors | Completed | USA | FRA | ESP | CAN | AUS | 0 |
NCT02419495 | Phase I | Cyclophosphamide Pemetrexed Disodium Eribulin Selinexor Carboplatin Paclitaxel Topotecan Dexamethasone Doxorubicin | Selinexor in Combination With Standard Chemotherapy | Active, not recruiting | USA | 0 |
NCT02422589 | Phase I | Warfarin Midazolam Ceritinib | A Phase I, Multi-center, Open Label, Drug-drug Interaction Study to Assess the Effect of Ceritinib on the Pharmacokinetics of Warfarin and Midazolam in Patients With ALK-positive Advanced Tumors | Completed | USA | ITA | ESP | 1 |
NCT02423057 | Phase I | TdCyd | Phase I Trial of 4'-Thio-2'-Deoxycytidine (TdCyd) in Patients With Advanced Solid Tumors | Suspended | USA | 0 |
NCT02423343 | Phase Ib/II | Galunisertib Nivolumab | A Study of Galunisertib (LY2157299) in Combination With Nivolumab in Advanced Refractory Solid Tumors and in Recurrent or Refractory NSCLC, Hepatocellular Carcinoma, or Glioma | Completed | USA | ESP | 0 |
NCT02423954 | Phase Ib/II | Temsirolimus Nivolumab Capecitabine Irinotecan | Study of Nivolumab Plus Chemotherapy in Patients With Advanced Cancer (NivoPlus) | Terminated | USA | 0 |
NCT02428712 | Phase Ib/II | PLX8394 | A Study of FORE8394 as a Single Agent in Patients With Advanced Unresectable Solid Tumors | Active, not recruiting | USA | 0 |
NCT02431260 | Phase I | INCB054329 | An Open-Label, Dose-Escalation Study of INCB054329 in Patients With Advanced Malignancies | Terminated | USA | 0 |
NCT02432274 | Phase Ib/II | Etoposide Lenvatinib Cyclophosphamide | Study of Lenvatinib in Children and Adolescents With Refractory or Relapsed Solid Malignancies | Completed | USA | ITA | GBR | FRA | ESP | DEU | 0 |
NCT02432326 | Phase I | Amcasertib Napabucasin | A Study of BBI608 and BBI503 Administered in Combination to Adult Patients With Advanced Solid Tumors | Completed | USA | 0 |
NCT02432963 | Phase I | MVAp53 + Pembrolizumab | Vaccine Therapy and Pembrolizumab in Treating Patients With Solid Tumors That Have Failed Prior Therapy | Active, not recruiting | USA | 0 |
NCT02433626 | Phase I | COTI-2 Cisplatin + COTI-2 | Study of COTI-2 as Monotherapy or Combination Therapy for the Treatment of Malignancies (COTI2-101) | Unknown status | USA | 0 |
NCT02439723 | Phase I | Regorafenib | Effects of LBM and PPIs on Pharmacokinetics and Safety of Regorafenib (BAY 73-4506) in Cancer Patients | Withdrawn | CAN | 0 |
NCT02440685 | Phase Ib/II | ASN002 | A Phase 1/2 Study To Evaluate ASN002 In Relapsed/Refractory Lymphoma And Advanced Solid Tumors | Terminated | USA | 1 |
NCT02442297 | Phase I | HER2 sensitized T-cells | T Cells Expressing HER2-specific Chimeric Antigen Receptors(CAR) for Patients With HER2-Positive CNS Tumors (iCAR) | Active, not recruiting | USA | 0 |
NCT02442414 | Phase I | Pirotinib | A Phase 1 Study of KBP-5209 in Patients With Advanced Solid Tumors | Completed | USA | 0 |
NCT02444793 | Phase I | Mogamulizumab + Utomilumab | A Study of PF-05082566 In Combination With Mogamulizumab In Patients With Advanced Solid Tumors | Terminated | USA | 0 |
NCT02448589 | Phase I | VIC-1911 | An Investigation of TAS-119 Monotherapy and in Combination With Docetaxel | Terminated | USA | ITA | GBR | ESP | 1 |
NCT02451553 | Phase I | Afatinib Capecitabine | Afatinib Dimaleate and Capecitabine in Treating Patients With Advanced Refractory Solid Tumors, Pancreatic Cancer or Biliary Cancer | Completed | USA | 0 |
NCT02452268 | Phase I | NIZ985 + Spartalizumab | A Phase I/Ib Study of NIZ985 in Combination With PDR001 in Adults With Metastatic Cancers | Terminated | USA | 0 |
NCT02452424 | Phase Ib/II | Pembrolizumab + Pexidartinib | A Combination Clinical Study of PLX3397 and Pembrolizumab To Treat Advanced Melanoma and Other Solid Tumors | Terminated | USA | 0 |
NCT02453620 | Phase I | Entinostat + Ipilimumab + Nivolumab | Entinostat, Nivolumab, and Ipilimumab in Treating Patients With Solid Tumors That Are Metastatic or Cannot Be Removed by Surgery or Locally Advanced or Metastatic HER2-Negative Breast Cancer | Active, not recruiting | USA | 0 |
NCT02454010 | Phase I | FF-21101(90Y) | A Dose Escalation Study of Radio-labeled Antibody for the Treatment of Advanced Cancer | Completed | USA | 0 |
NCT02456883 | Phase I | Gilteritinib | Study to Investigate the Absorption, Metabolism and Excretion of [14C] ASP2215 in Patients With Advanced Solid Tumors | Completed | USA | 0 |
NCT02457351 | Phase I | Roniciclib Itraconazole | Roniciclib (BAY 1000394) Drug-Drug Interaction (DDI) Study | Completed | CAN | 0 |
NCT02457793 | Phase I | Cobimetinib Ravoxertinib | A Study of the Safety, Tolerability, and Effects of Cobimetinib and GDC-0994 in Patients With Locally Advanced or Metastatic Solid Tumors | Completed | USA | 0 |
NCT02458638 | Phase II | Atezolizumab | An Open Label Study of MPDL3280A in Advanced Solid Tumors | Completed | USA | ITA | GBR | FRA | ESP | DEU | CAN | AUT | 10 |
NCT02460224 | Phase Ib/II | Ieramilimab Spartalizumab | Safety and Efficay of LAG525 Single Agent and in Combination With PDR001 in Patients With Advanced Malignancies | Completed | USA | ITA | FRA | ESP | DEU | CAN | BEL | AUS | 4 |
NCT02465060 | Phase II | Nivolumab + Relatlimab Dabrafenib + Trametinib | Targeted Therapy Directed by Genetic Testing in Treating Patients With Advanced Refractory Solid Tumors, Lymphomas, or Multiple Myeloma (The MATCH Screening Trial) | Active, not recruiting | USA | 2 |
NCT02466802 | Phase I | Regorafenib Sildenafil | Study of Regorafenib and Sildenafil for Advanced Solid Tumors | Completed | USA | 0 |
NCT02467361 | Phase Ib/II | Nivolumab Pembrolizumab Ipilimumab Napabucasin | A Study of BBI608 Administered in Combination With Immune Checkpoint Inhibitors in Adult Patients With Advanced Cancers | Completed | USA | 0 |
NCT02471846 | Phase I | Navoximod Atezolizumab | A Study of GDC-0919 and MPDL3280A Combination Treatment in Participants With Locally Advanced or Metastatic Solid Tumors | Completed | USA | FRA | ESP | 1 |
NCT02473497 | Expanded access | Crizotinib | Crizotinib (Xalkori) Expanded Access Protocol For The Treatment Of Adult Or Pediatric Patients | No longer available | USA | 0 |
NCT02476955 | Phase I | Miransertib Carboplatin + Paclitaxel | Open-label Phase 1b Study of ARQ 092 in Combination With Carboplatin Plus Paclitaxel | Terminated | USA | 0 |
NCT02478320 | Phase II | ABT-348 | Phase II Study of Ilorasertib (ABT348) in Patients With CDKN2A Deficient Solid Tumors | Terminated | USA | 0 |
NCT02481154 | Phase I | Vorasidenib | Study of Orally Administered AG-881 in Patients With Advanced Solid Tumors, Including Gliomas, With an IDH1 and/or IDH2 Mutation | Active, not recruiting | USA | 0 |
NCT02482168 | Phase I | Sotigalimab | Study of the CD40 Agonistic Monoclonal Antibody APX005M | Completed | USA | 0 |
NCT02482441 | Phase I | Rosmantuzumab Fluorouracil + Irinotecan + Leucovorin | A Phase 1a/b Dose Escalation Study of the Safety, Pharmacokinetics, and Pharmacodynamics of OMP-131R10 | Completed | USA | 0 |
NCT02483247 | Phase Ib/II | Paclitaxel Doxorubicin Capecitabine Nivolumab Sunitinib Pembrolizumab Amcasertib | A Study of BBI503 in Combination With Selected Anti-Cancer Therapeutics in Adult Patients With Advanced Cancer | Completed | USA | CAN | 0 |
NCT02483858 | Phase I | PQR309 | Study of Oral PQR309 in Patients With Advanced Solid Tumors | Completed | USA | 0 |
NCT02484404 | Phase Ib/II | Cediranib + Durvalumab Durvalumab + Olaparib | Phase 1 and 2 Study of MEDI4736 in Combination With Olaparib or Cediranib for Advanced Solid Tumors and Recurrent Ovarian Cancer | Recruiting | USA | 0 |
NCT02490800 | Phase Ib/II | BAL101553 | Phase 1/2a Study of Oral BAL101553 in Adult Patients With Solid Tumors or Glioblastoma or High-grade Glioma | Completed | GBR | DEU | BEL | 1 |
NCT02494258 | Phase II | Azacitidine | A Study to Evaluate Long-term Safety in Subjects With Solid Tumors and Hematological Disorders. | Active, not recruiting | USA | GBR | 0 |
NCT02499328 | Phase Ib/II | Danvatirsen + Durvalumab AZD5069 + Durvalumab Durvalumab Danvatirsen | Study to Assess Combination of MEDI4736 With Either AZD9150 or AZD5069 in Patients With Metastatic Squamous Cell Carcinoma of Head and Neck | Active, not recruiting | USA | ITA | GBR | ESP | DEU | BEL | 0 |
NCT02499861 | Phase Ib/II | Decitabine + Genistein | Phase I/II a Study of Decitabine in Combination With Genistein in Pediatric Relapsed or Refractory Malignancies | Completed | CAN | 0 |
NCT02500199 | Phase I | Pyrotinib | Phase I Study of Pyrotinib in Patients With HER2-positive Solid Tumors | Unknown status | USA | 0 |
NCT02503423 | Phase Ib/II | ASTX-660 | Phase 1-2 Study of ASTX660 in Subjects With Advanced Solid Tumors and Lymphomas | Active, not recruiting | USA | ITA | GBR | FRA | ESP | CAN | BEL | 1 |
NCT02503709 | Phase I | AT7519 Onalespib | Hsp90 Inhibitor AT13387 and CDKI AT7519 in Treating Patients With Solid Tumors That Are Metastatic or Cannot Be Removed by Surgery | Active, not recruiting | USA | 0 |
NCT02503774 | Phase I | Durvalumab Oleclumab | MEDI9447 Alone and in Combination With MEDI4736 in Adult Subjects With Select Advanced Solid Tumors | Completed | USA | AUS | 1 |
NCT02506517 | Phase II | Afatinib | A Study of Afatinib in Patients With Advanced Cancer With Changes in the HER Gene | Completed | CAN | 0 |
NCT02508532 | Phase I | Avapritinib | Phase 1 Study of BLU-285 in Patients With Gastrointestinal Stromal Tumors (GIST) and Other Relapsed and Refractory Solid Tumors | Completed | USA | ITA | GBR | FRA | ESP | DEU | BEL | 3 |
NCT02511795 | Phase I | Adavosertib Olaparib | AZD1775 Combined With Olaparib in Patients With Refractory Solid Tumors | Completed | USA | CAN | 0 |
NCT02516553 | Phase I | BI 894999 | BI 894999 First in Human Dose Finding Study in Advanced Malignancies | Completed | USA | FRA | ESP | DEU | BEL | 1 |
NCT02516813 | Phase I | Peposertib | Phase 1 Trial of MSC2490484A, an Inhibitor of a DNA-dependent Protein Kinase, in Combination With Radiotherapy | Completed | USA | DEU | BEL | 5 |
NCT02517398 | Phase I | Bintrafusp alfa | MSB0011359C (M7824) in Metastatic or Locally Advanced Solid Tumors | Completed | USA | ITA | GBR | FRA | ESP | DEU | CAN | BEL | AUS | 3 |
NCT02517918 | Phase I | Cyclophosphamide + Methotrexate + Sirolimus + Zoledronic acid | Metronomic Chemotherapy in Patients With Advanced Solid Tumor With Bone Metastasis and Advanced Pretreated Osteosarcoma a (METZOLIMOS) | Completed | FRA | 0 |
NCT02518958 | Phase I | Nivolumab | A Phase I, Open-Label, Multiple Ascending Dose Study of RRx-001 and Nivolumab | Completed | USA | 0 |
NCT02520752 | Phase I | Midazolam Capmatinib | A DDI Study to Assess the Effect of INC280 on the PK of Midazolam and Caffeine in Patients With cMET-dysregulated Advanced Solid Tumors | Completed | USA | ITA | GBR | FRA | ESP | 2 |
NCT02521844 | Phase I | ETC-159 | A Study to Evaluate the Safety and Tolerability of ETC-1922159 in Advanced Solid Tumours | Active, not recruiting | USA | 1 |
NCT02527434 | Phase II | Durvalumab + Tremelimumab Durvalumab | Study of Tremelimumab in Patients With Advanced Solid Tumors | Completed | USA | BEL | 3 |
NCT02528357 | Phase I | GSK3174998 Pembrolizumab | GSK3174998 Alone or With Pembrolizumab in Subjects With Advanced Solid Tumors | Completed | USA | FRA | CAN | 1 |
NCT02529553 | Phase I | LY3076226 | A Study of LY3076226 in Participants With Advanced or Metastatic Cancer | Completed | USA | CAN | 0 |
NCT02536183 | Phase I | ThermoDox | A Phase I Study of Lyso-thermosensitive Liposomal Doxorubicin and MR-HIFU for Pediatric Refractory Solid Tumors | Terminated | USA | 0 |
NCT02537418 | Phase I | Cisplatin + Etoposide Durvalumab Tremelimumab | Durvalumab With or Without Tremelimumab in Advanced Incurable Solid Malignancies Receiving Standard Chemotherapy Regimens | Active, not recruiting | CAN | 0 |
NCT02537561 | Phase I | Talazoparib Cisplatin + Gemcitabine | Talazoparib in Combination With Gemcitabine and Cisplatin in Patients With Advanced Solid Tumors | Withdrawn | 0 | |
NCT02540876 | Phase I | ABT-348 | Ilorasertib in Treating Patients With CDKN2A-deficient Advanced or Metastatic Solid Cancers That Cannot Be Removed by Surgery | Completed | USA | 0 |
NCT02541604 | Phase I | Atezolizumab | A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Immunogenicity, and Preliminary Efficacy of MPDL3280A (Anti-PD-L1 Antibody) in Pediatric and Young Adult Participants With Solid Tumors | Terminated | USA | ITA | GBR | FRA | ESP | DEU | CAN | 4 |
NCT02546531 | Phase I | Defactinib + Gemcitabine + Pembrolizumab | Defactinib Combined With Pembrolizumab and Gemcitabine in Patients With Advanced Cancer | Completed | USA | 0 |
NCT02549937 | Phase I | Surufatinib | A Multi-Center, Open-Label Study of Sulfatinib(HMPL-012) in Patients With Advanced Solid Tumors | Completed | USA | ITA | 0 |
NCT02551055 | Phase I | Docetaxel Paclitaxel Alisertib Mivavotinib Serabelisib | MLN1117 in Combination With Docetaxel, Paclitaxel, and Other Investigational Anticancer Agents to Treat Participants With Gastric and Gastroesophageal Adenocarcinoma | Terminated | USA | ESP | 0 |
NCT02551185 | Phase I | Citarinostat | ACY 241 in Combination With Paclitaxel in Patients With Advanced Solid Tumors | Completed | USA | 0 |
NCT02552953 | Phase I | CYC065 | A Pharmacologic Study of CYC065, a Cyclin Dependent Kinase Inhibitor, in Patients With Advanced Cancers | Completed | USA | 0 |
NCT02554812 | Phase Ib/II | Avelumab + PF-04518600 Avelumab + PD 0360324 Avelumab + Utomilumab Avelumab + PF-04518600 + Utomilumab | A Study Of Avelumab In Combination With Other Cancer Immunotherapies In Advanced Malignancies (JAVELIN Medley) | Terminated | USA | GBR | FRA | CAN | AUS | 3 |
NCT02556463 | Phase I | MEDI9197 Durvalumab + MEDI9197 | A Study of MEDI9197 in Subjects With Solid Tumors or CTCL and in Combination With Durvalumab and Palliative Radiation in Subjects With Solid Tumors | Terminated | USA | FRA | CAN | 0 |
NCT02558140 | Phase I | RG7386 | A Dose Escalation Study of RO6874813 in Participants With Locally Advanced or Metastatic Solid Tumors | Completed | USA | FRA | ESP | 0 |
NCT02559492 | Phase I | Epacadostat + Itacitinib Itacitinib + Parsaclisib | INCB039110 Combined With INCB024360 and/or INCB039110 Combined With INCB050465 in Advanced Solid Tumors | Terminated | USA | 0 |
NCT02561234 | Phase I | Pegzilarginase | A Multiple Dose, Dose Escalation Trial of AEB1102 in Patients With Advanced Solid Tumors | Completed | USA | 0 |
NCT02561455 | Phase Ib/II | Gilteritinib | Rollover Study for Subjects Who Have Participated in an Astellas Sponsored ASP2215 Trial | Completed | USA | 0 |
NCT02564198 | Phase I | Ramucirumab | A Study of Ramucirumab (LY3009806) in Children With Refractory Solid Tumors | Completed | USA | 0 |
NCT02564900 | Phase I | Trastuzumab deruxtecan | Study of DS-8201a in Subjects With Advanced Solid Malignant Tumors | Completed | USA | 1 |
NCT02565758 | Phase I | Gemcitabine Nivolumab Nab-paclitaxel ABBV-085 | ABBV-085, an Antibody Drug Conjugate, in Subjects With Advanced Solid Cancer Tumors | Completed | USA | FRA | ESP | 0 |
NCT02567396 | Phase I | Talazoparib | Talazoparib in Treating Patients With Advanced or Metastatic Solid Tumors That Cannot Be Removed by Surgery and Liver or Kidney Dysfunction | Withdrawn | 0 | |
NCT02568267 | Phase II | Entrectinib | Basket Study of Entrectinib (RXDX-101) for the Treatment of Patients With Solid Tumors Harboring NTRK 1/2/3 (Trk A/B/C), ROS1, or ALK Gene Rearrangements (Fusions) (STARTRK-2) | Active, not recruiting | USA | ITA | GBR | FRA | ESP | DEU | BEL | AUS | 8 |
NCT02571036 | Phase I | Ripretinib | A Safety, Tolerability and PK Study of DCC-2618 in Patients With Advanced Malignancies | Completed | USA | ITA | GBR | DEU | CAN | 1 |
NCT02574728 | Phase II | Celecoxib + Cyclophosphamide + Etoposide + Sirolimus | Sirolimus in Combination With Metronomic Chemotherapy in Children With Recurrent and/or Refractory Solid and CNS Tumors | Recruiting | USA | 0 |
NCT02575638 | Phase I | CZ48 | Safety Study of Camptothecin-20-O-Propionate Hydrate (CZ48) | Unknown status | USA | 0 |
NCT02575781 | Phase I | SAR428926 | A Study of SAR428926 in Patients With Advanced Solid Tumors | Completed | FRA | ESP | 1 |
NCT02576431 | Phase II | Larotrectinib | A Study to Test the Effect of the Drug Larotrectinib in Adults and Children With NTRK-fusion Positive Solid Tumors (NAVIGATE) | Active, not recruiting | USA | FRA | ESP | DEU | 14 |
NCT02576444 | Phase II | Adavosertib + Olaparib Olaparib Capivasertib + Olaparib Ceralasertib + Olaparib | OLAParib COmbinations (OLAPCO) | Terminated | USA | 0 |
NCT02576665 | Phase I | Toca 511 + Toca FC | A Study of Toca 511, a Retroviral Replicating Vector, Combined With Toca FC in Subjects With Solid Tumors (Toca6) | Terminated | USA | 0 |
NCT02579226 | Phase I | Irinotecan AZD2811 | A Phase I Study of Safety, Tolerability, and PK of AZD2811 in Patients With Advanced Solid Tumors | Completed | USA | 0 |
NCT02582827 | Phase I | ABI-011 | QUILT-3.014: A Trial of ABI-011 Administered Weekly in Patients With Advanced Solid Tumors or Lymphomas | Withdrawn | USA | 0 |
NCT02584933 | FDA approved | Ceritinib | Roll-over Study to Allow Access to Certinib (LDK378) for Patients Who Are on Ceritinib Treatment in a Novartis-sponsored Study | Recruiting | USA | ITA | FRA | ESP | DEU | BEL | AUS | 14 |
NCT02586987 | Phase I | Durvalumab + Selumetinib | A Study to Assess the Safety, Tolerability, Pharmacokinetics and Anti-tumour Activity of Ascending Doses of Selumetinib in Combination With MEDI4736 in Patients With Advanced Solid Tumours | Completed | USA | 0 |
NCT02587598 | Phase Ib/II | INCB053914 | Study of INCB053914 in Subjects With Advanced Malignancies | Terminated | USA | 0 |
NCT02587962 | Phase Ib/II | Birinapant + Pembrolizumab | Dose-escalation Study of Birinapant and Pembrolizumab in Solid Tumors | Terminated | USA | 0 |
NCT02588105 | Phase I | Olaparib AZD0156 | Study to Assess the Safety and Preliminary Efficacy of AZD0156 at Increasing Doses Alone or in Combination With Other Anti-cancer Treatment in Patients With Advanced Cancer | Completed | USA | GBR | ESP | 1 |
NCT02593708 | Phase I | Neratinib + Paclitaxel + Pertuzumab + Trastuzumab | Phase1 of Neratinib+Trastuzumab, Pertuzumab, Paclitaxel in Patients With Advanced Solid Tumors/HER2+ | Terminated | USA | 0 |
NCT02595866 | Phase I | Pembrolizumab | Pembrolizumab in Treating Patients With HIV and Relapsed, Refractory, or Disseminated Malignant Neoplasms | Active, not recruiting | USA | 0 |
NCT02595931 | Phase I | Berzosertib + Irinotecan | VX-970 and Irinotecan Hydrochloride in Treating Patients With Solid Tumors That Are Metastatic or Cannot Be Removed by Surgery | Active, not recruiting | USA | 0 |
NCT02597036 | Phase I | LY3127804 Ramucirumab | A Study of LY3127804 With Ramucirumab in Participants With Advanced Solid Tumors | Completed | USA | FRA | ESP | BEL | 0 |
NCT02598960 | Phase Ib/II | Nivolumab BMS-986156 | A Study of BMS-986156 Given Alone and in Combination With Nivolumab in Subjects With Advanced Solid Tumors | Completed | USA | ITA | FRA | ESP | DEU | CAN | BEL | AUS | 2 |
NCT02601950 | Phase II | Tazemetostat | A Study of Tazemetostat in Adult Participants With Soft Tissue Sarcoma | Active, not recruiting | USA | ITA | GBR | FRA | DEU | CAN | BEL | AUS | 1 |
NCT02605083 | Phase Ib/II | Tomivosertib | A Dose Escalation and Cohort-Expansion Study of Oral eFT508 in Subjects With Advanced Solid Tumors | Terminated | USA | 0 |
NCT02607813 | Phase I | LXH 254 + Spartalizumab LXH 254 | Phase I Study of LXH254 in Patients With Advanced Solid Tumors Haboring MAPK Pathway Alterations | Terminated | USA | ITA | FRA | ESP | DEU | CAN | 4 |
NCT02608125 | Phase I | PRN1371 | A Dose Escalation Study in Solid Tumors and a Dose Expansion Study of PRN1371 in Adult Patients With Metastatic Urothelial Carcinoma | Terminated | USA | ESP | 0 |
NCT02608268 | Phase Ib/II | Spartalizumab Sabatolimab | Safety and Efficacy of MBG453 as Single Agent and in Combination With PDR001 in Patients With Advanced Malignancies | Terminated | USA | ITA | CAN | 6 |
NCT02608385 | Phase I | Pembrolizumab | Study of PD1 Blockade by Pembrolizumab With Stereotactic Body Radiotherapy in Advanced Solid Tumors | Active, not recruiting | USA | 0 |
NCT02609230 | Phase I | ONC201 | A Dose-Escalation Study of Onc201 Administered Every One or Three Weeks in Advanced Solid Tumors and Multiple Myeloma | Completed | USA | 0 |
NCT02610075 | Phase I | Adavosertib | Study to Determine MTD of AZD1775 Monotherapy in Patients With Locally Advanced or Metastatic Solid Tumours. | Completed | USA | 0 |
NCT02610361 | Phase I | Lifirafenib | Study of the Safety and Pharmacokinetics of BGB-283 in Patients With Solid Tumors | Completed | AUS | 1 |
NCT02612285 | Phase II | SNX-5422 | Study of SNX-5422 in TP53 Null Cancers | Terminated | USA | 0 |
NCT02614456 | Phase I | Nivolumab Interferon gamma | Combination of Interferon-gamma and Nivolumab for Advanced Solid Tumors | Completed | USA | 0 |
NCT02617277 | Phase I | Adavosertib + Durvalumab | Safety, Tolerability and Pharmacokinetics of AZD1775 Plus MEDI4736 in Patients With Advanced Solid Tumours | Active, not recruiting | USA | 0 |
NCT02620839 | Phase I | Alpelisib + Cisplatin | Phase Ib Study of Alpelisib With Cisplatin in Patients With HPV+ Solid Tumor Malignancies | Terminated | USA | 0 |
NCT02624388 | Phase II | Genistein | Study of Genistein in Pediatric Oncology Patients (UVA-Gen001) | Terminated | USA | 0 |
NCT02626234 | Phase I | Capmatinib | A Drug-drug Interaction (DDI) Study to Assess the Effect of INC280 on the Pharmacokinetics of Digoxin and Rosuvastatin in Patients With cMET-dysregulated Advanced Solid Tumors | Completed | USA | ITA | GBR | ESP | BEL | AUT | 2 |
NCT02627274 | Phase I | RO6874281 | A Study Evaluating Safety, Pharmacokinetics, and Therapeutic Activity of RO6874281 in Participants With Advanced and/or Metastatic Solid Tumors | Completed | USA | ITA | GBR | FRA | ESP | CAN | BEL | 2 |
NCT02627430 | Phase I | Onalespib + Talazoparib | Talazoparib and HSP90 Inhibitor AT13387 in Treating Patients With Metastatic Advanced Solid Tumor or Recurrent Ovarian, Fallopian Tube, Primary Peritoneal, or Triple Negative Breast Cancer | Withdrawn | 0 | |
NCT02628067 | Phase II | Pembrolizumab | Study of Pembrolizumab (MK-3475) in Participants With Advanced Solid Tumors (MK-3475-158/KEYNOTE-158) | Recruiting | USA | ITA | FRA | ESP | DEU | CAN | AUS | 16 |
NCT02628535 | Phase I | Obrindatamab | Safety Study of MGD009 in B7-H3-expressing Tumors | Terminated | USA | CAN | AUS | 0 |
NCT02628574 | Phase I | TRX518 | Dose Escalation Study of TRX518 in Adults With Advanced Solid Tumors | Completed | USA | 0 |
NCT02630368 | Phase Ib/II | Avelumab + Cyclophosphamide + JX-594 Cyclophosphamide + JX-594 Cyclophosphamide | A Study of Metronomic CP and JX-594 in Patients With Advanced Breast Cancer and Advanced Soft-tissue Sarcoma (METROmaJX) (METROmaJX) | Recruiting | FRA | 0 |
NCT02631733 | Phase I | Liposomal irinotecan + Veliparib | Liposomal Irinotecan and Veliparib in Treating Patients With Solid Tumors | Active, not recruiting | USA | 0 |
NCT02632448 | Phase Ib/II | Gemcitabine + LY2880070 LY2880070 | A Study of LY2880070 in Participants With Advanced or Metastatic Cancer | Recruiting | USA | CAN | 2 |
NCT02632994 | Expanded access | LY3023414 LY2503029 | Master Rollover Protocol for Continued Safety Assessment of Study Drug | Available | USA | 0 |
NCT02635672 | Phase I | VIP152 | Phase I Dose Escalation Study for BAY 1251152 in Patients With Advanced Cancer | Active, not recruiting | USA | ESP | 1 |
NCT02637687 | Phase I | Larotrectinib | A Study to Test the Safety and Efficacy of the Drug Larotrectinib for the Treatment of Tumors With NTRK-fusion in Children (SCOUT) | Active, not recruiting | USA | ITA | GBR | FRA | ESP | DEU | CAN | AUS | 13 |
NCT02642016 | Phase I | CDX-0158 | A Study to Evaluate the Safety and Pharmacokinetics of KTN0158 in Adult Patients With Advanced Solid Tumors | Completed | USA | 0 |
NCT02643303 | Phase Ib/II | Durvalumab + Poly ICLC Tremelimumab | A Phase 1/2 Study of In Situ Vaccination With Tremelimumab and IV Durvalumab Plus PolyICLC in Subjects With Advanced, Measurable, Biopsy-accessible Cancers | Completed | USA | 0 |
NCT02644369 | Phase II | Pembrolizumab | Study of the Effects of Pembrolizumab in Patients With Advanced Solid Tumors (INSPIRE) | Active, not recruiting | CAN | 0 |
NCT02644460 | Phase I | Abemaciclib | Abemaciclib in Children With DIPG or Recurrent/Refractory Solid Tumors | Completed | USA | 0 |
NCT02646319 | Phase I | Nab-rapamycin | Nanoparticle Albumin-Bound Rapamycin in Treating Patients With Advanced Cancer With mTOR Mutations | Completed | USA | 0 |
NCT02646748 | Phase I | Itacitinib + Pembrolizumab Parsaclisib + Pembrolizumab | Pembrolizumab Combined With Itacitinib (INCB039110) and/or Pembrolizumab Combined With INCB050465 in Advanced Solid Tumors | Completed | USA | 0 |
NCT02646852 | Phase I | PLX038 | A Phase I Study of PLX038 in Patients With Advanced Solid Tumors | Completed | USA | 0 |
NCT02648490 | Phase I | Acetaminophen + Dexamethasone + Diphenhydramine + Ondansetron HLX07 | An Open-label, Phase 1 Study to Determine the Maximum Tolerated Dose of HLX07,in Patients With Advanced Solid Cancers | Completed | USA | 1 |
NCT02648711 | Phase I | NLG207 Bevacizumab | Alternative Dosing for CRLX101 Alone and With Avastin in Advanced Solid Tumors | Terminated | USA | 0 |
NCT02648724 | Phase Ib/II | SYM015 | Sym015 (Anti-MET) in Patients With Advanced Solid Tumor Malignancies | Completed | USA | ESP | 4 |
NCT02650401 | Phase I | Entrectinib | Study Of Entrectinib (Rxdx-101) in Children and Adolescents With Locally Advanced Or Metastatic Solid Or Primary CNS Tumors And/Or Who Have No Satisfactory Treatment Options (STARTRK-NG) | Active, not recruiting | USA | ITA | GBR | FRA | ESP | DEU | CAN | 4 |
NCT02650635 | Phase I | Cyclophosphamide + Motolimod + Pegfilgrastim | TLR8 Agonist VTX-2337 and Cyclophosphamide in Treating Patients With Metastatic, Persistent, Recurrent, or Progressive Solid Tumors | Terminated | USA | 0 |
NCT02650713 | Phase I | Atezolizumab + RO6958688 | A Study of the Safety, Pharmacokinetics, and Therapeutic Activity of RO6958688 in Combination With Atezolizumab in Participants With Locally Advanced and/or Metastatic Carcinoembryonic Antigen (CEA)-Positive Solid Tumors | Completed | USA | ITA | FRA | ESP | CAN | 2 |
NCT02650986 | Phase Ib/II | Anti-NY ESO-1 mTCR PBL + Cyclophosphamide + TGFbDNRII-transduced autologous TILs | Gene-Modified T Cells With or Without Decitabine in Treating Patients With Advanced Malignancies Expressing NY-ESO-1 | Active, not recruiting | USA | 0 |
NCT02651727 | Phase I | Gemcitabine + Nab-paclitaxel + VS-4718 | Ph 1 Study of VS-4718, a FAK Inhibitor, in Combination With Nab-paclitaxel and Gemcitabine in Advanced Cancer Subjects | Terminated | USA | 0 |
NCT02653196 | Phase II | Thiotepa Etoposide Alemtuzumab Palifermin Fludarabine + Melphalan Cyclosporine + Mycophenolate mofetil + Tacrolimus | A Multi-Institutional Phase II Feasibility Study of Allogeneic Hematopoietic Stem Cell Transplantation for Patients With Malignant Neuro-Epithelial and Other Solid Tumors | Terminated | USA | 0 |
NCT02656849 | Phase II | Roniciclib | BAY 1000394 for MCL-1-, MYC-, and CCNE1-Amplified Tumors | Withdrawn | USA | 0 |
NCT02658890 | Phase Ib/II | Ipilimumab + Linrodostat + Nivolumab Linrodostat + Nivolumab | An Investigational Immuno-therapy Study of BMS-986205 Given in Combination With Nivolumab and in Combination With Both Nivolumab and Ipilimumab in Cancers That Are Advanced or Have Spread | Completed | USA | ITA | FRA | ESP | DEU | CAN | AUS | 4 |
NCT02659631 | Phase I | PF-06671008 | PF-06671008 Dose Escalation Study in Advanced Solid Tumors | Terminated | USA | 0 |
NCT02660034 | Phase I | Pamiparib + Tislelizumab | The Safety, Pharmacokinetics and Antitumor Activity of BGB-A317 in Combination With BGB-290 in Participants With Advanced Solid Tumors | Completed | USA | GBR | FRA | ESP | AUS | 1 |
NCT02661542 | Phase Ib/II | FF-10502 | Study of FF-10502-01 in Patients With Advanced Solid Tumors and Lymphomas | Completed | USA | 0 |
NCT02665416 | Phase I | RO5520985 + Selicrelumab Bevacizumab + Selicrelumab | Study Evaluating the Safety, Pharmacokinetics (PK), Pharmacodynamics (PD), and Therapeutic Activity of RO7009789 With Vanucizumab in Metastatic Solid Tumors | Completed | USA | ITA | ESP | CAN | BEL | 2 |
NCT02667873 | Phase I | SL-801 | A Phase 1 Trial of a Novel XPO1 Inhibitor in Patients With Advanced Solid Tumors | Completed | USA | 0 |
NCT02668770 | Phase I | Ipilimumab + Lefitolimod | Ipilimumab (Immunotherapy) and MGN1703 (TLR Agonist) in Patients With Advanced Solid Malignancies | Active, not recruiting | USA | 0 |
NCT02669914 | Phase II | Durvalumab | MEDI4736 (Durvalumab) in Patients With Brain Metastasis From Epithelial-derived Tumors | Terminated | USA | 0 |
NCT02671955 | Phase I | Onvatilimab | A Study of Safety, Pharmacokinetics, Pharmacodynamics of JNJ-61610588 in Participants With Advanced Cancer | Terminated | USA | 0 |
NCT02673736 | Phase I | AC708 | A Study of PLX73086 in Advanced Solid Tumors and Locally Advanced or Refractory Tenosynovial Giant Cell Tumor | Terminated | USA | 0 |
NCT02674555 | Phase I | Naquotinib | A Study to Investigate the Absorption, Metabolism and Excretion of [14C]ASP8273 in Subjects With Solid Tumors | Withdrawn | 0 | |
NCT02675439 | Phase I | Ipilimumab + MIW815 MIW815 | Safety and Efficacy of MIW815 (ADU-S100) +/- Ipilimumab in Patients With Advanced/Metastatic Solid Tumors or Lymphomas | Terminated | USA | 0 |
NCT02675829 | Phase II | Ado-trastuzumab emtansine | Trial of Ado-Trastuzumab Emtansine for Patients With HER2 Amplified or Mutant Cancers | Recruiting | USA | 0 |
NCT02675946 | Phase I | CGX1321 CGX1321 + Pembrolizumab Cetuximab + CGX1321 + Encorafenib | CGX1321 in Subjects With Advanced Solid Tumors and CGX1321 With Pembrolizumab or Encorafenib + Cetuximab in Subjects With Advanced GI Tumors (Keynote 596) | Unknown status | USA | 1 |
NCT02677116 | Phase I | Doxorubicin Ifosfamide Irinotecan + Vincristine Sulfate Olaratumab | A Study of Olaratumab Alone and in Combination With Standard Chemotherapies in Children With Cancer | Completed | USA | 1 |
NCT02679131 | Phase I | Belinostat | To Evaluate Safety and Pharmacokinetics of Belinostat in Patients Who Have Mild, Moderate and Severe Renal Impairment. | Terminated | USA | 0 |
NCT02680795 | Phase I | Belinostat | To Evaluate the Safety and Pharmacokinetics of Belinostat in Patients Who Have Wild-type, Heterozygous, and Homozygous UGT1A1*28 Genotypes | Completed | USA | 0 |
NCT02683395 | Phase I | PLX51107 | A Study of PLX51107 in Advanced Malignancies | Terminated | USA | 0 |
NCT02686164 | Phase I | Lenvatinib + Midazolam | Phase 1 Study to Determine the Effect of Lenvatinib (E7080) on the Pharmacokinetics of Midazolam in Subjects With Advanced Solid Tumors | Completed | USA | 0 |
NCT02688088 | Phase I | Abemaciclib Caffeine + Dextromethorphan + Midazolam + Warfarin | A Study of Abemaciclib in Participants With Cancer That is Advanced or Has Spread to Another Part(s) of the Body | Completed | USA | 0 |
NCT02689336 | Phase II | Erlotinib + Temozolomide | Erlotinib in Combination With Temozolomide in Treating Relapsed/Recurrent/Refractory Pediatric Solid Tumors | Withdrawn | 0 | |
NCT02693535 | Phase II | Cobimetinib + Vemurafenib Atezolizumab + Talazoparib Regorafenib Larotrectinib Trastuzumab + Tucatinib Ipilimumab + Nivolumab Palbociclib Afatinib Entrectinib Talazoparib Pembrolizumab Temsirolimus Pertuzumab + Trastuzumab Atezolizumab + Pertuzumab/trastuzumab/hyaluronidase-zzxf Crizotinib Abemaciclib Sunitinib Olaparib | TAPUR: Testing the Use of Food and Drug Administration (FDA) Approved Drugs That Target a Specific Abnormality in a Tumor Gene in People With Advanced Stage Cancer (TAPUR) | Recruiting | USA | 0 |
NCT02694822 | Phase I | Zalifrelimab | AGEN-1884, an Anti-CTLA-4 Antibody, in Advanced Solid Cancers | Completed | USA | 0 |
NCT02697591 | Phase Ib/II | INCAGN01876 | An Open-Label, Dose-Escalation, Safety Study of INCAGN01876 in Subjects With Advanced or Metastatic Solid Tumors | Completed | USA | 0 |
NCT02702492 | Phase I | KPT-9274 KPT-9274 + Niacin | PAK4 and NAMPT in Patients With Solid MAlignancies or NHL (PANAMA) (PANAMA) | Terminated | USA | CAN | 0 |
NCT02703571 | Phase Ib/II | Ribociclib + Trametinib | Study of Safety and Efficacy of Ribociclib and Trametinib in Patients With Metastatic or Advanced Solid Tumors | Terminated | USA | ESP | DEU | CAN | BEL | AUS | 1 |
NCT02705105 | Phase Ib/II | Mogamulizumab + Nivolumab | Study of Mogamulizumab + Nivolumab in Subjects w/Locally Advanced or Metastatic Solid Tumors | Completed | USA | 0 |
NCT02705482 | Phase I | Tavolimab + Tremelimumab Durvalumab + Tavolimab | A Study to Evaluate MEDI0562 in Combination With Immune Therapeutic Agents in Adult Subjects With Advanced Solid Tumors | Completed | USA | FRA | 1 |
NCT02705963 | Phase I | Trametinib | A Drug-Drug Interaction Study to Assess the Effect of Trametinib on the Pharmacokinetics of an Oral Contraceptive in Female Patients With Solid Tumors | Completed | USA | GBR | ESP | BEL | 1 |
NCT02709889 | Phase Ib/II | Rovalpituzumab Tesirine | Rovalpituzumab Tesirine in Delta-Like Protein 3-Expressing Advanced Solid Tumors | Terminated | USA | 0 |
NCT02711137 | Phase Ib/II | INCB057643 | A Phase 1/2, Open-Label Safety and Tolerability Study of INCB057643 in Subjects With Advanced Malignancies | Terminated | USA | FRA | BEL | 0 |
NCT02712905 | Phase Ib/II | INCB059872 | An Open-Label, Dose-Escalation/Dose-Expansion Safety Study of INCB059872 in Subjects With Advanced Malignancies | Terminated | USA | BEL | 1 |
NCT02715284 | Phase I | Dostarlimab-gxly | A Phase 1 Dose Escalation and Cohort Expansion Study of TSR-042, an Anti-PD-1 Monoclonal Antibody, in Patients With Advanced Solid Tumors (GARNET) | Recruiting | USA | ITA | GBR | FRA | ESP | CAN | 7 |
NCT02716116 | Phase Ib/II | Mobocertinib | A Study of TAK-788 in Adults With Non-Small Cell Lung Cancer | Active, not recruiting | USA | ITA | GBR | ESP | DEU | 5 |
NCT02718911 | Phase I | LY3022855 + Tremelimumab Durvalumab + LY3022855 | A Study of LY3022855 in Combination With Durvalumab or Tremelimumab in Participants With Advanced Solid Tumors | Completed | USA | BEL | 2 |
NCT02719691 | Phase I | Alisertib + Sapanisertib | Phase I Study of MLN0128 and MLN8237 in Patients With Advanced Solid Tumors and Metastatic Triple-negative Breast Cancer | Completed | USA | 0 |
NCT02720068 | Phase I | MK-4280 + Pembrolizumab MK-4280 | Study of MK-4280 as Monotherapy and in Combination With Pembrolizumab (MK-3475) in Adults With Advanced Solid Tumors (MK-4280-001) | Active, not recruiting | 0 | |
NCT02722954 | Phase I | Demcizumab + Pembrolizumab | A Study of Demcizumab Plus Pembrolizumab +/- Chemotherapy | Completed | USA | GBR | 0 |
NCT02723864 | Phase I | Berzosertib + Cisplatin + Veliparib | Veliparib (ABT-888), an Oral PARP Inhibitor, and VX-970, an ATR Inhibitor, in Combination With Cisplatin in People With Refractory Solid Tumors | Completed | USA | 0 |
NCT02729298 | Phase I | Dubermatinib | First-in-human Study of Oral TP-0903 (a Novel Inhibitor of AXL Kinase) in Patients With Advanced Solid Tumors | Completed | USA | 0 |
NCT02730481 | Phase I | Oraxol | A Study to Evaluate the Safety, Tolerability, MTD, PK, and Activity of Oraxol in Subjects w Adv. Malignancies | Completed | USA | 0 |
NCT02731742 | Phase I | MK-1966 + SD-101 | Dose Evaluation of MK-1966 in Combination With SD-101 in Participants With Advanced Malignancies (MK-1966-001) | Terminated | 0 | |
NCT02737072 | Phase I | Durvalumab + LY2510924 | A Study of LY2510924 and Durvalumab in Participants With Solid Tumors | Terminated | 0 | |
NCT02737475 | Phase Ib/II | Ipilimumab BMS-986178 Nivolumab | Study of BMS-986178 Monotherapy or in Combination With Nivolumab or Ipilimumab in Subjects With Advanced Solid Tumors | Completed | USA | ITA | ESP | CAN | 2 |
NCT02740270 | Phase I | GWN 323 + Spartalizumab GWN 323 | Phase I/Ib Study of GWN323 Alone and in Combination With PDR001 in Patients With Advanced Malignancies and Lymphomas | Completed | USA | ESP | CAN | 3 |
NCT02740985 | Phase I | AZD4635 AZD4635 + Durvalumab | A Phase 1 Clinical Study of AZD4635 and Durvalumab in Patients With Advanced Solid Malignancies | Completed | USA | 0 |
NCT02743637 | Phase I | SDX-7320 | A Dose Escalation Study of SDX-7320 in Patients With Advanced Refractory or Late-Stage Solid Tumors (SDX-0101) | Completed | USA | 0 |
NCT02746081 | Phase I | BAY1436032 | Phase I Study of BAY1436032 in IDH1-mutant Advanced Solid Tumors | Active, not recruiting | USA | DEU | 2 |
NCT02747537 | Phase II | Irinotecan + Sorafenib | Treating Relapsed/Recurrent/Refractory Pediatric Solid Tumors With Sorafenib in Combination With Irinotecan | Withdrawn | 0 | |
NCT02747797 | Phase II | Lucitanib | Lucitanib (E3810) in Patients With Advanced Cancer and FGFR, VEGFR, or PDGFR Pathway Aberrations | Withdrawn | USA | 0 |
NCT02748837 | Phase I | ERY974 | A Study of ERY974 in Patient With Advanced Solid Tumors | Completed | USA | FRA | 1 |
NCT02754141 | Phase Ib/II | BMS-986179 + Nivolumab | A Study of BMS-986179 Administered in Combination With Nivolumab in Advanced Cancers | Completed | USA | ITA | FRA | DEU | CAN | AUS | 1 |
NCT02756845 | Phase I | Talimogene laherparepvec | Study of Talimogene Laherparepvec In Children With Advanced Non CNS Tumors | Completed | USA | ITA | FRA | ESP | CAN | BEL | 1 |
NCT02761694 | Phase I | ARQ 751 + Paclitaxel ARQ 751 ARQ 751 + Fulvestrant | ARQ 751 as a Single Agent or in Combination With Other Anti-Cancer Agents, in Solid Tumors With PIK3CA / AKT / PTEN Mutations | Terminated | USA | 0 |
NCT02762981 | Phase Ib/II | Nab-paclitaxel + Relacorilant | Study to Evaluate CORT125134 in Combination With Nab-paclitaxel in Patients With Solid Tumors | Completed | USA | 0 |
NCT02765165 | Phase Ib/II | Lomustine + USL311 USL311 | Phase 1/2 Study of USL311 Alone and in Combination With Lomustine in Subjects With Advanced Solid Tumors and Relapsed/Recurrent Glioblastoma Multiforme (GBM) | Terminated | USA | ESP | 0 |
NCT02769962 | Phase Ib/II | NLG207 + Olaparib | Trial of CRLX101, a Nanoparticle Camptothecin With Olaparib in People With Relapsed/Refractory Small Cell Lung Cancer | Recruiting | USA | 0 |
NCT02771626 | Phase Ib/II | Nivolumab + Telaglenastat | Study CB-839 in Combination With Nivolumab in Patients With ccRCC and Other Solid Tumors | Terminated | USA | 0 |
NCT02774291 | Phase I | Aldesleukin Cyclophosphamide + Fludarabine Filgrastim | Anti-ESO (Cancer/Test Antigen) mTCR-transduced Autologous Peripheral Blood Lymphocytes and Combination Chemotherapy in Treating Patients With Metastatic Cancer That Expresses NY-ESO-1 | Terminated | USA | 0 |
NCT02775292 | Phase I | Aldesleukin + Cyclophosphamide + Fludarabine Nivolumab NY-ESO-1 peptide vaccine | Gene-Modified T Cells, Vaccine Therapy, and Nivolumab in Treating Patients With Stage IV or Locally Advanced Solid Tumors Expressing NY-ESO-1 | Completed | USA | 0 |
NCT02780011 | Phase I | Alisertib + Brentuximab vedotin | Alsertib (MLN8237) and Brentuximab Vedotin for Relapsed/Refractory CD30-Positive Lymphomas and Solid Malignancies | Withdrawn | USA | 0 |
NCT02780804 | Phase I | Entinostat | Entinostat in Treating Pediatric Patients With Recurrent or Refractory Solid Tumors | Completed | USA | 0 |
NCT02783300 | Phase I | GSK3326595 | Dose Escalation Study of GSK3326595 in Participants With Solid Tumors and Non-Hodgkin's Lymphoma (NHL) | Completed | USA | FRA | CAN | 1 |
NCT02784795 | Phase I | Cisplatin + Gemcitabine + LY3039478 Carboplatin + Gemcitabine + LY3039478 LY3023414 + LY3039478 Abemaciclib + LY3039478 LY3039478 + Taladegib LY3039478 LY3023414 | A Study of LY3039478 in Participants With Advanced or Metastatic Solid Tumors | Completed | USA | FRA | ESP | 1 |
NCT02791334 | Phase I | LY3300054 + Necitumumab LY3300054 + Ramucirumab LY3300054 | A Study of Anti-PD-L1 Checkpoint Antibody (LY3300054) Alone and in Combination in Participants With Advanced Refractory Solid Tumors (PACT) | Active, not recruiting | USA | FRA | ESP | CAN | BEL | 2 |
NCT02792465 | Phase I | CFI-402257 | A Study of Investigational Drug CFI-402257 in Patients With Advanced Cancers | Active, not recruiting | CAN | 0 |
NCT02793466 | Phase I | Durvalumab | Durvalumab in Pediatric and Adolescent Patients | Completed | USA | 0 |
NCT02794571 | Phase I | Atezolizumab + Tiragolumab Tiragolumab | Safety and Pharmacokinetics (PK) of Escalating Doses of MTIG7192A as a Single Agent and in Combination With Atezolizumab in Locally Advanced or Metastatic Tumors | Active, not recruiting | USA | FRA | ESP | CAN | AUS | 2 |
NCT02797795 | Phase I | NEV801 | A Phase 1, Open-Label, Dose-Escalation Study of NEV801, Administered to Patients With Advanced Cancers | Unknown status | USA | 0 |
NCT02799095 | Phase I | ALKS 4230 | A Study of the Effects of ALKS 4230 on Subjects With Solid Tumors | Completed | USA | ESP | CAN | BEL | AUS | 2 |
NCT02801097 | Phase I | Irinotecan + RRx-001 | A Phase I, Multiple Ascending Dose Study to Assess the Safety and Tolerability of RRx-001 in Combination With Irinotecan in Metastatic or Advanced Cancer (PAYLOAD) (PAYLOAD) | Terminated | USA | 0 |
NCT02805660 | Phase Ib/II | Durvalumab + Mocetinostat | Phase 1/2 Study of Mocetinostat and Durvalumab in Patients With Advanced Solid Tumors and NSCLC | Terminated | USA | 0 |
NCT02808650 | Phase I | Prexasertib | Prexasertib in Treating Pediatric Patients With Recurrent or Refractory Solid Tumors | Completed | USA | 0 |
NCT02810418 | Phase Ib/II | LMB-100 LMB-100 + Nab-paclitaxel | Mesothelin-Targeted Immunotoxin LMB-100 Alone or in Combination With Nab-Paclitaxel in People With Previously Treated Metastatic and/or Locally Advanced Pancreatic Ductal Adenocarcinoma and Mesothelin Expressing Solid Tumors | Completed | USA | 0 |
NCT02811497 | Phase II | Azacitidine + Durvalumab | Study of Azacitidine and Durvalumab in Advanced Solid Tumors (METADUR) | Completed | CAN | 0 |
NCT02812875 | Phase I | CA-170 | A Study of CA-170 (Oral PD-L1, PD-L2 and VISTA Checkpoint Antagonist) in Patients With Advanced Tumors and Lymphomas | Completed | USA | GBR | ESP | 1 |
NCT02813135 | Phase Ib/II | Ribociclib + Temozolomide + Topotecan Adavosertib + Carboplatin Enasidenib Lirilumab + Nivolumab Irinotecan + Olaparib | European Proof-of-Concept Therapeutic Stratification Trial of Molecular Anomalies in Relapsed or Refractory Tumors (ESMART) | Recruiting | ITA | GBR | FRA | ESP | DEU | 2 |
NCT02817633 | Phase I | Cobolimab Cobolimab + unspecified PD-1 antibody | A Phase 1 Study of TSR-022, an Anti-TIM-3 Monoclonal Antibody, in Patients With Advanced Solid Tumors | Recruiting | USA | ESP | 0 |
NCT02819843 | Phase II | Talimogene laherparepvec | A Study of T-VEC (Talimogene Laherparepvec) With or Without Radiotherapy for Melanoma, Merkel Cell Carcinoma, or Other Solid Tumors | Active, not recruiting | USA | 0 |
NCT02827968 | Phase I | Envafolimab | Phase 1 Study of Anti-PD-L1 Monoclonal Antibody KN035 to Treat Locally Advanced or Metastatic Solid Tumors | Completed | USA | 0 |
NCT02829099 | Phase I | JNJ-64457107 | A Study of Safety, Pharmacokinetics and Pharmacodynamics of JNJ-64457107 in Participants With Advanced Stage Tumors | Completed | ESP | 1 |
NCT02829372 | Phase I | GBR1302 | Phase 1 Study of Single Agent GBR 1302 in Subjects With HER2 Positive Cancers (GBR 1302-101) | Terminated | USA | DEU | 0 |
NCT02829723 | Phase Ib/II | BLZ945 BLZ945 + Spartalizumab | Phase I/II Study of BLZ945 Single Agent or BLZ945 in Combination With PDR001 in Advanced Solid Tumors | Terminated | USA | ITA | ESP | 5 |
NCT02830724 | Phase Ib/II | Cyclophosphamide + Fludarabine Aldesleukin + Anti-hCD70 CAR T cells | Administering Peripheral Blood Lymphocytes Transduced With a CD70-Binding Chimeric Antigen Receptor to People With CD70 Expressing Cancers | Recruiting | USA | 0 |
NCT02832167 | Phase II | Nivolumab | An Open Label Investigational Immuno-therapy Trial of Nivolumab in Cancers That Are Advanced or Have Spread (CheckMate 627) | Completed | USA | DEU | 0 |
NCT02834013 | Phase 0 | Ipilimumab + Nivolumab | Nivolumab and Ipilimumab in Treating Patients With Rare Tumors | Active, not recruiting | USA | 1 |
NCT02834247 | Phase I | Mivavotinib + Nivolumab | A Study of TAK-659 in Combination With Nivolumab in Participants With Advanced Solid Tumors | Terminated | USA | ITA | GBR | ESP | 0 |
NCT02840994 | Phase Ib/II | CV301 + Nivolumab Nivolumab | A Trial of CV301 in Combination With Nivolumab Versus Nivolumab in Subjects With Previously Treated Non-Small Cell Lung Cancer | Completed | USA | 0 |
NCT02842125 | Phase I | Ad5CMV-p53 gene + Pembrolizumab Ad5CMV-p53 gene + Capecitabine Ad5CMV-p53 gene + Nivolumab | Safety and Efficacy of Intra-Arterial and Intra-Tumoral Ad-p53 With Capecitabine (Xeloda) or Anti-PD-1 in Liver Metastases of Solid Tumors and Recurrent Head and Neck Squamous Cell Cancer | Terminated | USA | 0 |
NCT02843165 | Phase II | unspecified PD-L1 antibody unspecified CTLA4 antibody unspecified PD-1 antibody | Checkpoint Blockade Immunotherapy Combined With Stereotactic Body Radiation in Advanced Metastatic Disease | Active, not recruiting | USA | 0 |
NCT02846766 | Phase II | Lenvatinib | Study of Lenvatinib in Patients With Advanced Cancer and Aberrations in FGF/FGFR Signaling | Withdrawn | USA | 0 |
NCT02856425 | Phase I | Nintedanib + Pembrolizumab | Trial Of Pembrolizumab And Nintedanib (PEMBIB) | Recruiting | FRA | 0 |
NCT02857270 | Phase I | LY3214996 Gemcitabine + LY3214996 + Nab-paclitaxel LY3214996 + Midazolam Abemaciclib + LY3214996 | A Study of LY3214996 Administered Alone or in Combination With Other Agents in Participants With Advanced/Metastatic Cancer | Completed | USA | FRA | AUS | 1 |
NCT02858310 | Phase I | Aldesleukin + Cyclophosphamide + Fludarabine + Pembrolizumab | E7 TCR T Cells With or Without PD-1 Blockade for Human Papillomavirus-Associated Cancers | Recruiting | USA | 0 |
NCT02859857 | Phase I | BXQ-350 | Phase 1 Study of BXQ-350 in Adult Patients With Advanced Solid Tumors | Completed | USA | 0 |
NCT02860780 | Phase I | Prexasertib + Ralimetinib | A Study of Prexasertib (LY2606368) in Combination With Ralimetinib in Participants With Advanced or Metastatic Cancer | Completed | USA | DEU | 0 |
NCT02861300 | Phase Ib/II | Capecitabine + Telaglenastat | CB-839 + Capecitabine in Solid Tumors and Fluoropyrimidine Resistant PIK3CA Mutant Colorectal Cancer | Active, not recruiting | USA | 0 |
NCT02862275 | Phase 0 | Atezolizumab | Atezolizumab in Treating Patients With Cancer Following Adoptive Cell Transfer | Active, not recruiting | USA | CAN | 0 |
NCT02864316 | Phase II | Nivolumab | Phase 2 Study of Nivolumab in Solid Tumors Induced by Prior Radiation Exposure | Terminated | USA | 0 |
NCT02867007 | Phase I | KHK2455 + Mogamulizumab | KHK2455 Alone and in Combination With Mogamulizumab in Subjects With Locally Advanced or Metastatic Solid Tumors | Completed | USA | FRA | 0 |
NCT02867592 | Phase II | Cabozantinib | Cabozantinib-S-Malate in Treating Younger Patients With Recurrent, Refractory, or Newly Diagnosed Sarcomas, Wilms Tumor, or Other Rare Tumors | Active, not recruiting | USA | 0 |
NCT02869217 | Phase I | Cyclophosphamide + Fludarabine TBI-1301 | Study of TBI-1301 (NY-ESO-1 Specific TCR Gene Transduced Autologous T Lymphocytes) in Patients With Solid Tumors | Active, not recruiting | CAN | 0 |
NCT02869295 | Phase I | NKTR-214 | A Phase 1 Dose Escalation and Expansion Study Of NKTR-214 In Subjects With Locally Advanced Or Metastatic Solid Tumors | Completed | USA | 0 |
NCT02873975 | Phase II | Prexasertib | A Study of LY2606368 (Prexasertib) in Patients With Solid Tumors With Replicative Stress or Homologous Repair Deficiency | Completed | USA | 0 |
NCT02875223 | Phase I | CC-90011 | A Safety and Efficacy Study of CC-90011 in Subjects With Relapsed and/or Refractory Solid Tumors and Non-Hodgkin's Lymphomas | Active, not recruiting | ITA | GBR | FRA | ESP | 1 |
NCT02875548 | Phase II | Tazemetostat | Tazemetostat Rollover Study (TRuST): An Open-Label Rollover Study | Enrolling by invitation | USA | GBR | FRA | BEL | AUS | 2 |
NCT02876510 | Phase I | Aldesleukin + Cyclophosphamide + Fludarabine + IMA101 T cells | ACTolog in Patients With Solid Cancers | Completed | USA | 0 |
NCT02886585 | Phase II | Pembrolizumab | Pembrolizumab In Central Nervous System Metastases | Active, not recruiting | USA | 0 |
NCT02889445 | Expanded access | DM-CHOC-PEN | A Phase I Trial of DM-CHOC-PEN in Adolescent and Young Adult (AYA) Subjects With Advanced Cancers | No longer available | USA | 0 |
NCT02890368 | Phase I | TTI-621 | Trial of Intratumoral Injections of TTI-621 in Subjects With Relapsed and Refractory Solid Tumors and Mycosis Fungoides | Terminated | USA | 0 |
NCT02892123 | Phase I | Capecitabine + ZW25 ZW25 Paclitaxel + ZW25 Vinorelbine + ZW25 | Trial of ZW25 (Zanidatamab) in Patients With Advanced HER2-expressing Cancers | Active, not recruiting | USA | CAN | 1 |
NCT02896335 | Phase II | Palbociclib | Palbociclib In Progressive Brain Metastases | Recruiting | USA | 0 |
NCT02897778 | Phase I | Entinostat | Cardiac Safety Study of Entinostat in Men and Women With Advanced Solid Tumors | Completed | USA | 0 |
NCT02898207 | Phase I | Olaparib + Onalespib | Olaparib and Onalespib in Treating Patients With Solid Tumors That Are Metastatic or Cannot Be Removed by Surgery or Recurrent Ovarian, Fallopian Tube, Primary Peritoneal, or Triple-Negative Breast Cancer | Completed | USA | 0 |
NCT02900157 | Phase I | Durvalumab + MEDI9090 | Study to Evaluate the Safety and Pharmacokinetics of MEDI9090 in Subjects With Advanced Solid Tumors | Completed | USA | 1 |
NCT02900651 | Phase Ib/II | MAK683 | Safety and Efficacy of MAK683 in Adult Patients With Advanced Malignancies | Active, not recruiting | USA | ITA | FRA | ESP | DEU | CAN | 4 |
NCT02903914 | Phase I | INCB001158 INCB001158 + Nivolumab | Arginase Inhibitor CB-1158 in Patients With Solid Tumors | Completed | USA | ITA | ESP | 1 |
NCT02904226 | Phase Ib/II | Nivolumab + Vopratelimab Vopratelimab | Dose Escalation and Expansion of JTX-2011 Alone or in Combination With Anti-PD-1 in Subjects With Advanced Solid Tumors (ICONIC) | Completed | USA | 0 |
NCT02906670 | Phase Ib/II | Pan-HER | Sym013 (Pan-HER) in Patients With Advanced Epithelial Malignancies | Terminated | USA | 0 |
NCT02908906 | Phase I | Cetrelimab | A Study to Evaluate the Safety, Pharmacokinetics, Pharmacodynamics, and Clinical Activity of JNJ-63723283, an Anti-PD-1 Monoclonal Antibody, in Participants With Advanced Cancers | Active, not recruiting | USA | GBR | ESP | 4 |
NCT02909452 | Phase I | Entinostat + Pembrolizumab | Continuation Study of Entinostat in Combination With Pembrolizumab in Patients With Advanced Solid Tumors | Completed | USA | 0 |
NCT02909777 | Phase I | CUDC-907 | Trial of CUDC-907 in Children and Young Adults With Relapsed or Refractory Solid Tumors, CNS Tumors, or Lymphoma | Active, not recruiting | USA | 0 |
NCT02912949 | Phase Ib/II | Zenocutuzumab | A Study of Zenocutuzumab (MCLA-128) in Patients With Solid Tumors Harboring an NRG1 Fusion (eNRGy) | Recruiting | USA | ITA | GBR | FRA | ESP | DEU | CAN | BEL | AUT | 9 |
NCT02913313 | Phase Ib/II | BMS-986207 + Nivolumab BMS-986207 | A Study to Evaluate the Safety and Tolerability of Monoclonal Antibody BMS-986207 Alone and in Combination With Nivolumab in Advanced (Solid Tumor) Cancers | Active, not recruiting | USA | CAN | AUS | 5 |
NCT02915172 | Phase I | Capecitabine + Lenvatinib | Lenvatinib and Capecitabine in Patients With Advanced Malignancies | Withdrawn | 0 | |
NCT02920996 | Phase II | Merestinib | Merestinib In Non-Small Cell Lung Cancer And Solid Tumors | Active, not recruiting | USA | 0 |
NCT02921919 | Phase II | Talazoparib | Open-Label Extension and Safety Study of Talazoparib | Completed | USA | GBR | FRA | DEU | CAN | 4 |
NCT02922764 | Phase I | RGX-104 Ipilimumab + RGX-104 Nivolumab + RGX-104 Carboplatin + Pembrolizumab + Pemetrexed Disodium + RGX-104 | A Study of RGX-104 With or Without Nivolumab in Patients With Advanced Solid Malignancies and Lymphoma | Recruiting | USA | 0 |
NCT02923349 | Phase Ib/II | INCAGN01949 | A Phase 1/2, Open-Label, Dose-Escalation, Safety Study of INCAGN01949 in Subjects With Advanced or Metastatic Solid Tumors | Completed | USA | GBR | ESP | 1 |
NCT02923466 | Phase Ib/II | Avelumab + VSV-hIFNbeta-NIS VSV-hIFNbeta-NIS | Trial of Intratumoral Administration of Recombinant Vesicular Stomatitis Virus Monotherapy and in Combination With Avelumab in Patients With Refractory Solid Tumors | Completed | USA | 0 |
NCT02925104 | Phase I | Capmatinib | A Dose Escalation Study to Assess PK, Safety and Tolerability of INC280 When Taken With Food in cMET Dysregulated Advanced Solid Tumors. | Completed | USA | GBR | ESP | DEU | AUT | 3 |
NCT02925234 | Phase II | Palbociclib Ribociclib Lenvatinib Ipilimumab + Nivolumab Trametinib Crizotinib Niraparib Selpercatinib Olaparib Erlotinib Erdafitinib Dabrafenib Dacomitinib Rucaparib Axitinib Panitumumab Pemigatinib Durvalumab Afatinib Entrectinib Tepotinib Alpelisib Atezolizumab + Bevacizumab Alectinib Regorafenib Cobimetinib + Vemurafenib Nilotinib Vismodegib Abemaciclib Sunitinib Nivolumab Cabozantinib Lorlatinib Talazoparib Dabrafenib + Trametinib Pembrolizumab Pertuzumab + Trastuzumab | The Drug Rediscovery Protocol (DRUP Trial) (DRUP) | Recruiting | 1 | |
NCT02926768 | Phase Ib/II | CK-101 | Phase I/II Study of CK-101 in NSCLC Patients and Other Advanced Solid Tumors | Completed | USA | AUS | 3 |
NCT02929862 | Phase Ib/II | LYC-55716 | Study of LYC-55716 in Adult Subjects With Locally Advanced or Metastatic Cancer | Completed | USA | 0 |
NCT02932280 | Phase Ib/II | Neratinib | Safety and Dose Finding Study of Neratinib in Children and Young Adults With Cancer That Has Returned or Not Responded to Treatment | Recruiting | USA | CAN | 0 |
NCT02932956 | Phase I | Cyclophosphamide + Fludarabine Anti-GPC3-scFvGC33-CAR autologous T Lymphocytes | Glypican 3-specific Chimeric Antigen Receptor Expressed in T Cells for Patients With Pediatric Solid Tumors (GAP) (GAP) | Active, not recruiting | USA | 0 |
NCT02934568 | Phase II | Ribociclib | Ribociclib (LEE011) Rollover Study for Continued Access | Recruiting | USA | FRA | ESP | 2 |
NCT02935907 | Phase I | APG-115 | APG-115 in Patients With Advanced Solid Tumors or Lymphomas | Completed | USA | 0 |
NCT02936102 | Phase I | FAZ053 FAZ053 + Spartalizumab | A Study of FAZ053 Single Agent and in Combination With PDR001 in Patients With Advanced Malignancies. | Active, not recruiting | USA | ITA | FRA | ESP | CAN | 4 |
NCT02937272 | Phase I | LY3200882 | A Study of LY3200882 in Participants With Solid Tumors | Active, not recruiting | USA | ITA | FRA | ESP | DEU | CAN | AUS | 1 |
NCT02938793 | Phase II | Durvalumab + Tremelimumab | Durvalumab in Combination With Tremelimumab in Subjects With Advanced Rare Solid Tumors | Recruiting | USA | 0 |
NCT02942095 | Phase I | Erlotinib + Ixazomib | Study of Ixazomib and Erlotinib in Solid Tumors | Completed | USA | 0 |
NCT02947165 | Phase I | NIS793 + Spartalizumab NIS793 | Phase I/Ib Study of NIS793 in Combination With PDR001 in Patients With Advanced Malignancies. | Completed | USA | ITA | DEU | CAN | AUT | 4 |
NCT02950064 | Phase I | BTP-114 | A Study to Determine the Safety of BTP-114 for Treatment in Patients With Advanced Solid Tumors With BRCA Mutations | Unknown status | USA | 0 |
NCT02952248 | Phase I | Ezabenlimab | A Trial to Find and Investigate a Safe Dose of a New Substance (BI 754091) for Patients With Solid Tumours | Completed | USA | GBR | CAN | 0 |
NCT02952989 | Phase I | SGN-2FF | A Safety Study of SGN-2FF for Patients With Advanced Solid Tumors | Terminated | USA | 0 |
NCT02953782 | Phase Ib/II | Cetuximab + Hu5F9-G4 | Trial of Hu5F9-G4 in Combination With Cetuximab in Patients With Solid Tumors and Advanced Colorectal Cancer | Completed | USA | 0 |
NCT02955251 | Phase I | ABBV-428 + Nivolumab ABBV-428 | A Study Evaluating Safety and Pharmacokinetics, and the Recommended Phase 2 Dose (RPTD) of ABBV-428 in Participants With Advanced Solid Tumors | Completed | USA | FRA | AUS | 1 |
NCT02955446 | Expanded access | Nirogacestat | Compassionate Use Protocol for PF-03084014 in Patients With Advanced Solid Tumor Malignancies | No longer available | USA | 0 |
NCT02955940 | Phase II | Ruxolitinib Capecitabine + Regorafenib Capecitabine + Regorafenib + Ruxolitinib | An Open-Label Study to Enable Continued Treatment Access for Subjects Previously Enrolled in Studies of Ruxolitinib | Active, not recruiting | USA | 0 |
NCT02959437 | Phase Ib/II | Azacitidine + Epacadostat + Pembrolizumab | Azacitidine Combined With Pembrolizumab and Epacadostat in Subjects With Advanced Solid Tumors (ECHO-206) | Terminated | USA | GBR | ESP | 0 |
NCT02961283 | Phase I | ASN003 | Study of ASN003 in Subjects With Advanced Solid Tumors | Terminated | USA | 0 |
NCT02963610 | Phase Ib/II | Lenalidomide + Pembrolizumab | Phase I/II Study of Lenalidomide Plus Pembrolizumab in Patients With Solid Tumors With Expansion in Non-small Cell Lung Cancer | Terminated | USA | 0 |
NCT02964013 | Phase I | Vibostolimab Pembrolizumab + Vibostolimab | Study of MK-7684 Alone and in Combination With Pembrolizumab in Advanced Solid Tumors (MK-7684-001) | Active, not recruiting | 0 | |
NCT02972034 | Phase I | MK-8353 + Pembrolizumab | Study of MK-8353 in Combination With Pembrolizumab (MK-3475) in Participants With Advanced Malignancies (MK-8353-013) | Completed | USA | CAN | 0 |
NCT02974738 | Phase I | Belzutifan | A Trial of PT2977 Tablets In Patients With Advanced Solid Tumors | Active, not recruiting | 0 | |
NCT02975882 | Phase I | Irinotecan + Nab-rapamycin + Temozolomide | Nanoparticle Albumin-Bound Rapamycin, Temozolomide, and Irinotecan Hydrochloride in Treating Pediatric Patients With Recurrent or Refractory Solid Tumors | Active, not recruiting | USA | 0 |
NCT02977156 | Phase I | Ipilimumab + JX-594 | Immunization Strategy With Intra-tumoral Injections of Pexa-Vec With Ipilimumab in Metastatic / Advanced Solid Tumors. (ISI-JX) | Completed | FRA | 0 |
NCT02982941 | Phase I | MGA271 | Enoblituzumab (MGA271) in Children With B7-H3-expressing Solid Tumors | Completed | USA | 0 |
NCT02987166 | Phase I | Pembrolizumab | HDCRT Plus Pembrolizumab in Advanced Malignancies (UVA-AM-001) | Completed | USA | 0 |
NCT02987504 | Phase I | Samalizumab | Study of Samalizumab in Patients With Advanced Cancer | Terminated | USA | 0 |
NCT02988817 | Phase Ib/II | Enapotamab vedotin | HuMax-AXL-ADC Safety Study in Patients With Solid Tumors | Completed | USA | GBR | ESP | BEL | 2 |
NCT02988960 | Phase I | ABBV-927 + Nivolumab ABBV-927 | A Study of ABBV-927, an Immunotherapy, in Participants With Advanced Solid Tumors | Active, not recruiting | USA | FRA | ESP | CAN | AUS | 2 |
NCT02990481 | Phase I | TRK-950 | A Study of TRK-950 in Patients With Advanced Solid Tumors | Completed | USA | FRA | 0 |
NCT02992964 | Phase Ib/II | Nivolumab | Pilot Study of Nivolumab in Pediatric Patients With Hypermutant Cancers | Terminated | USA | FRA | CAN | AUS | 1 |
NCT02994953 | Phase I | Avelumab + NHS-IL12 | A Phase Ib Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of Avelumab in Combination With M9241(NHS-IL12) | Terminated | USA | ITA | FRA | ESP | BEL | 2 |
NCT02997163 | Phase I | Talazoparib | An Open-Label Pharmacokinetics and Safety Study of Talazoparib | Completed | USA | CAN | 0 |
NCT02997176 | Phase I | Talazoparib | An Open-Label Pharmacokinetics and Safety Study of Talazoparib (MDV3800) | Completed | USA | 0 |
NCT03000257 | Phase I | Budigalimab | A Study of ABBV-181 in Participants With Advanced Solid Tumors | Completed | USA | FRA | ESP | CAN | BEL | AUT | AUS | 3 |
NCT03005782 | Phase I | Cemiplimab + Fianlimab Fianlimab | Study of REGN3767 (Anti-LAG-3) With or Without REGN2810 (Anti-PD1) in Advanced Cancers | Active, not recruiting | USA | GBR | AUS | 2 |
NCT03006172 | Phase I | Inavolisib + Letrozole + Palbociclib Inavolisib Fulvestrant + Inavolisib Inavolisib + Letrozole | To Evaluate the Safety, Tolerability, and Pharmacokinetics of Inavolisib Single Agent in Participants With Solid Tumors and in Combination With Endocrine and Targeted Therapies in Participants With Breast Cancer | Recruiting | USA | GBR | FRA | ESP | CAN | 0 |
NCT03008018 | Phase I | KA2507 | Safety,Tolerability and MTD KA2507 (HDAC6 Inhibitor) in Patients With Solid Tumours | Completed | USA | 0 |
NCT03010176 | Phase I | Pembrolizumab + Ulevostinag Ulevostinag | Study of MK-1454 Alone or in Combination With Pembrolizumab in Participants With Advanced/Metastatic Solid Tumors or Lymphomas (MK-1454-001) | Completed | USA | GBR | FRA | 2 |
NCT03013218 | Phase I | Evorpacept Atezolizumab + Evorpacept Evorpacept + Trastuzumab | A Study of ALX148 in Patients With Advanced Solid Tumors and Lymphoma | Active, not recruiting | USA | 1 |
NCT03013491 | Phase II | CX-072 + Ipilimumab CX-072 + Vemurafenib CX-072 | A Trial to Find Safe and Active Doses of an Investigational Drug CX-072 for Patients With Solid Tumors or Lymphomas | Completed | USA | GBR | ESP | 3 |
NCT03017833 | Phase I | Metformin + Sapanisertib | Study of TAK-228 (MLN0128) in Combination With Metformin in Patients With Advanced Cancers | Completed | USA | 0 |
NCT03030378 | Phase I | Interleukin-12 + Pembrolizumab | Pembrolizumab and Recombinant Interleukin-12 in Treating Patients With Solid Tumors | Active, not recruiting | USA | 0 |
NCT03030417 | Phase I | LMP744 | Indenoisoquinoline LMP744 in Adults With Relapsed Solid Tumors and Lymphomas | Completed | USA | 0 |
NCT03035253 | Phase I | Fluorouracil + Irinotecan + Leucovorin + Navicixizumab | A Study of OMP-305B83 in Subjects With Metastatic Colorectal Cancer | Terminated | USA | 0 |
NCT03037385 | Phase Ib/II | Pralsetinib | Phase 1/2 Study of the Highly-selective RET Inhibitor, Pralsetinib (BLU-667), in Participants With Thyroid Cancer, Non-Small Cell Lung Cancer, and Other Advanced Solid Tumors (ARROW) | Active, not recruiting | USA | ITA | GBR | FRA | ESP | DEU | BEL | 6 |
NCT03040973 | Phase II | Capmatinib + Nazartinib Capmatinib Capmatinib + Gefitinib | Study to Allow Patients Previously Participating in a Novartis Sponsored Trial to Continue Receiving INC280 Treatment as Single Agent or in Combination With Other Treatments. | Recruiting | USA | ITA | FRA | ESP | DEU | CAN | BEL | 3 |
NCT03042910 | Phase I | Talazoparib | A Study to Assess the Effects of Talazoparib on Cardiac Repolarization in Patients With Advanced Solid Tumors | Completed | USA | 0 |
NCT03051035 | Phase I | KO-947 | First-in-Human Study of KO-947 in Non-Hematological Malignancies | Terminated | USA | ESP | 0 |
NCT03052205 | Phase I | IMO-2125 | A Study of Intratumoral IMO-2125 in Patients With Refractory Solid Tumors | Completed | USA | 1 |
NCT03052569 | Expanded access | RXDX-105 | Expanded Access to RXDX-105 for Cancers With RET Alterations | No longer available | USA | 0 |
NCT03057145 | Phase I | Olaparib + Prexasertib | Combination Study of Prexasertib and Olaparib in Patients With Advanced Solid Tumors | Completed | USA | 0 |
NCT03058289 | Phase Ib/II | INT230-6 INT230-6 + unspecified PD-1 antibody | A Phase 1/2 Safety Study of Intratumorally Dosed INT230-6 (IT-01) | Completed | USA | CAN | 0 |
NCT03059823 | Phase I | Retifanlimab | A Phase 1 Study of MGA012 in Patients With Advanced Solid Tumors | Active, not recruiting | USA | ITA | GBR | FRA | ESP | DEU | BEL | AUS | 8 |
NCT03061188 | Phase I | Nivolumab + Veliparib | Nivolumab and Veliparib in Treating Patients With Recurrent or Refractory Stage IV Solid Tumors That Cannot Be Removed by Surgery or Lymphoma With or Without Alterations in DNA Repair Genes | Unknown status | USA | 0 |
NCT03065062 | Phase I | Gedatolisib + Palbociclib | Study of the CDK4/6 Inhibitor Palbociclib (PD-0332991) in Combination With the PI3K/mTOR Inhibitor Gedatolisib (PF-05212384) for Patients With Advanced Squamous Cell Lung, Pancreatic, Head & Neck and Other Solid Tumors | Recruiting | USA | 0 |
NCT03065387 | Phase I | Everolimus + Neratinib Neratinib + Palbociclib Neratinib + Trametinib | Neratinib and Everolimus, Palbociclib, or Trametinib in Treating Participants With Refractory and Advanced or Metastatic Solid Tumors With EGFR Mutation/Amplification, HER2 Mutation/Amplification, or HER3/4 Mutation or KRAS Mutation | Active, not recruiting | USA | 0 |
NCT03066661 | Expanded access | Entrectinib | Expanded Access to Entrectinib for Cancers With NTRK1/2/3, ROS1, or ALK Gene Fusions | No longer available | USA | 0 |
NCT03069469 | Phase I | Vimseltinib | Study of DCC-3014 in Patients With Advanced Malignancies | Active, not recruiting | USA | ITA | GBR | FRA | ESP | CAN | AUS | 2 |
NCT03071757 | Phase I | ABBV-368 ABBV-368 + Nivolumab | A Study of the Safety, Tolerability and Pharmacokinetics of ABBV-368 as a Single Agent and Combination in Subjects With Locally Advanced or Metastatic Solid Tumors | Completed | USA | FRA | ESP | 3 |
NCT03080311 | Phase I | APG-1252 | A Study of APG-1252 in Patients With SCLC or Other Solid Tumors | Completed | USA | 0 |
NCT03082209 | Phase I | ABBV-621 | A Study of the Safety and Tolerability of ABBV-621 in Participants With Previously Treated Solid Tumors and Hematologic Malignancies | Completed | USA | ESP | 2 |
NCT03085914 | Phase Ib/II | Epacadostat + Fluorouracil + Leucovorin + Nivolumab + Oxaliplatin Epacadostat + Gemcitabine + Nab-paclitaxel + Nivolumab Carboplatin + Epacadostat + Paclitaxel + Pembrolizumab Carboplatin + Epacadostat + Pembrolizumab + Pemetrexed Disodium Cyclophosphamide + Epacadostat + Pembrolizumab | A Study of Epacadostat in Combination With a PD-1 Inhibitor and Chemotherapy in Subjects With Advanced or Metastatic Solid Tumors (ECHO-207) | Completed | USA | 0 |
NCT03087591 | Phase I | APN401 | APN401 in Treating Patients With Recurrent or Metastatic Pancreatic Cancer, Colorectal Cancer, or Other Solid Tumors That Cannot Be Removed by Surgery | Completed | USA | 0 |
NCT03089645 | Phase I | MEDI5083 Durvalumab + MEDI5083 | MEDI5083 Alone and in Combination With Durvalumab in Subjects With Select Advanced Solid Tumors | Completed | USA | AUS | 0 |
NCT03091478 | Phase II | Pembrolizumab | Pembrolizumab in Patients With Leptomeningeal Disease | Terminated | USA | 0 |
NCT03092934 | Phase Ib/II | LY3295668 | A Study of AK-01 (LY3295668) in Solid Tumors | Completed | CAN | 0 |
NCT03093116 | Phase Ib/II | Repotrectinib | A Study of Repotrectinib (TPX-0005) in Patients With Advanced Solid Tumors Harboring ALK, ROS1, or NTRK1-3 Rearrangements (TRIDENT-1) | Recruiting | USA | ITA | GBR | FRA | ESP | DEU | CAN | BEL | AUS | 11 |
NCT03096054 | Phase I | LY3143921 | A CR-UK Phase I Trial of LY3143921 | Active, not recruiting | GBR | 0 |
NCT03096340 | Phase I | IT-141 | Safety and Pharmacokinetic Study of IT-141 in Monotherapy in Patients With Advanced Cancer | Terminated | USA | 0 |
NCT03098550 | Phase Ib/II | Daratumumab + Nivolumab | A Study to Test the Safety and Effectiveness of Nivolumab Combined With Daratumumab in Patients With Advanced Solid Tumors or Tumors That Have Spread | Completed | USA | ITA | FRA | ESP | DEU | CAN | AUS | 2 |
NCT03099109 | Phase I | LY3321367 LY3300054 + LY3321367 | A Study of LY3321367 Alone or With LY3300054 in Participants With Advanced Relapsed/Refractory Solid Tumors | Completed | USA | ESP | 2 |
NCT03099161 | Phase I | Preladenant Pembrolizumab + Preladenant | Study of Preladenant (MK-3814) Alone and With Pembrolizumab (MK-3475) in Participants With Advanced Solid Tumors (MK-3814A-062) | Terminated | USA | CAN | 1 |
NCT03099174 | Phase I | Abemaciclib + Xentuzumab Abemaciclib + Letrozole + Xentuzumab Abemaciclib + Anastrozole + Xentuzumab Abemaciclib + Fulvestrant + Xentuzumab | This Study in Patients With Different Types of Cancer (Solid Tumours) Aims to Find a Safe Dose of Xentuzumab in Combination With Abemaciclib With or Without Hormonal Therapies. The Study Also Tests How Effective These Medicines Are in Patients With Lung and Breast Cancer. | Active, not recruiting | USA | FRA | ESP | 4 |
NCT03101839 | Phase I | AZD4785 | Phase I Dose-Escalation Study of AZD4785 in Patients With Advanced Solid Tumours | Completed | USA | GBR | 0 |
NCT03102320 | Phase I | Anetumab ravtansine Anetumab ravtansine + Gemcitabine Anetumab ravtansine + Cisplatin | Phase 1b Multi-indication Study of Anetumab Ravtansine in Mesothelin Expressing Advanced Solid Tumors (ARCS-Multi) | Completed | USA | ITA | GBR | FRA | ESP | CAN | BEL | AUS | 4 |
NCT03104699 | Phase Ib/II | Balstilimab | Phase 1 / 2 Study of AGEN2034 in Advanced Tumors and Cervical Cancer | Completed | USA | FRA | ESP | BEL | AUS | 4 |
NCT03108131 | Phase II | Atezolizumab + Cobimetinib | Cobimetinib and Atezolizumab in Advanced Rare Tumors | Active, not recruiting | USA | 0 |
NCT03110107 | Phase Ib/II | Ipilimumab BMS-986218 + Nivolumab BMS-986218 | First-In-Human Study of Monoclonal Antibody BMS-986218 by Itself and in Combination With Nivolumab in Patients With Advanced Solid Tumors | Active, not recruiting | USA | ITA | FRA | ESP | DEU | CAN | BEL | AUS | 9 |
NCT03113188 | Phase I | CBP501 + Cisplatin + Nivolumab | CBP501, Cisplatin and Nivolumab in Advanced Refractory Tumors | Completed | USA | 0 |
NCT03114319 | Phase I | TNO155 | Dose Finding Study of TNO155 in Adult Patients With Advanced Solid Tumors | Recruiting | USA | ITA | ESP | CAN | 5 |
NCT03118349 | Phase I | MVT-1075 + MVT-5873 | Study of 177Lu Human Monoclonal Antibody 5B1 (MVT-1075) in Combination With a Blocking Dose of MVT-5873 as Radioimmunotherapy | Terminated | USA | 0 |
NCT03119428 | Phase I | Etigilimab | A Study of OMP-313M32 in Subjects With Locally Advanced or Metastatic Solid Tumors | Terminated | USA | 0 |
NCT03123744 | Phase II | Palbociclib | Histology-Independent Study of Palbociclib in Patients With Advanced Cancer | Withdrawn | USA | 0 |
NCT03125200 | Phase I | ADCT-502 | Study of ADCT-502 in Patients With Advanced Solid Tumors With HER2 Expression | Terminated | USA | BEL | 0 |
NCT03126110 | Phase Ib/II | INCAGN01876 + Ipilimumab + Nivolumab INCAGN01876 + Nivolumab INCAGN01876 + Ipilimumab | Phase 1/2 Study Exploring the Safety, Tolerability, and Efficacy of INCAGN01876 Combined With Immune Therapies in Advanced or Metastatic Malignancies | Completed | USA | ESP | BEL | AUS | 0 |
NCT03127098 | Phase Ib/II | ALT-803 + ETBX-011 | QUILT-3.040: ETBX-011 (Ad5 [E1-, E2b-]-CEA(6D)) Vaccine in Combination With ALT-803 (Super-agonist IL-15) in Subjects Having CEA-Expressing Cancer | Completed | USA | 0 |
NCT03127215 | Phase II | Olaparib + Trabectedin | Study of Olaparib/Trabectedin vs. Doctor's Choice in Solid Tumors (NCT-PMO-1603) | Active, not recruiting | DEU | 0 |
NCT03132155 | Phase II | AMG 337 | QUILT-3.031: AMG 337 in Subjects With Advanced or Metastatic Clear Cell Sarcoma | Terminated | USA | 0 |
NCT03132792 | Phase I | AFPc332T | AFPc332T in Advanced HCC | Active, not recruiting | USA | GBR | FRA | ESP | 0 |
NCT03134638 | Phase I | Carboplatin + SY-1365 SY-1365 Fulvestrant + SY-1365 | A Study of SY-1365 in Adult Patients With Advanced Solid Tumors | Terminated | USA | FRA | CAN | 0 |
NCT03138083 | Phase Ib/II | OMO-1 OMO-1 + unspecified EGFR tyrosine kinase inhibitor | OMO-1 in Solid Malignancies | Terminated | USA | GBR | FRA | BEL | 1 |
NCT03138538 | Phase I | M8891 | M8891 First in Human in Solid Tumors | Terminated | USA | 0 |
NCT03138889 | Phase Ib/II | NKTR-214 + Pembrolizumab Carboplatin + Nab-paclitaxel + NKTR-214 + Pembrolizumab Carboplatin + NKTR-214 + Paclitaxel + Pembrolizumab Cisplatin + NKTR-214 + Pembrolizumab Carboplatin + NKTR-214 + Pembrolizumab + Pemetrexed Disodium | Bempegaldesleukin and Pembrolizumab With or Without Chemotherapy in Locally Advanced or Metastatic Solid Tumors | Terminated | USA | FRA | ESP | DEU | AUS | 0 |
NCT03139370 | Phase I | Cyclophosphamide + Fludarabine KITE-718 | Safety and Efficacy of MAGE-A3/A6 T Cell Receptor Engineered T Cells (KITE-718) in HLA-DPB1*04:01 Positive Adults With Advanced Cancers | Terminated | USA | 0 |
NCT03144661 | Phase I | INCB062079 | An Open-Label Safety and Tolerability Study of INCB062079 in Subjects With Advanced Hepatocellular Carcinoma and Other Malignancies | Terminated | USA | BEL | 0 |
NCT03147976 | Phase II | AMG 337 | QUILT-3.036: AMG 337 in Subjects With Advanced or Metastatic Solid Tumors | Withdrawn | USA | 0 |
NCT03148418 | Phase II | Atezolizumab | A Study in Participants Previously Enrolled in a Genentech? and/or F. Hoffmann-La Roche Ltd-Sponsored Atezolizumab Study | Active, not recruiting | USA | ITA | GBR | FRA | ESP | DEU | CAN | BEL | AUT | AUS | 22 |
NCT03149549 | Phase Ib/II | CX-2009 | PROCLAIM-CX-2009: A Trial to Find Safe and Active Doses of an Investigational Drug CX-2009 for Patients With Selected Solid Tumors | Terminated | USA | GBR | ESP | 1 |
NCT03150810 | Phase Ib/II | Pamiparib + Temozolomide | Study to Assess Safety, Tolerability and Clinical Activity of BGB-290 in Combination With Temozolomide (TMZ) in Participants With Locally Advanced or Metastatic Solid Tumors | Completed | USA | GBR | ESP | AUS | 0 |
NCT03154294 | Phase I | Paclitaxel + Sapanisertib + Serabelisib | Evaluation of the Safety and Tolerability of TAK-228 With TAK-117 and Paclitaxel in Advanced Solid Tumors | Unknown status | USA | 0 |
NCT03155620 | Phase II | Tazemetostat Larotrectinib LY3023414 Vemurafenib Palbociclib Olaparib Ulixertinib Erdafitinib Selumetinib Ensartinib | Targeted Therapy Directed by Genetic Testing in Treating Pediatric Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphomas, or Histiocytic Disorders (The Pediatric MATCH Screening Trial) | Recruiting | USA | CAN | AUS | 1 |
NCT03156114 | Phase I | Ezabenlimab Miptenalimab | This Study Tests the New Medicine BI 754111 Alone or in Combination With Another New Substance BI 754091 in Patients With Advanced Cancer. The Study Tests Different Doses to Find the Best Dose for Continuous Treatment. | Completed | USA | GBR | ESP | CAN | 1 |
NCT03157128 | Phase Ib/II | Selpercatinib | A Study of Selpercatinib (LOXO-292) in Participants With Advanced Solid Tumors, RET Fusion-Positive Solid Tumors, and Medullary Thyroid Cancer (LIBRETTO-001) (LIBRETTO-001) | Recruiting | USA | ITA | GBR | FRA | ESP | DEU | CAN | AUS | 8 |
NCT03162627 | Phase I | Olaparib + Selumetinib | Selumetinib and Olaparib in Solid Tumors | Active, not recruiting | USA | 0 |
NCT03164603 | Phase I | NLG802 | NLG802 Indoleamine 2,3-Dioxygenase (IDO) Inhibitor in Advanced Solid Tumors | Completed | USA | 0 |
NCT03166631 | Phase I | BI 891065 + Ezabenlimab BI 891065 | A Trial to Find the Safe Dose for BI 891065 Alone and in Combination With BI 754091 in Patients With Incurable Tumours or Tumours That Have Spread | Terminated | USA | 0 |
NCT03168061 | Phase Ib/II | NC-6300 | Dose-Escalation and Expansion Trial of NC-6300 in Patients With Advanced Solid Tumors or Soft Tissue Sarcoma | Unknown status | USA | 0 |
NCT03172936 | Phase I | MIW815 + Spartalizumab | Study of the Safety and Efficacy of MIW815 With PDR001 to Patients With Advanced/Metastatic Solid Tumors or Lymphomas | Terminated | USA | ESP | DEU | CAN | AUS | 3 |
NCT03175224 | Phase Ib/II | Vebreltinib | APL-101 Study of Subjects With NSCLC With c-Met EXON 14 Skip Mutations and c-Met Dysregulation Advanced Solid Tumors (SPARTA) | Recruiting | USA | ITA | GBR | FRA | ESP | CAN | AUS | 6 |
NCT03179436 | Phase Ib/II | MK-1308 + Pembrolizumab MK-1308 | Safety, Pharmacokinetics (PK), and Efficacy of MK-1308 in Combination With Pembrolizumab (MK-3475) in Advanced Solid Tumors (MK-1308-001) | Active, not recruiting | USA | ITA | FRA | ESP | CAN | AUS | 10 |
NCT03188965 | Phase I | BAY1895344 | First-in-human Study of ATR Inhibitor BAY1895344 in Patients With Advanced Solid Tumors and Lymphomas | Completed | USA | GBR | CAN | 4 |
NCT03190941 | Phase Ib/II | Cyclophosphamide anti-KRAS G12V mTCR cells Fludarabine Aldesleukin | Administering Peripheral Blood Lymphocytes Transduced With a Murine T-Cell Receptor Recognizing the G12V Variant of Mutated RAS in HLA-A*11:01 Patients | Recruiting | USA | 0 |
NCT03192345 | Phase I | Cemiplimab + SAR439459 SAR439459 | A First-in-human Study of the Safety, Pharmacokinetics, Pharmacodynamics and Anti-tumor Activity of SAR439459 Monotherapy and Combination of SAR439459 and REGN2810 in Patients With Advanced Solid Tumors | Terminated | USA | ITA | GBR | FRA | ESP | DEU | CAN | BEL | AUS | 4 |
NCT03194893 | Phase III | Crizotinib Alectinib | A Rollover Study of Alectinib in Patients With Anaplastic Lymphoma Kinase (ALK)-Positive or Rearranged During Transfection (RET)-Positive Cancer | Recruiting | USA | ITA | FRA | ESP | 6 |
NCT03195699 | Phase I | C188-9 | Phase I Study of Oral STAT3 Inhibitor, C188-9, in Patients With Advanced Cancers | Active, not recruiting | USA | 0 |
NCT03203525 | Phase I | Bevacizumab + Fluorouracil + Leucovorin + Oxaliplatin Bevacizumab + Doxorubicin + Temsirolimus | Study of the NovoTTF-100L System to Enhance Antitumor Activity in Patients With Predominant Hepatic Metastatic Cancer | Recruiting | USA | 0 |
NCT03205176 | Phase I | AZD5153 | Phase I Study of AZD5153 in Patients With Relapsed or Refractory Solid Tumors and Lymphomas | Completed | USA | CAN | 0 |
NCT03207347 | Phase II | Niraparib | A Trial of Niraparib in BAP1 and Other DNA Damage Response (DDR) Deficient Neoplasms (UF-STO-ETI-001) | Completed | USA | 0 |
NCT03209401 | Phase I | Carboplatin + Niraparib | Niraparib Plus Carboplatin in Patients With Homologous Recombination Deficient Advanced Solid Tumor Malignancies | Terminated | USA | 0 |
NCT03210714 | Phase II | Erdafitinib | Erdafitinib in Treating Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With FGFR Mutations (A Pediatric MATCH Treatment Trial) | Active, not recruiting | USA | 1 |
NCT03212274 | Phase II | Olaparib | Olaparib in Treating Patients With Advanced Glioma, Cholangiocarcinoma, or Solid Tumors With IDH1 or IDH2 Mutations | Active, not recruiting | USA | 0 |
NCT03213652 | Phase II | Ensartinib | Ensartinib in Treating Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With ALK or ROS1 Genomic Alterations (A Pediatric MATCH Treatment Trial) | Recruiting | USA | AUS | 1 |
NCT03213665 | Phase II | Tazemetostat | Tazemetostat in Treating Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With EZH2, SMARCB1, or SMARCA4 Gene Mutations (A Pediatric MATCH Treatment Trial) | Active, not recruiting | USA | 1 |
NCT03213678 | Phase II | LY3023414 | Samotolisib in Treating Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With TSC or PI3K/MTOR Mutations (A Pediatric MATCH Treatment Trial) | Active, not recruiting | USA | 1 |
NCT03213691 | Phase II | Selumetinib | Selumetinib Sulfate in Treating Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With Activating MAPK Pathway Mutations (A Pediatric MATCH Treatment Trial) | Active, not recruiting | USA | 1 |
NCT03213704 | Phase II | Larotrectinib | Larotrectinib in Treating Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With NTRK Fusions (A Pediatric MATCH Treatment Trial) | Active, not recruiting | USA | 1 |
NCT03215511 | Phase Ib/II | Selitrectinib | A Study to Test the Safety of the Investigational Drug Selitrectinib in Children and Adults That May Treat Cancer | Completed | USA | ITA | FRA | ESP | DEU | BEL | AUS | 3 |
NCT03217253 | Phase I | Tazemetostat | Tazemetostat in Treating Patients With Metastatic or Unresectable Solid Tumors or B-Cell Lymphomas With Liver Dysfunction | Withdrawn | USA | 0 |
NCT03217669 | Phase I | Epacadostat + Sirolimus | Epacadostat (INCB24360) in Combination With Sirolimus in Advanced Malignancy | Active, not recruiting | USA | 0 |
NCT03217747 | Phase Ib/II | Avelumab + PF-04518600 + Utomilumab Avelumab + Utomilumab Avelumab + PF-04518600 | Avelumab, Utomilumab, Anti-OX40 Antibody PF-04518600, and Radiation Therapy in Treating Patients With Advanced Malignancies | Active, not recruiting | USA | 0 |
NCT03218826 | Phase I | AZD8186 + Docetaxel | PI3Kbeta Inhibitor AZD8186 and Docetaxel in Treating Patients Advanced Solid Tumors With PTEN or PIK3CB Mutations That Are Metastatic or Cannot Be Removed by Surgery | Active, not recruiting | USA | 0 |
NCT03219268 | Phase I | MGD013 | A Study of MGD013 in Patients With Unresectable or Metastatic Neoplasms | Completed | USA | ESP | AUS | 5 |
NCT03220035 | Phase II | Vemurafenib | Vemurafenib in Treating Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With BRAF V600 Mutations (A Pediatric MATCH Treatment Trial) | Active, not recruiting | USA | 1 |
NCT03220347 | Phase I | CC-90010 | A Study to Assess the Safety, Tolerability, Pharmacokinetics and Preliminary Efficacy of CC-90010 in Subjects With Advanced Solid Tumors and Relapsed/Refractory Non-Hodgkin's Lymphomas | Active, not recruiting | ITA | FRA | ESP | 1 |
NCT03221400 | Phase Ib/II | STA-8666 | PEN-866 in Patients With Advanced Solid Malignancies | Unknown status | USA | 0 |
NCT03225105 | Phase I | M3541 | M3541 in Combination With Radiotherapy in Subjects With Solid Tumors | Terminated | USA | 0 |
NCT03229200 | FDA approved | Ibrutinib | Extended Treatment Protocol for Subjects Continuing to Benefit From Ibrutinib. | Enrolling by invitation | USA | ITA | GBR | FRA | ESP | CAN | AUS | 10 |
NCT03229278 | Phase I | Nivolumab + Pembrolizumab + Trigriluzole | Trigriluzole With Nivolumab and Pembrolizumab in Treating Patients With Metastatic or Unresectable Solid Malignancies or Lymphoma | Completed | USA | 0 |
NCT03233204 | Phase II | Olaparib | Olaparib in Treating Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With Defects in DNA Damage Repair Genes (A Pediatric MATCH Treatment Trial) | Active, not recruiting | USA | 1 |
NCT03236857 | Phase I | Venetoclax | A Study of the Safety and Pharmacokinetics of Venetoclax in Pediatric and Young Adult Patients With Relapsed or Refractory Malignancies | Completed | USA | GBR | FRA | DEU | CAN | AUS | 2 |
NCT03236935 | Phase I | L-NMMA + Pembrolizumab | Phase Ib of L-NMMA and Pembrolizumab | Active, not recruiting | USA | 0 |
NCT03237390 | Phase I | Gemcitabine + Ribociclib | Ribociclib and Gemcitabine Hydrochloride in Treating Patients With Advanced or Metastatic Solid Tumors | Completed | USA | 0 |
NCT03238027 | Phase I | SNDX-6352 Durvalumab + SNDX-6352 | A Phase 1, Open-label, Dose Escalation Trial to Investigate SNDX-6352 in Patients With Solid Tumors | Completed | USA | 0 |
NCT03239145 | Phase I | Pembrolizumab + Trebananib | Phase Ib Study to Test the Safety and Potential Synergy of Pembrolizumab (Anti-PD-1) and AMG386 (Angiopoietin-2 (Ang-2) in Patients With Advanced Solid Tumor | Active, not recruiting | USA | 0 |
NCT03240861 | Phase I | Busulfan + Fludarabine Aldesleukin + LV-NY-ESO TCR/sr39TK PBSC + RV-NY-ESO TCR PBMC Filgrastim + Plerixafor | Genetically Engineered PBMC and PBSC Expressing NY-ESO-1 TCR After a Myeloablative Conditioning Regimen to Treat Patients With Advanced Cancer (NYESO SCT) | Terminated | USA | 0 |
NCT03241173 | Phase Ib/II | INCAGN01949 + Ipilimumab INCAGN01949 + Nivolumab INCAGN01949 + Ipilimumab + Nivolumab | A Study Exploring the Safety and Efficacy of INCAGN01949 in Combination With Immune Therapies in Advanced or Metastatic Malignancies | Completed | USA | 0 |
NCT03245151 | Phase Ib/II | Everolimus + Lenvatinib | Study of Lenvatinib in Combination With Everolimus in Recurrent and Refractory Pediatric Solid Tumors, Including Central Nervous System Tumors | Completed | USA | CAN | 0 |
NCT03245736 | Phase II | Tisotumab vedotin-tftv | Tisotumab Vedotin Continued Treatment in Patients With Solid Tumors. | Completed | USA | GBR | 0 |
NCT03249792 | Phase I | MK-2118 + Pembrolizumab MK-2118 | Study of MK-2118 Administered as Intratumoral Injection as Monotherapy and in Combination With Pembrolizumab (MK-3475) in the Treatment of Adults With Advance/Metastatic Solid Tumors or Lymphomas (MK-2118-001) | Completed | USA | 1 |
NCT03250832 | Phase I | TSR-033 TSR-033 + unspecified PD-1 antibody | Study of TSR-033 With an Anti-PD-1 | Completed | USA | FRA | 0 |
NCT03251378 | Phase I | Fruquintinib | The Evaluation of Safety, Tolerability, and Pharmacokinetics for Fruquintinib in Solid Tumors | Active, not recruiting | USA | 0 |
NCT03251924 | Phase Ib/II | BMS-986226 + Nivolumab BMS-986226 + Ipilimumab BMS-986226 | A Dose Escalation and Combination Immunotherapy Study to Evaluate BMS-986226 Alone or in Combination With Nivolumab or Ipilimumab in Patients With Advanced Solid Tumors | Terminated | USA | ESP | CAN | 1 |
NCT03252938 | Phase I | Eftilagimod alpha Avelumab + Eftilagimod alpha | Feasibility and Safety of IMP321 for Advanced Stage Solid Tumors | Recruiting | DEU | 0 |
NCT03253679 | Phase II | Adavosertib | WEE1 Inhibitor AZD1775 in Treating Patients With Advanced Refractory Solid Tumors With CCNE1 Amplification | Completed | USA | 0 |
NCT03255070 | Phase I | ARX-788 | A Dose-escalation, Expansion Study of ARX788, in Advanced Solid Tumors Subjects With HER2 Expression (ACE-Pan Tumor 01) | Completed | USA | AUS | 0 |
NCT03260322 | Phase Ib/II | ASP8374 ASP8374 + Pembrolizumab | A Multiple-dose Study of ASP8374, an Immune Checkpoint Inhibitor, as a Single Agent and in Combination With Pembrolizumab in Subjects With Advanced Solid Tumors | Completed | USA | ITA | GBR | ESP | CAN | 4 |
NCT03270176 | Phase I | Avelumab + Xevinapant | A Dose-Finding Study of the Second Mitochondrial Activator of Caspases (SMAC) Mimetic Debio 1143 When Given in Combination With Avelumab to Participants With Advanced Solid Malignancies and to Participants With Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC) After Platinum-Based Therapy | Completed | CAN | 2 |
NCT03272464 | Phase I | Dabrafenib + Itacitinib + Trametinib | INCB039110 in Combination With Dabrafenib and Trametinib in Patients With BRAF-mutant Melanoma and Other Solid Tumors. | Terminated | USA | 0 |
NCT03274661 | Phase II | Pembrolizumab | Pembrolizumab Activity in Patients With HR Competent and Deficient Tumors | Completed | USA | 0 |
NCT03277352 | Phase Ib/II | Epacadostat + INCAGN01876 + Pembrolizumab | INCAGN01876 in Combination With Immune Therapies in Subjects With Advanced or Metastatic Malignancies | Terminated | USA | 0 |
NCT03284385 | Phase II | Adavosertib | Testing AZD1775 in Advanced Solid Tumors That Have a Mutation Called SETD2 | Active, not recruiting | USA | 0 |
NCT03286296 | Phase I | LZM009 | LZM009 to Treat Patients With Advanced Solid Tumors | Completed | USA | 0 |
NCT03289962 | Phase I | Autogene cevumeran Atezolizumab + Autogene cevumeran | A Study of RO7198457 as a Single Agent and in Combination With Atezolizumab in Participants With Locally Advanced or Metastatic Tumors | Active, not recruiting | USA | GBR | ESP | DEU | CAN | BEL | 2 |
NCT03291938 | Phase I | IACS-010759 | Study to Evaluate the Safety and Tolerability of IACS-010759 in Subjects With Advanced Solid Tumors and Lymphoma | Completed | USA | 0 |
NCT03295942 | Phase I | OMP-336B11 | A Study of OMP-336B11 in Subjects With Locally Advanced or Metastatic Tumors | Terminated | USA | 0 |
NCT03297424 | Phase Ib/II | PLX2853 | A Study of PLX2853 in Advanced Malignancies. | Completed | USA | 0 |
NCT03297606 | Phase II | Bosutinib Palbociclib Vismodegib Ipilimumab + Nivolumab Cobimetinib + Vemurafenib Temsirolimus Olaparib Erlotinib Crizotinib Sunitinib Afatinib Dasatinib Pertuzumab + Trastuzumab Axitinib | Canadian Profiling and Targeted Agent Utilization Trial (CAPTUR) (CAPTUR) | Recruiting | CAN | 0 |
NCT03301896 | Phase I | LHC165 + Spartalizumab LHC165 | Phase I/Ib Study of LHC165 Single Agent and in Combination With PDR001 in Patients With Advanced Malignancies | Terminated | USA | ITA | ESP | DEU | BEL | 2 |
NCT03306420 | Phase I | MS201408-0005A + MS201408-0005B MS201408-0005A + MS201408-0005C MS201408-0005A | First-in-Human Study of MS201408-0005A as Single Agent and in Combinations | Terminated | USA | 0 |
NCT03307785 | Phase I | Carboplatin + Dostarlimab-gxly + Paclitaxel Dostarlimab-gxly + Niraparib | Study of Niraparib or Carboplatin-Paclitaxel in Combination With TSR-042 | Active, not recruiting | USA | 0 |
NCT03310541 | Phase I | Capivasertib Capivasertib + Enzalutamide Capivasertib + Fulvestrant | AZD5363 in Patients With Advanced Solid Tumors Harboring AKT Mutations | Completed | USA | 0 |
NCT03310879 | Phase II | Abemaciclib | Study of the CDK4/6 Inhibitor Abemaciclib in Solid Tumors Harboring Genetic Alterations in Genes Encoding D-type Cyclins or Amplification of CDK4 or CDK6 | Recruiting | USA | 0 |
NCT03311412 | Phase I | Sym021 | Sym021 (Anti-PD-1) in Patients With Advanced Solid Tumor Malignancies or Lymphomas | Completed | USA | CAN | 0 |
NCT03313557 | Phase I | Adavosertib | AZD1775 Continued Access Study to Assess Safety and Tolerability for Patients Enrolled in AZD1775 Clinical Pharmacology Studies | Completed | USA | GBR | FRA | 1 |
NCT03313778 | Phase I | mRNA-4157 + Pembrolizumab mRNA-4157 | Safety, Tolerability, and Immunogenicity of mRNA-4157 Alone and in Combination in Participants With Solid Tumors (KEYNOTE-603) | Recruiting | USA | 0 |
NCT03314935 | Phase Ib/II | INCB001158 + Paclitaxel Cisplatin + Gemcitabine + INCB001158 Fluorouracil + INCB001158 + Leucovorin + Oxaliplatin | A Phase 1/2 Study of INCB001158 in Combination With Chemotherapy in Subjects With Solid Tumors | Completed | USA | GBR | BEL | 0 |
NCT03317496 | Phase II | Avelumab + Cisplatin + Gemcitabine Avelumab + Carboplatin + Pemetrexed Disodium | Safety And Efficacy Study Of Avelumab Plus Chemotherapy With Or Without Other Anti-Cancer Immunotherapy Agents In Patients With Advanced Malignancies | Terminated | USA | ITA | GBR | ESP | CAN | AUS | 2 |
NCT03318445 | Phase I | Rucaparib Irinotecan + Rucaparib | Rucaparib and Irinotecan in Cancers With Mutations in DNA Repair | Completed | USA | 0 |
NCT03319459 | Phase I | FATE-NK100 FATE-NK100 + Trastuzumab Cetuximab + FATE-NK100 | FATE-NK100 as Monotherapy and in Combination With Monoclonal Antibody in Subjects With Advanced Solid Tumors | Completed | USA | 0 |
NCT03320330 | Phase Ib/II | Pepinemab | VX15/2503 in Treating Younger Patients With Recurrent, Relapsed, or Refractory Solid Tumors | Active, not recruiting | USA | 0 |
NCT03322384 | Phase Ib/II | Epacadostat + SD-101 | Phase I/II Trial of Epacadostat, Intralesional SD101, Radiotherapy in Patients With Lymphoma | Completed | USA | 0 |
NCT03323034 | Phase I | Irinotecan + MLN4924 + Temozolomide | Pevonedistat, Irinotecan Hydrochloride, and Temozolomide in Treating Patients With Recurrent or Refractory Solid Tumors or Lymphoma | Active, not recruiting | USA | 0 |
NCT03323398 | Phase I | mRNA-2416 | Dose Escalation Study of mRNA 2416 for Intratumoral Injection to Patients With Advanced Malignancies | Terminated | USA | 0 |
NCT03329001 | Phase I | Niraparib | Crossover Study to Assess the Relative Bioavailability of Niraparib Tablet Compared to Niraparib Capsule | Active, not recruiting | USA | 0 |
NCT03330405 | Phase II | Avelumab + Talazoparib | Javelin Parp Medley: Avelumab Plus Talazoparib In Locally Advanced Or Metastatic Solid Tumors | Terminated | USA | GBR | CAN | BEL | AUS | 4 |
NCT03330561 | Phase I | PRS-343 | PRS-343 in HER2-Positive Solid Tumors | Completed | USA | 0 |
NCT03330990 | Phase I | Entrectinib | Evaluate the Effect of Entrectinib on the Pharmacokinetics of Midazolam in Cancer Patients | Completed | USA | 0 |
NCT03332355 | Phase I | PAC-1 + Temozolomide | Procaspase Activating Compound-1 (PAC-1) in the Treatment of Advanced Malignancies - Component 2 | Terminated | USA | 0 |
NCT03333824 | Phase I | Adavosertib | Effects of AZD1775 on the PK Substrates for CYP3A, CYP2C19, CYP1A2 and on QT Interval in Patients With Advanced Cancer | Completed | USA | 0 |
NCT03335540 | Phase I | Linrodostat + Nivolumab Nivolumab + Relatlimab Cabiralizumab + Nivolumab Lirilumab + Nivolumab BMS-986156 + Nivolumab Ipilimumab + Nivolumab Nivolumab | An Adaptive Study to Match Patients With Solid Tumors to Various Immunotherapy Combinations Based Upon a Broad Biomarker Assessment | Completed | USA | 0 |
NCT03340506 | FDA approved | Trametinib Dabrafenib Dabrafenib + Trametinib | Dabrafenib and/or Trametinib Rollover Study | Recruiting | USA | FRA | ESP | DEU | AUT | 7 |
NCT03343613 | Phase I | LY3300054 + LY3381916 LY3381916 | A Study of LY3381916 Alone or in Combination With LY3300054 in Participants With Solid Tumors | Terminated | USA | ITA | FRA | ESP | BEL | 1 |
NCT03345485 | Phase Ib/II | Tinostamustine | Study of the Safety, Pharmacokinetics and Efficacy of EDO-S101, in Patients With Advanced Solid Tumors | Completed | USA | CAN | 0 |
NCT03347123 | Phase Ib/II | Epacadostat + Ipilimumab + Nivolumab Epacadostat + Lirilumab + Nivolumab | A Study of Epacadostat and Nivolumab in Combination With Immune Therapies in Subjects With Advanced or Metastatic Malignancies (ECHO-208) | Terminated | USA | 0 |
NCT03348514 | Phase I | CPX-POM | Safety, Dose Tolerance, Pharmacokinetics, and Pharmacodynamics Study of CPX-POM in Patients With Advanced Solid Tumors | Completed | USA | 0 |
NCT03351231 | Phase Ib/II | BMS-986242 + Nivolumab | An Investigational Immuno-Therapy Study of Experimental Medication BMS-986242 Given in Combination With Nivolumab in Patients With Advanced Cancer | Terminated | USA | 0 |
NCT03355066 | Phase I | SM08502 | A Study Evaluating the Safety and Pharmacokinetics of Orally Administered SM08502 in Subjects With Advanced Solid Tumors | Active, not recruiting | USA | 0 |
NCT03359733 | Phase I | Mivavotinib | A Study to Evaluate the Effect of Food on the Pharmacokinetics (PK) of TAK-659 in Participants With Advanced Solid Tumor | Withdrawn | USA | 0 |
NCT03359850 | Phase I | Niraparib | Pharmacokinetic and Safety Study of Niraparib With Normal or Moderate Hepatic Impairment Patients | Completed | USA | 0 |
NCT03361228 | Phase Ib/II | Epacadostat + INCB001158 Epacadostat + INCB001158 + Pembrolizumab | A Study to Evaluate the Safety, Tolerability, and Antitumor Activity of INCB001158 Plus Epacadostat, With or Without Pembrolizumab, in Advanced Solid Tumors | Terminated | USA | 0 |
NCT03362723 | Phase I | Idasanutlin | A Study to Investigate the Bioequivalence or Relative Bioavailability of Three New Idasanutlin Tablet Variants Following Oral Administration in Participants With Solid Tumors | Completed | USA | CAN | 0 |
NCT03363893 | Phase Ib/II | Samuraciclib Fulvestrant + Samuraciclib | Modular Study to Evaluate CT7001 Alone in Cancer Patients With Advanced Malignancies | Completed | USA | GBR | 0 |
NCT03364049 | Phase I | MK-7162 + Pembrolizumab | Study of MK-7162 in Combination With Pembrolizumab (MK-3475) in Adult Participants With Advanced Solid Tumors (MK-7162-002) | Completed | USA | CAN | 2 |
NCT03364400 | Phase I | VT1021 | Phase 1 Study Evaluating VT1021 in Patients With Advanced Solid Tumors | Active, not recruiting | USA | 0 |
NCT03365791 | Phase II | Ieramilimab Spartalizumab | PDR001 Plus LAG525 for Patients With Advanced Solid and Hematologic Malignancies | Completed | USA | 0 |
NCT03366103 | Phase Ib/II | Navitoclax + Vistusertib | Navitoclax and Vistusertib in Treating Patients With Relapsed Small Cell Lung Cancer and Other Solid Tumors | Terminated | USA | 0 |
NCT03366116 | Phase I | Aza-TdCyd | 5-aza-4'-Thio-2'-Deoxycytidine (Aza-TdC) in People With Advanced Solid Tumors | Recruiting | USA | 0 |
NCT03369223 | Phase Ib/II | BMS-986242 BMS-986249 + Nivolumab | An Investigational Immunotherapy Study of BMS-986249 Alone and in Combination With Nivolumab in Solid Cancers That Are Advanced or Have Spread | Active, not recruiting | USA | ITA | ESP | DEU | CAN | AUS | 5 |
NCT03373097 | Phase Ib/II | GD2-CART01 | Anti-GD2 CAR T Cells in Pediatric Patients Affected by High Risk and/or Relapsed/Refractory Neuroblastoma or Other GD2-positive Solid Tumors | Recruiting | ITA | 0 |
NCT03375086 | Phase I | APX3330 | A Study of APX3330 in Patients With Advanced Solid Tumors (APX3330) | Completed | USA | 0 |
NCT03382340 | Phase Ib/II | IMX-110 | IMX-110 in Patients With Advanced Solid Tumors | Active, not recruiting | USA | AUS | 0 |
NCT03384316 | Phase I | ETBX-011 + ETBX-051 + ETBX-061 | Multi-Targeted Recombinant Ad5 (CEA/MUC1/Brachyury) Based Immunotherapy Vaccine Regimen in People With Advanced Cancer | Completed | USA | 0 |
NCT03386526 | Phase Ib/II | APG-1387 | APG-1387 in Patients With Advanced Solid Tumors or Hematologic Malignancies | Completed | USA | 0 |
NCT03386721 | Phase II | Atezolizumab + RO6874281 | Study to Evaluate the Therapeutic Activity of RO6874281 as a Combination Therapy in Participants With Advanced and/or Metastatic Solid Tumors | Terminated | USA | GBR | FRA | ESP | DEU | BEL | 9 |
NCT03388632 | Phase I | Ipilimumab + rhIL-15 Nivolumab + rhIL-15 Ipilimumab + Nivolumab + rhIL-15 | Recombinant Interleukin-15 in Combination With Checkpoint Inhibitors Nivolumab and Ipilimumab in People With Refractory Cancers | Recruiting | USA | 0 |
NCT03396211 | Phase I | Nivolumab + Rivoceranib | Study to Evaluate Apatinib Plus Nivolumab in Patients With Unresectable or Metastatic Cancer | Completed | USA | 0 |
NCT03396445 | Phase I | MK-5890 MK-5890 + Pembrolizumab | Safety and Pharmacokinetics Study of MK-5890 as Monotherapy and in Combination With Pembrolizumab (MK-3475) in Adults With Advanced Solid Tumors (MK-5890-001) | Active, not recruiting | USA | ESP | 5 |
NCT03398720 | Phase I | HTI-1066 | Safety and Tolerability of HTI-1066 in Subjects With Advanced Solid Tumors | Unknown status | USA | 0 |
NCT03400332 | Phase Ib/II | BMS-986253 + Nivolumab | An Investigational Immuno-Therapy Study of Experimental Medication BMS-986253 Given in Combination With Nivolumab in Patients With Advanced Cancers | Active, not recruiting | USA | ITA | GBR | FRA | ESP | DEU | CAN | BEL | AUS | 3 |
NCT03406949 | Phase I | Obrindatamab + Retifanlimab | MGD009/MGA012 Combination in Relapsed/Refractory Cancer | Completed | USA | 0 |
NCT03407976 | Phase Ib/II | Pembrolizumab + Rivoceranib | Apatinib With Pembrolizumab in Previously Treated Advanced Malignancies | Terminated | USA | 0 |
NCT03410927 | Phase Ib/II | TAS0728 | A Study of TAS0728 in Patients With Solid Tumors With HER2 or HER3 Abnormalities | Terminated | USA | GBR | FRA | ESP | 0 |
NCT03412877 | Phase II | Aldesleukin + Cyclophosphamide + Fludarabine + iTCR-transduced PBL Aldesleukin + Cyclophosphamide + Fludarabine + iTCR-transduced PBL + Pembrolizumab | Administration of Autologous T-Cells Genetically Engineered to Express T-Cell Receptors Reactive Against Mutated Neoantigens in People With Metastatic Cancer | Recruiting | USA | 0 |
NCT03415126 | Phase I | ERAS-007 | A Study of ASN007 in Patients With Advanced Solid Tumors | Completed | USA | 0 |
NCT03416335 | Phase Ib/II | DSP-0509 DSP-0509 + Pembrolizumab | A Study of DSP-0509 in Patients With Advanced Solid Tumors to Determine the Safety and the Pharmacokinetic Profile | Completed | USA | 0 |
NCT03416816 | Phase I | DSP-0337 | A Study of DSP-0337 in Patients With Advanced Solid Tumors to Determine the Safety and the Pharmacokinetic Profile | Terminated | USA | 0 |
NCT03420430 | Expanded access | GL-ONC1 | Expanded Access to Provide GL-ONC1 for the Treatment of Advanced Cancers With No Standard of Care | Temporarily not available | USA | 0 |
NCT03421353 | Phase Ib/II | Cisplatin + Danvatirsen + Durvalumab + Gemcitabine Carboplatin + Danvatirsen + Durvalumab + Gemcitabine Cisplatin + Danvatirsen + Durvalumab + Fluorouracil Danvatirsen + Durvalumab Carboplatin + Danvatirsen + Durvalumab + Nab-paclitaxel | AZD9150 Plus Durvalumab Alone or in Combination With Chemotherapy in Patients With Advanced, Solid Tumours and in Patients With Non-Small-Cell Lung Cancer | Active, not recruiting | USA | 0 |
NCT03422679 | Phase Ib/II | CB-103 | Study of CB-103 in Adult Patients With Advanced or Metastatic Solid Tumours and Haematological Malignancies | Terminated | USA | FRA | ESP | DEU | 2 |
NCT03423628 | Phase I | AZD1390 | A Study to Assess the Safety and Tolerability of AZD1390 Given With Radiation Therapy in Patients With Brain Cancer | Recruiting | USA | GBR | 0 |
NCT03425279 | Phase Ib/II | Mecbotamab Vedotin | CAB-AXL-ADC Safety and Efficacy Study in Patients With Solid Tumors | Recruiting | USA | 2 |
NCT03428802 | Phase II | Pembrolizumab | Pembrolizumab in Treating Participants With Metastatic, Recurrent or Locally Advanced Cancer and Genomic Instability | Recruiting | USA | 0 |
NCT03429218 | Phase I | TP-0184 | First-in-human Study of Oral TP-0184 in Patients With Advanced Solid Tumors | Completed | USA | 0 |
NCT03429803 | Phase I | Tovorafenib | DAY101 In Gliomas and Other Tumors | Active, not recruiting | USA | 0 |
NCT03430882 | Phase I | Carboplatin + Paclitaxel + Sapanisertib | TAK228 With Carbo and Taxol in Advanced Malignancies | Completed | USA | 0 |
NCT03431948 | Phase I | Nivolumab + Urelumab Cabiralizumab + Nivolumab | Stereotactic Body Radiotherapy (SBRT) Plus Immunotherapy for Cancer (C4 MOSART) | Completed | USA | 0 |
NCT03435250 | Phase I | AG-270 + Docetaxel AG-270 + Gemcitabine + Nab-paclitaxel AG-270 | Study of AG-270 in Participants With Advanced Solid Tumors or Lymphoma With MTAP Loss | Terminated | USA | FRA | ESP | 0 |
NCT03435952 | Phase I | Clostridium novyi-NT spores + Doxycycline + Pembrolizumab | Pembrolizumab With Intratumoral Injection of Clostridium Novyi-NT | Recruiting | USA | 0 |
NCT03440437 | Phase I | FS118 | FS118 First in Human Study in Patients With Advanced Malignancies After PD-1/PD-L1 Containing Therapy | Active, not recruiting | USA | FRA | 0 |
NCT03444714 | Phase I | RiMO-301 | Phase I Study of RiMO-301 With Radiation in Advanced Tumors | Recruiting | USA | 0 |
NCT03444753 | Phase I | BMS-986299 + Ipilimumab + Nivolumab BMS-986299 | An Investigational Immunotherapy Study of BMS-986299 Alone and in Combination With Nivolumab and Ipilimumab in Participants With Solid Cancers That Have Spread or Cannot be Removed | Terminated | USA | 0 |
NCT03445858 | Phase I | Decitabine + Pembrolizumab | Pembrolizumab in Combination With Decitabine and Hypofractionated Index Lesion Radiation in Pediatrics and Young Adults | Active, not recruiting | USA | 0 |
NCT03446040 | Phase Ib/II | BMS-986258 + Nivolumab BMS-986258 | An Investigational Immunotherapy Study of BMS-986258 Alone and in Combination With Nivolumab in Participants With Solid Cancers That Are Advanced or Have Spread | Active, not recruiting | USA | CAN | AUS | 1 |
NCT03447314 | Phase I | GSK1795091 + GSK3174998 GSK3174998 | Study of a Combination of GSK1795091 and Immunotherapies in Subjects With Advanced Solid Tumors | Completed | USA | ESP | CAN | 1 |
NCT03447470 | Phase I | Nivolumab + RXC004 RXC004 | Study to Evaluate the Safety and Tolerability of RXC004 in Advanced Malignancies | Active, not recruiting | GBR | 0 |
NCT03448042 | Phase I | BTRC 4017A | A Study of Runimotamab in Participants With Locally Advanced or Metastatic HER2-Expressing Cancers | Recruiting | USA | ITA | GBR | FRA | ESP | CAN | BEL | AUS | 6 |
NCT03449381 | Phase I | BI 907828 | This Study Aims to Find the Best Dose of BI 907828 (Brigimadlin) in Patients With Different Types of Advanced Cancer (Solid Tumors) | Recruiting | USA | ESP | DEU | CAN | BEL | 6 |
NCT03451825 | Phase Ib/II | Avelumab | Phase I/II Study of Avelumab in Pediatric Cancer Subjects | Completed | USA | CAN | BEL | 2 |
NCT03454035 | Phase I | Palbociclib + Ulixertinib | Phase I Trial of Ulixertinib/Palbociclib in Patients With Advanced Pancreatic and Other Solid Tumors | Recruiting | USA | 0 |
NCT03458728 | Phase Ib/II | Copanlisib | Safety, Tolerability, Efficacy and Pharmacokinetics of Copanlisib in Pediatric Patients | Terminated | USA | 0 |
NCT03459222 | Phase Ib/II | Linrodostat + Nivolumab + Relatlimab Ipilimumab + Nivolumab + Relatlimab | An Investigational Study of Immunotherapy Combinations in Participants With Solid Cancers That Are Advanced or Have Spread | Active, not recruiting | USA | ITA | GBR | FRA | ESP | AUS | 1 |
NCT03461952 | Phase II | Nivolumab Ipilimumab + Nivolumab | Nivolumab Ipilimumab in Patients With hyperMutated Cancers Detected in Blood (NIMBLe) (NIMBLe) | Terminated | USA | CAN | 0 |
NCT03463473 | Phase I | MSB2311 | A Phase I Study of MSB2311 in Advanced Solid Tumors | Completed | USA | 0 |
NCT03468426 | Phase I | BI 836880 + Ezabenlimab | A Study to Test Different Doses of BI 836880 Combined With Ezabenlimab in Patients With Advanced Non-small Cell Lung Cancer Followed by Other Types of Advanced Solid Tumours | Active, not recruiting | USA | GBR | FRA | ESP | DEU | AUS | 6 |
NCT03471286 | Phase I | Epacadostat | A Window of Opportunity Study to Investigate Mechanisms of Actions of Novel Therapeutic Agents in Patients With Resectable Solid Tumor Malignancies | Terminated | USA | 0 |
NCT03474640 | Phase I | Toripalimab-tpzi | Safety, Tolerability and Pharmacokinetics of an Anti-PD-1 Monoclonal Antibody in Subjects With Advanced Malignancies | Unknown status | USA | 0 |
NCT03475953 | Phase Ib/II | Avelumab + Regorafenib | A Phase I/II Study of Regorafenib Plus Avelumab in Solid Tumors (REGOMUNE) | Recruiting | FRA | 0 |
NCT03477175 | Phase II | Lenvatinib | Study to Assess the Long-term Safety of Lenvatinib Monotherapy, a Lenvatinib Combination Regimen, or a Comparator Treatment Arm to Cancer Patients in Eisai Sponsored Lenvatinib Trials | Completed | USA | ITA | DEU | BEL | AUS | 6 |
NCT03478462 | Phase I | CLR 131 | Dose Escalation Study of CLR 131 in Children and Adolescents With Relapsed or Refractory Malignant Brain Cancer, Neuroblastoma, Rhabdomyosarcoma, Ewings Sarcoma, and Osteosarcoma | Active, not recruiting | USA | CAN | AUS | 0 |
NCT03486301 | Phase I | BDB001 BDB001 + Pembrolizumab | Clinical Study of BDB001 as a Mono-therapy or in Combination With Pembrolizumab | Active, not recruiting | USA | 0 |
NCT03486314 | Phase I | Carboplatin + Docetaxel + MLN4924 + Paclitaxel MLN4924 + Rifampin | A Study to Evaluate the Effects of Rifampin on Pharmacokinetics (PK) of Pevonedistat in Participants With Advanced Solid Tumors | Completed | USA | 0 |
NCT03486730 | Phase Ib/II | BT1718 | BT1718 in Patients With Advanced Solid Tumours. | Completed | GBR | 0 |
NCT03486873 | Phase III | Pembrolizumab | Long-term Safety and Efficacy Extension Study for Participants With Advanced Tumors Who Are Currently on Treatment or in Follow-up in a Pembrolizumab (MK-3475) Study (MK-3475-587/KEYNOTE-587) | Recruiting | USA | ITA | GBR | FRA | ESP | DEU | CAN | BEL | AUT | AUS | 39 |
NCT03489343 | Phase I | Sym023 | Sym023 (Anti-TIM-3) in Patients With Advanced Solid Tumor Malignancies or Lymphomas | Completed | USA | CAN | 0 |
NCT03489369 | Phase I | Sym022 | Sym022 (Anti-LAG-3) in Patients With Advanced Solid Tumor Malignancies or Lymphomas | Completed | USA | CAN | 0 |
NCT03493945 | Phase Ib/II | ALT-803 + Bintrafusp alfa + Epacadostat + FPV-Brachyury + MVA-BN-Brachyury Bintrafusp alfa + FPV-Brachyury + MVA-BN-Brachyury ALT-803 + Bintrafusp alfa + FPV-Brachyury + MVA-BN-Brachyury ALT-803 + Bintrafusp alfa | Phase I/II Study of Immunotherapy Combination BN-Brachyury Vaccine, M7824, ALT-803 and Epacadostat (QuEST1). | Recruiting | USA | 0 |
NCT03495323 | Phase I | LY3300054 + Prexasertib | A Study of Prexasertib (LY2606368), CHK1 Inhibitor, and LY3300054, PD-L1 Inhibitor, in Patients With Advanced Solid Tumors | Completed | USA | 0 |
NCT03495882 | Phase Ib/II | Balstilimab + Zalifrelimab | Subjects With Metastatic or Locally Advanced Solid Tumors, and Expansion Into Select Solid Tumors (Cervical) | Completed | USA | ESP | AUS | 6 |
NCT03496519 | Phase I | Durvalumab + Trabectedin | Assessing the Combination of Durvalumab (MEDI4736) and Trabectedin in Solid Tumors | Withdrawn | 0 | |
NCT03498521 | Phase II | Atezolizumab + Paclitaxel Carboplatin Carboplatin + Paclitaxel Olaparib Vismodegib Alectinib Bevacizumab + Erlotinib Cisplatin + Gemcitabine Cobimetinib + Vemurafenib Ipatasertib + Paclitaxel Cisplatin + Paclitaxel Gemcitabine Atezolizumab Entrectinib Pertuzumab + Trastuzumab Paclitaxel + Pertuzumab + Trastuzumab Ipatasertib Carboplatin + Gemcitabine | A Phase II Randomized Study Comparing the Efficacy and Safety of Targeted Therapy or Cancer Immunotherapy Versus Platinum-Based Chemotherapy in Patients With Cancer of Unknown Primary Site (CUPISCO) | Active, not recruiting | ITA | GBR | FRA | ESP | DEU | AUT | AUS | 26 |
NCT03502733 | Phase I | Copanlisib + Nivolumab | Copanlisib and Nivolumab in Treating Patients With Metastatic Solid Tumors or Lymphoma | Active, not recruiting | USA | 0 |
NCT03504488 | Phase Ib/II | BA3021 | CAB-ROR2-ADC Safety and Efficacy Study in Patients With Solid Tumors | Recruiting | USA | ITA | ESP | DEU | 4 |
NCT03507491 | Phase I | Gemcitabine + Nab-paclitaxel | Nab-paclitaxel in Combination With Gemcitabine for Pediatric Relapsed and Refractory Solid Tumors | Active, not recruiting | USA | 0 |
NCT03510104 | Phase I | MRX-2843 | Pharmacokinetic and Safety Study of MRX-2843 in Adults With Relapsed/Refractory Advanced and/or Metastatic Solid Tumors | Active, not recruiting | USA | 0 |
NCT03511222 | Phase I | Pembrolizumab + Vorolanib Nivolumab + Vorolanib | Vorolanib (X-82) Combined With Checkpoint Inhibitors in Patients With Solid Tumors | Terminated | USA | 0 |
NCT03512340 | Phase I | SRF231 | Study of SRF231 in Patients With Advanced Solid and Hematologic Cancers | Completed | USA | CAN | 0 |
NCT03514121 | Phase I | FPA150 | FPA150 in Patients With Advanced Solid Tumors | Completed | USA | 1 |
NCT03515551 | Phase Ib/II | IMCnyeso | Safety and Efficacy of IMCnyeso in Advanced NY-ESO-1 and/or LAGE-1A Positive Cancers | Terminated | USA | GBR | CAN | 0 |
NCT03517956 | Phase I | Copanlisib + Rogaratinib | Phase 1 Study of the Combination of Rogaratinib With Copanlisib in Patients With Fibroblast Growth Factor Receptor (FGFR)-Positive, Locally Advanced or Metastatic Solid Tumors (ROCOCO) | Completed | USA | ESP | DEU | BEL | 2 |
NCT03518554 | Phase I | JAB-3068 | A First in Human, Dose Escalation Study of JAB-3068 in Adult Patients With Advanced Solid Tumors | Unknown status | USA | 0 |
NCT03518606 | Phase Ib/II | Durvalumab + Tremelimumab + Vinorelbine | Metronomic Oral Vinorelbine Plus Anti-PD-L1/Anti-CTLA4 ImmunothErapy in Patients With Advanced Solid Tumours (MOVIE) | Active, not recruiting | FRA | 0 |
NCT03520075 | Phase Ib/II | ASTX029 | Study of ASTX029 in Subjects With Advanced Solid Tumors | Recruiting | USA | GBR | FRA | ESP | 0 |
NCT03522142 | Phase I | INCB081776 INCB081776 + Nivolumab | A Study Exploring the Safety and Tolerability of INCB081776 in Participants With Advanced Solid Tumors | Active, not recruiting | USA | 4 |
NCT03525795 | Phase Ib/II | CPI-1205 + Ipilimumab | ORIOn-E: A Study Evaluating CPI-1205 in Patients With Advanced Solid Tumors | Completed | USA | 0 |
NCT03525925 | Phase I | Ibrutinib + Nivolumab | Ibrutinib and Nivolumab in Treating Participants With Metastatic Solid Tumors | Unknown status | USA | 0 |
NCT03526250 | Phase II | Palbociclib | Palbociclib in Treating Patients With Relapsed or Refractory Rb Positive Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With Activating Alterations in Cell Cycle Genes (A Pediatric MATCH Treatment Trial) | Active, not recruiting | USA | 1 |
NCT03526835 | Phase I | MCLA-158 | A Study of Bispecific Antibody MCLA-158 in Patients With Advanced Solid Tumors | Recruiting | USA | GBR | FRA | ESP | BEL | 1 |
NCT03530397 | Phase I | Carboplatin + Pembrolizumab + Pemetrexed Disodium Durvalumab Carboplatin + MEDI5752 + Pemetrexed Disodium MEDI5752 | A Study to Evaluate MEDI5752 in Subjects With Advanced Solid Tumors | Active, not recruiting | USA | ITA | FRA | ESP | AUS | 4 |
NCT03536728 | Phase I | AMXT1501 + Eflornithine | Oral AMXT 1501 Dicaprate in Combination With DFMO | Completed | USA | 0 |
NCT03539484 | Phase I | RO7172508 | A Study of RO7172508 in Patients With Locally Advanced and/or Metastatic CEA-Positive Solid Tumors | Terminated | ESP | CAN | BEL | 1 |
NCT03543813 | Phase Ib/II | CX-2029 | PROCLAIM-CX-2029: A Trial to Find Safe and Active Doses of an Investigational Drug CX-2029 for Patients With Solid Tumors or DLBCL | Completed | USA | GBR | ESP | 1 |
NCT03549000 | Phase I | NZV930 + Spartalizumab + Taminadenant NZV930 + Spartalizumab NZV930 + Taminadenant NZV930 | A Phase I/Ib Study of NZV930 Alone and in Combination With PDR001 and /or NIR178 in Patients With Advanced Malignancies. | Terminated | USA | GBR | ESP | CAN | AUS | 2 |
NCT03556228 | Phase I | VMD-928 | Selective TrkA Inhibitor VMD-928 to Treat TrkA Overexpression Driven Solid Tumors or Lymphoma | Recruiting | USA | 1 |
NCT03558139 | Phase I | Avelumab + Hu5F9-G4 | A Trial of Hu5F9-G4 With Avelumab in Ovarian Cancer | Completed | USA | 0 |
NCT03560882 | Phase I | Atorvastatin | A Pilot Trial of Atorvastatin in Tumor Protein 53 (p53) -Mutant and p53 Wild-Type Malignancies | Recruiting | USA | 0 |
NCT03564691 | Phase I | MK-4830 + Pembrolizumab MK-4830 | Study of MK-4830 as Monotherapy and in Combination With Pembrolizumab (MK-3475) in Participants With Advanced Solid Tumors (MK-4830-001) | Active, not recruiting | USA | FRA | ESP | CAN | AUS | 7 |
NCT03565445 | Phase I | ASP1948 + Nivolumab ASP1948 | A Study of ASP1948, Targeting an Immune Modulatory Receptor, in Subjects With Advanced Solid Tumors | Completed | USA | ITA | GBR | ESP | CAN | 4 |
NCT03565991 | Phase II | Avelumab + Talazoparib | Javelin BRCA/ATM: Avelumab Plus Talazoparib in Patients With BRCA or ATM Mutant Solid Tumors | Terminated | USA | ITA | GBR | FRA | ESP | BEL | 3 |
NCT03568058 | Phase I | Pembrolizumab | Personalized Immunotherapy in Adults With Advanced Cancers Immunotherapy in Adults With Advanced Cancers | Active, not recruiting | USA | 0 |
NCT03568656 | Phase Ib/II | CCS1477 Abiraterone + CCS1477 CCS1477 + Enzalutamide | Study to Evaluate CCS1477 in Advanced Tumours | Recruiting | USA | GBR | FRA | ESP | 2 |
NCT03573310 | Phase I | JNJ-64619178 | A Study of JNJ-64619178, an Inhibitor of PRMT5 in Participants With Advanced Solid Tumors, NHL, and Lower Risk MDS | Active, not recruiting | USA | ESP | DEU | CAN | 1 |
NCT03573544 | Phase Ib/II | OBI-888 | This Study is to Evaluate Safe and Effective Treatment Dose of OBI-888 in Patients With Locally Advanced or Metastatic Solid Tumors. | Terminated | USA | 1 |
NCT03576131 | Phase Ib/II | GEN1029 | GEN1029 (HexaBody-DR5/DR5) Safety Trial in Patients With Malignant Solid Tumors | Terminated | USA | GBR | ESP | 0 |
NCT03579628 | Phase I | AsiDNA + Carboplatin AsiDNA + Carboplatin + Paclitaxel AsiDNA | AsiDNA (a DNA Repair Inhibitor) Administered IntraVenously in Advanced Solid Tumors (DRIIV-1) | Completed | FRA | BEL | 0 |
NCT03588039 | Phase I | Oraxol + Pembrolizumab | Study of Oraxol and Pembrolizumab in Subjects With Advanced Solid Tumors | Terminated | USA | 0 |
NCT03589339 | Phase I | NBTXR3 NBTXR3 + unspecified PD-1 antibody | NBTXR3 Activated by Radiotherapy for Patients With Advanced Cancers Treated With An Anti-PD-1 Therapy | Recruiting | USA | 0 |
NCT03589651 | Phase I | Parsaclisib + Retifanlimab Epacadostat + Retifanlimab | INCMGA00012 in Combination With Other Therapies in Patients With Advanced Solid Tumors | Completed | USA | 0 |
NCT03590054 | Phase I | Abexinostat + Pembrolizumab | Abexinostat in Combination With Pembrolizumab in Patients With Advanced Solid Tumor Malignancies | Active, not recruiting | USA | 0 |
NCT03592264 | Phase Ib/II | OBI-3424 | This Study is to Evaluate OBI-3424 Safe and Effective Treatment Dose in Subjects With Hepatocellular Carcinoma or Castrate Resistant Prostate Cancer | Recruiting | USA | 0 |
NCT03593226 | Phase Ib/II | AGI-134 | Study to Evaluate Safety & Tolerability of AGI-134 in Solid Tumour | Completed | USA | GBR | 1 |
NCT03595059 | Phase I | Docetaxel + Mirzotamab clezutoclax Mirzotamab clezutoclax + Paclitaxel Mirzotamab clezutoclax | A Study With ABBV-155 Alone and in Combination With Taxane Therapy in Adults With Relapsed and/or Refractory Solid Tumors | Active, not recruiting | USA | ESP | CAN | AUS | 6 |
NCT03596372 | Phase I | BAY1834942 | Study of BAY1834942 in Patients With Solid Tumors | Completed | USA | CAN | 1 |
NCT03600883 | Phase Ib/II | Midazolam + Sotorasib Sotorasib + unspecified PD-1 antibody Sotorasib + unspecified PD-L1 antibody Sotorasib | A Phase 1/2, Study Evaluating the Safety, Tolerability, PK, and Efficacy of Sotorasib (AMG 510) in Subjects With Solid Tumors With a Specific KRAS Mutation (CodeBreaK 100) | Active, not recruiting | USA | FRA | ESP | DEU | CAN | BEL | AUT | AUS | 8 |
NCT03601897 | Phase I | Paclitaxel + Rebastinib | A Safety, Tolerability and PK Study of Rebastinib in Patients With Advanced Solid Tumors | Completed | USA | 0 |
NCT03602079 | Phase Ib/II | A166 | Study of A166 in Patients With Relapsed/Refractory Cancers Expressing HER2 Antigen or Having Amplified HER2 Gene | Completed | USA | 0 |
NCT03603964 | Phase II | Guadecitabine | Guadecitabine Extension Study | Terminated | USA | ITA | ESP | CAN | AUT | 4 |
NCT03604445 | Phase I | BI 905677 | This Study Aims to Find and Test a Safe Dose of BI 905677 in Patients With Different Types of Cancer (Solid Tumours) | Terminated | USA | ESP | 2 |
NCT03604783 | Phase I | TP-1287 | Phase I, First-in-human Study of Oral TP-1287 in Patients With Advanced Solid Tumors | Terminated | USA | 0 |
NCT03607890 | Phase II | Nivolumab + Relatlimab | Study of Nivolumab and Relatlimab in Advanced Mismatch Repair Deficient Cancers Resistant to Prior PD-(L)1 Inhibitor | Recruiting | USA | 0 |
NCT03611595 | Phase I | Cabozantinib + Isotretinoin | Cabozantinib in Combination With 13-cis-Retinoic Acid in Children With Relapsed or Refractory Solid Tumors | Recruiting | USA | 0 |
NCT03611868 | Phase Ib/II | APG-115 + Pembrolizumab | A Study of APG-115 in Combination With Pembrolizumab in Patients With Metastatic Melanomas or Advanced Solid Tumors | Recruiting | USA | AUS | 0 |
NCT03616574 | Phase I | CA102N CA102N + Trifluridine-tipiracil hydrochloride | First-in-human Study of CA102N Monotherapy and of CA102N Combined With Trifluridine/Tipiracil (LONSURF) in Subjects With Advanced Solid Tumors | Completed | USA | 0 |
NCT03616834 | Phase II | Tomivosertib | eFT508 in Combination With PD-1/PD-L1 Inhibitor Therapy | Completed | USA | 0 |
NCT03618381 | Phase I | EGFR806CAR(2G)-EGFRt CD19CAR(2G)-T2A-HER2tG + EGFR806CAR(2G)-EGFRt | EGFR806 CAR T Cell Immunotherapy for Recurrent/Refractory Solid Tumors in Children and Young Adults | Recruiting | USA | 0 |
NCT03620318 | Expanded access | Crenolanib | Individual Patient Compassionate Use of Crenolanib | Available | ITA | 0 |
NCT03620643 | Phase II | Crizotinib Crizotinib + Fulvestrant | Crizotinib in Lobular Breast, Diffuse Gastric and Triple Negative Lobular Breast Cancer or CDH1-mutated Solid Tumours (ROLo) | Active, not recruiting | GBR | 0 |
NCT03621982 | Phase I | Camidanlumab tesirine | Study of ADCT-301 in Patients With Selected Advanced Solid Tumors | Terminated | USA | GBR | BEL | 0 |
NCT03634982 | Phase I | RMC-4630 | Dose Escalation of RMC-4630 Monotherapy in Relapsed/Refractory Solid Tumors | Unknown status | USA | 0 |
NCT03635632 | Phase I | C7R-GD2.CART cells Cyclophosphamide + Fludarabine | C7R-GD2.CART Cells for Patients With Relapsed or Refractory Neuroblastoma and Other GD2 Positive Cancers (GAIL-N) | Active, not recruiting | USA | 0 |
NCT03637491 | Phase II | Avelumab + Binimetinib + Talazoparib Avelumab + Binimetinib | A Study of Avelumab, Binimetinib and Talazoparib in Patients With Locally Advanced or Metastatic RAS-mutant Solid Tumors | Terminated | USA | BEL | 1 |
NCT03647163 | Phase I | Pembrolizumab + VSV-hIFNbeta-NIS | Combination Therapy With Intravenous VSV-IFNbeta-NIS and Pembrolizumab in Refractory NSCLC and HCC | Recruiting | USA | 0 |
NCT03648372 | Phase I | Subasumstat | A Study to Evaluate the Safety, Tolerability and Pharmacokinetics (PK) of TAK-981 in Adult Participants With Metastatic Solid Tumors or Lymphomas | Terminated | USA | 0 |
NCT03650348 | Phase I | Atezolizumab + PRS-343 | PRS-343 in Combination With Atezolizumab in HER2-Positive Solid Tumors | Unknown status | USA | 0 |
NCT03651271 | Phase II | Ipilimumab + Nivolumab Nivolumab | Treatment With Nivolumab and Ipilimumab or Nivolumab Alone According to the Percentage of Tumoral CD8 Cells in Advanced Metastatic Cancer | Completed | USA | 0 |
NCT03652077 | Phase I | INCAGN02390 | A Safety and Tolerability Study of INCAGN02390 in Select Advanced Malignancies | Completed | USA | 0 |
NCT03654547 | Phase I | Tinengotinib | Safety of TT-00420 Monotherapy in Patients With Advanced Solid Tumors and Triple Negative Breast Cancer | Active, not recruiting | USA | 1 |
NCT03654716 | Phase I | ALRN-6924 + Cytarabine ALRN-6924 | Phase 1 Study of the Dual MDM2/MDMX Inhibitor ALRN-6924 in Pediatric Cancer | Completed | USA | 0 |
NCT03661632 | Phase Ib/II | BMS-986310 + Nivolumab | An Investigational Immunotherapy Study of BMS-986310 Administered Alone and in Combination With Nivolumab in Patients With Advanced Solid Tumors | Completed | USA | CAN | BEL | 0 |
NCT03665129 | Phase I | Avdoralimab + Durvalumab | IPH5401 (Anti-C5aR) in Combination With Durvalumab in Patients With Advanced Solid Tumors (STELLAR-001) | Terminated | USA | FRA | 0 |
NCT03665285 | Phase Ib/II | NC318 | A Safety and Tolerability Study of NC318 in Subjects With Advanced or Metastatic Solid Tumors | Completed | USA | 0 |
NCT03666273 | Phase I | BAY1905254 BAY1905254 + Pembrolizumab | A First-in-human Study of ILDR2 (Immunoglobulin-like Domain Containing Receptor 2) Function-blocking Antibody BAY1905254 | Active, not recruiting | USA | 0 |
NCT03666988 | Phase I | GSK3368715 | First Time in Humans (FTIH) Study of GSK3368715 in Participants With Solid Tumors and Diffuse Large B-cell Lymphoma (DLBCL) | Terminated | USA | ESP | CAN | AUS | 0 |
NCT03667716 | Phase I | COM701 COM701 + Nivolumab | COM701 in Subjects With Advanced Solid Tumors | Active, not recruiting | USA | 0 |
NCT03668119 | Phase II | Ipilimumab + Nivolumab Nivolumab | A Study of Nivolumab Combined With Ipilimumab and Nivolumab Alone in Patients With Advanced or Metastatic Solid Tumors of High Tumor Mutational Burden (TMB-H) (CheckMate 848) | Completed | USA | ITA | GBR | FRA | ESP | DEU | CAN | BEL | AUS | 8 |
NCT03669601 | Phase I | Ceralasertib + Gemcitabine | AZD6738 & Gemcitabine as Combination Therapy (ATRiUM) | Recruiting | GBR | 0 |
NCT03673787 | Phase Ib/II | Atezolizumab + Ipatasertib | A Trial of Ipatasertib in Combination With Atezolizumab (IceCAP) | Unknown status | GBR | 0 |
NCT03678883 | Phase Ib/II | Carboplatin + Elraglusib + Paclitaxel Elraglusib + Irinotecan Doxorubicin + Elraglusib Elraglusib + Lomustine Carboplatin + Elraglusib Elraglusib + Gemcitabine + Nab-paclitaxel Elraglusib Elraglusib + Gemcitabine | 9-ING-41 in Patients With Advanced Cancers | Active, not recruiting | USA | FRA | ESP | CAN | BEL | 2 |
NCT03680560 | Phase I | ACTR707 + Trastuzumab ACTR087 + Trastuzumab | Study of ACTR T Cell Product in Combination With Trastuzumab in Subjects With HER2-Positive Advanced Solid Tumor Cancers | Terminated | USA | 0 |
NCT03681951 | Phase Ib/II | GSK3145095 GSK3145095 + Pembrolizumab | First-time-in-human (FTIH) Study of GSK3145095 Alone and in Combination With Other Anticancer Agents in Adults With Advanced Solid Tumors | Terminated | USA | 0 |
NCT03682289 | Phase II | Ceralasertib + Olaparib Olaparib | Phase II Trial of AZD6738 Alone and in Combination With Olaparib | Recruiting | USA | 0 |
NCT03684785 | Phase Ib/II | AST-008 + Pembrolizumab | Intratumoral AST-008 Combined With Pembrolizumab in Patients With Advanced Solid Tumors | Terminated | USA | 0 |
NCT03684811 | Phase Ib/II | Cisplatin + Gemcitabine + Olutasidenib Azacitidine + Olutasidenib Olutasidenib Nivolumab + Olutasidenib | A Study of FT-2102 in Patients With Advanced Solid Tumors and Gliomas With an IDH1 Mutation | Completed | USA | GBR | FRA | ESP | AUS | 1 |
NCT03685591 | Phase I | PF-06952229 Enzalutamide + PF-06952229 Letrozole + Palbociclib + PF-06952229 | PF-06952229 Treatment in Adult Patients With Advanced Solid Tumors | Terminated | USA | 0 |
NCT03686124 | Phase I | IMA-203 | TCR-engineered T Cells in Solid Tumors | Recruiting | USA | DEU | 0 |
NCT03690154 | Phase I | FN-1501 | Study to Evaluate the Safety, Tolerability, Pharmacokinetics (PK) and Anti-tumor Activity of FN-1501 Monotherapy in Patients With Advanced Solid Tumors | Terminated | USA | AUS | 0 |
NCT03690869 | Phase Ib/II | Cemiplimab | REGN2810 in Pediatric Patients With Relapsed, Refractory Solid, or Central Nervous System (CNS) Tumors and Safety and Efficacy of REGN2810 in Combination With Radiotherapy in Pediatric Patients With Newly Diagnosed or Recurrent Glioma | Terminated | USA | 0 |
NCT03693014 | Phase II | A Study of Several Radiation Doses for Patients With Progression on Immunotherapy/Checkpoint Inhibitors | Recruiting | USA | 0 | |
NCT03696030 | Phase I | HER2 CAR-T cells | HER2-CAR T Cells in Treating Patients With Recurrent Brain or Leptomeningeal Metastases | Recruiting | USA | 0 |
NCT03696771 | Phase I | NJH395 | Study to Determine Safety and Dose of NJH395 in Non-breast HER2+ Advanced Cancer | Completed | USA | ITA | 2 |
NCT03697304 | Phase II | Ezabenlimab Miptenalimab | Platform Trial Evaluating Safety and Efficacy of BI 754091 Anti- PD-1 Based Combination Therapies in PD-(L)1 naïve and PD- (L)1 Pretreated Patient Populations With Advanced/Metastatic Solid Tumours. | Active, not recruiting | USA | GBR | CAN | 0 |
NCT03698994 | Phase II | Ulixertinib | Ulixertinib in Treating Patients With Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With MAPK Pathway Mutations (A Pediatric MATCH Treatment Trial) | Active, not recruiting | USA | 1 |
NCT03706274 | Phase I | CX-188 | PROCLAIM-CX-188: A Trial to Find Safe and Active Doses of an Investigational Drug CX-188 for Patients With Solid Tumors | Withdrawn | USA | 0 |
NCT03707093 | Phase I | ADG106 | Study of CD137 Agonist ADG106 With Advanced or Metastatic Solid Tumors and/or Non-Hodgkin Lymphoma | Completed | USA | 0 |
NCT03708328 | Phase I | RO7121661 | A Dose Escalation and Expansion Study of Lomvastomig, a PD-1/TIM-3 Bispecific Antibody, in Participants With Advanced and/or Metastatic Solid Tumors | Active, not recruiting | USA | FRA | ESP | 3 |
NCT03709680 | Phase I | Irinotecan + Palbociclib + Temozolomide | Study Of Palbociclib Combined With Chemotherapy In Pediatric Patients With Recurrent/Refractory Solid Tumors | Active, not recruiting | USA | ITA | GBR | FRA | ESP | DEU | CAN | BEL | 13 |
NCT03711058 | Phase Ib/II | Copanlisib + Nivolumab | Study of PI3Kinase Inhibition (Copanlisib) and Anti-PD-1 Antibody Nivolumab in Relapsed/Refractory Solid Tumors With Expansions in Mismatch-repair Proficient (MSS) Colorectal Cancer | Active, not recruiting | USA | 0 |
NCT03715504 | Phase I | TP-3654 | Phase I Study of TP-3654 in Patients With Advanced Solid Tumors | Completed | USA | 0 |
NCT03715933 | Phase I | INBRX-109 | Phase 1 Study of INBRX-109 in Subjects With Locally Advanced or Metastatic Solid Tumors Including Sarcomas | Recruiting | USA | 0 |
NCT03717415 | Phase Ib/II | Carboplatin + Rebastinib | A Study of Rebastinib (DCC-2036) in Combination With Carboplatin in Patients With Advanced or Metastatic Solid Tumors | Completed | USA | 0 |
NCT03718091 | Phase II | Berzosertib | M6620 (VX-970) in Selected Solid Tumors | Completed | USA | 0 |
NCT03721679 | Phase Ib/II | Cemiplimab + Poly ICLC Atezolizumab + Poly ICLC Pembrolizumab + Poly ICLC Durvalumab + Poly ICLC Nivolumab + Poly ICLC | Poly-ICLC (Hiltonol) and Anti-PD1 or Anti-PD-L1 | Terminated | USA | 0 |
NCT03724890 | Phase I | Avelumab + Peposertib | Study of Avelumab-M3814 Combinations | Completed | USA | 0 |
NCT03725436 | Phase I | ALRN-6924 + Paclitaxel | ALRN-6924 and Paclitaxel in Treating Patients With Advanced, Metastatic, or Unresectable Solid Tumors | Active, not recruiting | USA | 0 |
NCT03726294 | Phase I | NBM-BMX | A Safety and Pharmacokinetic Study of NBM-BMX Administered Orally to Patients With Advanced Cancer | Completed | USA | 0 |
NCT03729596 | Phase Ib/II | MGC018 MGC018 + Retifanlimab | MGC018 With or Without MGA012 in Advanced Solid Tumors | Terminated | USA | ESP | AUS | 1 |
NCT03735628 | Phase Ib/II | Copanlisib + Nivolumab | An Study to Evaluate the Safety and Efficacy of Copanlisib in Combination With Nivolumab in Patients With Advanced Solid Tumors | Completed | USA | CAN | 0 |
NCT03739931 | Phase I | mRNA-2752 mRNA-2752 + Tremelimumab Durvalumab + mRNA-2752 | Dose Escalation Study of mRNA-2752 for Intratumoral Injection to Patients With Advanced Malignancies | Active, not recruiting | USA | AUS | 1 |
NCT03742895 | Phase II | Olaparib | Efficacy and Safety of Olaparib (MK-7339) in Participants With Previously Treated, Homologous Recombination Repair Mutation (HRRm) or Homologous Recombination Deficiency (HRD) Positive Advanced Cancer (MK-7339-002 / LYNK-002) | Recruiting | USA | ITA | GBR | FRA | ESP | CAN | AUS | 14 |
NCT03744403 | Phase I | Sugemalimab | A Phase I Study of CS1001 in Advanced Solid Tumors | Completed | USA | 0 |
NCT03744468 | Phase Ib/II | BGB-A425 + Tislelizumab | Study of BGB-A425 in Combination With Tislelizumab in Advanced Solid Tumors | Recruiting | USA | ITA | FRA | ESP | AUS | 2 |
NCT03744715 | Phase II | Poziotinib | A Study to Allow Continued Treatment of Patients Who Have Participated in a Spectrum-Sponsored Poziotinib Study | Terminated | USA | 0 |
NCT03745326 | Phase Ib/II | Aldesleukin + anti-KRAS G12D mTCR cells + Cyclophosphamide + Fludarabine | Administering Peripheral Blood Lymphocytes Transduced With a Murine T-Cell Receptor Recognizing the G12D Variant of Mutated RAS in HLA-A*11:01 Patients | Recruiting | USA | 0 |
NCT03745989 | Phase I | MK-8353 + Selumetinib | Study of MK-8353 + Selumetinib in Advanced/Metastatic Solid Tumors (MK-8353-014) | Completed | USA | CAN | 1 |
NCT03746431 | Phase Ib/II | 225Ac-FPI-1434 | A Phase 1/2 Study of [225Ac]-FPI-1434 Injection | Recruiting | USA | CAN | AUS | 0 |
NCT03752398 | Phase I | Izuralimab | A Study of XmAb23104 in Subjects With Selected Advanced Solid Tumors (DUET-3) (DUET-3) | Active, not recruiting | USA | 0 |
NCT03756818 | Phase I | Mivavotinib + Paclitaxel | TAK-659 and Paclitaxel in Treating Patients With Advanced Solid Tumors | Completed | USA | 0 |
NCT03761017 | Phase I | MGD019 | MGD019 DART Protein in Unresectable/Metastatic Cancer | Active, not recruiting | USA | ESP | 3 |
NCT03761914 | Phase Ib/II | Galinpepimut-S Galinpepimut-S + Pembrolizumab Pembrolizumab Sargramostim | Galinpepimut-S in Combination With Pembrolizumab in Patients With Selected Advanced Cancers | Unknown status | USA | 0 |
NCT03762447 | Phase I | INCB086550 | A Study Exploring the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of INCB086550 in Participants With Advanced Solid Tumors | Completed | USA | ITA | GBR | FRA | BEL | 0 |
NCT03763149 | Phase I | IBI188 | A Study Evaluating the Safety, Tolerability, and Initial Efficacy of Recombinant Human Anti-cluster Differentiation Antigen 47 (CD47) Monoclonal Antibody Injection (IBI188) in Patients With Advanced Malignant Tumors and Lymphomas | Completed | USA | 0 |
NCT03767075 | Phase II | Atezolizumab | A Modular Multi-Basket Trial to Improve Personalized Medicine in Cancer Patients (Basket of Baskets) (BoB) | Recruiting | ITA | GBR | FRA | ESP | DEU | 2 |
NCT03767348 | Phase Ib/II | Nivolumab + RP1 RP1 | Study of RP1 Monotherapy and RP1 in Combination With Nivolumab (IGNYTE) | Recruiting | USA | GBR | FRA | ESP | DEU | 0 |
NCT03770494 | Phase I | LY3405105 | A Study of LY3405105 in Participants With Advanced Cancer | Terminated | USA | FRA | ESP | CAN | 1 |
NCT03775525 | Phase I | Study Evaluating GZ17-6.02 in Patients With Advanced Solid Tumors or Lymphoma (GEN602) | Active, not recruiting | USA | 0 | |
NCT03775850 | Phase Ib/II | EDP1503 EDP1503 + Pembrolizumab | A Study of EDP1503 in Patients With Colorectal Cancer, Breast Cancer, and Checkpoint Inhibitor Relapsed Tumors | Completed | USA | CAN | 0 |
NCT03780517 | Phase I | DS-5010 | Safety, Efficacy, and Tolerability of BOS172738 in Patients With Advanced Rearranged During Transfection (RET) Gene-Altered Tumors | Completed | USA | FRA | ESP | BEL | 3 |
NCT03781362 | Phase I | CPI-100 Capecitabine + CPI-100 | Study of CPI-100 in Patients With Advanced Tumors | Completed | USA | 0 |
NCT03783403 | Phase I | CC-95251 CC-95251 + Cetuximab | A Study of CC-95251, a Monoclonal Antibody Directed Against SIRP?, With Cetuximab in Subjects With Advanced Solid Cancers | Active, not recruiting | USA | ITA | GBR | FRA | ESP | CAN | AUS | 1 |
NCT03784677 | Phase I | SOR-C13 | SOR-C13 in Treating Patients With Advanced Refractory Solid Tumors | Completed | USA | 0 |
NCT03785249 | Phase Ib/II | Adagrasib Adagrasib + Afatinib Adagrasib + Cetuximab Adagrasib + Pembrolizumab | Phase 1/2 Study of MRTX849 in Patients With Cancer Having a KRAS G12C Mutation KRYSTAL-1 | Recruiting | USA | 1 |
NCT03786484 | Phase I | PBF 999 | Study of PBF-999 in Solid Tumour Advanced Cancer | Completed | ESP | 0 |
NCT03790488 | Phase I | Pimivalimab | Study of a PD-1 Inhibitor (JTX-4014) in Subjects With Solid Tumor Malignancies | Completed | USA | 0 |
NCT03792724 | Phase Ib/II | Nivolumab + Urelumab | Phase I-II Study of Intratumoral Urelumab Combined With Nivolumab in Patients With Solid Tumors (INTRUST) | Unknown status | ESP | 0 |
NCT03797326 | Phase II | Lenvatinib + Pembrolizumab | Efficacy and Safety of Pembrolizumab (MK-3475) Plus Lenvatinib (E7080/MK-7902) in Previously Treated Participants With Select Solid Tumors (MK-7902-005/E7080-G000-224/LEAP-005) | Active, not recruiting | USA | ITA | GBR | FRA | ESP | DEU | CAN | AUS | 9 |
NCT03797391 | Phase Ib/II | EMB-01 | A Dose Escalation With Expansion Study of EMB-01 in Participants With Advanced/Metastatic Solid Tumors | Recruiting | USA | 1 |
NCT03799003 | Phase I | ASP1951 | A Study of ASP1951 in Subjects With Advanced Solid Tumors | Completed | USA | CAN | 2 |
NCT03804515 | Phase I | Poziotinib | A Mass Balance and Pharmacokinetics Study of 14C-Labeled Poziotinib in Cancer Patients Suitable for Treatment With Poziotinib | Terminated | USA | 0 |
NCT03809624 | Phase II | INBRX-105 INBRX-105 + Pembrolizumab | Study of INBRX-105 and INBRX-105 With Pembrolizumab in Patients With Solid Tumors Including Head and Neck Cancer (PDL1x41BB) | Recruiting | USA | 0 |
NCT03810872 | Phase II | Afatinib + Paclitaxel | An Explorative Study of Afatinib in the Treatment of Advanced Cancer Carrying an EGFR, a HER2 or a HER3 Mutation | Unknown status | BEL | 0 |
NCT03811652 | Phase I | MEDI7247 | A Multiple Ascending Dose Study of MEDI7247 in Advanced or Metastatic Solid Tumors | Completed | USA | CAN | 0 |
NCT03815643 | Phase III | Avelumab | Avelumab Program Rollover Study | Active, not recruiting | USA | ITA | GBR | FRA | ESP | DEU | BEL | AUS | 14 |
NCT03815682 | Phase I | Pembrolizumab + RPTR-147 RPTR-147 | RPTR-147 in Patients With Selected Solid Tumors and Lymphomas | Terminated | USA | 0 |
NCT03816332 | Phase I | Ipilimumab + Nivolumab + Prednisone + Tacrolimus | Tacrolimus, Nivolumab, and Ipilimumab in Treating Kidney Transplant Recipients With Selected Unresectable or Metastatic Cancers | Active, not recruiting | USA | 0 |
NCT03816345 | Phase I | Nivolumab | Nivolumab in Treating Patients With Autoimmune Disorders and Advanced, Metastatic, or Unresectable Cancer | Recruiting | USA | CAN | 0 |
NCT03821233 | Phase I | ZW49 | A Dose Finding Study of ZW49 in Patients With HER2-Positive Cancers | Active, not recruiting | USA | CAN | AUS | 1 |
NCT03821935 | Phase I | ABBV-151 ABBV-151 + Budigalimab | Study to Determine the Safety, Tolerability, Pharmacokinetics and RP2D of ABBV-151 as a Single Agent and in Combination With ABBV-181 in Participants With Locally Advanced or Metastatic Solid Tumors | Recruiting | USA | FRA | ESP | CAN | BEL | AUS | 5 |
NCT03822117 | Phase II | Pemigatinib | Efficacy and Safety of Pemigatinib in Previously Treated Locally Advanced/Metastatic or Surgically Unresectable Solid Tumor Malignancies Harboring Activating FGFR Mutations or Translocations (FIGHT-207) | Terminated | USA | ITA | GBR | FRA | ESP | DEU | 5 |
NCT03829254 | Phase Ib/II | NUC-7738 NUC-7738 + Pembrolizumab | A Safety, Pharmacokinetic and Clinical Activity Study of NUC-7738 in Patients With Advanced Solid Tumours and Lymphoma | Recruiting | GBR | 0 |
NCT03829436 | Phase I | TPST-1120 Nivolumab + TPST-1120 Docetaxel + TPST-1120 Cetuximab + TPST-1120 | TPST-1120 as Monotherapy and in Combination With (Nivolumab, Docetaxel or Cetuximab) in Subjects With Advanced Cancers | Completed | USA | 0 |
NCT03829501 | Phase Ib/II | Atezolizumab + KY1044 KY1044 | Safety and Efficacy of KY1044 and Atezolizumab in Advanced Cancer | Active, not recruiting | USA | ITA | GBR | 3 |
NCT03830918 | Phase Ib/II | Niraparib + Temozolomide | Niraparib and Temozolomide in Treating Patients With Extensive-Stage Small Cell Lung Cancer With a Complete or Partial Response to Platinum-Based First-Line Chemotherapy | Recruiting | USA | 0 |
NCT03831295 | Phase I | BMS-986178 + SD-101 | SD-101 and BMS-986178 in Treating Patients With Advanced or Metastatic Solid Malignancies | Completed | USA | 0 |
NCT03832569 | Phase II | Pembrolizumab | Study of Pembrolizumab Following Surgery in Patients With Microsatellite Instability High (MSI-H) Solid Tumors | Recruiting | USA | 0 |
NCT03833427 | Phase I | Pembrolizumab + Selumetinib | Study of Selumetinib (MK-5618) in Combination With Pembrolizumab (MK-3475) in Participants With Advanced/Metastatic Solid Tumors (MK-5618-001) | Completed | USA | CAN | 0 |
NCT03834220 | Phase II | Debio 1347 | Basket Trial in Solid Tumors Harboring a Fusion of FGFR1, FGFR2 or FGFR3- (FUZE Clinical Trial) | Terminated | USA | GBR | FRA | ESP | AUT | AUS | 17 |
NCT03834662 | Phase I | BMS-986416 | A Trial of AVID200, a Transforming Growth Factor beta (TGFbeta) Inhibitor, in Patients Malignancies | Unknown status | USA | CAN | 0 |
NCT03834948 | Phase I | AO-176 | AO-176 in Multiple Solid Tumor Malignancies | Completed | USA | 0 |
NCT03834961 | Phase II | Larotrectinib | Larotrectinib in Treating Patients With Previously Untreated TRK Fusion Solid Tumors and TRK Fusion Relapsed Acute Leukemia | Active, not recruiting | USA | CAN | 0 |
NCT03835949 | Phase I | Atezolizumab + Uliledlimab | Study of TJ004309 in Combination With Atezolizumab (Tecentriq) in Patients With Advanced or Metastatic Cancer | Unknown status | USA | 0 |
NCT03836352 | Phase II | Maveropepimut-S + Pembrolizumab Cyclophosphamide + Maveropepimut-S + Pembrolizumab | Study of an Immunotherapeutic, DPX-Survivac, in Combination With Low Dose Cyclophosphamide & Pembrolizumab, in Subjects With Selected Advanced & Recurrent Solid Tumors | Active, not recruiting | USA | CAN | 0 |
NCT03837899 | Phase Ib/II | Durvalumab + Tremelimumab Durvalumab | Durvalumab and Tremelimumab for Pediatric Malignancies | Active, not recruiting | USA | ITA | GBR | FRA | ESP | DEU | 1 |
NCT03839342 | Phase II | Binimetinib + Encorafenib | Binimetinib and Encorafenib for the Treatment of Advanced Solid Tumors With Non-V600E BRAF Mutations (BEAVER) | Active, not recruiting | CAN | 0 |
NCT03841110 | Phase I | FT500 + Pembrolizumab Atezolizumab + FT500 FT500 + Nivolumab FT500 | FT500 as Monotherapy and in Combination With Immune Checkpoint Inhibitors in Subjects With Advanced Solid Tumors | Completed | USA | 0 |
NCT03842228 | Phase I | Copanlisib + Durvalumab + Olaparib | Testing the Combination of the Anti-cancer Drugs Copanlisib, Olaparib, and MEDI4736 (Durvalumab) in Patients With Advanced Solid Tumors With Selected Mutations | Active, not recruiting | USA | 0 |
NCT03842865 | Expanded access | FANG vaccine | Expanded Access of Vigil in Solid Tumors | Temporarily not available | USA | 0 |
NCT03843359 | Phase I | GSK3745417 GSK3745417 + Pembrolizumab | Phase 1 First Time in Humans (FTIH), Open Label Study of GSK3745417 Administered to Subjects With Advanced Solid Tumors | Active, not recruiting | USA | FRA | ESP | CAN | AUS | 3 |
NCT03843775 | Phase Ib/II | Binimetinib + Encorafenib | A Study of Binimetinib and Encorafenib in Advanced BRAF Mutant Cancers | Completed | USA | 0 |
NCT03845166 | Phase I | XL092 | A Study of XL092 in Subjects With Solid Tumors | Active, not recruiting | USA | ITA | GBR | FRA | ESP | DEU | BEL | AUS | 2 |
NCT03847649 | Phase II | Durvalumab Durvalumab + Prednisone | Durvalumab Retreatment in Patients Who Discontinued Prior Checkpoint Therapy Due to Immune Toxicity | Recruiting | CAN | 0 |
NCT03853109 | Phase I | AMG 404 | AMG 404 in Patients With Advanced Solid Tumors. | Completed | USA | GBR | ESP | CAN | BEL | AUS | 7 |
NCT03854227 | Phase I | PF-06939999 | A Dose Escalation Study Of PF-06939999 In Participants With Advanced Or Metastatic Solid Tumors | Terminated | USA | 0 |
NCT03859752 | Phase I | TR1801-ADC | TR1801-ADC in Patients With Tumors That Express c-Met | Suspended | USA | 0 |
NCT03860272 | Phase I | Botensilimab | Fc-Engineered Anti-CTLA-4 Monoclonal Antibody in Advanced Cancer | Recruiting | USA | GBR | 0 |
NCT03861403 | Phase Ib/II | Avelumab + Cyclophosphamide + TRX518 | A Dose Escalation and Expansion Study of TRX518 in Combination With Cyclophosphamide Plus Avelumab in Advanced Solid Tumors | Terminated | USA | 0 |
NCT03861793 | Phase I | ALKS 4230 + Pembrolizumab ALKS 4230 | A Dose Escalation and Cohort Expansion Study of Subcutaneously-Administered Cytokine (ALKS 4230) as a Single Agent and in Combination With Anti-PD-1 Antibody (Pembrolizumab) in Patients With Select Advanced or Metastatic Solid Tumors (ARTISTRY-2) | Completed | USA | ESP | CAN | 3 |
NCT03864042 | Phase I | Caffeine + Dextromethorphan + Losartan + Midazolam + Omeprazole Modafinil Bupropion + Rosuvastatin Binimetinib + Encorafenib | Pharmacokinetic Drug-drug Interaction Study of Encorafenib and Binimetinib on Probe Drugs in Patients With BRAF V600-mutant Melanoma or Other Advanced Solid Tumors | Active, not recruiting | USA | ESP | CAN | BEL | 1 |
NCT03868423 | Phase II | Brigatinib | Brigatinib in Treating Patients With ALK and ROS1 Gene Alterations and Locally Advanced or Metastatic Solid Cancers | Withdrawn | USA | 0 |
NCT03871348 | Phase I | SAR441000 Cemiplimab + SAR441000 | A First-in-Human Dose Escalation and Expansion Study to Evaluate Intratumoral Administration of SAR441000 as Monotherapy and in Combination With Cemiplimab in Patients With Advanced Solid Tumors | Terminated | USA | FRA | ESP | DEU | BEL | 1 |
NCT03872427 | Phase II | Telaglenastat | Testing Whether Cancers With Specific Mutations Respond Better to Glutaminase Inhibitor, Telaglenastat Hydrochloride, Anti-Cancer Treatment, BeGIN Study | Active, not recruiting | USA | 0 |
NCT03872947 | Phase I | Pembrolizumab + TRK-950 Carboplatin + Gemcitabine + TRK-950 Imiquimod + TRK-950 Paclitaxel + Ramucirumab + TRK-950 Nivolumab + TRK-950 Cisplatin + Gemcitabine + TRK-950 Fluorouracil + Irinotecan + Leucovorin + TRK-950 | A Study of TRK-950 in Combinations With Anti-Cancer Treatment Regimens in Patients With Advanced Solid Tumors | Recruiting | USA | FRA | 0 |
NCT03873883 | Phase I | EOS100850 + Pembrolizumab EOS100850 | First-in-Human Study of EOS100850 in Patients With Cancer | Active, not recruiting | USA | GBR | FRA | ESP | BEL | 1 |
NCT03875820 | Phase I | Defactinib + RO5126766 | Phase I Trial of Defactinib and VS-6766. (FRAME) | Active, not recruiting | GBR | 0 |
NCT03878095 | Phase II | Ceralasertib + Olaparib | Testing Olaparib and AZD6738 in IDH1 and IDH2 Mutant Tumors | Suspended | USA | 0 |
NCT03881488 | Phase I | CTX-471 | Study of CTX-471 in Patients Post PD-1/PD-L1 Inhibitors in Metastatic or Locally Advanced Malignancies | Recruiting | USA | 0 |
NCT03884556 | Phase I | Gemcitabine + Nab-paclitaxel + TTX-030 Docetaxel + TTX-030 Pembrolizumab + TTX-030 TTX-030 | TTX-030 Single Agent and in Combination With Immunotherapy or Chemotherapy for Patients With Advanced Cancers | Completed | USA | 0 |
NCT03886831 | Phase I | PRT543 | A Study of PRT543 in Participants With Advanced Solid Tumors and Hematologic Malignancies | Completed | USA | 0 |
NCT03889275 | Phase I | Durvalumab Durvalumab + MEDI5395 MEDI5395 | A Study of MEDI5395 in Combination With Durvalumab in Subjects With Select Advanced Solid Tumors | Completed | USA | GBR | 0 |
NCT03889795 | Phase I | Digoxin + Metformin + Simvastatin | Phase IB Metformin, Digoxin, Simvastatin in Solid Tumors | Recruiting | USA | 0 |
NCT03891953 | Phase I | DKY709 DKY709 + Spartalizumab | Study of Safety and Efficacy of DKY709 Alone or in Combination With PDR001 in Patients With Advanced Solid Tumors. | Active, not recruiting | USA | ESP | DEU | 3 |
NCT03893955 | Phase I | ABBV-368 + ABBV-927 + Nab-paclitaxel ABBV-368 + ABBV-927 ABBV-368 + ABBV-927 + Budigalimab ABBV-927 + Budigalimab + Carboplatin ABBV-927 + Carboplatin ABBV-368 + ABBV-927 + Carboplatin | A Study to Determine the Safety, Tolerability, Pharmacokinetics, and Preliminary Efficacy of ABBV-927 With ABBV-368, Budigalimab (ABBV-181) and/or Chemotherapy in Participants With Locally Advanced or Metastatic Solid Tumors | Active, not recruiting | USA | FRA | ESP | AUS | 2 |
NCT03894540 | Phase I | IACS-6274 IACS-6274 + Pembrolizumab IACS-6274 + Paclitaxel | A Phase I, Dose Escalation and Dose Expansion Study of IPN60090 in Patients With Advanced Solid Tumours | Terminated | USA | 0 |
NCT03894618 | Phase I | SL-279252 | SL-279252 (PD1-Fc-OX40L) in Subjects With Advanced Solid Tumors or Lymphomas | Active, not recruiting | USA | ESP | CAN | BEL | 0 |
NCT03895684 | Phase I | Seclidemstat | Phase 1 Trial of the LSD1 Inhibitor SP-2577 (Seclidemstat) in Patients With Advanced Solid Tumors | Completed | USA | 0 |
NCT03899792 | Phase Ib/II | Selpercatinib | A Study of Oral LOXO-292 (Selpercatinib) in Pediatric Participants With Advanced Solid or Primary Central Nervous System (CNS) Tumors (LIBRETTO-121) | Recruiting | USA | ITA | GBR | FRA | ESP | DEU | CAN | AUS | 3 |
NCT03905148 | Phase Ib/II | Lifirafenib + PD-0325901 | Study of the Safety and Pharmacokinetics of BGB-283 (Lifirfenib) and PD-0325901 (Mirdametinib) in Participants With Advanced or Refractory Solid Tumors | Recruiting | USA | AUS | 0 |
NCT03906331 | Expanded access | Selpercatinib | Expanded Access for the Treatment of Cancers With Rearranged During Transfection (RET) Activation | Available | USA | ITA | FRA | ESP | DEU | AUS | 6 |
NCT03906643 | Phase I | HS-201 | HS-201, an HSP90 Inhibitor-linked Verteporfin for Detection of Solid Malignancies | Withdrawn | USA | 0 |
NCT03907475 | Phase II | Durvalumab Durvalumab + Nab-paclitaxel Capecitabine + Durvalumab Durvalumab + Pegylated liposomal doxorubicin Durvalumab + Gemcitabine Durvalumab + Paclitaxel Carboplatin + Durvalumab | Durvalumab in Combination With Chemotherapy in Treating Patients With Advanced Solid Tumors, (DURVA+ Study) | Recruiting | USA | 0 |
NCT03907969 | Phase Ib/II | AZD7648 + Pegylated liposomal doxorubicin AZD7648 + Olaparib AZD7648 | A Clinical Trial to Evaluate AZD7648 Alone and in Combination With Other Anti-cancer Agents in Patients With Advanced Cancers | Completed | USA | GBR | 0 |
NCT03911557 | Phase II | Durvalumab + Tremelimumab | Durvalumab and Tremelimumab Combination in Somatically Hypermutated Recurrent Solid Tumors | Active, not recruiting | USA | 0 |
NCT03917381 | Phase Ib/II | GEN1046 | GEN1046 Safety Trial in Patients With Malignant Solid Tumors | Active, not recruiting | USA | ITA | ESP | 7 |
NCT03918278 | Phase I | MK-0482 MK-0482 + Pembrolizumab | A Study of MK-0482 as Monotherapy and in Combination With Pembrolizumab (MK-3475) in Participants With Advanced Solid Tumors (MK-0482-001) | Active, not recruiting | USA | ITA | ESP | CAN | AUS | 3 |
NCT03919292 | Phase Ib/II | Divalproex sodium + Neratinib | Neratinib + Valproate in Advanced Solid Tumors, w/Expansion Cohort in Ras-Mutated Ca | Recruiting | USA | 0 |
NCT03920839 | Phase I | Carboplatin + Paclitaxel + Retifanlimab Cisplatin + Gemcitabine + Retifanlimab Cisplatin + Pemetrexed Disodium + Retifanlimab Carboplatin + Pemetrexed Disodium + Retifanlimab | INCMGA00012 Plus Chemotherapy in Participants With Advanced Solid Tumors (POD1UM-105) | Withdrawn | 0 | |
NCT03922204 | Phase I | MCLA-145 | A Study of Bispecific Antibody MCLA-145 in Patients With Advanced or Metastatic Malignancies | Recruiting | USA | ESP | BEL | 1 |
NCT03928314 | Phase I | Nab-paclitaxel + ORIC-101 | Study of ORIC-101 in Combination With Anticancer Therapy | Terminated | USA | 0 |
NCT03931681 | Phase I | OKI-179 | A Study of OKI-179 in Patients With Solid Tumors | Completed | USA | 0 |
NCT03934359 | Phase I | DN1508052 | A Study to Evaluate the Safety, Tolerability of DN1508052-01 in Advanced Solid Tumors | Completed | USA | 0 |
NCT03934372 | Phase Ib/II | Ponatinib | Safety and Efficacy of Ponatinib for Treatment of Pediatric Recurrent or Refractory Leukemias, Lymphomas or Solid Tumors | Recruiting | ITA | GBR | FRA | ESP | DEU | BEL | 3 |
NCT03934814 | Phase I | Lemzoparlimab Lemzoparlimab + Pembrolizumab Lemzoparlimab + Rituximab | Study of TJ011133 Subjects With Relapsed/Refractory Advanced Solid Tumors and Lymphoma | Completed | USA | 1 |
NCT03936465 | Phase I | BMS986158 CC-90010 | Study of the Bromodomain (BRD) and Extra-Terminal Domain (BET) Inhibitors BMS-986158 and BMS-986378 in Pediatric Cancer | Recruiting | USA | CAN | 0 |
NCT03936959 | Phase I | LY3434172 | A Study of LY3434172, a PD-1 and PD-L1 Bispecific Antibody, in Advanced Cancer | Completed | USA | FRA | BEL | AUS | 1 |
NCT03941262 | Phase I | Avelumab + SNK01 SNK01 Pembrolizumab + SNK01 | Safety of SNK01 in Subjects With Pathologically Confirmed Metastatic and/or Unresectable Cancer Refractory to Conventional Therapy | Completed | USA | 0 |
NCT03943004 | Phase I | DFP-14927 | Trial of DFP-14927 in Advanced Solid Tumors | Recruiting | USA | 0 |
NCT03946800 | Phase I | MEDI1191 Durvalumab + MEDI1191 | A Study of MEDI1191 Alone and in Combination With Durvalumab in Subjects With Advanced Solid Tumors | Completed | USA | ESP | 0 |
NCT03947385 | Phase Ib/II | IDE196 | Study of IDE196 in Patients With Solid Tumors Harboring GNAQ/11 Mutations or PRKC Fusions | Recruiting | USA | CAN | AUS | 0 |
NCT03948763 | Phase I | mRNA 5671 mRNA 5671 + Pembrolizumab | A Study of mRNA-5671/V941 as Monotherapy and in Combination With Pembrolizumab (V941-001) | Completed | USA | AUS | 5 |
NCT03950297 | Phase I | 609A | Phase 1, First in Human, Open-Label, Dose-Escalation Study of 609A | Unknown status | USA | 0 |
NCT03950570 | Phase I | ORIN1001 + Paclitaxel ORIN1001 | ORIN1001 in Patients With Advanced Solid Tumors and Relapsed Refractory Metastatic Breast Cancer | Active, not recruiting | USA | 0 |
NCT03951116 | Phase I | FCN-437 | Study of FCN-437c in Patients With Advanced Solid Tumors (FCN-437c) | Completed | USA | 0 |
NCT03953235 | Phase Ib/II | GRT-C903 + GRT-R904 + Ipilimumab + Nivolumab | A Study of a Personalized Cancer Vaccine Targeting Shared Neoantigens | Completed | USA | 0 |
NCT03953742 | Phase I | CPI-200 | Study of CPI-200 in Patients With Advanced Tumors | Completed | USA | 0 |
NCT03954067 | Phase I | ASP9801 | A Study of an Intratumoral Oncolytic Virus in Patients With Advanced Metastatic Solid Tumors | Active, not recruiting | USA | 0 |
NCT03954704 | Phase I | Fluorouracil + GS-1423 + Leucovorin + Oxaliplatin GS-1423 | Study of GS-1423 in Participants With Advanced Solid Tumors | Terminated | USA | 0 |
NCT03956680 | Phase I | Ipilimumab + Nivolumab BMS-986301 | An Investigational Immunotherapy Study of BMS-986301 Alone or in Combination With Nivolumab, and Ipilimumab in Participants With Advanced Solid Cancers | Active, not recruiting | USA | CAN | 0 |
NCT03964233 | Phase I | BI 907828 + Ezabenlimab + Miptenalimab BI 907828 + Ezabenlimab | A Study in Patients With Different Types of Advanced Cancer (Solid Tumors) to Test Different Doses of BI 907828 in Combination With BI 754091 (Ezabenlimab) and BI 754111 or BI 907828 in Combination With BI 754091 (Ezabenlimab) | Recruiting | USA | GBR | FRA | ESP | DEU | BEL | AUS | 4 |
NCT03964727 | Phase II | Sacituzumab govitecan-hziy | A Study of Sacituzumab Govitecan in Metastatic Solid Tumors (Tropics-03) | Active, not recruiting | USA | FRA | ESP | CAN | BEL | AUS | 2 |
NCT03965845 | Phase Ib/II | Palbociclib + Telaglenastat | A Study of Telaglenastat (CB-839) in Combination With Palbociclib in Patients With Solid Tumors | Completed | USA | 0 |
NCT03967093 | Phase I | BXQ-350 | A Study of BXQ-350 in Children and Young Adults With Relapsed Solid Tumors | Terminated | USA | 0 |
NCT03967938 | Phase II | Olaparib | Efficacy of Olaparib in Advanced Cancers Occurring in Patients With Germline Mutations or Somatic Tumor Mutations in Homologous Recombination Genes (1-2018 BSMO) | Recruiting | BEL | 0 |
NCT03968653 | Phase I | Carboplatin + Debio 0123 | Study of Oral Debio 0123 in Combination With Carboplatin in Participants With Advanced Solid Tumors | Recruiting | ESP | 1 |
NCT03975387 | Phase Ib/II | ASTX295 | Study of ASTX295 in Patients With Solid Tumors With Wild-Type p53 | Active, not recruiting | USA | 0 |
NCT03976050 | Phase I | Tunlametinib | Phase I Study of HL-085 in Patients With Advanced Solid Tumors | Terminated | USA | 0 |
NCT03977467 | Phase II | Atezolizumab + Carboplatin Atezolizumab + Tiragolumab Atezolizumab + Cisplatin Atezolizumab + Bevacizumab + Carboplatin Atezolizumab + Bevacizumab + Cisplatin | Atezolizumab and Tiragolumab in Patients With NSCLC or Advanced Solid Tumors Having Had Prior Treatment With a PD-1 Inhibitor | Active, not recruiting | USA | 0 |
NCT03986606 | Phase I | PSB205 | A Study of PSB205 in Subjects With Advanced Solid Tumors | Unknown status | USA | 0 |
NCT03987685 | Phase I | HM30181A + Topotecan | Evaluate Oral Topotecan With HM30181A Monotherapy in Patients With Advanced Malignancies | Completed | USA | GBR | 0 |
NCT03989115 | Phase Ib/II | Cobimetinib + RMC-4630 Osimertinib + RMC-4630 | Dose-Escalation/Expansion of RMC-4630 and Cobimetinib in Relapsed/Refractory Solid Tumors and RMC-4630 and Osimertinib in EGFR Positive Locally Advanced/Metastatic NSCLC | Completed | USA | 1 |
NCT03990233 | Phase I | Effi-DEM Effi-DEM + Ezabenlimab | A Trial of BI 765063 Monotherapy and in Combination With BI 754091 in Patients With Advanced Solid Tumours | Active, not recruiting | FRA | BEL | 0 |
NCT03990454 | Phase I | SLC-391 | Safety Study of SLC-391 in Subjects With Solid Tumors | Completed | CAN | 0 |
NCT03992131 | Phase Ib/II | Lucitanib + Rucaparib Rucaparib + Sacituzumab govitecan-hziy | A Study to Evaluate Rucaparib in Combination With Other Anticancer Agents in Patients With a Solid Tumor (SEASTAR) | Terminated | USA | 0 |
NCT03993379 | Phase II | CX-072 | PROCLAIM: CX-072-002: Study of PD-L1 Probody Therapeutic CX-072 in Combination With Other Anticancer Therapy in Adults With Solid Tumors | Terminated | USA | ESP | AUS | 2 |
NCT03993873 | Phase Ib/II | TPX-0022 | Study of TPX-0022 in Patients With Advanced NSCLC, Gastric Cancer or Solid Tumors Harboring Genetic Alterations in MET (SHIELD-1) | Active, not recruiting | USA | FRA | ESP | 2 |
NCT03994601 | Phase Ib/II | BMS-986288 BMS-986288 + Nivolumab | An Investigational Immunotherapy Study of BMS-986288 Alone and in Combination With Nivolumab in Advanced Solid Cancers | Recruiting | USA | ITA | FRA | ESP | CAN | 2 |
NCT03994796 | Phase II | Abemaciclib GDC-0084 Entrectinib | Genetic Testing in Guiding Treatment for Patients With Brain Metastases | Recruiting | USA | 0 |
NCT03995472 | Phase I | SHR-1316 + SHR1501 | A Study of SHR-1501 Combined With SHR-1316 in Patients With Advanced Tumors | Completed | AUS | 1 |
NCT04001101 | Phase II | unspecified PD-1 antibody | Anti-PD-1 +/- RT for MSI-H Solid Tumors | Withdrawn | USA | 0 |
NCT04003623 | Phase II | Pemigatinib | Efficacy and Safety of Pemigatinib in Participants With Solid Tumors With FGFR Mutations or Translocations (FIGHT-208) | Terminated | USA | 0 |
NCT04006301 | Phase I | JNJ-74699157 | First-in-Human Study of JNJ-74699157 in Participants With Tumors Harboring the KRAS G12C Mutation | Completed | USA | FRA | 0 |
NCT04007744 | Phase I | Pembrolizumab + Sonidegib | Sonidegib and Pembrolizumab in Treating Patients With Advanced Solid Tumors | Recruiting | USA | 0 |
NCT04008797 | Phase I | Lenvatinib E7386 + Lenvatinib | A Study of E7386 in Combination With Other Anticancer Drug in Participants With Solid Tumor | Recruiting | USA | FRA | 3 |
NCT04009681 | Phase Ib/II | THOR-707 + unspecified PD-L1 antibody THOR-707 + unspecified PD-1 antibody THOR-707 THOR-707 + unspecified CTLA4 antibody | A Study Evaluating Safety and Therapeutic Activity of THOR-707 in Adult Subjects With Advanced or Metastatic Solid Tumors (THOR-707-101) | Recruiting | USA | ESP | AUS | 3 |
NCT04020185 | Phase Ib/II | IMSA101 + unspecified PD-L1 antibody IMSA101 + unspecified PD-1 antibody IMSA101 | Safety and Efficacy Study of IMSA101 in Refractory Malignancies | Completed | USA | 0 |
NCT04021043 | Phase Ib/II | BMS-986156 + Ipilimumab + Nivolumab BMS-986156 + Nivolumab | BMS-986156, Ipilimumab, and Nivolumab With or Without Stereotactic Body Radiation Therapy in Treating Patients With Advanced or Metastatic Lung/Chest or Liver Cancers | Active, not recruiting | USA | 0 |
NCT04029688 | Phase Ib/II | Idasanutlin + Venetoclax Cyclophosphamide + Idasanutlin + Topotecan Cytarabine + Fludarabine + Idasanutlin Cytarabine + Hydrocortisone + Methotrexate Cytarabine Methotrexate Idasanutlin Cyclophosphamide + Idasanutlin | A Study Evaluating the Safety, Tolerability, Pharmacokinetics, and Preliminary Activity of Idasanutlin in Combination With Either Chemotherapy or Venetoclax in the Treatment of Pediatric and Young Adult Participants With Relapsed/Refractory Acute Leukemias or Solid Tumors | Recruiting | USA | GBR | FRA | ESP | CAN | 1 |
NCT04029922 | Phase I | MT-5111 | Study of MT-5111 in HER2-positive Solid Tumors (MT-5111) | Terminated | USA | AUS | 1 |
NCT04034238 | Phase I | LMB-100 + Tofacitinib | Mesothelin-Targeted Immunotoxin LMB-100 in Combination With Tofacitinib in Persons With Previously Treated Pancreatic Adenocarcinoma, Cholangiocarcinoma and Other Mesothelin Expressing Solid Tumors | Completed | USA | 0 |
NCT04036682 | Phase Ib/II | Zipalertinib | A Phase 1/2 Trial of CLN-081 in Patients With Non-Small Cell Lung Cancer (REZILIENT1) | Recruiting | USA | 7 |
NCT04042116 | Phase Ib/II | Lucitanib + Nivolumab | A Study to Evaluate Lucitanib in Combination With Nivolumab in Patients With a Solid Tumor | Suspended | USA | ITA | ESP | DEU | BEL | AUT | 0 |
NCT04045496 | Phase I | A First-in-Human, Phase 1 Study of JAB-3312 in Adult Patients With Advanced Solid Tumors | Unknown status | USA | 0 | |
NCT04047290 | Phase I | Ivonescimab | A Study of AK112, a PD-1/VEGF Bispecific Antibody, for Advanced Solid Tumors | Recruiting | AUS | 0 |
NCT04047862 | Phase I | BGBA1217 + Tislelizumab BGBA1217 + Cisplatin + Pemetrexed Disodium + Tislelizumab BGBA1217 + Carboplatin + Pemetrexed Disodium + Tislelizumab BGBA1217 + Cisplatin + Paclitaxel + Tislelizumab BGBA1217 + Carboplatin + Paclitaxel + Tislelizumab BGBA1217 + Carboplatin + Nab-paclitaxel + Tislelizumab BGBA1217 + Capecitabine + Tislelizumab BGBA1217 + Cisplatin + Etoposide + Tislelizumab BGBA1217 + Cisplatin + Fluorouracil + Tislelizumab BGBA1217 + Carboplatin + Etoposide + Tislelizumab BGBA1217 + Capecitabine + Oxaliplatin + Tislelizumab | Study of Ociperlimab (BGB-A1217) in Combination With Tislelizumab in Advanced Solid Tumors | Active, not recruiting | USA | AUS | 2 |
NCT04049617 | Phase Ib/II | Evixapodlin | Safety, Tolerability, Pharmacokinetics, and Efficacy of GS-4224 in Participants With Advanced Solid Tumors | Terminated | USA | 1 |
NCT04050709 | Phase I | PD-L1.t-haNK cells | QUILT 3.064: PD-L1 t-haNK In Subjects With Locally Advanced Or Metastatic Solid Cancers | Active, not recruiting | USA | 0 |
NCT04053673 | Phase I | RBN-2397 | RBN-2397, an Oral PARP7 Inhibitor, in Patients With Solid Tumors , FIH, MAD Study | Recruiting | USA | ESP | 0 |
NCT04056910 | Phase II | Ivosidenib + Nivolumab | Ivosidenib (AG-120) With Nivolumab in IDH1 Mutant Tumors | Completed | USA | 0 |
NCT04058756 | Phase I | Spartalizumab | Rollover Study for Continued Safety and Tolerability in Subjects Treated With Spartalizumab Alone or in Combination With Other Study Treatments | Recruiting | USA | ITA | FRA | ESP | DEU | CAN | BEL | 10 |
NCT04059588 | Phase I | 2141 V-11 | A Study Investigating the Safety and Tolerability of an Immune Treatment in Cancer Patients With Lesions to the Skin | Completed | USA | 0 |
NCT04064359 | Phase I | MEN1309 | Safety and Preliminary Efficacy of OBT076 in Recurrent/Metastatic CD205+ Solid Tumors | Recruiting | USA | FRA | ESP | BEL | 1 |
NCT04068194 | Phase Ib/II | Avelumab Avelumab + Peposertib | Testing the Combination of New Anti-cancer Drug Nedisertib With Avelumab and Radiation Therapy for Advanced/Metastatic Solid Tumors and Hepatobiliary Malignancies | Recruiting | USA | 0 |
NCT04069026 | Phase I | BAY2416964 | A First-in-Humans Dose Finding Study for an Aryl Hydrocarbon Receptor Inhibitor (AhRi) in Patients With Advanced Cancer | Completed | USA | GBR | ESP | DEU | CAN | 0 |
NCT04074967 | Phase Ib/II | Ipilimumab + Pexmetinib Nivolumab + Pexmetinib | Study of ARRY-614 Plus Either Nivolumab or Ipilimumab | Active, not recruiting | USA | 0 |
NCT04078152 | FDA approved | Durvalumab | Durvalumab Long-Term Safety and Efficacy Study (WAVE) | Active, not recruiting | USA | GBR | FRA | ESP | DEU | CAN | BEL | AUS | 23 |
NCT04082572 | Phase II | Pembrolizumab | Pembrolizumab Before Surgery for the Treatment of Mismatch Repair Deficient Locally Advanced Solid Cancers | Active, not recruiting | USA | 0 |
NCT04083599 | Phase Ib/II | GEN1042 | GEN1042 Safety Trial in Subjects With Malignant Solid Tumors | Recruiting | USA | ITA | GBR | FRA | ESP | DEU | 6 |
NCT04083976 | Phase II | Erdafitinib | A Study of Erdafitinib in Participants With Advanced Solid Tumors and Fibroblast Growth Factor Receptor (FGFR) Gene Alterations (RAGNAR) | Active, not recruiting | USA | ITA | GBR | FRA | ESP | DEU | BEL | AUS | 7 |
NCT04084366 | Phase Ib/II | OBI-999 | Phase 1/2 Study of OBI-999 in Patients With Advanced Solid Tumors | Terminated | USA | 0 |
NCT04084951 | Phase I | SQZ-PBMC-HPV Atezolizumab + SQZ-PBMC-HPV | Study of SQZ-PBMC-HPV in Patients With HPV16+ Recurrent, Locally Advanced or Metastatic Solid Tumors | Completed | USA | DEU | CAN | 0 |
NCT04087018 | Phase I | Zimberelimab | Study to Evaluate Safety and Clinical Activity of AB122 in Biomarker Selected Participants With Advanced Solid Tumors | Active, not recruiting | USA | 0 |
NCT04089449 | Phase I | PRT811 | A Study of PRT811 in Participants With Advanced Solid Tumors, Gliomas and Myelofibrosis | Completed | USA | 0 |
NCT04089527 | Phase I | FT-1101 | Study to Evaluate the Safety, Tolerability, Pharmacokinetic and Pharmacodynamic of CC-95775 in Subjects With Advanced Solid Tumors and Relapsed/Refractory Non-Hodgkin Lymphoma | Completed | FRA | ESP | 0 |
NCT04094610 | Phase Ib/II | Repotrectinib | A Study of Repotrectinib in Pediatric and Young Adult Subjects Harboring ALK, ROS1, OR NTRK1-3 Alterations | Recruiting | USA | ITA | GBR | FRA | ESP | CAN | AUS | 4 |
NCT04095273 | Phase I | BAY1895344 + Pembrolizumab | Study to Test How Well Patients With Advanced Solid Tumors Respond to Treatment With the ATR Inhibitor BAY1895344 in Combination With Pembrolizumab, to Find the Optimal Dose for Patients, How the Drug is Tolerated and the Way the Body Absorbs, Distributes and Discharges the Drug | Completed | USA | GBR | ESP | DEU | 1 |
NCT04096638 | Phase I | Nivolumab + SB 11285 SB 11285 | Evaluating Safety and Efficacy of SB 11285 Alone and in Combination With Nivolumab in Patients With Advanced Solid Tumors | Recruiting | USA | 0 |
NCT04098068 | Phase II | Pembrolizumab | Study of MK-3475 (Pembrolizumab) in Patients With Microsatellite Unstable (MSI) Tumors (Cohort D) | Active, not recruiting | USA | 0 |
NCT04099277 | Phase I | LY3435151 + Pembrolizumab LY3435151 | A Study of LY3435151 in Participants With Solid Tumors | Terminated | USA | 1 |
NCT04101357 | Phase Ib/II | BNT411 Atezolizumab + BNT411 + Carboplatin + Etoposide | Safety, Pharmacokinetics, Pharmacodynamics, and Preliminary Efficacy Trial of BNT411 | Active, not recruiting | USA | GBR | ESP | DEU | 0 |
NCT04104776 | Phase Ib/II | Tulmimetostat Irinotecan + Tulmimetostat | A Study of CPI-0209 in Patients With Advanced Solid Tumors | Recruiting | USA | ITA | GBR | FRA | ESP | 2 |
NCT04105335 | Phase I | CEBPA-51 + Pembrolizumab | A Study of MTL-CEBPA in Combination With a PD-1 Inhibitor in Patients With Advanced Solid Tumours (TIMEPOINT) (TIMEPOINT) | Active, not recruiting | GBR | 0 |
NCT04111107 | Phase II | Precision Medicine for Patients With Identified Actionable Mutations | Terminated | USA | 0 | |
NCT04111445 | Phase I | ADG116 | Study of ADG116 in Patients With Advanced/Metastatic Solid Tumors | Terminated | USA | 0 |
NCT04111458 | Phase I | BI 1701963 BI 1701963 + Trametinib | A Study to Test Different Doses of BI 1701963 Alone and Combined With Trametinib in Patients With Different Types of Advanced Cancer (Solid Tumours With KRAS Mutation) | Active, not recruiting | USA | DEU | 1 |
NCT04112498 | Phase I | Nivolumab + Relatlimab + rHuPH20 | A Phase 1, Bioavailability Study of Relatlimab in Combination With Nivolumab | Completed | USA | 0 |
NCT04114136 | Phase II | Nivolumab Metformin + Nivolumab Pembrolizumab Metformin + Pembrolizumab Pembrolizumab + Rosiglitazone Nivolumab + Rosiglitazone | Anti-PD-1 mAb Plus Metabolic Modulator in Solid Tumor Malignancies | Recruiting | USA | 0 |
NCT04116320 | Phase I | unspecified PD-1 antibody Imiquimod Imiquimod + unspecified PD-1 antibody | Focused Ultrasound Ablation and PD-1 Antibody Blockade in Advanced Solid Tumors (AM-003) | Active, not recruiting | USA | 0 |
NCT04116541 | Phase II | Alectinib Cabozantinib Ribociclib + Siremadlin | A Study Evaluating the Activity of Anti-cancer Treatments Targeting Tumor Molecular Alterations/Characteristics in Advanced / Metastatic Tumors. (MegaMOST) | Recruiting | FRA | 0 |
NCT04116710 | Phase I | HS-110 + HS-130 | A Phase 1 Study of HS130 in Combination With Viagenpumatucel-L (HS110) in Patients With Solid Tumors | Completed | USA | 0 |
NCT04121442 | Phase Ib/II | Isunakinra + unspecified PD-1 antibody Isunakinra Isunakinra + unspecified PD-L1 antibody | Isunakinra Alone and in Combination With a PD-1/PD-L1 Inhibitor in Patients With Solid Tumors | Recruiting | USA | 0 |
NCT04121676 | Phase I | AGEN2373 | A Study in Subjects With Advanced Cancer | Recruiting | USA | 0 |
NCT04122339 | Phase I | MAX-10181 | MAX-10181 Given Orally to Patients With Advanced Solid Tumor | Unknown status | AUS | 0 |
NCT04122625 | Phase Ib/II | Nivolumab + Xevinapant | Study to Assess Safety and Efficacy of the Second Mitochondrial-derived Activator of Caspases (SMAC) Mimetic Debio 1143 (SMARTPLUS-106) | Completed | USA | FRA | ESP | 0 |
NCT04123366 | Phase II | Olaparib + Pembrolizumab | Study of Olaparib (MK-7339) in Combination With Pembrolizumab (MK-3475) in the Treatment of Homologous Recombination Repair Mutation (HRRm) and/or Homologous Recombination Deficiency (HRD)-Positive Advanced Cancer (MK-7339-007/KEYLYNK-007) | Active, not recruiting | USA | ITA | FRA | ESP | DEU | CAN | AUS | 16 |
NCT04128423 | Phase I | AMV-564 | Study of AMV564 in Subjects With Advanced Solid Tumors | Unknown status | USA | 0 |
NCT04130516 | Phase Ib/II | LNS8801 LNS8801 + Pembrolizumab | Study Assessing MTD, Safety, Tolerability, PK and Anti-tumor Effects of LNS8801alone and With Pembrolizumab | Recruiting | USA | 0 |
NCT04130542 | Phase I | LVGN6051 | Phase 1 Trial of LVGN6051 as Single Agent and in Combination Therapy in Advanced or Metastatic Malignancy | Recruiting | USA | 0 |
NCT04135352 | Phase I | Pembrolizumab + V938 | A Study of Intratumoral/Intralesional Administration of V938 in Combination With Pembrolizumab (MK-3475) in Participants With Advanced/Metastatic or Recurrent Malignancies (V938-001) | Terminated | USA | CAN | 1 |
NCT04136834 | Phase I | Pegtomarginase | A Phase I Open-label Study for Subjects With Advanced Malignancies (PT01) | Unknown status | USA | 0 |
NCT04137900 | Phase I | Icatolimab | Safety, Tolerability and Pharmacokinetics of a Monoclonal Antibody Specific to B-and T-Lymphocyte Attenuator (BTLA) for Injection in Subjects With Advanced Malignancies | Recruiting | USA | 0 |
NCT04140500 | Phase I | RO7247669 | Dose Escalation Study of a PD1-LAG3 Bispecific Antibody in Patients With Advanced and/or Metastatic Solid Tumors | Recruiting | USA | GBR | ESP | 10 |
NCT04140526 | Phase Ib/II | ONC-392 ONC-392 + Pembrolizumab | Safety, PK and Efficacy of ONC-392 in Monotherapy and in Combination of Anti-PD-1 in Advanced Solid Tumors and NSCLC | Recruiting | USA | AUS | 0 |
NCT04143711 | Phase Ib/II | DF1001 DF1001 + Pembrolizumab | Study of DF1001 in Patients With Advanced Solid Tumors | Recruiting | USA | FRA | BEL | 2 |
NCT04143789 | Phase Ib/II | AP-002 | Evaluation of AP-002 in Patients With Solid Tumors | Unknown status | USA | 0 |
NCT04144140 | Phase I | E7766 | Study of Intratumorally Administered Stimulator of Interferon Genes (STING) Agonist E7766 in Participants With Advanced Solid Tumors or Lymphomas - INSTAL-101 | Terminated | USA | GBR | FRA | ESP | 1 |
NCT04147234 | Phase I | BI 1387446 BI 1387446 + Ezabenlimab | A Study to Find the Best Dose of BI 1387446 Alone or in Combination With BI 754091 in Patients With Different Types of Advanced or Metastatic Cancer (Solid Tumors) | Active, not recruiting | USA | GBR | ESP | 0 |
NCT04147247 | Phase I | BI 905681 | A Trial to Find the Safe Dose for BI 905681 in Patients With Incurable Tumours or Tumours That Have Spread | Completed | USA | 0 |
NCT04156100 | Phase I | AGEN1223 | A Study in Subjects With Advanced Solid Tumors | Terminated | USA | 0 |
NCT04157517 | Phase I | TAK-573 | A Safety, Tolerability, Pharmacokinetics (PK), and Pharmacodynamics Study | Completed | USA | AUS | 0 |
NCT04157985 | Phase III | Nivolumab Ipilimumab Pembrolizumab Atezolizumab | Evaluation of the Length of Treatment With PD-1/PD-L1 Inhibitors in Patients With Advanced Solid Tumors | Recruiting | USA | 0 |
NCT04158336 | Phase Ib/II | ZN-c3 Talazoparib + ZN-c3 Pembrolizumab + ZN-c3 | A Study of ZN-c3 in Participants With Solid Tumors | Recruiting | USA | 0 |
NCT04158583 | Phase I | RO7296682 | A Study to Evaluate the Safety and Tolerability of RO7296682 in Participants With Advanced Solid Tumors. | Terminated | ESP | CAN | BEL | AUS | 1 |
NCT04161391 | Phase Ib/II | TPX-0046 | Study of TPX-0046, A RET/SRC Inhibitor in Adult Subjects With Advanced Solid Tumors Harboring RET Fusions or Mutations | Terminated | USA | 1 |
NCT04164199 | Phase III | Pamiparib + Tislelizumab Pemetrexed Disodium + Tislelizumab Tislelizumab Capecitabine + Tislelizumab Pamiparib | Study of Tislelizumab and/or Pamiparib Containing Treatments in Participants With Advanced Malignancies | Enrolling by invitation | 4 | |
NCT04165031 | Phase Ib/II | Cetuximab + LY3499446 Erlotinib + LY3499446 LY3499446 Abemaciclib + LY3499446 Docetaxel | A Study of LY3499446 in Participants With Advanced Solid Tumors With KRAS G12C Mutation | Terminated | USA | AUS | 0 |
NCT04165330 | Phase Ib/II | Anlotinib + Nivolumab | Evaluation of AL3818 in Combination With Nivolumab in Solid Tumors | Active, not recruiting | USA | 0 |
NCT04165772 | Phase II | Dostarlimab-gxly + Fluorouracil Dostarlimab-gxly Capecitabine + Dostarlimab-gxly | Study of Induction PD-1 Blockade in Subjects With Locally Advanced Mismatch Repair Deficient Solid Tumors | Recruiting | USA | 0 |
NCT04167137 | Phase I | SYNB1891 Atezolizumab + SYNB1891 | Safety and Tolerability of SYNB1891 Injection Alone or in Combination With Atezolizumab in Adult Subjects | Unknown status | USA | 0 |
NCT04170153 | Phase I | M1774 | M1774 in Participants With Metastatic or Locally Advanced Unresectable Solid Tumors | Recruiting | USA | GBR | ESP | 2 |
NCT04171219 | Phase II | Pembrolizumab + Talabostat mesylate | Talabostat and Pembrolizumab for the Treatment of Advanced Solid Cancers | Active, not recruiting | USA | 0 |
NCT04171700 | Phase II | Rucaparib | A Study to Evaluate Rucaparib in Patients With Solid Tumors and With Deleterious Mutations in HRR Genes (LODESTAR) | Terminated | USA | 0 |
NCT04172597 | Phase II | Poziotinib | A Study of Poziotinib in Patients With EGFR or HER2 Activating Mutations in Advanced Malignancies | Terminated | USA | 0 |
NCT04180215 | Phase Ib/II | HB-201 + HB-202 HB-201 + Nivolumab HB-201 HB-201 + HB-202 + Nivolumab | A Study of TheraT Vector(s) Expressing HPV 16+ in Patients With HPV 16+ Confirmed Cancers | Recruiting | USA | ESP | 1 |
NCT04180371 | Phase Ib/II | BT5528 + Nivolumab BT5528 | Study BT5528-100 in Patients With Advanced Solid Tumors Associated With EphA2 Expression | Recruiting | USA | GBR | ESP | BEL | 1 |
NCT04184869 | Phase I | Belinostat Atazanavir + Belinostat | Extension Study for Patients Who Had Not Met Criteria for Discontinuation in Previous Sponsored Belinostat Trials | Completed | USA | 0 |
NCT04185883 | Phase Ib/II | Fluorouracil + Irinotecan + Panitumumab + Sotorasib AMG 404 + Sotorasib Carboplatin + Docetaxel + Paclitaxel + Pembrolizumab + Pemetrexed Disodium + Sotorasib Sotorasib + TNO155 Atezolizumab + Sotorasib Pembrolizumab + Sotorasib Sotorasib Everolimus + Sotorasib Bevacizumab-awwb + Fluorouracil + Oxaliplatin + Sotorasib Bevacizumab-awwb + Fluorouracil + Irinotecan + Sotorasib BI 1701963 + Sotorasib Palbociclib + Sotorasib Afatinib + Sotorasib RMC-4630 + Sotorasib Panitumumab + Sotorasib + Trametinib | Sotorasib Activity in Subjects With Advanced Solid Tumors With KRAS p.G12C Mutation (CodeBreak 101) | Recruiting | USA | ITA | GBR | ESP | DEU | CAN | BEL | AUT | AUS | 4 |
NCT04186637 | Phase I | ALPN-202 | An Open-label Study of ALPN-202 in Subjects With Advanced Malignancies (NEON-1) | Terminated | USA | AUS | 0 |
NCT04189445 | Phase II | Futibatinib | Futibatinib in Patients With Specific FGFR Aberrations | Active, not recruiting | USA | ITA | GBR | FRA | ESP | DEU | BEL | 8 |
NCT04190628 | Phase I | ABM-1310 ABM-1310 + Cobimetinib | Safety and Tolerability of ABM-1310 in Patients With Advanced Solid Tumors | Active, not recruiting | USA | 0 |
NCT04192344 | Phase I | ABSK021 | A Study to Assess the Safety, Tolerability, and Pharmacokinetics of ABSK021 in Patients With Advanced Solid Tumor | Recruiting | USA | 0 |
NCT04192981 | Phase I | GDC-0084 | GDC-0084 With Radiation Therapy for People With PIK3CA-Mutated Solid Tumor Brain Metastases or Leptomeningeal Metastases | Recruiting | USA | 0 |
NCT04195555 | Phase II | Ivosidenib | Ivosidenib in Treating Patients With Advanced Solid Tumors, Lymphoma, or Histiocytic Disorders With IDH1 Mutations (A Pediatric MATCH Treatment Trial) | Active, not recruiting | USA | AUS | 1 |
NCT04196530 | Phase I | Atezolizumab + BDB001 | BDB001-102 Open Label Dose Escalation Combination w Atezolizumab | Active, not recruiting | USA | 0 |
NCT04197713 | Phase I | Adavosertib + Olaparib | Testing the Sequential Combination of the Anti-cancer Drugs Olaparib Followed by Adavosertib (AZD1775) in Patients With Advanced Solid Tumors With Selected Mutations and PARP Resistance, STAR Study | Active, not recruiting | USA | 0 |
NCT04198766 | Phase I | INBRX-106 INBRX-106 + Pembrolizumab | Study of INBRX-106 and INBRX-106 in Combination With Pembrolizumab in Subjects With Locally Advanced or Metastatic Solid Tumors (Hexavalent OX40 Agonist) | Recruiting | USA | 0 |
NCT04198818 | Phase Ib/II | HH2710 | A Study to Evaluate the Safety, Tolerability and Pharmacokinetics of HH2710 in Patient With Advanced Tumors | Terminated | USA | 1 |
NCT04200404 | Phase Ib/II | Regorafenib + Sugemalimab | A Study of CS1001 in Combination With Regorafenib in Patients With Advanced or Refractory Solid Tumors | Completed | AUS | 0 |
NCT04200963 | Phase I | KYN-175 | KYN-175 in Patients With Advanced or Metastatic Solid Tumors and Urothelial Carcinoma | Completed | USA | 0 |
NCT04205227 | Phase Ib/II | ENB003 + Pembrolizumab | ENB003 Plus Pembrolizumab Phase 1b/2a in Solid Tumors | Active, not recruiting | USA | AUS | 0 |
NCT04208958 | Phase Ib/II | Nivolumab + Vancomycin + VE800 | Study of VE800 and Nivolumab in Patients With Selected Types of Advanced or Metastatic Cancer (Consortium-IO) | Completed | USA | 0 |
NCT04209465 | Phase I | BDTX-189 | A Study of BDTX-189, an Orally Available Allosteric ErbB Inhibitor, in Patients With Advanced Solid Tumors. | Terminated | USA | FRA | ESP | 1 |
NCT04209595 | Phase Ib/II | PLX038 + Rucaparib | PLX038 (PEGylated SN38) and Rucaparib in Solid Tumors and Small Cell Cancers | Active, not recruiting | USA | 0 |
NCT04214093 | Phase I | AZD0466 | A Study of AZD0466 in Patients With Advanced Hematologic or Solid Tumors | Terminated | USA | 0 |
NCT04214418 | Phase Ib/II | Atezolizumab + Cobimetinib + Hydroxychloroquine | Study of Combination Therapy With the MEK Inhibitor, Cobimetinib, Immune Checkpoint Blockade, Atezolizumab, and the AUTOphagy Inhibitor, Hydroxychloroquine in KRAS-mutated Advanced Malignancies (MEKiAUTO) | Active, not recruiting | USA | 0 |
NCT04215978 | Phase I | BGB-A445 + Tislelizumab BGB-A445 | Safety and Preliminary Effectiveness of BGB-A445 in Combination With Tislelizumab in Participants With Advanced Solid Tumors | Active, not recruiting | USA | CAN | AUS | 4 |
NCT04219254 | Phase Ib/II | BI-1206 + Pembrolizumab | A Study of BI-1206 in Combination With Pembrolizumab in Subjects With Advanced Solid Tumors | Recruiting | USA | 1 |
NCT04222413 | Phase I | Metarrestin | Metarrestin (ML-246) in Subjects With Metastatic Solid Tumors | Recruiting | USA | 0 |
NCT04225117 | Phase II | Enfortumab vedotin-ejfv | A Study to Evaluate Enfortumab Vedotin in Subjects With Locally Advanced or Metastatic Malignant Solid Tumors (EV-202) | Recruiting | USA | CAN | 1 |
NCT04233567 | Phase II | Infigratinib | Infigratinib for the Treatment of Advanced or Metastatic Solid Tumors in Patients With FGFR Gene Mutations | Active, not recruiting | USA | 0 |
NCT04234113 | Phase I | SOT101 Pembrolizumab + SOT101 | Study of SO-C101 and SO-C101in Combination With Pembro in Adult Patients With Advanced/Metastatic Solid Tumors | Active, not recruiting | USA | FRA | ESP | 1 |
NCT04235101 | Phase I | Niraparib + Trastuzumab Duocarmazine | Phase I Study of SYD985 With Niraparib in Patients With Solid Tumors | Completed | GBR | BEL | 1 |
NCT04236414 | Phase I | Olaparib | Investigating Safety, Tolerability, Efficacy and PK of Olaparib in Paediatric Patients With Solid Tumours | Recruiting | USA | ITA | GBR | FRA | ESP | DEU | CAN | AUT | AUS | 8 |
NCT04237649 | Phase I | KAZ954 + Spartalizumab KAZ954 + Taminadenant KAZ954 KAZ954 + NZV930 | KAZ954 Alone and With PDR001, NZV930 and NIR178 in Advanced Solid Tumors | Terminated | USA | ITA | ESP | CAN | 4 |
NCT04238819 | Phase I | Abemaciclib + Temozolomide Abemaciclib + Irinotecan + Temozolomide | A Study of Abemaciclib (LY2835219) in Combination With Temozolomide and Irinotecan and Abemaciclib in Combination With Temozolomide in Children and Young Adult Participants With Solid Tumors | Recruiting | USA | ITA | FRA | ESP | DEU | CAN | BEL | AUS | 1 |
NCT04239092 | Phase I | Elraglusib + Irinotecan Elraglusib | 9-ING-41 in Pediatric Patients With Refractory Malignancies. | Active, not recruiting | USA | 0 |
NCT04241835 | Phase I | Tazemetostat | A Study of Oral Tazemetostat in Subjects With Moderate and Severe Hepatic Impairment With Advanced Malignancies | Recruiting | USA | FRA | BEL | 2 |
NCT04242147 | Phase I | KD033 | A Study to Investigate the Safety, Pharmacokinetics, Pharmacodynamics, and Preliminary Efficacy of KD033 in Subjects With Metastatic or Locally Advanced Solid Tumors. | Terminated | USA | 0 |
NCT04242199 | Phase I | INCB099280 | Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of INCB099280 in Participants With Advanced Solid Tumors | Recruiting | USA | FRA | BEL | AUS | 1 |
NCT04246671 | Phase Ib/II | TAEK-VAC-HerBy Pertuzumab + TAEK-VAC-HerBy + Trastuzumab Ado-trastuzumab emtansine + TAEK-VAC-HerBy TAEK-VAC-HerBy + Trastuzumab | TAEK-VAC-HerBy Vaccine for Brachyury and HER2 Expressing Cancer | Active, not recruiting | USA | 0 |
NCT04247126 | Phase I | SY-5609 | A Study of SY 5609, a Selective CDK7 Inhibitor, in Advanced Solid Tumors | Completed | USA | 0 |
NCT04249843 | Phase I | BGB3245 | Study of Safety, Pharmacokinetics, and Antitumor Activity of BGB-3245 in Participants With Advanced or Refractory Tumors | Recruiting | USA | AUS | 0 |
NCT04250155 | Phase I | RO7310729 Atezolizumab + RO7310729 | An Open-Label Dose-Escalation Study to Evaluate XmAb24306 as a Single Agent and in Combination With Atezolizumab in Participants With Locally Advanced or Metastatic Solid Tumors | Recruiting | USA | ITA | ESP | CAN | BEL | AUS | 3 |
NCT04250597 | Phase I | GNX102 | Study of GNX102 in Patients With Advanced Solid Tumors | Terminated | USA | 1 |
NCT04252339 | Phase I | GDC-1971 | RLY-1971 in Subjects With Advanced or Metastatic Solid Tumors | Completed | USA | 0 |
NCT04257110 | Phase I | BB-1701 | A First-in-human Study of Multiple Doses of BB-1701 in Subjects With Locally Advanced/Metastatic HER2 Expressing Solid Tumors | Active, not recruiting | USA | 1 |
NCT04257617 | Phase I | ZL1201 | A Trial of ZL-1201 in Subjects With Advanced Cancer | Completed | USA | 1 |
NCT04259450 | Phase Ib/II | AFM24 | Study to Assess AFM24 in Advanced Solid Cancers | Active, not recruiting | USA | GBR | ESP | DEU | 1 |
NCT04260529 | Phase Ib/II | Cypep-1 Cypep-1 + Pembrolizumab | CyPep-1 Injections in Cancer Inducing Lymphocyte Infiltrate Accumulations (CICILIA) | Active, not recruiting | FRA | ESP | 1 |
NCT04260802 | Phase Ib/II | OC-001 + unspecified PD-L1 antibody OC-001 + unspecified PD-1 antibody OC-001 | A Study to Evaluate the Safety and Pharmacokinetics of OC-001 in Patients With Locally Advanced or Metastatic Cancers | Recruiting | CAN | 0 |
NCT04261075 | Phase I | Durvalumab + IPH5201 + Oleclumab Durvalumab + IPH5201 IPH5201 | IPH5201 as Monotherapy or in Combination With Durvalumab +/- Oleclumab in Subjects With Advanced Solid Tumors | Completed | USA | FRA | ESP | 1 |
NCT04261439 | Phase I | NIZ985 NIZ985 + Spartalizumab | A Phase I/Ib Study of NIZ985 Alone and in Combination With Spartalizumab | Terminated | USA | ITA | ESP | DEU | BEL | 2 |
NCT04262466 | Phase Ib/II | IMC-F106C IMC-F106C + unspecified PD-1 antibody IMC-F106C + unspecified PD-L1 antibody | Safety and Efficacy of IMC-F106C as a Single Agent and in Combination With Checkpoint Inhibitors | Recruiting | USA | GBR | FRA | 1 |
NCT04266912 | Phase Ib/II | Avelumab + Berzosertib | Avelumab and M6620 for the Treatment of DDR Deficient Metastatic or Unresectable Solid Tumors | Active, not recruiting | USA | 0 |
NCT04267939 | Phase I | BAY1895344 + Niraparib | ATR Inhibitor BAY 1895344 Plus Niraparib Phase 1b Study in Advanced Solid Tumors and Ovarian Cancer | Terminated | USA | 0 |
NCT04270864 | Phase I | IMO-2125 + Ipilimumab + Nivolumab | Intratumoral Tilsotolimod, a TLR-9 Agonist, Together With Intratumoral Ipilimumab and Intravenous Nivolumab in Patients With Advanced Cancers (PRIMO) | Active, not recruiting | FRA | 0 |
NCT04272034 | Phase I | INCB099318 | Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of INCB099318 in Participants With Advanced Solid Tumors | Active, not recruiting | USA | GBR | BEL | 4 |
NCT04273061 | Phase II | Atezolizumab | Investigating the Effects of Atezolizumab in People Whose Tumour DNA or RNA Indicates Possible Sensitivity (CAPTIV-8) | Recruiting | CAN | 0 |
NCT04276376 | Phase II | Atezolizumab + Rucaparib | Efficacy and Safety of the Combination of Rucaparib (PARP Inhibitor) and Atezolizumab (Anti-PD-L1 Antibody) in Patients With DNA Repair-deficient or Platinum-sensitive Solid Tumors (ARIANES) | Suspended | FRA | 0 |
NCT04278144 | Phase I | BDC-1001 + Pembrolizumab BDC-1001 | A First-in-human Study Using BDC-1001 as a Single Agent and in Combination With Nivolumab in Advanced HER2-Expressing Solid Tumors | Recruiting | USA | ITA | FRA | ESP | 1 |
NCT04282018 | Phase Ib/II | BGB-10188 + Zanubrutinib BGB-10188 + Tislelizumab BGB-10188 | Study of BGB-10188 as Monotherapy, and in Combination With Zanubrutinib, and Tislelizumab | Recruiting | AUS | 1 |
NCT04284774 | Phase II | Tipifarnib | Tipifarnib for the Treatment of Advanced Solid Tumors, Lymphoma, or Histiocytic Disorders With HRAS Gene Alterations, a Pediatric MATCH Treatment Trial | Active, not recruiting | USA | 1 |
NCT04287868 | Phase Ib/II | Bintrafusp alfa + NHS-IL12 + PDS0101 | Combination Immunotherapy in Subjects With Advanced HPV Associated Malignancies | Active, not recruiting | USA | 0 |
NCT04291079 | Phase I | SRK-181 + unspecified PD-L1 antibody SRK-181 SRK-181 + unspecified PD-1 antibody | SRK-181 Alone or in Combination With Anti-PD-(L)1 Antibody Therapy in Patients With Locally Advanced or Metastatic Solid Tumors | Active, not recruiting | USA | 1 |
NCT04293094 | Phase I | AMG 650 | Study of AMG 650 in Adult Participants With Advanced Solid Tumors | Completed | USA | ITA | ESP | CAN | BEL | AUS | 1 |
NCT04294576 | Phase I | BJ-001 + Pembrolizumab BJ-001 | Safety Study of BJ-001, and IL-15 Fusion Protein, for Locally Advanced/Metastatic Solid Tumors (FIH) | Active, not recruiting | USA | 0 |
NCT04294628 | Phase I | Trastuzumab deruxtecan | Testing the Biological Effects of DS-8201a on Patients With Advanced Cancer | Recruiting | USA | 0 |
NCT04295863 | Phase I | Nivolumab Pembrolizumab | Comparing Dosing Intervals of Nivolumab or Pembrolizumab in Locally Advanced or Metastatic Cancers | Recruiting | USA | 0 |
NCT04299880 | Phase I | Gemcitabine + Nab-paclitaxel + Napabucasin Napabucasin Bevacizumab Napabucasin + Paclitaxel Napabucasin + Nivolumab Fluorouracil + Irinotecan + Leucovorin + Napabucasin | Rollover Study to Provide Continued Access to Napabucasin for Patients Enrolled in Boston Biomedical-sponsored Protocols | Completed | USA | FRA | 2 |
NCT04301011 | Phase Ib/II | TBio-6517 Pembrolizumab + TBio-6517 | Study of TBio-6517 Given Alone or in Combination With Pembrolizumab in Solid Tumors (RAPTOR) | Terminated | USA | CAN | 1 |
NCT04303858 | Phase I | Atezolizumab + RO7284755 RO7284755 | A Study to Evaluate Safety and Anti-Tumor Activity of RO7284755 Alone or in Combination With Atezolizumab in Participants With Advanced and/or Metastatic Solid Tumors | Recruiting | ESP | CAN | BEL | 3 |
NCT04306224 | Phase I | IMC-002 | A Study of IMC-002 in Subjects With Metastatic or Locally Advanced Solid Tumors and Relapsed or Refractory Lymphomas | Unknown status | USA | 1 |
NCT04308330 | Phase I | Cefixime + Irinotecan + Temozolomide + Vincristine Sulfate Cefixime + Irinotecan + Temozolomide + Vincristine Sulfate + Vorinostat | Vorinostat in Combination With Chemotherapy in Relapsed/Refractory Solid Tumors and CNS Malignancies (NYMC195) | Recruiting | USA | 0 |
NCT04316169 | Phase I | Abemaciclib + Anastrozole + Hydroxychloroquine Abemaciclib + Fulvestrant + Hydroxychloroquine Abemaciclib + Hydroxychloroquine Abemaciclib + Hydroxychloroquine + Letrozole | Hydroxychloroquine, Abemaciclib and Endocrine Therapy in Hormone Receptor Positive (HR+)/Her 2 Negative Breast Cancer | Withdrawn | USA | 0 |
NCT04317105 | Phase Ib/II | Copanlisib + Ipilimumab + Nivolumab Copanlisib + Nivolumab | Testing the Addition of an Anti-cancer Drug, Copanlisib, to the Usual Immunotherapy (Nivolumab With or Without Ipilimumab) in Patients With Advanced Solid Cancers That Have Changes in the Following Genes: PIK3CA and PTEN | Active, not recruiting | USA | CAN | 0 |
NCT04319224 | Phase Ib/II | Vopratelimab Nivolumab + Vopratelimab Ipilimumab + Vopratelimab | Vopratelimab (JTX-2011) Alone and in Combination With Anti-PD-1 or Anti-CTLA-4 in Subjects With Advanced and/or Refractory Solid Tumors | Completed | USA | 0 |
NCT04319757 | Phase I | ACE1702 + Cyclophosphamide + Fludarabine | ACE1702 in Subjects With Advanced or Metastatic HER2-expressing Solid Tumors | Recruiting | USA | 1 |
NCT04320888 | Phase II | Selpercatinib | Selpercatinib for the Treatment of Advanced Solid Tumors, Lymphomas, or Histiocytic Disorders With Activating RET Gene Alterations, a Pediatric MATCH Treatment Trial | Active, not recruiting | USA | AUS | 1 |
NCT04324814 | Phase I | SHR-1701 | A Trial of SHR-1701 in Subjects With Advanced Solid Tumors | Completed | AUS | 0 |
NCT04328740 | Phase I | Ipilimumab + Nivolumab + TP-1454 TP-1454 | Phase 1 Study of Oral TP-1454 | Recruiting | USA | 0 |
NCT04330664 | Phase Ib/II | Adagrasib + TNO155 | Adagrasib in Combination With TNO155 in Patients With Cancer (KRYSTAL 2) | Active, not recruiting | USA | 0 |
NCT04332653 | Phase Ib/II | NT-I7 + Pembrolizumab | NT-I7 (Efineptakin Alfa) in Combination With Pembrolizumab in Participants With Advanced Solid Tumors | Active, not recruiting | USA | 0 |
NCT04336098 | Phase I | SRF617 | Study of SRF617 in Patients With Advanced Solid Tumors | Completed | USA | CAN | 0 |
NCT04336241 | Phase I | Nivolumab + RP2 RP2 | Study of RP2 Monotherapy and RP2 in Combination With Nivolumab in Patients With Solid Tumors | Recruiting | GBR | ESP | 0 |
NCT04338685 | Phase I | RO7119929 + Tocilizumab | A Study Evaluating Safety, Pharmacokinetics, Pharmacodynamics, And Clinical Activity Of RO7119929 (TLR7 Agonist) In Participants With Unresectable Advanced Or Metastatic Hepatocellular Carcinoma, Biliary Tract Cancer, Or Solid Tumors With Hepatic Metastases | Completed | USA | ESP | 4 |
NCT04344795 | Phase I | TPST-1495 Pembrolizumab + TPST-1495 | Phase 1a/1b Study of TPST-1495 Alone and With Pembrolizumab in Subjects With Solid Tumors | Recruiting | USA | 0 |
NCT04347226 | Phase II | BMS-986253 | Anti-Interleukin-8 (Anti-IL-8) for Cancer Patients With COVID-19 | Terminated | USA | 0 |
NCT04348916 | Phase I | ONCR-177 + Pembrolizumab ONCR-177 | Study of ONCR-177 Alone and in Combination With PD-1 Blockade in Adult Subjects With Advanced and/or Refractory Cutaneous, Subcutaneous or Metastatic Nodal Solid Tumors | Terminated | USA | CAN | 0 |
NCT04349969 | Phase I | AK117 | Phase 1, Dose Escalation and Dose Expansion Study of AK117, a CD47-targeting Antibody | Completed | AUS | 0 |
NCT04353102 | Phase I | YH002 | A Study to Evaluate the Safety, Tolerability and How YH002 Enters, Moves Through and Exits the Body in Subjects With Advanced Solid Malignancies | Completed | AUS | 0 |
NCT04354246 | Phase I | COM902 | COM902 (A TIGIT Inhibitor) in Subjects With Advanced Malignancies | Recruiting | USA | 0 |
NCT04357756 | Phase I | Toripalimab-tpzi + YH001 | A Study to Assess YH001 in Combination With Toripalimab Injection in Subjects With Advanced Solid Tumors | Completed | AUS | 0 |
NCT04362748 | Phase I | AMG 256 | Study of AMG 256 in Adult Subjects With Advanced Solid Tumors | Completed | USA | ESP | BEL | AUS | 0 |
NCT04363242 | Phase I | SYN125 SYN004 + SYN125 | A Study to Find the MTD of SYN125 in People With Solid Tumors and the MTD of SYN125 With a Fixed Dose of SYN004 in People in Patients With Epithelial Cancers With EGFR Expressions | Active, not recruiting | USA | 0 |
NCT04370704 | Phase Ib/II | INCAGN02385 + INCAGN02390 + Retifanlimab INCAGN02385 + INCAGN02390 | Study of Combination Therapy With INCMGA00012 (Anti-PD-1), INCAGN02385 (Anti-LAG-3), and INCAGN02390 (Anti-TIM-3) in Participants With Select Advanced Malignancies | Active, not recruiting | USA | AUS | 0 |
NCT04372706 | Phase Ib/II | RTX-240 | RTX-240 Monotherapy | Terminated | USA | 0 |
NCT04374877 | Phase I | SRF388 | Study of SRF388 in Patients With Advanced Solid Tumors | Recruiting | USA | 2 |
NCT04377932 | Phase I | Cyclophosphamide + Fludarabine AGAR T cells | Interleukin-15 Armored Glypican 3-specific Chimeric Antigen Receptor Expressed in T Cells for Pediatric Solid Tumors | Recruiting | USA | 0 |
NCT04383210 | Phase II | Seribantumab | Study of Seribantumab in Adult Patients With NRG1 Gene Fusion Positive Advanced Solid Tumors | Active, not recruiting | USA | CAN | AUS | 1 |
NCT04383938 | Phase Ib/II | APR-246 + Pembrolizumab | Phase 1/2 Study of APR-246 in Combination With Pembrolizumab in Subjects With Solid Tumor Malignancies | Completed | USA | 0 |
NCT04387071 | Phase Ib/II | INCAGN01949 + Vidutolimod | CMP-001 and INCAGN01949 for Patients With Stage IV Pancreatic Cancer and Other Cancers Except Melanoma | Terminated | USA | 0 |
NCT04387084 | Phase I | Durvalumab Pembrolizumab Avelumab Cemiplimab Atezolizumab Nivolumab | Short-term Fasting Prior to PD-1/PD-L1 Inhibitor Therapy for of Advanced or Metastatic Skin Malignancy | Recruiting | USA | 0 |
NCT04390737 | Phase I | HH2853 | A Phase I Study to Evaluate the Safety and Clinical Activity of HH2853. | Recruiting | USA | 1 |
NCT04393454 | Phase II | Sirolimus | Study to Evaluate the Efficacy and Safety of Sirolimus in Subjects With Metastatic, Mismatch Repair Deficient Solid Tumors After Immunotherapy | Terminated | USA | 0 |
NCT04396821 | Phase I | TST001 | A Trial to Evaluate Safety and Tolerability of TST001 in Advanced or Metastatic Solid Tumors | Recruiting | USA | 0 |
NCT04404569 | Phase I | BXQ-350 | Continued Treatment for Participants Enrolled in Studies of BXQ-350 | Enrolling by invitation | USA | 0 |
NCT04408599 | Phase Ib/II | NC410 | A Safety and Tolerability Study of NC410 in Subjects With Advanced or Metastatic Solid Tumors | Terminated | USA | 0 |
NCT04410224 | Phase I | ASN004 | Study of ASN004 in Patients With Advanced Solid Tumors (ASN004) | Active, not recruiting | USA | 0 |
NCT04410653 | Phase II | Afatinib | Afatinib in Advanced NRG1-Rearranged Malignancies | Active, not recruiting | DEU | 0 |
NCT04416568 | Phase II | Ipilimumab + Nivolumab | Study of Nivolumab and Ipilimumab in Children and Young Adults With INI1-Negative Cancers | Recruiting | USA | 0 |
NCT04417465 | Phase I | ABBV-CLS-579 ABBV-CLS-579 + unspecified PD-1 antibody | First In Human Study With ABBV-CLS-579 When Given Alone Or In Combination With Programmed Cell Death-1 Inhibitor In Participants With Locally Advanced Or Metastatic Tumors | Recruiting | USA | FRA | ESP | 4 |
NCT04418167 | Phase I | JSI-1187 Dabrafenib + JSI-1187 | JSI-1187-01 Monotherapy and in Combination With Dabrafenib for Advanced Solid Tumors With MAPK Pathway Mutations | Suspended | USA | 0 |
NCT04418661 | Phase Ib/II | Pembrolizumab + RMC-4630 Adagrasib + RMC-4630 | Safety and Efficacy Study of SAR442720 in Combination With Other Agents in Advanced Malignancies | Active, not recruiting | USA | ESP | AUS | 5 |
NCT04420884 | Phase I | Pembrolizumab + TAK-676 TAK-676 | TAK-676 as Single Agent (SA) and in Combination With Pembrolizumab in Advanced or Metastatic Solid Tumors | Recruiting | USA | GBR | FRA | CAN | BEL | AUT | 6 |
NCT04423029 | Phase Ib/II | DF6002 DF6002 + Nivolumab | A Study to Assess DF6002 (BMS-986415) Alone and in Combination With Nivolumab in Participants With Locally Advanced or Metastatic Solid Tumors | Recruiting | USA | FRA | ESP | AUS | 0 |
NCT04424641 | Phase Ib/II | GEN1044 | A Study on the Safety of GEN1044 (DuoBody-CD3x5T4) in Subjects With Malignant Solid Tumors | Terminated | USA | ESP | 2 |
NCT04429542 | Phase I | BCA101 BCA101 + Pembrolizumab | Study of Safety and Tolerability of BCA101 Monotherapy and in Combination Therapy in Patients With EGFR-driven Advanced Solid Tumors | Recruiting | USA | CAN | 0 |
NCT04430348 | Phase I | PTX-35 | PTX-35 in Patients With Advanced Solid Tumors | Terminated | USA | 0 |
NCT04430842 | Phase I | QBS10072S | Dose Escalation Study to Assess the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of QBS10072S | Completed | AUS | 0 |
NCT04432597 | Phase Ib/II | PRGN-2009 Bintrafusp alfa + PRGN-2009 | HPV Vaccine PRGN-2009 Alone or in Combination With Anti-PDL1/TGF-Beta Trap (M7824) in Subjects With HPV Associated Cancers | Active, not recruiting | USA | 0 |
NCT04434482 | Phase I | Senaparib + Temozolomide | IMP4297 in Combination With Temozolomide in Patients With Advanced Solid Tumors and Small Cell Lung Cancer | Recruiting | USA | AUS | 3 |
NCT04434560 | Phase II | Ipilimumab + Nivolumab | Neoadjuvant Immunotherapy in Brain Metastases | Terminated | USA | 0 |
NCT04440735 | Phase Ib/II | Atezolizumab + DSP107 DSP107 | A Study of DSP107 Alone and in Combination With Atezolizumab for Patients With Advanced Solid Tumors | Recruiting | USA | 0 |
NCT04440943 | Phase I | CDX-527 | A Study of the PD-L1xCD27 Bispecific Antibody CDX-527 in Patients With Advanced Malignancies | Completed | USA | 0 |
NCT04442126 | Phase Ib/II | NM21-1480 | A Study of NM21-1480 in Adult Patients With Advanced Solid Tumors | Terminated | USA | ESP | 1 |
NCT04443088 | Phase I | INV-1120 | A Phase 1, Multi-Center, Safety, Dose Escalation, Pharmacokinetics of INV-1120 in Adult Patients Advanced Solid Tumors | Recruiting | USA | 0 |
NCT04444427 | Phase Ib/II | GLR2007 | Evaluation of GLR2007 for Advanced Solid Tumors | Completed | USA | 0 |
NCT04446260 | Phase I | Trastuzumab rezetecan | A Study of SHR-A1811 in Subjects With Advanced Malignant Solid Tumors | Recruiting | USA | AUS | 3 |
NCT04446351 | Phase I | Dostarlimab-gxly + GSK6097608 GSK6097608 | Study of the Safety and Effectiveness of GSK6097608 in Participants With Advanced Solid Tumors | Recruiting | USA | CAN | 2 |
NCT04447755 | Phase II | Lenvatinib | A Study of Lenvatinib (MK-7902) in Pediatric Participants With Relapsed or Refractory Solid Malignancies (MK-7902-013/E7080) (E7080-G000-231) | Active, not recruiting | USA | ITA | FRA | ESP | BEL | AUS | 14 |
NCT04449549 | Phase II | Nilotinib + Paclitaxel | Rapid Analysis and Response Evaluation of Combination Anti-Neoplastic Agents in Rare Tumors (RARE CANCER) Trial: RARE 1 Nilotinib and Paclitaxel | Recruiting | USA | 0 |
NCT04449874 | Phase I | Atezolizumab + Divarasib Bevacizumab + Divarasib Cetuximab + Divarasib Divarasib + Erlotinib Divarasib | A Study to Evaluate the Safety, Pharmacokinetics, and Activity of GDC-6036 Alone or in Combination in Participants With Advanced or Metastatic Solid Tumors With a KRAS G12C Mutation | Recruiting | USA | ITA | GBR | ESP | DEU | CAN | BEL | AUS | 11 |
NCT04450732 | Phase I | GQ1001 | Safety of GQ1001 in Adult Patients With HER2-Positive Advanced Solid Tumors | Recruiting | USA | AUS | 1 |
NCT04450901 | Phase I | YBL-006 | Dose Escalation/Dose Expansion Study of YBL-006 in Patients With Advanced Solid Tumors | Active, not recruiting | AUS | 2 |
NCT04455620 | Phase Ib/II | BNT151 | BNT151 as a Monotherapy and in Combination With Other Anti-cancer Agents in Patients With Solid Tumors | Active, not recruiting | USA | ESP | 0 |
NCT04457778 | Phase I | M6223 Bintrafusp alfa + M6223 | First in Human Study of M6223 in Participants With Metastatic or Locally Advanced Solid Unresectable Tumors | Completed | USA | CAN | 0 |
NCT04458259 | Phase I | PF-07265807 | A Study of PF-07265807 In Participants With Advanced or Metastatic Solid Tumors | Active, not recruiting | USA | ITA | ESP | CAN | AUS | 3 |
NCT04460456 | Phase I | SBT6050 Pembrolizumab + SBT6050 Cemiplimab + SBT6050 | A Study of SBT6050 Alone and in Combination With PD-1 Inhibitors in Subjects With Advanced HER2 Expressing Solid Tumors | Active, not recruiting | USA | AUS | 1 |
NCT04465487 | Phase I | Cemiplimab + REGN6569 | Study of REGN6569 and Cemiplimab in Adult Patients With Advanced Solid Tumor Malignancies | Recruiting | USA | ESP | 0 |
NCT04469127 | Phase Ib/II | AIP-303 | A Study of AIP-303 in HER2 Positive Breast Cancer and/or Metastatic Breast Cancer Patients (Heroine01) | Not yet recruiting | USA | 1 |
NCT04469530 | Phase II | Celecoxib + Cyclophosphamide + Etoposide + Sirolimus | Sirolimus in Combination With Metronomic Chemotherapy in Children With High-Risk Solid Tumors (AflacST1903) | Recruiting | USA | 0 |
NCT04471415 | Phase Ib/II | DRP-104 Atezolizumab + DRP-104 | Study to Investigate DRP-104 in Adults With Advanced Solid Tumors | Terminated | USA | ESP | DEU | 2 |
NCT04471727 | Phase Ib/II | Atezolizumab + HPN328 HPN328 | Study in Patients With Advanced Cancers Associated With Expression of DLL3 | Recruiting | USA | 0 |
NCT04474470 | Phase Ib/II | Cetuximab + NT219 NT219 | A Study to Evaluate NT219 Alone and in Combination With ERBITUX (Cetuximab) in Adults With Advanced Solid Tumors and Head and Neck Cancer | Active, not recruiting | USA | 1 |
NCT04475523 | Phase I | Onvatilimab | Phase 1 Study of CI-8993 Anti-VISTA Antibody in Patients With Advanced Solid Tumor Malignancies | Completed | USA | AUS | 0 |
NCT04482309 | Phase II | Trastuzumab deruxtecan | A Phase 2 Study of T-DXd in Patients With Selected HER2 Expressing Tumors (DPT02) | Active, not recruiting | USA | ITA | GBR | ESP | CAN | BEL | AUS | 8 |
NCT04485013 | Phase I | TTX-080 | TTX-080 HLA-G Antagonist in Subjects With Advanced Cancers | Active, not recruiting | USA | 0 |
NCT04488003 | Phase II | Ulixertinib | Study of Ulixertinib for Patients With Advanced Malignancies Harboring MEK or Atypical BRAF Alterations | Terminated | USA | 0 |
NCT04491942 | Phase I | BAY1895344 + Cisplatin BAY1895344 + Cisplatin + Gemcitabine | Testing the Addition of an Anti-cancer Drug, BAY 1895344, to the Usual Chemotherapy Treatment (Cisplatin, or Cisplatin and Gemcitabine) for Advanced Solid Tumors With Emphasis on Urothelial Cancer | Active, not recruiting | USA | CAN | 0 |
NCT04492488 | Phase Ib/II | MRG002 | A Study of MRG002 in Patients With HER2-Positive Advanced Solid Tumors and Locally Advanced or Metastatic Gastric/Gastroesophageal Junction (GEJ) Cancer | Unknown status | USA | 0 |
NCT04497116 | Phase Ib/II | RP-3500 + Talazoparib RP-3500 | Study of RP-3500 in Advanced Solid Tumors | Active, not recruiting | USA | GBR | CAN | 1 |
NCT04500548 | Phase I | Nivolumab Ipilimumab + Nivolumab | Testing the Combination of Two Immunotherapy Drugs (Nivolumab and Ipilimumab) in Children, Adolescent, and Young Adult Patients With Relapsed/Refractory Cancers That Have an Increased Number of Genetic Changes, The 3CI Study | Withdrawn | USA | CAN | 0 |
NCT04501276 | Phase I | ADG116 ADG106 + ADG116 ADG116 + unspecified PD-1 antibody | A Phase 1b Study of ADG116, ADG116 Combined With Anti-PD-1 Antibody or Anti-CD137 Antibody in Solid Tumors Patients | Active, not recruiting | USA | AUS | 0 |
NCT04502602 | Phase I | Neratinib + Niraparib | Niraparib and Neratinib in Advanced Solid Tumors With Expansion Cohort in Advanced Ovarian Cancer (iNNOVATE) | Recruiting | USA | 0 |
NCT04503265 | Phase Ib/II | AMXI-5001 | A Trial of AMXI-5001 for Treatment in Patients With Advanced Malignancies | Recruiting | USA | 0 |
NCT04504669 | Phase I | AZD8701 + Durvalumab AZD8701 | First Time in Human Study of AZD8701 With or Without Durvalumab in Participants With Advanced Solid Tumours | Active, not recruiting | USA | FRA | ESP | CAN | 0 |
NCT04504916 | Phase II | VLS-101 | A Study of VLS-101 in Patients With Solid Tumors | Completed | USA | CAN | 0 |
NCT04504942 | Phase II | Leronlimab | Basket Study of Leronlimab (PRO 140) in Patients With CCR5+ Locally Advanced or Metastatic Solid Tumors | Unknown status | USA | 0 |
NCT04511845 | Phase I | SPYK04 | A Dose-Escalation Study of SPYK04 in Patients With Locally Advanced or Metastatic Solid Tumors (With Expansion). | Recruiting | USA | 1 |
NCT04514484 | Phase I | Cabozantinib + Nivolumab | Testing the Combination of the Anti-cancer Drugs XL184 (Cabozantinib) and Nivolumab in Patients With Advanced Cancer and HIV | Active, not recruiting | USA | 0 |
NCT04514497 | Phase I | BAY1895344 + Irinotecan BAY1895344 + Topotecan | Testing the Addition of an Anti-cancer Drug, BAY 1895344, to Usual Chemotherapy for Advanced Stage Solid Tumors, With a Specific Focus on Patients With Small Cell Lung Cancer, Poorly Differentiated Neuroendocrine Cancer, and Pancreatic Cancer | Active, not recruiting | USA | 0 |
NCT04518046 | Phase I | Ipilimumab + Nivolumab + Sitravatinib | Study of Sitravatinib, Nivolumab and Ipilimumab in Advanced or Metastatic Clear-Cell Renal Cell Carcinoma or Other Solid Malignancies | Active, not recruiting | USA | 0 |
NCT04520711 | Phase I | CDX-1140 + Pembrolizumab + TSA/TAA-specific TCR engineered T cells | Study of Adoptively Transferred, Gene-engineered T Cells With CD40 Activation and PD-1 Blockade in Incurable Cancers | Active, not recruiting | USA | 0 |
NCT04521413 | Phase Ib/II | CFI-402411 + Pembrolizumab CFI-402411 | Safety and Efficacy Study of CFI-402411 in Subjects With Advanced Solid Malignancies | Recruiting | USA | CAN | 1 |
NCT04521621 | Phase Ib/II | Coxsackievirus A21 + Pembrolizumab | A Study of Gebasaxturev (V937) in Combination With Pembrolizumab (MK-3475) in Participants With Advanced/Metastatic Solid Tumors (V937-013) | Completed | USA | ITA | FRA | ESP | DEU | CAN | 8 |
NCT04521686 | Phase I | LY3410738 | Study of LY3410738 Administered to Patients With Advanced Solid Tumors With IDH1 or IDH2 Mutations | Active, not recruiting | USA | FRA | ESP | AUS | 5 |
NCT04525014 | Phase I | Irinotecan + RRx-001 + Temozolomide | RRx-001 Given With Irinotecan and Temozolomide for Pediatric Patients With Recurrent or Progressive Malignant Solid and Central Nervous System Tumors (PIRATE) | Active, not recruiting | USA | 0 |
NCT04526106 | Phase I | RLY-4008 | REFOCUS: A First-in-Human Study of Highly Selective FGFR2 Inhibitor, RLY-4008, in Patients With ICC and Other Advanced Solid Tumors | Active, not recruiting | USA | ITA | GBR | FRA | ESP | DEU | AUS | 6 |
NCT04528836 | Phase I | BBP-398 | First-in-Human Study of the SHP2 Inhibitor BBP-398 in Patients With Advanced Solid Tumors | Recruiting | USA | 0 |
NCT04534283 | Phase II | Abemaciclib + LY3214996 | A Basket Trial of an ERK1/2 Inhibitor (LY3214996) in Combination With Abemaciclib. | Terminated | USA | 0 |
NCT04537715 | Phase I | Itraconazole + Tazemetostat Rifampin + Tazemetostat | Study to Describe the Interaction Between Tazemetostat and Itraconazole and Between Tazemetostat and Rifampin in Participants With Advanced Cancer | Completed | USA | ESP | 0 |
NCT04543188 | Phase I | Binimetinib + Midazolam + PF-07284890 Binimetinib + PF-07284890 PF-07284890 | A FIH Study of PF-07284890 in Participants With BRAF V600 Mutant Solid Tumors With and Without Brain Involvement | Active, not recruiting | USA | CAN | 1 |
NCT04544995 | Phase I | Dostarlimab-gxly + Niraparib | Dose Escalation and Cohort Expansion Study of Niraparib and Dostarlimab in Pediatric Participants With Solid Tumors | Suspended | GBR | FRA | ESP | DEU | 2 |
NCT04551521 | Phase II | Atezolizumab Atezolizumab + Ipatasertib Atezolizumab + Pertuzumab + Trastuzumab Atezolizumab + Cobimetinib Alectinib Atezolizumab + Cobimetinib + Vemurafenib | CRAFT: The NCT-PMO-1602 Phase II Trial | Recruiting | DEU | 0 |
NCT04551885 | Phase I | Cyclophosphamide + Fludarabine Avelumab + FT516 Aldesleukin | FT516 in Combination With Monoclonal Antibodies in Advanced Solid Tumors | Terminated | USA | 0 |
NCT04553692 | Phase I | Bevacizumab + Fluorouracil + IGM-8444 + Irinotecan + Leucovorin Fluorouracil + IGM-8444 + Irinotecan + Leucovorin IGM-8444 | Study of IGM-8444 as a Single Agent and in Combination With Chemotherapy-based Regimens in Subjects With Solid Cancers | Recruiting | USA | FRA | ESP | AUS | 1 |
NCT04555837 | Phase Ib/II | Alisertib + Pembrolizumab | Alisertib and Pembrolizumab for the Treatment of Patients With Rb-deficient Head and Neck Squamous Cell Cancer | Active, not recruiting | USA | 0 |
NCT04557384 | Phase I | Ramucirumab | A Study of Ramucirumab (LY3009806) Given by Injection Under the Skin in Participants With Advanced Cancer | Terminated | USA | 1 |
NCT04557449 | Phase I | Letrozole + PF-07220060 Fulvestrant + PF-07220060 PF-07220060 | Study to Test the Safety and Tolerability of PF-07220060 in Participants With Advance Solid Tumors (CDK4i) | Recruiting | USA | GBR | 6 |
NCT04561362 | Phase Ib/II | BT8009 BT8009 + Pembrolizumab | Study BT8009-100 in Subjects With Nectin-4 Expressing Advanced Malignancies | Recruiting | USA | ITA | GBR | FRA | ESP | CAN | 0 |
NCT04564027 | Phase II | Ceralasertib | A Study Investigating DNA-damage Response Agents in Molecularly Altered Advanced Cancer | Active, not recruiting | USA | FRA | ESP | 0 |
NCT04564417 | Phase I | W0180 Pembrolizumab + W0180 | First-In-Human (FIH) Study of W0180 as Single Agent and in Combination With Pembrolizumab in Adults With Locally Advanced or Metastatic Solid Tumors | Terminated | FRA | ESP | 0 |
NCT04565275 | Phase Ib/II | ICP-192 | A Study of ICP-192 in Patients With Advanced Solid Tumors | Recruiting | USA | AUS | 0 |
NCT04566393 | Expanded access | Ulixertinib | Expanded Access to Ulixertinib (BVD-523) in Patients With Advanced MAPK Pathway-Altered Malignancies | Available | USA | 0 |
NCT04570839 | Phase Ib/II | BMS-986207 + COM701 + Nivolumab Nivolumab | COM701 in Combination With BMS-986207 and Nivolumab in Subjects With Advanced Solid Tumors. | Active, not recruiting | USA | 0 |
NCT04572152 | Phase I | AK119 + Cadonilimab | A Study of AK119 (Anti-CD73) in Combination With AK104 in Subjects With Advanced Solid Tumors | Active, not recruiting | AUS | 0 |
NCT04572451 | Phase I | BMS-986253 + Nivolumab | Safety of SBRT With Anti-PD1 and Anti-IL-8 for the Treatment of Multiple Metastases in Advanced Solid Tumors | Recruiting | USA | 0 |
NCT04574583 | Phase Ib/II | Bintrafusp alfa + FPV-CV301 + MVA-BN-CV301 + SX-682 | Phase I/II Trial Investigating the Safety, Tolerability, Pharmacokinetics, Immune and Clinical Activity of SX-682 in Combination With BinTrafusp Alfa (M7824 or TGF-beta "Trap"/PD-L1) With CV301 TRICOM in Advanced Solid Tumors (STAT) | Active, not recruiting | USA | 0 |
NCT04579380 | Phase II | Trastuzumab + Tucatinib Fulvestrant + Trastuzumab + Tucatinib | Basket Study of Tucatinib and Trastuzumab in Solid Tumors With HER2 Alterations | Active, not recruiting | USA | ITA | GBR | ESP | DEU | BEL | 4 |
NCT04579757 | Phase Ib/II | Surufatinib + Tislelizumab | Surufatinib in Combination With Tislelizumab in Subjects With Advanced Solid Tumors | Active, not recruiting | USA | 0 |
NCT04585035 | Phase Ib/II | D-1553 | Study to Evaluate D-1553 in Subjects With Solid Tumors | Active, not recruiting | USA | AUS | 2 |
NCT04585750 | Phase Ib/II | PC14586 + Pembrolizumab PC14586 | The Evaluation of PC14586 in Patients With Advanced Solid Tumors Harboring a TP53 Y220C Mutation (PYNNACLE) | Recruiting | USA | ITA | GBR | FRA | ESP | DEU | AUS | 2 |
NCT04585958 | Phase I | Olaparib + Trastuzumab deruxtecan | Testing the Combination of DS-8201a and Olaparib in HER2-Expressing Cancers With Expansion in Patients With Endometrial Cancer | Recruiting | USA | 0 |
NCT04586270 | Phase I | TAS0612 | A Study of TAS0612 in Participants With Advanced or Metastatic Solid Tumor Cancer | Recruiting | USA | FRA | 0 |
NCT04586335 | Phase I | CYH33 + Olaparib | Study of CYH33 in Combination With Olaparib an Oral PARP Inhibitor in Patients With Advanced Solid Tumors. | Recruiting | USA | AUS | 1 |
NCT04587479 | Phase I | JAB-8263 | A First-in-Human Study of JAB-8263 in Adult Patients With Advanced Solid Tumors | Unknown status | USA | 0 |
NCT04588545 | Phase Ib/II | Pertuzumab + Trastuzumab | Radiation Therapy Followed by Intrathecal Trastuzumab/Pertuzumab in HER2+ Breast Leptomeningeal Disease | Recruiting | USA | 0 |
NCT04589845 | Phase II | Alectinib Ado-trastuzumab emtansine Ipatasertib Inavolisib Entrectinib Atezolizumab Idasanutlin | Tumor-Agnostic Precision Immuno-Oncology and Somatic Targeting Rational for You (TAPISTRY) Platform Study | Recruiting | USA | ITA | GBR | FRA | ESP | DEU | CAN | BEL | AUS | 16 |
NCT04591431 | Phase II | Everolimus Nivolumab Itacitinib Erlotinib Ponatinib Pemigatinib Ipatasertib Ipilimumab Cobimetinib Atezolizumab Palbociclib Entrectinib Vemurafenib Lapatinib Trastuzumab Brigatinib Alectinib Ado-trastuzumab emtansine Pertuzumab Vismodegib | The Rome Trial From Histology to Target: the Road to Personalize Target Therapy and Immunotherapy (ROME) | Active, not recruiting | ITA | 0 |
NCT04592484 | Phase Ib/II | CDK-002 | A First-in-Human Study of CDK-002 (exoSTING) in Subjects With Advanced/Metastatic, Recurrent, Injectable Solid Tumors | Completed | USA | GBR | 0 |
NCT04592653 | Phase Ib/II | ALKS 4230 ALKS 4230 + Pembrolizumab | Less Frequent IV Dosing & Tumor Microenvironment (TME) Study of Nemvaleukin Alfa (ALKS 4230) Monotherapy and in Combination With Pembrolizumab (ARTISTRY-3) (ARTISTRY-3) | Recruiting | USA | ESP | 0 |
NCT04601402 | Phase I | Avelumab + GEN-001 | GEN-001 (Live Biotherapeutic Product) and Avelumab Combination Study for Patients With Solid Tumors Who Have Progressed on Anti-PD-(L)1 Therapy | Completed | USA | 0 |
NCT04605614 | Phase I | Pembrolizumab | 64Cu-DOTA-pembrolizumab PET for the Study of PD1 Expression | Withdrawn | 0 | |
NCT04606381 | Phase I | Amivantamab-vmjw + Lazertinib Amivantamab-vmjw + Lazertinib + rHuPH20 Amivantamab-vmjw Amivantamab-vmjw + rHuPH20 | A Study of Amivantamab Subcutaneous (SC) Administration for the Treatment of Advanced Solid Malignancies (PALOMA) | Recruiting | USA | GBR | CAN | 1 |
NCT04609579 | Phase I | SNX281 Pembrolizumab + SNX281 | Study of SNX281 in Subjects With Advanced Solid Tumors and Lymphoma | Terminated | USA | 0 |
NCT04613492 | Phase I | Durvalumab + MEDI9253 | A Study of MEDI9253 in Combination With Durvalumab in Select Solid Tumors | Active, not recruiting | USA | FRA | 0 |
NCT04616534 | Phase I | BAY1895344 + Gemcitabine | Testing the Addition of an Anti-cancer Drug, BAY 1895344 ATR Inhibitor, to the Chemotherapy Treatment (Gemcitabine) for Advanced Pancreatic and Ovarian Cancer, and Advanced Solid Tumors | Active, not recruiting | USA | 0 |
NCT04617522 | Phase I | Sacituzumab govitecan-hziy | Study to Determine an Appropriate Starting Dose of Sacituzumab Govitecan-hziy in Participants With Advanced or Metastatic Solid Tumor and Moderate Liver Impairment | Recruiting | USA | FRA | 0 |
NCT04618393 | Phase Ib/II | EMB-02 | A Study of EMB-02 in Participants With Advanced Solid Tumors | Recruiting | USA | AUS | 1 |
NCT04626635 | Phase Ib/II | Cemiplimab + REGN7075 | REGN7075 in Combination With Cemiplimab in Adult Participants With Advanced Solid Tumors | Recruiting | USA | 0 |
NCT04628780 | Phase I | PF-07209960 | Study to Test the Safety and Tolerability of PF-07209960 in Advanced or Metastatic Solid Tumors | Terminated | USA | 0 |
NCT04631029 | Phase I | Atezolizumab + Carboplatin + Entinostat + Etoposide Atezolizumab + Entinostat | Testing the Addition of an Anti-cancer Drug, Entinostat, to the Usual Chemotherapy and Immunotherapy Treatment (Atezolizumab, Carboplatin and Etoposide) for Previously Untreated Aggressive Lung Cancer That Has Spread | Completed | USA | 0 |
NCT04632992 | Phase II | Ipatasertib Atezolizumab + Capecitabine Entrectinib Atezolizumab + Docetaxel Ado-trastuzumab emtansine + Atezolizumab Capecitabine + Pertuzumab/trastuzumab/hyaluronidase-zzxf Paclitaxel + Pertuzumab/trastuzumab/hyaluronidase-zzxf Alectinib Inavolisib Pertuzumab/trastuzumab/hyaluronidase-zzxf Docetaxel + Pertuzumab/trastuzumab/hyaluronidase-zzxf Atezolizumab + Paclitaxel Ado-trastuzumab emtansine + Tucatinib | A Study Evaluating Targeted Therapies in Participants Who Have Advanced Solid Tumors With Genomic Alterations or Protein Expression Patterns Predictive of Response (MyTACTIC) | Completed | USA | 0 |
NCT04635995 | Phase I | LVGN7409 | Phase 1 Trial of LVGN7409 (CD40 Agonist Antibody) as Single Agent and Combination Therapies in Advanced or Metastatic Malignancy | Recruiting | USA | 0 |
NCT04639219 | Phase II | Trastuzumab deruxtecan | A Study of T-DXd for the Treatment of Solid Tumors Harboring HER2 Activating Mutations (DPT01) | Active, not recruiting | USA | ITA | FRA | ESP | CAN | BEL | 3 |
NCT04640246 | Phase Ib/II | TBX-3400 | Study of TBX-3400 in Subjects With Solid Malignant Tumors Resistant or Refractory to Standard Therapies | Unknown status | USA | 1 |
NCT04642365 | Phase I | Atezolizumab + RO7296682 | A Study to Evaluate the Safety and Tolerability of RO7296682 in Combination With Atezolizumab in Participants With Advanced Solid Tumors. | Completed | USA | ESP | CAN | BEL | AUS | 1 |
NCT04644068 | Phase I | AZD5305 + Carboplatin + Paclitaxel AZD5305 + Paclitaxel AZD5305 + Carboplatin AZD5305 | Study of AZD5305 as Monotherapy and in Combination With Anti-cancer Agents in Patients With Advanced Solid Malignancies (PETRA) | Recruiting | USA | ITA | GBR | ESP | CAN | AUS | 7 |
NCT04644315 | Phase II | Alectinib | A Home-Based Approach Study to Evaluate the Efficacy and Safety of Alectinib in Locally-Advanced or Metastatic ALK-Positive Solid Tumors (ALpha-T) | Terminated | USA | 0 |
NCT04645069 | Phase I | ADG126 ADG106 + ADG126 ADG126 + unspecified PD-1 antibody | ADG126, ADG126 in Combination With Toripalimab, and ADG126 in Combination With ADG106 in Advanced/Metastatic Solid Tumors | Recruiting | USA | AUS | 1 |
NCT04648202 | Phase I | FS120 | FS120 First in Human Study in Patients With Advanced Malignancies | Recruiting | USA | ESP | 0 |
NCT04648254 | Phase I | Q702 | Oral Axl/Mer/CSF1R Selective Tyrosine Kinase Inhibitor in Patients With Advanced Solid Tumor | Recruiting | USA | 0 |
NCT04649385 | Phase I | BGB-15025 BGB-15025 + Tislelizumab | BGB-15025 Alone and in Combination With Anti-PD-1 Monoclonal Antibody Tislelizumab in Participants With Advanced Solid Tumors | Recruiting | USA | AUS | 3 |
NCT04655183 | Phase Ib/II | Niraparib + VX-803 Niraparib | Study of M4344 in Combination With Niraparib | Withdrawn | 0 | |
NCT04657068 | Phase Ib/II | ART0380 + Gemcitabine ART0380 Gemcitabine | A Study of ART0380 for the Treatment of Advanced or Metastatic Solid Tumors | Recruiting | USA | GBR | ESP | 0 |
NCT04659096 | Phase I | ION537 | A Study of ION537 in Patients With Molecularly Selected Advanced Solid Tumors | Completed | USA | 0 |
NCT04659629 | Phase I | NL-201 | NL-201 in Patients With Relapsed or Refractory Cancer | Active, not recruiting | USA | CAN | AUS | 0 |
NCT04660929 | Phase I | CT-0508 | CAR-macrophages for the Treatment of HER2 Overexpressing Solid Tumors | Recruiting | USA | 0 |
NCT04662580 | Phase I | ARX517 | ARX517 in Subjects With Advanced Solid Tumor (ARX517) | Recruiting | USA | 0 |
NCT04665206 | Phase I | VT3989 | Study to Evaluate VT3989 in Patients With Metastatic Solid Tumors Enriched for Tumors With NF2 Gene Mutations | Recruiting | USA | AUS | 0 |
NCT04666688 | Phase Ib/II | LYT-200 LYT-200 + unspecified PD-1 antibody Gemcitabine + LYT-200 + Nab-paclitaxel | LYT-200 Alone and in Combination With Chemotherapy or Anti-PD-1 in Patients With Metastatic Solid Tumors | Recruiting | USA | 0 |
NCT04669899 | Phase I | JTX 8064 JTX 8064 + Pimivalimab JTX 8064 + Pembrolizumab | Study of JTX 8064, as Monotherapy and in Combination With a PD-1 Inhibitor, in Adult Subjects With Advanced Refractory Solid Tumors | Completed | USA | 0 |
NCT04670679 | Phase I | ERAS-601 | FLAGSHP-1: A Dose Escalation/Expansion Study of ERAS-601 in Patients With Advanced or Metastatic Solid Tumors | Active, not recruiting | USA | AUS | 0 |
NCT04672460 | Phase I | Talazoparib | A Bioequivalence Study Between the Proposed and Current Talazoparib Capsule Formulation and Food Effect Study for the Proposed Talazoparib Capsule Formulation in Participants With Advanced Solid Tumors | Completed | USA | AUS | 0 |
NCT04675996 | Phase I | INT-1B3 | First-in-Human Study of INT-1B3 in Patients With Advanced Solid Tumors | Terminated | BEL | 1 |
NCT04676334 | Phase III | Rucaparib | CATCH-R: A Rollover Study to Provide Continued Access to Rucaparib (CATCH-R) | Completed | ITA | GBR | CAN | 3 |
NCT04676633 | Phase I | Cotsiranib | Open-Label Study for Safety, Tolerability, PK and Anti-Tumor Activity of STP705 Administered Intratumorally in Cholangiocarcinoma, Hepatocellular Carcinoma or Liver Metastases in Subjects With Advanced/Metastatic or Surgically Unresectable Solid Tumors Who Are Refractory to Standard Therapy | Active, not recruiting | USA | 1 |
NCT04678648 | Phase I | RSC-1255 | A Trial of RSC-1255 for Treatment of Patients With Advanced Malignancies | Recruiting | USA | 0 |
NCT04678908 | Phase I | HB0025 | A Study of Injection HB0025 in Patients With Advanced Solid Tumors | Recruiting | USA | 1 |
NCT04678921 | Phase I | MOR210 | Study of TJ210001 Administered in Subjects With Relapsed or Refractory Advanced Solid Tumors | Completed | USA | 0 |
NCT04681248 | Expanded access | DKN-01 | Expanded Access Use of DKN-01 for the Treatment of Advanced Solid Tumors | Available | USA | 0 |
NCT04683250 | Phase Ib/II | Vepafestinib | Study of RET Inhibitor TAS0953/HM06 in Patients With Advanced Solid Tumors With RET Gene Abnormalities ((MARGARET)) | Recruiting | USA | 1 |
NCT04683354 | Phase I | Tunlametinib | Phase I Study of HL-085 in Patients With Advanced Solid Tumor Tumors | Completed | USA | 0 |
NCT04686383 | Phase I | CAL056 mesylate | Safety, Tolerability, and Pharmacokinetics of CAL056 Mesylate in Patients With Resistant or Refractory Solid Tumors | Completed | USA | 1 |
NCT04690699 | Phase Ib/II | PVSRIPO + unspecified PD-1 antibody | LUMINOS-103: A Basket Trial Evaluating the Safety and Efficacy of PVSRIPO and PVSRIPO in Combination With Anti-PD-1/L1 Checkpoint Inhibitors in Patients With Advanced Solid Tumors | Recruiting | USA | 0 |
NCT04691375 | Phase I | Pembrolizumab + PY314 PY314 | A Study of PY314 in Subjects With Advanced Solid Tumors | Active, not recruiting | USA | 0 |
NCT04693468 | Phase I | Axitinib + Talazoparib Crizotinib + Talazoparib Palbociclib + Talazoparib | Talazoparib and Palbociclib, Axitinib, or Crizotinib for the Treatment of Advanced or Metastatic Solid Tumors, TalaCom Trial | Recruiting | USA | 0 |
NCT04695847 | Phase I | M1231 | M1231 in Participants With Solid Tumors | Completed | USA | CAN | 0 |
NCT04699188 | Phase Ib/II | JDQ443 JDQ443 + TNO155 JDQ443 + Tislelizumab + TNO155 JDQ443 + Tislelizumab | Study of JDQ443 in Patients With Advanced Solid Tumors Harboring the KRAS G12C Mutation (KontRASt-01) | Recruiting | USA | ITA | FRA | ESP | DEU | CAN | BEL | AUS | 8 |
NCT04704661 | Phase I | Ceralasertib + Trastuzumab deruxtecan | Testing the Combination of Two Anti-cancer Drugs, DS-8201a and AZD6738, for The Treatment of Patients With Advanced Solid Tumors Expressing the HER2 Protein or Gene, The DASH Trial | Recruiting | USA | 0 |
NCT04705818 | Phase II | Durvalumab + Tazemetostat | Combining Epigenetic And Immune Therapy to Beat Cancer. (CAIRE) | Recruiting | FRA | 0 |
NCT04706962 | Phase I | TH1902 | TH1902 in Patients With Advanced Solid Tumors | Recruiting | USA | CAN | 0 |
NCT04708470 | Phase Ib/II | Bintrafusp alfa + Entinostat + NHS-IL12 Entinostat + NHS-IL12 | A Phase I/II Study of Combination Immunotherapy for Advanced Cancers Including HPV-Associated Malignancies, Small Bowel, and Colon Cancers | Recruiting | USA | 0 |
NCT04710043 | Phase I | BNT152 BNT153 | Dose Escalation Trial of BNT152+153 in Patients With Cancer | Recruiting | USA | 1 |
NCT04713371 | Phase II | Cyclophosphamide + Ipilimumab + Pembrolizumab + Sargramostim | A Phase 2 Trial for Patients With Metastatic Solid Cancer | Recruiting | USA | 0 |
NCT04713891 | Phase I | KF-0210 Atezolizumab + KF-0210 | A Study of KF-0210 in Advanced Solid Tumors Patients | Unknown status | AUS | 0 |
NCT04717375 | Phase Ib/II | BND-22 | Study of BND-22 in Participants With Advanced Solid Tumors | Recruiting | USA | 1 |
NCT04718675 | Phase I | KB-0742 | A Dose Escalation and Cohort Expansion Study of KB-0742 in Participants With Relapsed or Refractory Solid Tumors or Non-Hodgkin Lymphoma | Recruiting | USA | GBR | ESP | 0 |
NCT04720976 | Phase Ib/II | JAB-3312 + Pembrolizumab Binimetinib + JAB-3312 | JAB-3312 Activity in Adult Patients With Advanced Solid Tumors | Recruiting | USA | 0 |
NCT04721015 | Phase I | ABBV-637 + Docetaxel ABBV-637 + Osimertinib ABBV-637 | Study of Intravenous (IV) ABBV-637 Alone or in Combination With IV Docetaxel/Osimertinib to Assess Adverse Events and Change in Disease Activity in Adult Participants With Relapsed/Refractory (R/R) Solid Tumors | Active, not recruiting | USA | FRA | ESP | AUS | 4 |
NCT04725331 | Phase Ib/II | BT-001 BT-001 + Pembrolizumab | A Clinical Trial Assessing BT-001 Alone and in Combination With Pembrolizumab in Metastatic or Advanced Solid Tumors | Recruiting | FRA | BEL | 0 |
NCT04725474 | Phase I | CTL-002 | First-in-Human Study of the GDF-15 Neutralizing Antibody CTL-002 in Patients With Advanced Cancer (GDFATHER) (GDFATHER) | Recruiting | ESP | DEU | 1 |
NCT04726332 | Phase I | Abiraterone + Prednisone + XL102 Fulvestrant + XL102 XL102 | Study of XL102 as Single-Agent and Combination Therapy in Subjects With Solid Tumors (QUARTZ-101) | Active, not recruiting | USA | 0 |
NCT04727151 | Phase Ib/II | Cyclophosphamide + Fludarabine + TAC01-HER2 | TAC T-cells for the Treatment of HER2-positive Solid Tumors (TACTIC-2) | Active, not recruiting | USA | CAN | 0 |
NCT04727554 | Phase I | AMG 404 + AMG 994 | Study of AMG 994 Monotherapy and AMG 994 and AMG 404 Combination Therapy in Participants With Advanced Solid Tumors | Completed | USA | GBR | FRA | ESP | DEU | CAN | BEL | AUS | 2 |
NCT04729348 | Phase II | Lenvatinib + Pembrolizumab | Pembrolizumab And Lenvatinib In Leptomeningeal Metastases | Terminated | USA | 0 |
NCT04729725 | Phase I | Cemiplimab + SAR439459 | Strategic Alliance: Phase 1b Trial Assessing Combination of TGF-beta Inhibitor and PD-1 Inhibitor Cemiplimab | Terminated | USA | 0 |
NCT04730349 | Phase Ib/II | Nivolumab + NKTR-214 | A Study of Bempegaldesleukin (BEMPEG: NKTR-214) in Combination With Nivolumab in Children, Adolescents and Young Adults With Recurrent or Treatment-resistant Cancer (PIVOT IO 020) | Terminated | USA | ITA | FRA | ESP | DEU | AUS | 0 |
NCT04735796 | Phase I | LM-102 | Study of LM-102 in Subjects in Advanced Tumors | Terminated | USA | 0 |
NCT04735978 | Phase I | RP3 Nivolumab + RP3 | Study of RP3 Monotherapy and RP3 in Combination With Nivolumab in Patients With Solid Tumours | Active, not recruiting | USA | GBR | FRA | ESP | 1 |
NCT04737122 | Phase I | LM-061 LM-061 + Toripalimab-tpzi | Study of LM-061 in Subjects in Advanced Tumors | Terminated | AUS | 0 |
NCT04739293 | Phase I | Narazaciclib | Study of ON 123300 in Patients With Advanced Cancer | Recruiting | USA | 0 |
NCT04739618 | Phase II | Ipilimumab + Pembrolizumab + Sargramostim | Metastatic Solid Cancer Clinical Trial | Unknown status | USA | 0 |
NCT04740424 | Phase I | FS222 | FS222 First in Human Study in Patients With Advanced Malignancies | Recruiting | ESP | 1 |
NCT04742959 | Phase Ib/II | Tinengotinib Nab-paclitaxel + Tinengotinib | Study of TT-00420 Tablet as Monotherapy and Combination Therapy in Patients With Advanced Solid Tumors | Active, not recruiting | USA | 0 |
NCT04746612 | Phase I | HH30134 | A Phase I Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of HH30134 in Patients With Advanced Solid Tumours | Terminated | AUS | 1 |
NCT04761198 | Phase Ib/II | Etigilimab + Nivolumab | A Study of Etigilimab and Nivolumab in Subjects With Locally Advanced or Metastatic Tumors. | Completed | USA | GBR | 0 |
NCT04761601 | Phase I | Gemcitabine + Paclitaxel + UCT-01-097 UCT-01-097 | First in Human Study of UCT-01-097 in Participants With Advanced Solid Tumors | Terminated | USA | 0 |
NCT04762602 | Phase I | HMPL-306 | A Study of HMPL-306 in Advanced Solid Tumors With IDH Mutations | Active, not recruiting | USA | ESP | 0 |
NCT04762641 | Phase I | ABL503 | This is a Study to Evaluate the Safety and Tolerability of ABL503, and to Determine the Maximum Tolerated Dose (MTD) and Recommended Phase 2 Dose (RP2D) of ABL503 in Subjects With Any Progressive Locally Advanced or Metastatic Solid Tumors | Recruiting | USA | 1 |
NCT04768296 | Phase II | Berzosertib + Topotecan | Berzosertib + Topotecan in Relapsed Platinum-Resistant Small-Cell Lung Cancer (DDRiver SCLC 250) | Completed | USA | ITA | FRA | ESP | BEL | 2 |
NCT04768868 | Phase I | IMP7068 | The Safety and Pharmacokinetics Preliminary Efficacy of IMP7068 in Patients With Advanced Solid Tumors (WEE1) | Recruiting | USA | 2 |
NCT04770246 | Phase II | TAS-117 | TAS-117 in Patients With Advanced Solid Tumors Harboring Germline PTEN Mutations | Terminated | USA | GBR | FRA | AUT | 0 |
NCT04771520 | Phase II | Avapritinib | Avapritinib for the Treatment of CKIT or PDGFRA Mutation-Positive Locally Advanced or Metastatic Malignant Solid Tumors | Recruiting | USA | 0 |
NCT04772989 | Phase I | AB308 + Zimberelimab | A Study to Evaluate AB308 in Combination With AB122 in Participants With Advanced Malignancies (ARC-12) | Active, not recruiting | USA | ESP | 1 |
NCT04773782 | Phase Ib/II | Avapritinib | A Study of Avapritinib in Pediatric Patients With Solid Tumors Dependent on KIT or PDGFRA Signaling | Recruiting | USA | ITA | GBR | FRA | DEU | CAN | AUT | AUS | 1 |
NCT04774718 | Phase Ib/II | Alectinib | A Study Evaluating the Safety, Pharmacokinetics, and Efficacy of Alectinib in Pediatric Participants With ALK Fusion-Positive Solid or CNS Tumors | Recruiting | USA | ITA | GBR | FRA | ESP | DEU | CAN | AUS | 3 |
NCT04774952 | Phase I | RMC-5552 | Dose Escalation of RMC-5552 Monotherapy in Relapsed/Refractory Solid Tumors | Active, not recruiting | USA | 0 |
NCT04775485 | Phase II | Tovorafenib | A Study to Evaluate DAY101 in Pediatric and Young Adult Patients With Relapsed or Progressive Low-Grade Glioma and Advance Solid Tumors (FIREFLY-1) | Recruiting | USA | GBR | DEU | CAN | AUS | 6 |
NCT04777994 | Phase I | ABBV-CLS-484 + unspecified PD-1 antibody ABBV-CLS-484 | A Phase 1 Study With ABBV-CLS-484 in Subjects With Locally Advanced or Metastatic Tumors | Recruiting | USA | FRA | ESP | 3 |
NCT04779151 | Phase II | Dostarlimab-gxly + Niraparib | Basket Trial Exploring the Efficacy and Safety of the Combination of Niraparib and Dostarlimab (NIRADO) | Recruiting | FRA | 0 |
NCT04780217 | Phase Ib/II | T3011 Pembrolizumab + T3011 | A Clinical Study of Intravenous T3011 Given as a Single Agent and in Combination With Intravenous Pembrolizumab in Participants With Advanced or Metastatic Solid Tumors | Active, not recruiting | USA | 0 |
NCT04785287 | Phase Ib/II | BMS-986218 BMS-986218 + Nivolumab | Anti-CTLA4-NF mAb (BMS986218), Nivolumab, and Stereotactic Body Radiation Therapy for the Treatment of Metastatic Solid Malignancies | Active, not recruiting | USA | 0 |
NCT04787042 | Phase Ib/II | Pembrolizumab + ST-067 ST-067 Obinutuzumab + ST-067 | Phase 1a and Phase 2 Study for Safety, Preliminary Efficacy, PK and PD of ST-067 | Recruiting | USA | 0 |
NCT04789668 | Phase Ib/II | Bintrafusp alfa + Pimasertib | Bintrafusp Alfa and Pimasertib for the Treatment of Patients With Brain Metastases | Completed | USA | 0 |
NCT04794699 | Phase I | IDE397 | Study of IDE397 in Participants With Solid Tumors Harboring MTAP Deletion | Recruiting | USA | FRA | ESP | AUS | 2 |
NCT04795661 | Phase II | Pembrolizumab | Immunotherapy in MSI/dMMR Tumors in Perioperative Setting. (IMHOTEP) | Active, not recruiting | FRA | 0 |
NCT04795713 | Phase I | MT-6402 | Study of MT-6402 in Subjects With Advanced Solid Cancer That Expresses PD-L1 | Recruiting | USA | 0 |
NCT04796012 | Phase Ib/II | Atezolizumab + Irinotecan + Temozolomide + Vincristine Sulfate | VITAS: Atezolizumab in Combination With Chemotherapy for Pediatric Relapsed/Refractory Solid Tumors | Recruiting | USA | 0 |
NCT04799054 | Phase Ib/II | Pembrolizumab + TransCon TLR7/8 Agonist TransCon TLR7/8 Agonist | A Study of TransCon TLR7/8 Agonist With or Without Pembrolizumab in Patients With Advanced or Metastatic Solid Tumors | Recruiting | USA | ESP | AUS | 2 |
NCT04800627 | Phase Ib/II | MLN4924 + Pembrolizumab | Pevonedistat and Pembrolizumab for the Treatment of dMMR/MSI-H Metastatic or Locally Advanced Unresectable Solid Tumor | Terminated | USA | 0 |
NCT04800822 | Phase I | PF-07284892 Cetuximab + Encorafenib + PF-07284892 Lorlatinib + PF-07284892 Binimetinib + PF-07284892 | PF-07284892 in Participants With Advanced Solid Tumors | Active, not recruiting | USA | 0 |
NCT04801095 | Phase I | WM-S1-030 | A Phase I Study of WM-S1-030 in Patients With Advanced Solid Tumors | Recruiting | AUS | 1 |
NCT04801966 | Phase 0 | Palbociclib Alpelisib Atezolizumab Vemurafenib Ribociclib Talazoparib Cobimetinib Trametinib Abemaciclib Dabrafenib Nivolumab Binimetinib Pembrolizumab Encorafenib | Safety and Oversight of the Individually Tailored Treatment Approach: A Novel Pilot Study (TAILOR) | Terminated | AUS | 0 |
NCT04802174 | Phase Ib/II | Berzosertib + Lurbinectedin | A Phase I/II Trial of Lurbinectedin With Berzosertib, an ATR Kinase Inhibitor in Small Cell Cancers and High Grade Neuroendocrine Cancers | Recruiting | USA | 0 |
NCT04802876 | Phase II | Tislelizumab Spartalizumab | Efficacy of Tislelizumab and Spartalizumab Across Multiple Cancer-types in Patients With PD1-high mRNA Expressing Tumors (ACROPOLI) | Recruiting | ESP | 0 |
NCT04808362 | Phase Ib/II | OMO-103 | Phase 1/2 Study to Evaluate Safety, PK and Efficacy of the MYC-Inhibitor OMO-103 in Solid Tumours (MYCure) | Active, not recruiting | ESP | 0 |
NCT04826341 | Phase Ib/II | Berzosertib + Sacituzumab govitecan-hziy | A Phase I/II Study of Sacituzumab Govitecan Plus Berzosertib in Small Cell Lung Cancer, Extra-Pulmonary Small Cell Neuroendocrine Cancer and Homologous Recombination-Deficient Cancers Resistant to PARP Inhibitors | Recruiting | USA | 0 |
NCT04827576 | Phase II | Docetaxel + Hu5F9-G4 | Study of Magrolimab in Patients With Solid Tumors (ELEVATELung&UC) | Active, not recruiting | USA | GBR | FRA | ESP | 1 |
NCT04827810 | Phase I | G-TPP | A Phase I Safety and Pharmacokinetic Study of Gamitrinib Administered Intravenously to Patients With Advanced Cancer | Suspended | USA | 0 |
NCT04837196 | Phase Ib/II | ASP7517 + Pembrolizumab ASP7517 | Study of ASP7517 Alone and With Pembrolizumab in Participants With Advanced Solid Tumors Expressing WT1 Antigen | Active, not recruiting | USA | 0 |
NCT04837677 | Phase I | PRT1419 | A Study of PRT1419 in Patients With Advanced Solid Tumors | Completed | USA | 0 |
NCT04839991 | Phase I | CB307 | Study of CB307 in Patients With Advanced and/or Metastatic PSMA-positive Tumours. (POTENTIA) | Recruiting | USA | GBR | ESP | 1 |
NCT04840394 | Phase I | BDB018 BDB018 + Pembrolizumab | Clinical Study of BDB018: Monotherapy and in Combination With Pembrolizumab in Subjects With Advanced Solid Tumors | Active, not recruiting | USA | 0 |
NCT04840589 | Phase I | Ipilimumab + Nivolumab + ZEN-3694 Nivolumab + ZEN-3694 | Testing the Combination of ZEN003694 and Nivolumab With or Without Ipilimumab in Solid Tumors | Recruiting | USA | 0 |
NCT04843709 | Phase Ib/II | MRG004A | A Study of MRG004A in Patients With Tissue Factor Positive Advanced or Metastatic Solid Tumors | Recruiting | USA | 1 |
NCT04844073 | Phase Ib/II | MVC-101 | A Dose Escalation and Expansion Study of MVC-101 in Patients With Advanced Cancer | Recruiting | USA | AUS | 1 |
NCT04851119 | Phase Ib/II | BC2059 | Tegavivint for the Treatment of Recurrent or Refractory Solid Tumors, Including Lymphomas and Desmoid Tumors | Recruiting | USA | 0 |
NCT04851834 | Phase Ib/II | Cisplatin + NTX-301 NTX-301 NTX-301 + Temozolomide Carboplatin + NTX-301 | NTX-301 Monotherapy in Advanced Solid Tumours and in Combination With Platinum-based Chemotherapy in Advanced Ovarian & Bladder Cancer and in Combination With Temozolomide in High-grade Glioma | Terminated | AUS | 0 |
NCT04853017 | Phase Ib/II | ELI-002 | A Study of ELI-002 in Subjects With KRAS Mutated Pancreatic Ductal Adenocarcinoma (PDAC) and Other Solid Tumors (AMPLIFY-201) | Active, not recruiting | USA | 0 |
NCT04855656 | Phase I | RP-6306 | Study of RP-6306 in Advanced Solid Tumors | Recruiting | USA | CAN | 1 |
NCT04855929 | Phase Ib/II | ANV419 | A Study Evaluating Safety and Therapeutic Activity of ANV419 in Patients With Advanced Cancer and Multiple Myeloma. (ANV419-001) | Recruiting | GBR | ESP | 1 |
NCT04857138 | Phase I | RO7300490 Atezolizumab + RO7300490 | A Study to Evaluate Safety, Pharmacokinetics and Anti-Tumor Activity of RO7300490, as Single Agent or in Combination With Atezolizumab in Participants With Advanced Solid Tumors | Completed | GBR | FRA | ESP | 2 |
NCT04857372 | Phase I | IAG933 | A Phase I Study of IAG933 in Patients With Advanced Mesothelioma and Other Solid Tumors | Recruiting | USA | ITA | GBR | FRA | ESP | DEU | CAN | AUS | 3 |
NCT04859777 | Phase I | MPT-0118 + Pembrolizumab MPT-0118 | A Study of MPT-0118 in Subjects With Advanced or Metastatic Refractory Solid Tumors | Unknown status | USA | 0 |
NCT04866134 | Phase Ib/II | ERAS-007 | A Study of ERAS-007 in Patients With Advanced or Metastatic Solid Tumors (HERKULES-1) (HERKULES-1) | Active, not recruiting | USA | 0 |
NCT04868877 | Phase Ib/II | MCLA-129 | A Phase 1/2 Study Evaluating MCLA-129, a Human Anti-EGFR and Anti-c-MET Bispecific Antibody, in Patients With Advanced NSCLC and Other Solid Tumors | Recruiting | USA | ITA | FRA | ESP | DEU | BEL | 3 |
NCT04870944 | Phase Ib/II | CBL0137 | CBL0137 for the Treatment of Relapsed or Refractory Solid Tumors, Including CNS Tumors and Lymphoma | Recruiting | USA | 0 |
NCT04872166 | Phase I | BTX-A51 | A Study of BTX-A51 in People With Advanced Solid Tumor or Non-Hodgkin Lymphoma | Recruiting | USA | 0 |
NCT04875806 | Phase Ib/II | NC762 | A Safety and Tolerability Study of NC762 in Subjects With Advanced or Metastatic Solid Tumors | Active, not recruiting | USA | 0 |
NCT04879121 | Phase II | Larotrectinib | Larotrectinib for the Treatment of NTRK Amplification Positive, Locally Advanced or Metastatic Solid Tumors | Recruiting | USA | 0 |
NCT04881045 | Phase I | PF-07257876 | Study to Test the Safety and Tolerability of PF-07257876 in Participants With Selected Advanced Tumors. | Active, not recruiting | USA | ESP | 0 |
NCT04882917 | Phase I | M4076 | First-in-human Study of M4076 in Advanced Solid Tumors (DDRiver Solid Tumors 410) | Completed | USA | CAN | 0 |
NCT04886622 | Phase I | DT2216 | A Study of DT2216 in Relapsed/Refractory Malignancies | Completed | USA | 0 |
NCT04886804 | Phase I | BI 1810631 | A Study to Test Different Doses of Zongertinib in People With Different Types of Advanced Cancer (Solid Tumours With Changes in the HER2 Gene) | Recruiting | USA | ITA | GBR | FRA | ESP | DEU | BEL | AUT | AUS | 9 |
NCT04887870 | Phase II | Ipilimumab + Sitravatinib Nivolumab + Sitravatinib Enfortumab vedotin-ejfv + Sitravatinib Pembrolizumab + Sitravatinib Sitravatinib | Study of Sitravatinib With or Without Other Anticancer Therapies Receiving Clinical Benefit From Parent Study | Enrolling by invitation | USA | 0 |
NCT04890093 | Phase Ib/II | STA-8666 + Temozolomide + Vincristine Sulfate | Vincristine and Temozolomide in Combination With PEN-866 for Adolescents and Young Adults With Relapsed or Refractory Solid Tumors | Not yet recruiting | USA | 0 |
NCT04890613 | Phase I | CX-5461 | Study of CX-5461 in Patients With Solid Tumours and BRCA1/2, PALB2 or Homologous Recombination Deficiency (HRD) Mutation | Recruiting | USA | CAN | 0 |
NCT04891718 | Phase I | MVC-101 + Nivolumab | CIVO Intratumoural Microdosing of Anti-Cancer Therapies in Australia | Withdrawn | AUS | 0 |
NCT04892017 | Phase Ib/II | DCC-3116 + Sotorasib Binimetinib + DCC-3116 DCC-3116 DCC-3116 + Trametinib | A Phase 1/2 Study of DCC-3116 in Patients With MAPK Pathway Mutant Solid Tumors | Recruiting | USA | 0 |
NCT04892043 | Phase I | Ipilimumab + SQZ-AAC-HPV SQZ-AAC-HPV Ipilimumab + Nivolumab + SQZ-AAC-HPV | Study of SQZ-AAC-HPV in Patients With HPV16+ Recurrent, Locally Advanced or Metastatic Solid Tumors | Terminated | USA | 0 |
NCT04895709 | Phase Ib/II | BMS-986340 + Docetaxel BMS-986340 BMS-986340 + Nivolumab | A Study of BMS-986340 as Monotherapy and in Combination With Nivolumab or Docetaxel in Participants With Advanced Solid Tumors | Recruiting | USA | ITA | ESP | DEU | CAN | AUS | 2 |
NCT04896697 | Phase Ib/II | XTX101 Pembrolizumab + XTX101 | XTX101 Monotherapy and XTX101 and Pembrolizumab Combination Therapy in Patients With Advanced Solid Tumors | Recruiting | USA | 0 |
NCT04897321 | Phase I | Cyclophosphamide + Fludarabine + Mesna + Retroviral vector transduced B7-H3 CAR T cells | B7-H3-Specific Chimeric Antigen Receptor Autologous T-Cell Therapy for Pediatric Patients With Solid Tumors (3CAR) | Recruiting | USA | 0 |
NCT04898543 | Phase I | ALT-803 + m-ceNK cells | QUILT-3.076: Study of Autologous M-CENK in Subjects With Locally Advanced or Metastatic Solid Tumors | Recruiting | USA | 0 |
NCT04900519 | Phase I | STI-6643 | Study of the Safety and Efficacy of STI-6643 in Subjects With Advanced Solid Tumors | Recruiting | USA | 0 |
NCT04900818 | Phase I | TJ033721 | Study of TJ033721 in Subjects With Advanced or Metastatic Solid Tumors | Recruiting | USA | 1 |
NCT04901702 | Phase Ib/II | Irinotecan + Temozolomide Irinotecan + Talazoparib | Study of Onivyde With Talazoparib or Temozolomide in Children With Recurrent Solid Tumors and Ewing Sarcoma | Recruiting | USA | CAN | 0 |
NCT04901806 | Phase Ib/II | PBI-200 | Study of PBI-200 in Subjects With NTRK-Fusion-Positive Solid Tumors | Terminated | USA | ITA | GBR | FRA | ESP | DEU | AUS | 4 |
NCT04902040 | Phase Ib/II | Atezolizumab + Avelumab + Durvalumab + Nivolumab + Pembrolizumab + Plinabulin Atezolizumab + Avelumab + Durvalumab + Nivolumab + Pembrolizumab | Plinabulin in Combination With Radiation/Immunotherapy in Patients With Select Advanced Cancers After Progression on PD-1 or PD-L1 Targeted Antibodies | Recruiting | USA | 0 |
NCT04902443 | Phase I | Nivolumab + Pomalidomide | Pomalidomide and Nivolumab in People With Virus-Associated Malignancies With or Without HIV | Recruiting | USA | 0 |
NCT04903873 | Phase Ib/II | EU101 | A Study to Evaluate Safety, Efficacy, and Pharmacokinetics in Participants With Advanced Solid Tumors | Recruiting | USA | 1 |
NCT04905914 | Phase Ib/II | ATRN-119 | Study Of ATRN-119 In Patients With Advanced Solid Tumors | Recruiting | USA | 0 |
NCT04908176 | Phase I | Avapritinib + Midazolam | A Drug-drug Interaction Study of Avapritinib and Midazolam | Recruiting | USA | 0 |
NCT04913025 | Phase II | Pembrolizumab Nivolumab | REduced Frequency ImmuNE Checkpoint Inhibition in Cancers (REFINE) | Recruiting | GBR | 0 |
NCT04913285 | Phase I | Binimetinib + Exarafenib Exarafenib | A Study to Evaluate KIN-2787 in Participants With BRAF and/or NRAS Mutation Positive Solid Tumors | Recruiting | USA | FRA | ESP | AUS | 4 |
NCT04913337 | Phase Ib/II | NGM707 + Pembrolizumab NGM707 | Study of NGM707 as Monotherapy and in Combination With Pembrolizumab in Advanced or Metastatic Solid Tumor Malignancies | Recruiting | USA | 2 |
NCT04914117 | Phase I | RC118 | A Study of RC118 in Patients With Locally Advanced Unresectable/Metastatic Solid Tumours | Completed | AUS | 0 |
NCT04914286 | Phase Ib/II | GFH018 + Toripalimab-tpzi | A Study of GFH018 in Combination With Toripalimab in Patients With Advanced Solid Tumors | Completed | AUS | 1 |
NCT04919811 | Phase II | Taletrectinib | Taletrectinib Phase 2 Global Study in ROS1 Positive NSCLC (TRUST-II) | Recruiting | USA | ITA | FRA | ESP | CAN | 4 |
NCT04920383 | Phase I | ALPN-202 + unspecified PD-1 antibody | ALPN-202 With PD-1 Inhibition in Advanced Malignancies (NEON-2) | Terminated | USA | 0 |
NCT04925284 | Phase I | XB002 Nivolumab + XB002 | Study of XB002 in Subjects With Solid Tumors (JEWEL-101) | Recruiting | USA | ITA | GBR | FRA | ESP | BEL | AUS | 1 |
NCT04925609 | Phase Ib/II | Brigatinib | Brigatinib in Pediatric and Young Adult Patients With ALK+ ALCL, IMT or Other Solid Tumors (Briga-PED) | Recruiting | FRA | 1 |
NCT04928677 | Phase I | Codrituzumab | A Study of Codrituzumab in Children and Young Adults With Solid Tumors and Have Not Responded to Treatment or Have Come Back After Treatment | Recruiting | USA | 0 |
NCT04936178 | Phase I | NB003 | A Study of NB003 in Patients With Advanced Malignancies | Recruiting | USA | GBR | FRA | ESP | 2 |
NCT04939701 | Phase Ib/II | ASP0739 + Pembrolizumab ASP0739 | Study of ASP0739 Alone and With Pembrolizumab in Advanced Solid Tumors With NY-ESO-1 Expression Participants | Completed | USA | 0 |
NCT04946864 | Phase Ib/II | APG-2575 + Palbociclib APG-2575 | A Study to Investigate the Safety, Tolerability, of APG-2575 as a Single Agent or in Combination for Breast Cancer | Recruiting | USA | 0 |
NCT04949191 | Phase II | Pemigatinib Pembrolizumab + Pemigatinib Pemigatinib + Retifanlimab | The Purpose of the Study is to Continue to Provide Pemigatinib to Patients With Advanced Malignancies. | Active, not recruiting | USA | ITA | 2 |
NCT04949425 | Phase I | Adavosertib | A Study to Assess the Safety and Tolerability of Adavosertib for Patients With Advanced Solid Tumours | Terminated | USA | GBR | 0 |
NCT04954599 | Phase Ib/II | CP-506 CP-506 + Ipilimumab Carboplatin + CP-506 Cemiplimab + CP-506 CP-506 + Durvalumab CP-506 + Pembrolizumab CP-506 + Nivolumab Avelumab + CP-506 Atezolizumab + CP-506 | Phase 1/2 Clinical Trial of CP-506 (HAP) in Monotherapy or With Carboplatin or ICI | Recruiting | BEL | 1 |
NCT04956640 | Phase I | LY3214996 + LY3537982 LY3537982 + Sintilimab Erlotinib + LY3537982 Abemaciclib + LY3537982 LY3537982 Cetuximab + LY3537982 LY3295668 + LY3537982 | Study of LY3537982 in Cancer Patients With a Specific Genetic Mutation (KRAS G12C) | Recruiting | USA | FRA | CAN | AUS | 2 |
NCT04957290 | Phase Ib/II | NOX66 | A Study of NOX66 and External Beam Radiotherapy in Patients With Metastatic Castration-resistant Prostate Cancer and Other Solid Tumors | Terminated | USA | 0 |
NCT04957615 | Phase II | Nivolumab | Nivolumab for the Treatment of Metastatic or Unresectable Solid Tumors With ARID1A Mutation and CXCL13 Expression | Recruiting | USA | 0 |
NCT04958226 | Phase I | Capivasertib + Midazolam | A Study to Assess the Effect of Capivasertib on Midazolam in Patients With Advanced Solid Tumours | Completed | USA | 0 |
NCT04958434 | Phase I | TST005 | Study of TST005 in Patients With Locally Advanced or Metastatic Solid Tumors | Terminated | USA | 0 |
NCT04959266 | Phase I | Adavosertib + Omeprazole Adavosertib + Rifampin Adavosertib + Itraconazole | A Study to Assess the Effects of Itraconazole, Rifampicin, and Omeprazole on Pharmacokinetics of Adavosertib | Terminated | USA | ESP | 0 |
NCT04964375 | Phase I | ABSK043 | A Study to Assess Safety, Tolerability, and Pharmacokinetics of ABSK043 in Patients With Advanced Solid Tumor | Unknown status | AUS | 0 |
NCT04965818 | Phase Ib/II | Binimetinib + Futibatinib | Phase 1b/2 Study of Futibatinib in Combination With Binimetinib in Patients With Advanced KRAS Mutant Cancer | Terminated | USA | 0 |
NCT04969887 | Phase II | Ipilimumab + Nivolumab | Combination Immunotherapy in Rare Cancers Under InvesTigation (MOST-CIRCUIT) | Active, not recruiting | AUS | 1 |
NCT04970992 | Phase I | DZ-002 | A Pharmacokinetic and Pharmacodynamic Study of DZ-002 in Patients With Advanced Solid Malignancies or Lymphoma | Recruiting | USA | 0 |
NCT04972110 | Phase Ib/II | Niraparib + RP-3500 Olaparib + RP-3500 | Study of RP-3500 With Niraparib or Olaparib in Advanced Solid Tumors (ATTACC) | Recruiting | USA | 0 |
NCT04973163 | Phase I | BI 1823911 + Midazolam BI 1701963 + BI 1823911 | A Study to Test Different Doses of BI 1823911 Alone and Combined With Other Medicines in People With Different Types of Advanced Cancer With KRAS Mutation | Active, not recruiting | USA | GBR | ESP | BEL | 0 |
NCT04975256 | Phase I | Adagrasib + BI 1701963 | Adagrasib in Combination With BI 1701963 in Patients With Cancer (KRYSTAL 14) | Completed | USA | 0 |
NCT04975958 | Phase I | Atezolizumab + Buparlisib Atezolizumab + Buparlisib + E7046 Atezolizumab + E7046 | Double/Triple Combinations of AN2025, AN0025 and Atezolizumab in Advanced Solid Tumors | Recruiting | USA | 0 |
NCT04977453 | Phase Ib/II | GI-101 GI-101 + Pembrolizumab GI-101 + Lenvatinib | GI-101 as a Single Agent or in Combination With Pembrolizumab, Lenvatinib or Local Radiotherapy in Advanced Solid Tumors | Recruiting | USA | 1 |
NCT04982926 | Phase I | TAS2940 | A Study of TAS2940 in Participants With Locally Advanced or Metastatic Solid Tumor Cancer | Recruiting | USA | FRA | 0 |
NCT04983745 | Phase II | Dostarlimab-gxly + Niraparib | Niraparib and Dostarlimab in HRD Solid Tumors (DIDO) | Recruiting | USA | 0 |
NCT04983810 | Phase Ib/II | CYC065 | A Study to Investigate Fadraciclib (CYC065), in Subjects With Advanced Solid Tumors and Lymphoma | Recruiting | USA | ESP | 1 |
NCT04985604 | Phase Ib/II | Pimasertib + Tovorafenib Tovorafenib | Tovorafenib (DAY101) Monotherapy or in Combination With Other Therapies for Patients With Melanoma and Other Solid Tumors | Recruiting | USA | FRA | ESP | CAN | BEL | AUS | 1 |
NCT04985721 | Phase II | Pamiparib + Tislelizumab | A Trial of Pamiparib With Tislelizumab in Patients With Advanced Tumours With Homologous Recombination Repair Defects (IMPARP-HRD) | Recruiting | AUS | 0 |
NCT04986865 | Phase I | ATG-101 | A Study of Evaluating the Safety and Efficacy of ATG-101 in Patients With Metastatic/Advanced Solid Tumors and Mature B-cell Non-Hodgkin Lymphomas (PROBE) | Recruiting | USA | AUS | 0 |
NCT04987112 | Phase I | CAN1012 | Intratumoral CAN1012 in Subjects With Solid Tumors | Recruiting | USA | 0 |
NCT04990739 | Phase I | MTB-9655 | Study of MTB-9655, an Inhibitor of ACSS2, in Patients With Advanced Solid Tumors | Unknown status | USA | 1 |
NCT04991480 | Phase Ib/II | ART4215 + Talazoparib ART4215 | A Study of ART4215 for the Treatment of Advanced or Metastatic Solid Tumors | Active, not recruiting | USA | GBR | 0 |
NCT04992013 | Phase II | Niraparib | Niraparib in Tumors Metastatic to the CNS | Recruiting | USA | 0 |
NCT04999202 | Phase I | BAY2416964 + Pembrolizumab BAY2416964 | A Study to Learn How Safe the Study Drug BAY 2416964 (AhR Inhibitor) in Combination With the Treatment Pembrolizumab is, How This Combination Affects the Body, the Maximum Amount That Can be Given, How it Moves Into, Through and Out of the Body and Its Action Against Advanced Solid Cancers in Adults | Active, not recruiting | USA | ITA | GBR | 1 |
NCT05001516 | Phase Ib/II | TPX-4589 | Study of Turning Point Therapeutics LM-302 in Patients With Advance Solid Tumors | Active, not recruiting | USA | 0 |
NCT05002140 | Phase I | XRD-0394 | Trial of XRD-0394, a Kinase Inhibitor, in Combination With Palliative Radiotherapy in Advanced Cancer Patients | Completed | USA | 0 |
NCT05002270 | Phase Ib/II | Cetuximab + Glecirasib Glecirasib | JAB-21822 Activity in Adult Patients With Advanced Solid Tumors Harboring KRAS G12C Mutation | Recruiting | USA | 0 |
NCT05004116 | Phase Ib/II | Irinotecan + Repotrectinib + Temozolomide | A Study of Repotrectinib in Combination With Chemotherapy in Children and Young Adults With Solid Tumor Cancer | Recruiting | USA | 0 |
NCT05007782 | Phase I | GS-1811 GS-1811 + Pembrolizumab | Study to Evaluate the Safety and Tolerability of GS-1811 as Monotherapy and in Combination With Pembrolizumab in Adults With Advanced Solid Tumors | Recruiting | USA | ESP | AUS | 1 |
NCT05010096 | Phase I | BAY1895344 + Copanlisib | BAY1895344 and Copanlisib for the Treatment of Molecularly Selected Patients With Advanced Solid Tumors | Withdrawn | 0 | |
NCT05012397 | Phase II | Milademetan | Milademetan in Advanced/Metastatic Solid Tumors | Terminated | USA | 0 |
NCT05012618 | Phase I | LUNA18 | A Dose-escalation Study of LUNA18 in Patients With Locally Advanced or Metastatic Solid Tumors (With Expansion). | Recruiting | USA | 1 |
NCT05013554 | Phase I | SAR443216 | Dose Escalation and Expansion Study of SAR443216 in Participants With Relapsed/Refractory HER2 Expressing Solid Tumors | Terminated | USA | FRA | ESP | BEL | 2 |
NCT05017012 | Phase I | MK-3475A + Pembrolizumab MK-3475A + Pembrolizumab + Pemetrexed Disodium Carboplatin + MK-3475A + Pembrolizumab MK-3475A + Paclitaxel + Pembrolizumab MK-3475A + Nab-paclitaxel + Pembrolizumab Axitinib + MK-3475A + Pembrolizumab Cisplatin + MK-3475A + Pembrolizumab | A Study to Evaluate the Bioavailability of Pembrolizumab (MK-3475) Via Subcutaneous (SC) Injection of MK-3475A (Pembrolizumab Formulated With MK-5180) In Advanced Solid Tumors (MK-3475A-C18) | Active, not recruiting | ESP | 5 |
NCT05018273 | Phase I | Atezolizumab + VB10.NEO | Study of VB10.NEO in Combination With Atezolizumab in Solid Tumors | Recruiting | USA | ESP | DEU | 0 |
NCT05021120 | Phase I | AK127 + Cadonilimab | A Study to Evaluate the Safety, Pharmacokinetics, and Antitumor Activity of AK127 in Combination With AK104 in Advanced and Metastatic Solid Tumours | Recruiting | AUS | 0 |
NCT05023486 | Phase Ib/II | NP-G2-044 NP-G2-044 + unspecified PD-L1 antibody | NP-G2-044 as Monotherapy and Combination Therapy in Patients With Advanced or Metastatic Solid Tumor Malignancies | Recruiting | USA | 0 |
NCT05023655 | Phase II | Tazemetostat | Phase II Study of Tazemetostat in Solid Tumors Harboring an ARID1A Mutation | Recruiting | USA | 0 |
NCT05024968 | Phase II | Sintilimab | Sintilimab in Cancer of Unknown Primary | Active, not recruiting | USA | 0 |
NCT05025085 | Phase I | AGEN1777 AGEN1777 + unspecified PD-1 antibody | A Study Investigating AGEN1777 in Participants With Advanced Solid Tumors | Active, not recruiting | USA | 0 |
NCT05027139 | Phase Ib/II | Evorpacept + ZW25 | A Study of Zanidatamab (ZW25) With Evorpacept (ALX148) in Patients With Advanced HER2-expressing Cancer | Recruiting | USA | 0 |
NCT05029882 | Phase I | ABBV-400 + Bevacizumab ABBV-400 Bevacizumab + Trifluridine-tipiracil hydrochloride | Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Advanced Solid Tumors Receiving Intravenous (IV) ABBV-400 as Monotherapy and in Combination With IV Bevacizumab | Recruiting | USA | FRA | ESP | AUS | 6 |
NCT05036291 | Phase I | NB004 | A Study of NB004 in Patients With Advanced Solid Tumors | Recruiting | USA | 0 |
NCT05037149 | Phase I | STP707 | Ph. 1, Evaluation of Safety, Tolerability, PK, Anti-tumor Activity of STP707 IV in Subjects With Solid Tumors | Recruiting | USA | 0 |
NCT05038150 | Phase I | SGN1 | Study of SGN1 in Patients With Advanced Solid Tumor | Recruiting | USA | 1 |
NCT05038839 | Phase I | Cabozantinib + Pamiparib | Cabozantinib and Pamiparib for the Treatment of Advanced of Refractory Solid Tumors | Active, not recruiting | USA | 0 |
NCT05039632 | Phase Ib/II | Ipilimumab + NBTXR3 + Nivolumab | NBTXR3, Radiation Therapy, Ipilimumab, and Nivolumab for the Treatment of Lung and/or Liver Metastases From Solid Malignancy | Recruiting | USA | 0 |
NCT05039801 | Phase I | Bevacizumab + IACS-6274 + Paclitaxel IACS-6274 | IACS-6274 With or Without Bevacizumab and Paclitaxel for the Treatment of Advanced Solid Tumors | Recruiting | USA | 0 |
NCT05040932 | Phase I | YH004 | Study of YH004 (4-1BB Agonist Antibody) in Advanced or Metastatic Malignancy | Completed | AUS | 0 |
NCT05041309 | Phase II | KITE-585 KITE-222 Brexucabtagene autoleucel KITE-718 axicabtagene ciloleucel KITE-439 | Long-term Follow-up Study for Participants of Kite-Sponsored Interventional Studies Treated With Gene-Modified Cells | Enrolling by invitation | USA | GBR | FRA | DEU | CAN | AUS | 3 |
NCT05041972 | Phase II | ARX-788 | ARX788 in Selected HER2-mutated or HER2-amplified/Overexpressed Solid Tumors (ACE-Pan Tumor-02) | Withdrawn | USA | 0 |
NCT05047536 | Phase I | KZR-261 | KZR-261 in Subjects With Advanced Solid Malignancies | Recruiting | USA | 0 |
NCT05052255 | Phase Ib/II | RVU120 | RVU120 (SEL120) in Patients With Relapse/Refractory Metastatic or Advanced Solid Tumors | Recruiting | ESP | 1 |
NCT05052268 | Phase Ib/II | XTX202 | XTX202 in Patients With Advanced Solid Tumors | Recruiting | USA | 0 |
NCT05053971 | Phase Ib/II | Entinostat + ZEN-3694 | Testing A New Anti-cancer Drug Combination, Entinostat and ZEN003694, for Advanced and Refractory Solid Tumors and Lymphomas | Recruiting | USA | 0 |
NCT05054348 | Phase I | IO-108 + Pembrolizumab IO-108 | Dose Escalation Study of IO-108 and IO-108+Pembrolizumab in Solid Tumors | Active, not recruiting | USA | 0 |
NCT05055609 | Phase I | TRE-515 | Open-Label, Dose-Escalation With Expansion to Assess the Safety, Tolerability, and PK of TRE-515 in Subjects With Solid Tumors | Recruiting | USA | 0 |
NCT05060432 | Phase Ib/II | EOS-448 + Pembrolizumab EOS-448 + EOS100850 | Study of EOS-448 With Standard of Care and/or Investigational Therapies in Participants With Advanced Solid Tumors (TIG-006) | Recruiting | USA | ITA | GBR | FRA | ESP | BEL | 0 |
NCT05061537 | Phase I | PF-06801591 + PF-07263689 PF-07263689 | Study of PF-07263689 in Participants With Selected Advanced Solid Tumors | Terminated | USA | 0 |
NCT05064280 | Phase II | Lenvatinib Pembrolizumab | Phase II Study of Pembrolizumab in Combination With Lenvatinib in Patients With TNBC, NSCLC, and Other Tumor Types and Brain Metastases | Recruiting | USA | 0 |
NCT05065710 | Phase Ib/II | ZL-1211 | A Study of ZL-1211 in Patients With Advanced Solid Tumor | Recruiting | USA | 1 |
NCT05067283 | Phase I | MK-1084 MK-1084 + Pembrolizumab Carboplatin + MK-1084 + Pembrolizumab + Pemetrexed Disodium Cetuximab + MK-1084 Cetuximab + Fluorouracil + Leucovorin + MK-1084 + Oxaliplatin | A Study of MK-1084 as Monotherapy and in Combination With Pembrolizumab (MK-3475) in Participants With KRAS G12C Mutant Advanced Solid Tumors (MK-1084-001) | Recruiting | USA | ESP | CAN | AUS | 11 |
NCT05069935 | Phase I | Atezolizumab + FT538 Cetuximab + FT538 FT538 + Trastuzumab FT538 + Pembrolizumab FT538 + Nivolumab Avelumab + FT538 Cyclophosphamide + Fludarabine | FT538 in Combination With Monoclonal Antibodies in Advanced Solid Tumors | Terminated | USA | 0 |
NCT05071183 | Phase Ib/II | Repotrectinib + Trametinib | A Study of Repotrectinib in Combination With Other Anticancer Therapies for the Treatment of Subjects With KRAS-Mutant Solid Tumors | Terminated | USA | 0 |
NCT05071209 | Phase Ib/II | BAY1895344 | Elimusertib for the Treatment of Relapsed or Refractory Solid Tumors | Active, not recruiting | USA | CAN | 0 |
NCT05073484 | Phase I | BAT6021 BAT1308 + BAT6021 | Assessment of Safety and Preliminary Efficacy With BAT6021 in Solid Tumor Patients | Terminated | AUS | 0 |
NCT05074472 | Phase Ib/II | ZB131 | A Phase 1/2, First-in-Human, Open Label, Dose Escalation Study Of A CSP Targeting Functional Antibody in Solid Tumors | Completed | USA | 0 |
NCT05075564 | Phase I | ES002023 | A Study of ES002023 (Anti-CD39 Antibody) in Patients With Locally Advanced or Metastatic Solid Tumors | Active, not recruiting | USA | 0 |
NCT05075993 | Phase I | Bevacizumab + Cyclophosphamide + LVGN3616 + LVGN6051 + LVGN7409 LVGN3616 + LVGN6051 + LVGN7409 + Nab-paclitaxel Bevacizumab + Cyclophosphamide + LVGN3616 + LVGN6051 LVGN3616 + LVGN6501 + Nab-paclitaxel | Study of LVGN3616 and LVGN6501±LVGN7409 in Combination With Nab-Paclitaxel or Bevacizumab and Cyclophosphamide in Metastatic Solid Tumors | Recruiting | USA | 0 |
NCT05076552 | Phase I | TACH101 | A Study to Assess the Safety, Pharmacokinetics, and Antitumor Activity of Oral TACH101 in Participants With Advanced or Metastatic Cancer | Recruiting | USA | 0 |
NCT05076591 | Phase I | IMM2902 | IMM2902, a HER2/SIRPalpha Bispecific mAb-Trap Antibody-receptor Fusion Protein, in Patients With HER2-expressing Advanced Solid Tumors | Recruiting | USA | 0 |
NCT05078671 | FDA approved | Olaparib Cobicistat + Olaparib | Pharmacokinetic Boosting of Olaparib to Improve Exposure, Tolerance and Cost-effectiveness (PROACTIVE) | Recruiting | 1 | |
NCT05081609 | Phase Ib/II | TransCon IL-2 beta/gamma Pembrolizumab + TransCon IL-2 beta/gamma | IL Believe: A Study of TransCon IL-2 beta/gamma Alone or in Combination With Pembrolizumab or Chemotherapy in Participants With Locally Advanced or Metastatic Solid Tumors (IL Believe) | Recruiting | USA | AUS | 1 |
NCT05082025 | Phase II | Copanlisib + Fulvestrant | Phase 2 Study of PI3K Inhibitor Copanlisib in Combination With Fulvestrant in Selected ER+ and/or PR+ Cancers With PI3K (PIK3CA, PIK3R1) and/or PTEN Alterations | Active, not recruiting | USA | 0 |
NCT05082259 | Phase I | ASTX-660 + Pembrolizumab | ASTEROID: A Trial of ASTX660 in Combination With Pembrolizumab (ASTEROID) | Recruiting | GBR | 0 |
NCT05082545 | Phase I | SHR-1316 + SHR-2002 | Phase I Study of SHR-2002 + SHR-1316 in Patients With Advanced Malignant Tumors | Active, not recruiting | AUS | 0 |
NCT05082610 | Phase I | HMBD-002 HMBD-002 + Pembrolizumab | A Study of HMBD-002, a Monoclonal Antibody Targeting VISTA, as Monotherapy and Combined With Pembrolizumab | Recruiting | USA | 0 |
NCT05083481 | Phase Ib/II | ASP1570 | A Study of ASP1570 in Adults With Locally Advanced or Metastatic Solid Tumors | Recruiting | USA | 1 |
NCT05086692 | Phase Ib/II | MDNA11 + Pembrolizumab | A Beta-only IL-2 ImmunoTherapY Study (ABILITY-1) | Recruiting | USA | CAN | AUS | 1 |
NCT05091528 | Phase Ib/II | SBT6050 + Trastuzumab deruxtecan SBT6050 + Trastuzumab + Tucatinib Capecitabine + SBT6050 + Trastuzumab + Tucatinib | A Safety and Activity Study of SBT6050 in Combination With Other HER2-directed Therapies for HER2-positive Cancers | Terminated | USA | 0 |
NCT05093322 | Phase Ib/II | Gemcitabine + Surufatinib | A Study of Surufatinib in Combination With Gemcitabine in Pediatric, Adolescent, and Young Adult Patients With Recurrent or Refractory Solid Tumors | Completed | USA | 0 |
NCT05094336 | Phase Ib/II | AMG193 AMG193 + Docetaxel | AMG 193, Methylthioadenosine (MTA) Cooperative Protein Arginine Methyltransferase 5 (PRMT5) Inhibitor, Alone and in Combination With Docetaxel in Advanced Methylthioadenosine Phosphorylase (MTAP)-Null Solid Tumors (MTAP) | Recruiting | USA | GBR | FRA | DEU | CAN | BEL | AUT | AUS | 5 |
NCT05094804 | Phase Ib/II | Nivolumab + OR2805 OR2805 + Pembrolizumab OR2805 | A Study of OR2805, a Monoclonal Antibody Targeting CD163, Alone and in Combination With a PD-1 Inhibitor | Recruiting | USA | 0 |
NCT05097599 | Phase II | Binimetinib + Encorafenib Trastuzumab deruxtecan Enfortumab vedotin-ejfv Talazoparib Lorlatinib | Strata PATH (Precision Indications for Approved Therapies) (Strata PATH) | Recruiting | USA | 0 |
NCT05098132 | Phase I | STK012 Pembrolizumab + STK012 | Phase 1a/1b Study of STK-012 Monotherapy and in Combination With Pembrolizumab in Subjects With Solid Tumors | Recruiting | USA | 0 |
NCT05098405 | Phase I | MP0317 | First-in-human Safety and Tolerability of MP0317 in Patients With Relapsed/Refractory Advanced Solid Tumors | Terminated | FRA | 1 |
NCT05099549 | Phase Ib/II | AFM24 + SNK01 | Safety, Tolerability, and Anti-Tumor Activity of AFM24 in Combination With SNK01 in Subjects With Advanced/Metastatic EGFR-Expressing Cancers | Terminated | USA | 0 |
NCT05101070 | Phase Ib/II | Pembrolizumab + S-531011 Pembrolizumab S-531011 | S-531011 as Monotherapy and in Combination With an Immune Checkpoint Inhibitor in Advanced or Metastatic Solid Tumors (aCCeleR8-001) | Recruiting | USA | 1 |
NCT05102214 | Phase Ib/II | HLX301 | HLX301 (TIGIT×PDL1 Bispecific) in Patients With Locally Advanced or Metastatic Solid Tumors | Recruiting | AUS | 0 |
NCT05103046 | Phase I | UCT-03-008 | First in Human Study of UCT-03-008 in Participants With Advanced Solid Tumors | Recruiting | USA | 0 |
NCT05103345 | Phase I | SGN1 | Study of SGN1 Administered Via Intratumoral Injection in Patients With Advanced Solid Tumor | Recruiting | 2 | |
NCT05103358 | Phase II | Nab-rapamycin | Phase 2 Basket Trial of Nab-sirolimus in Patients With Malignant Solid Tumors With Pathogenic Alterations in TSC1/TSC2 Genes (PRECISION 1) | Recruiting | USA | 2 |
NCT05103683 | Phase I | TORL-1-23 | First in Human Study of TORL-1-23 in Participants With Advanced Cancer | Recruiting | USA | 0 |
NCT05108623 | Phase I | AgenT-797 AgenT-797 + Nivolumab AgenT-797 + Pembrolizumab | A Study Investigating agenT-797 in Participants With Relapsed/Refractory Solid Tumors | Recruiting | USA | 0 |
NCT05109975 | Phase I | Debio 0123 | A Study to Evaluate Safety and Preliminary Anti-tumor Activity of Debio 0123 as Monotherapy in Adult Participants With Advanced Solid Tumors | Recruiting | USA | ESP | 1 |
NCT05111561 | Phase I | Binimetinib + ZEN-3694 | Testing the Combination of the Anticancer Drugs ZEN003694 and Binimetinib in Patients With Advanced/Metastatic or Unresectable Solid Tumors With RAS Alterations and Triple Negative Breast Cancer | Recruiting | USA | 0 |
NCT05112549 | Phase I | Nivolumab | Intrathecal Application of PD1 Antibody in Metastatic Solid Tumors With Leptomeningeal Disease (IT-PD1/ NOA 26) (IT-PD1) | Recruiting | DEU | 0 |
NCT05114668 | Phase I | EVT801 | Safety, Tolerability, and Pharmacokinetics of EVT801 in Patients With Advanced Solid Tumours | Recruiting | FRA | 0 |
NCT05115292 | Phase I | BJ-005 | A First-in-Human, Phase 1 Dose-Escalation and Cohort Expansion Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of BJ-005 in Patients With Advanced Solid Tumor or Lymphoma | Active, not recruiting | USA | 0 |
NCT05116891 | Phase Ib/II | Cisplatin + Gemcitabine + Nidanilimab Docetaxel + Nidanilimab Fluorouracil + Leucovorin + Nidanilimab + Oxaliplatin | A Phase 1/2 Study of CAN04 in Combination With Different Chemotherapy Regimens in Subjects With Advanced Solid Tumors | Completed | FRA | ESP | 0 |
NCT05117177 | Phase I | EOS100850 | New Formulation Study of Inupadenant (EOS100850) in Patients With Cancer | Recruiting | GBR | BEL | 0 |
NCT05117476 | Phase I | CLN-619 CLN-619 + Pembrolizumab | A Study of CLN-619 Alone and in Combination With Pembrolizumab in Advanced Solid Tumors | Recruiting | USA | ESP | AUS | 1 |
NCT05118789 | Phase Ib/II | NUV-520 | A Study of NVL-520 in Patients With Advanced NSCLC and Other Solid Tumors Harboring ROS1 Rearrangement (ARROS-1) | Recruiting | USA | FRA | ESP | DEU | CAN | BEL | AUS | 4 |
NCT05119933 | Phase Ib/II | YL-15293 | A Phase 1/2, Study of YL-15293 in Subjects With Advanced Solid Tumors With a KRAS G12C Mutation | Unknown status | USA | 0 |
NCT05120596 | Phase Ib/II | Pembrolizumab + T3P-Y058-739 T3P-Y058-739 | First in Human Study of T3P-Y058-739 (T3P) | Recruiting | GBR | 1 |
NCT05120960 | Phase I | Tepotinib Osimertinib + Tepotinib | A Phase 1a/1b Study to Determine the Recommended Phase 2 Dose, of Tepotinib in Participants With MET Alterations and Brain Tumors | Recruiting | USA | 0 |
NCT05121948 | Phase I | HC-7366 | A Study of HC-7366 to Establish the Maximum Tolerated Dose (MTD) and Recommended Phase 2 Dose (RP2D) | Terminated | USA | 0 |
NCT05123482 | Phase Ib/II | AZD8205 | First in Human Study to Evaluate AZD8205 in Patients With Advanced or Metastatic Solid Malignancies | Recruiting | USA | GBR | ESP | CAN | BEL | AUS | 8 |
NCT05128487 | Phase Ib/II | NDI-101150 NDI-101150 + Pembrolizumab | A Study of NDI 1150-101 in Patients With Solid Tumors | Recruiting | USA | 0 |
NCT05128825 | Phase II | ZN-c3 | A Study of ZN-c3 in Subjects With Malignant Tumors | Recruiting | USA | AUS | 0 |
NCT05129280 | Phase I | RO7444973 + Tocilizumab RO7444973 | A Study to Evaluate Safety, Pharmacokinetics, and Preliminary Anti-tumor Activity of RO7444973 in Participants With Unresectable and/or Metastatic MAGE-A4-positive Solid Tumors | Terminated | USA | GBR | ESP | BEL | AUS | 1 |
NCT05135975 | Phase II | Cabozantinib | A Study of Cabozantinib as a Maintenance Agent to Prevent Progression or Recurrence in High-Risk Pediatric Solid Tumors | Recruiting | USA | 0 |
NCT05142241 | Phase II | Talazoparib + Temozolomide | Testing the Combination of Anti-Cancer Drugs Talazoparib and Temozolomide in Patients >= 18 Years Old With Advanced Stage Rare Cancers, RARE 2 Study | Recruiting | USA | 0 |
NCT05142592 | Phase I | IPG7236 | IPG7236 in Patients With Advanced Solid Tumors | Unknown status | USA | 0 |
NCT05143970 | Phase I | IPH5301 IPH5301 + Paclitaxel + Trastuzumab | A Phase 1 First-In-Human Study of the Anti-CD73 IPH5301 Alone or in Combination With Chemotherapy and Trastuzumab in Patients With Advanced Solid Tumors (CHANCES) | Recruiting | FRA | 0 |
NCT05144334 | Phase I | BTX-1188 | A Study of BTX-1188 in Subjects With Advanced Malignancies | Terminated | USA | 0 |
NCT05144698 | Phase II | RAPA-201 | RAPA-201 Therapy of Solid Tumors | Recruiting | USA | 0 |
NCT05147272 | Phase I | Gemcitabine + RP-6306 | Study of RP-6306 With Gemcitabine in Advanced Solid Tumors | Active, not recruiting | USA | GBR | CAN | 0 |
NCT05147350 | Phase I | Fluorouracil + Irinotecan + Leucovorin + RP-6306 | Study of RP-6306 With FOLFIRI in Advanced Solid Tumors (MINOTAUR) | Active, not recruiting | USA | GBR | ESP | CAN | 0 |
NCT05150457 | Phase I | BNA035 | Safety and Preliminary Efficacy of BNA035 in Patients With Advanced Solid Tumors | Recruiting | AUS | 0 |
NCT05150691 | Phase Ib/II | DB-1303 | A Study of DB-1303 in Advanced/Metastatic Solid Tumors | Recruiting | USA | AUS | 2 |
NCT05155332 | Phase I | BI 1831169 + Ezabenlimab BI 1831169 | A Study to Test Different Doses of BI 1831169 Alone and in Combination With Ezabenlimab in People With Different Types of Advanced Cancer (Solid Tumors). | Recruiting | USA | FRA | ESP | DEU | BEL | AUT | 0 |
NCT05156866 | Phase I | TORL-2-307-ADC | First in Human Study of TORL-2-307-ADC in Participants With Advanced Cancer | Recruiting | USA | 1 |
NCT05159388 | Phase Ib/II | PRS-344/S095012 | A Study of PRS-344/S095012 (PD-L1x4-1BB Bispecific Antibody-Anticalin Fusion) in Patients With Solid Tumors | Recruiting | USA | ESP | BEL | AUS | 0 |
NCT05159440 | Phase I | TORL-2-307-MAB | First in Human Study of TORL-2-307-MAB in Participants With Advanced Cancer | Recruiting | USA | 1 |
NCT05159518 | Phase I | PRT2527 | A Study of PRT2527 in Participants With Advanced Solid Tumors | Completed | USA | 0 |
NCT05159700 | Phase I | PRJ1-3024 | A Phase I Study, Evaluating the Safety, Pharmacokinetics and Efficacy of PRJ1-3024 in Subjects With Advanced Solid Tumors | Recruiting | USA | 0 |
NCT05162443 | Expanded access | Adagrasib | Expanded Access of Adagrasib (MRTX849) in Patients With Advanced Solid Tumors Who Have a KRAS G12C Mutation | Approved for marketing | USA | 0 |
NCT05162755 | Phase I | S095029 S095029 + Sym021 Futuximab + S095029 + Sym021 Modotuximab + S095029 + Sym021 | S095029 as Monotherapy and in Combination With Sym021 in Patients With Advanced Solid Tumor Malignancies Followed by an Expansion Part With Triple Combinations in Patients With Metastatic Gastric or Colorectal Cancers | Active, not recruiting | USA | CAN | 0 |
NCT05163028 | Phase I | HBI-2376 | A Dose Escalation Study of SHP2 Inhibitor in Patients With Solid Tumors Harboring KRAS of EGFR Mutations | Recruiting | USA | 1 |
NCT05163041 | Phase Ib/II | BT7480 BT7480 + Nivolumab | Study BT7480-100 in Patients With Advanced Malignancies Associated With Nectin-4 Expression | Recruiting | USA | GBR | 0 |
NCT05169437 | Phase II | Niraparib | Niraparib in the Treatment of Patients With Advanced PALB2 Mutated Tumors (PAVO) | Active, not recruiting | USA | 0 |
NCT05169697 | Phase I | YH001 + YH002 | A Study to Assess YH002 in Combination With YH001 in Subjects With Advanced Solid Tumors | Recruiting | AUS | 1 |
NCT05176483 | Phase I | Nivolumab + NKTR-214 XL092 Nivolumab + NKTR-214 + XL092 Ipilimumab + Nivolumab + XL092 Nivolumab + XL092 Ipilimumab + Nivolumab | Study of XL092 in Combination With Immuno-Oncology Agents in Subjects With Solid Tumors (STELLAR-002) | Recruiting | USA | ITA | GBR | FRA | ESP | DEU | BEL | AUT | AUS | 4 |
NCT05176509 | Phase I | Pembrolizumab + YH001 + YH003 | A Study to Evaluate the Combination of YH003, YH001 and Pembrolizumab in Subjects With Advanced Solid Tumors | Recruiting | AUS | 0 |
NCT05178888 | Phase I | Adagrasib + Palbociclib | Adagrasib in Combination With Palbociclib in Patients With Advanced Solid Tumors (KRYSTAL-16) | Active, not recruiting | USA | 0 |
NCT05180474 | Phase Ib/II | GEN1047 | GEN1047 for Solid Tumors - First in Human (FIH) Trial | Recruiting | USA | ITA | GBR | FRA | ESP | BEL | 3 |
NCT05180799 | Phase Ib/II | BA3071 + Nivolumab BA3071 | A Phase 1/2 Study of BA3071 | Recruiting | USA | AUS | 0 |
NCT05188664 | Phase Ib/II | Toripalimab-tpzi + TPX-4589 TPX-4589 | Study of LaNova Medicines(LM)-302 in Combination With Toripalimab in Patients With Advanced Solid Tumors | Terminated | AUS | 0 |
NCT05198349 | Phase I | M1069 | First in Human Study of M1069 in Advanced Solid Tumors | Terminated | USA | CAN | 0 |
NCT05199272 | Phase Ib/II | 23ME-00610 | A Phase 1/2a Study of 23ME-00610 in Patients With Advanced Solid Malignancies | Recruiting | USA | CAN | 0 |
NCT05199285 | Phase II | Ipilimumab + Nivolumab | Nivolumab and Ipilimumab for the Treatment of Patients With Locally Advanced, Metastatic, or Unresectable Liver Cancer | Recruiting | USA | 0 |
NCT05199584 | Phase II | Taladegib | A Study Evaluating the Safety and Efficacy of ENV-101 (Taladegib) in Patients With Advanced Solid Tumors Harboring PTCH1 Loss of Function Mutations | Active, not recruiting | USA | 0 |
NCT05199753 | Phase Ib/II | LM-108 LM-108 + unspecified PD-1 antibody | Study of LM-108 as a Single Agent or in Combination With Anti-PD-1 Antibody in Subjects With Advanced Solid Tumours | Recruiting | AUS | 0 |
NCT05200013 | Phase I | BAT7104 | BAT7104 in Patients With Advanced Solid Tumours | Active, not recruiting | AUS | 0 |
NCT05200273 | Phase I | AK114 | A Study to Evaluate the Safety, Pharmacokinetics, and Antitumor Activity of AK114 | Unknown status | AUS | 0 |
NCT05200559 | Phase Ib/II | E7777 + Pembrolizumab | T-regulatory Cell Depletion With E7777 Combined With Pembrolizumab in Recurrent or Metastatic Solid Tumors | Recruiting | USA | 0 |
NCT05203172 | FDA approved | Encorafenib Binimetinib + Encorafenib Binimetinib + Encorafenib + Ribociclib Binimetinib + Cetuximab + Encorafenib Binimetinib | The FLOTILLA Study: Providing Continued Access to The Study Medicines Encorafenib and Binimetinib for Participants in Prior Clinical Trials | Recruiting | USA | ITA | GBR | FRA | ESP | DEU | CAN | AUS | 9 |
NCT05204290 | Phase I | Pembrolizumab | A Pilot Study of Combined Decompressive Spine Radiosurgery and Pembrolizumab | Recruiting | USA | 0 |
NCT05204862 | Phase Ib/II | TU2218 TU2218 + unspecified PD-1 antibody | Phase 1/2 Study of TU2218 Alone and in Combination With Checkpoint Inhibitors in Patients With Advanced Solid Tumors | Recruiting | USA | 1 |
NCT05205109 | Phase I | ATG-037 | A Study to Assess the Safety, Pharmacokinetics, Pharmacodynamics, and Preliminary Efficacy of ATG 037 Monotherapy and Combination Therapy With Pembrolizumab in Patients | Recruiting | AUS | 1 |
NCT05210413 | Phase Ib/II | Pazopanib + Spartalizumab | Spartalizumab and Low-dose PAzopanib in Refractory or Relapsed Solid TumOrs of Pediatric and Young Adults (SPARTO) | Not yet recruiting | FRA | 0 |
NCT05215574 | Phase I | NGM831 NGM831 + Pembrolizumab | Study of NGM831 as Monotherapy and in Combination With Pembrolizumab in Advanced or Metastatic Solid Tumors | Recruiting | USA | 0 |
NCT05216432 | Phase I | RLY-2608 Fulvestrant + RLY-2608 | First-in-Human Study of Mutant-selective PI3Kalpha Inhibitor, RLY-2608, as a Single Agent in Advanced Solid Tumor Patients and in Combination With Fulvestrant in Patients With Advanced Breast Cancer | Recruiting | USA | ITA | FRA | ESP | 0 |
NCT05220098 | Phase Ib/II | TAK-280 | First-in-Human Study of TAK-280 in Participants With Unresectable Locally Advanced or Metastatic Cancer | Recruiting | USA | AUS | 0 |
NCT05222165 | Phase Ib/II | Infigratinib | Study With Infigratinib in Subjects With Advanced Solid and CNS Tumors or Recurrent or Progressive Low-Grade Glioma With Selected FGFR1-3 Alterations (NEWEL) | Withdrawn | USA | DEU | CAN | 0 |
NCT05225584 | Phase I | KT-333 | Safety, PK, PD, Clinical Activity of KT-333 in Adult Patients With Refractory Lymphoma, Large Granular Lymphocytic Leukemia, Solid Tumors | Recruiting | USA | 0 |
NCT05226507 | Phase I | NXP800 | A Phase 1 Clinical Study of NXP800 in Subjects With Advanced Cancers | Recruiting | USA | GBR | 0 |
NCT05226871 | Phase II | Letrozole + Palbociclib Cetuximab + Palbociclib Cetuximab Fulvestrant + Palbociclib | Study for Participants Continuing From Pfizer-sponsored Palbociclib (a Study Medicine) Studies | Recruiting | USA | 3 |
NCT05227326 | Phase I | AOH1996 | AOH1996 for the Treatment of Refractory Solid Tumors | Recruiting | USA | 0 |
NCT05228015 | Phase I | IK-930 | Oral TEAD Inhibitor Targeting the Hippo Pathway in Subjects With Advanced Solid Tumors | Recruiting | USA | 0 |
NCT05228600 | Phase I | YL-13027 | YL-13027 in Patients With Advanced Solid Tumors | Unknown status | USA | 0 |
NCT05231746 | Phase I | hSTC810 | A Study of hSTC810 With Advanced/Metastatic Solid Tumors (STCUBE-001) | Completed | USA | 1 |
NCT05233436 | Phase I | PF-07265028 PF-06801591 + PF-07265028 | PF-07265028 As Single Agent And In Combination With Sasanlimab in Advanced or Metastatic Solid Tumors | Terminated | USA | 1 |
NCT05234853 | Phase I | PUR001 | Safety of PUR001 Monotherapy in Patients With Advanced Solid Tumors | Recruiting | USA | 0 |
NCT05238831 | Phase II | Vemurafenib Vinorelbine Palbociclib Irinotecan Alpelisib Capecitabine Atezolizumab Paclitaxel Entrectinib Cobimetinib Nab-paclitaxel Fulvestrant Carboplatin Olaparib Pertuzumab/trastuzumab/hyaluronidase-zzxf Niraparib Vismodegib Alectinib Letrozole Ado-trastuzumab emtansine Bevacizumab Eribulin Anastrozole | SMMART Adaptive Clinical Treatment (ACT) Trial | Withdrawn | 0 | |
NCT05238922 | Phase I | INCB123667 | Study of INCB123667 in Subjects With Advanced Solid Tumors | Recruiting | USA | ITA | GBR | FRA | 3 |
NCT05240898 | Phase I | KSQ-4279 | A Phase 1 Study of KSQ-4279 Alone and in Combination in Patients With Advanced Solid Tumors | Recruiting | USA | 0 |
NCT05241834 | Phase I | LOXO-260 | A Study of LOXO-260 in Cancer Patients With a Change in a Particular Gene (RET) That Has Not Responded to Treatment | Recruiting | USA | 0 |
NCT05242822 | Phase I | KIN-3248 | A Study to Evaluate KIN-3248 in Participants With Advanced Tumors Harboring FGFR2 and//or FGFR3 Gene Alterations | Active, not recruiting | USA | ESP | 4 |
NCT05244551 | Phase I | ABSK061 | A Study to Assess Safety, Tolerability, and Pharmacokinetics of ABSK061 in Patients With Advanced Solid Tumors | Recruiting | USA | 1 |
NCT05245500 | Phase Ib/II | MRTX1719 | Phase 1/2 Study of MRTX1719 in Solid Tumors With MTAP Deletion | Recruiting | USA | 0 |
NCT05251714 | Phase Ib/II | CFI-402257 CFI-402257 + Fulvestrant | CFI-402257, a Potent and Selective TTK Inhibitor, in Solid Tumors and With Fulvestrant in Breast Cancer | Recruiting | USA | 0 |
NCT05252390 | Phase Ib/II | NUV-868 NUV-868 + Olaparib Enzalutamide + NUV-868 | NUV-868 as Monotherapy and in Combination With Olaparib or Enzalutamide in Adult Patients With Advanced Solid Tumors | Recruiting | USA | AUS | 0 |
NCT05252416 | Phase Ib/II | BLU-222 + Carboplatin BLU-222 + Fulvestrant + Ribociclib BLU-222 + Fulvestrant | (VELA) Study of BLU-222 in Advanced Solid Tumors | Recruiting | USA | ITA | GBR | 0 |
NCT05255484 | Phase Ib/II | LM-108 + unspecified PD-1 antibody LM-108 | Study of LM-108 as a Single Agent or in Combination With Pembrolizumab in Subjects With Advanced Solid Tumours | Terminated | USA | 0 |
NCT05262400 | Phase II | Letrozole + PF-07104091 + PF-07220060 Fulvestrant + PF-07104091 + PF-07220060 PF-07104091 + PF-07220060 | A Study to Learn About the Study Medicine (Called PF-07220060 in Combination With PF-07104091) In Participants With Breast Cancer and Solid Tumors | Recruiting | USA | ESP | 7 |
NCT05262530 | Phase Ib/II | BNT142 | Safety and Preliminary Efficacy Trial of BNT142 in Patients With CLDN6-positive Solid Tumors | Recruiting | USA | GBR | ESP | 1 |
NCT05263180 | Phase I | EMB-09 | A Study of EMB-09 in Participants With Advanced or Metastatic Solid Tumors. | Recruiting | AUS | 1 |
NCT05266612 | Phase I | VG2025 | A Clinical Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Biologic Effect of VG2025 in Subjects With Advanced Malignant Solid Tumors | Recruiting | USA | 0 |
NCT05267626 | Phase Ib/II | Aldesleukin + AU-007 AU-007 | Study of AU-007, A Monoclonal Antibody That Binds to IL-2 and Inhibits IL-2Ra Binding, in Patients With Unresectable Locally Advanced or Metastatic Cancer | Recruiting | USA | AUS | 0 |
NCT05267899 | Phase I | WGI-0301 | A Phase I First in Human Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of WGI-0301 in Patients With Advanced Solid Tumors | Recruiting | USA | 0 |
NCT05268666 | Phase Ib/II | JBI-802 | A Study of Orally Administered JBI-802, an LSD1/HDAC6 Inhibitor, in Patients With Advanced Solid Tumors | Recruiting | USA | 0 |
NCT05269316 | Phase I | IMP9064 | Study to Evaluate IMP9064 as a Monotherapy or in Combination in Patients With Advanced Solid Tumors | Recruiting | USA | AUS | 2 |
NCT05269381 | Phase I | Cyclophosphamide + Neoantigen peptide vaccine + Pembrolizumab + Sargramostim | Personalized Neoantigen Peptide-Based Vaccine in Combination With Pembrolizumab for Treatment of Advanced Solid Tumors (PNeoVCA) | Recruiting | USA | 0 |
NCT05270213 | Phase I | RBS2418 | RBS2418 Evaluation in Subjects With Unresectable or Metastatic Tumors | Recruiting | USA | 0 |
NCT05272709 | Phase Ib/II | TT-702 | TT-702 in Patients With Advanced Solid Tumours. (CURATE) | Recruiting | GBR | 0 |
NCT05275478 | Phase Ib/II | TNG908 | Safety and Tolerability of TNG908 in Patients With MTAP-deleted Solid Tumors | Recruiting | USA | FRA | 0 |
NCT05277168 | Phase Ib/II | SHR-A1904 | A TRIAL TO EVALUATE THE SAFETY, TOLERABILITY, PHARMACOKINETICS, AND EFFICACY OF SHR-A1904 IN SUBJECTS WITH ADVANCED SOLID TUMORS | Recruiting | USA | AUS | 0 |
NCT05277402 | Phase I | ADG116 + Pembrolizumab | ADG116 in Combination With Pembrolizumab in Patients With Advanced/Metastatic Solid Tumors | Completed | USA | 0 |
NCT05278975 | Phase Ib/II | Thiostrepton | Study of RSO-021 in Patients With Malignant Pleural Effusion Due to Advanced/Metastatic Solid Tumors Including Mesothelioma | Recruiting | GBR | 0 |
NCT05279300 | Phase I | CS5001 | A Study of CS5001 in Patients With Advanced Solid Tumors and Lymphomas | Recruiting | USA | AUS | 1 |
NCT05286801 | Phase Ib/II | Atezolizumab + Tiragolumab | Tiragolumab and Atezolizumab for the Treatment of Relapsed or Refractory SMARCB1 or SMARCA4 Deficient Tumors | Recruiting | USA | CAN | AUS | 0 |
NCT05287399 | Phase I | ASC61 | Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of ASC61in Subjects With Advanced Solid Tumors | Recruiting | USA | 0 |
NCT05290597 | Phase I | IBI363 | A Phase 1, Open-label, Multicenter, Dose Escalation Study of IBI363 (PD1-IL2m) in Subjects With Advanced Solid Malignancies or Lymphomas | Recruiting | AUS | 0 |
NCT05300048 | Phase I | Serabelisib Nab-paclitaxel + Serabelisib | Combination of Serabelisib and Insulin Suppressing Diet With or Without Nab-paclitaxel in Subjects With Advanced Solid Tumors With PIK3CA Mutations | Active, not recruiting | USA | 0 |
NCT05300438 | Phase I | TSN084 | Phase I Study of TSN084 in Patients With Advanced Malignant Tumors. | Recruiting | USA | 0 |
NCT05302921 | Phase II | Ipilimumab + Nivolumab | Neoadjuvant Dual Checkpoint Inhibition and Cryoablation in Relapsed/Refractory Pediatric Solid Tumors | Active, not recruiting | USA | 0 |
NCT05303532 | Phase III | Durvalumab | Roll Over StudY for Patients Who Have Completed a Previous Oncology Study With Durvalumab (ROSY-D) | Enrolling by invitation | USA | ITA | GBR | FRA | ESP | DEU | CAN | AUS | 19 |
NCT05306444 | Phase I | HBM7008 | HBM7008 -Study on Subjects With Advanced Solid Tumors | Recruiting | USA | AUS | 0 |
NCT05307705 | Phase I | Abemaciclib + Anastrozole + LOXO-783 Abemaciclib + Exemestane + LOXO-783 Abemaciclib + Letrozole + LOXO-783 LOXO-783 + Paclitaxel Fulvestrant + LOXO-783 LOXO-783 + LY3484356 Abemaciclib + Fulvestrant + LOXO-783 Abemaciclib + LOXO-783 + LY3484356 Letrozole + LOXO-783 LOXO-783 Anastrozole + LOXO-783 Exemestane + LOXO-783 | A Study of LOXO-783 in Patients With Breast Cancer/Other Solid Tumors (PIKASSO-01) | Recruiting | USA | GBR | FRA | ESP | DEU | CAN | BEL | AUS | 4 |
NCT05309187 | Phase I | IO-202 + Pembrolizumab IO-202 | Dose-Escalation and Dose-Expansion Study of IO-202 and IO-202+Pembrolizumab in Solid Tumors | Active, not recruiting | USA | 0 |
NCT05311618 | Phase I | NGM438 NGM438 + Pembrolizumab | Study of NGM438 as Monotherapy and in Combination With Pembrolizumab in Advanced or Metastatic Solid Tumors | Recruiting | USA | 0 |
NCT05315700 | Phase Ib/II | Carboplatin + ORIC-114 + Pemetrexed Disodium ORIC-114 | Ph 1/2 Study of ORIC-114 in Patients With Advanced Solid Tumors Harboring an EGFR or HER2 Alteration | Recruiting | USA | CAN | AUS | 1 |
NCT05317078 | Phase I | AMG 794 | A Phase 1 Safety, Tolerability, and Pharmacokinetics Study of AMG 794 With Claudin 6-positive Non-small Cell Lung Cancer, Epithelial Ovarian Cancer, and Other Malignant Solid Tumor Indications | Active, not recruiting | USA | AUS | 1 |
NCT05318573 | Phase II | Gemcitabine + Pembrolizumab | A Study to Evaluate Safety, Efficacy of FF-10832 in Combination With Pembrolizumab in Solid Tumors | Recruiting | USA | 0 |
NCT05320588 | Phase Ib/II | BIO-106 BIO-106 + Pembrolizumab | A Phase 1/2 Study in Patients With Advanced Cancers | Recruiting | USA | 0 |
NCT05322408 | Phase I | HCW9218 | HCW9218 in Select Advanced Solid Tumors | Active, not recruiting | USA | 0 |
NCT05323045 | Phase I | BYON3521 | A First-in-human Dose-escalation and Expansion Study With the Antibody-drug Conjugate BYON3521 | Recruiting | ITA | GBR | BEL | 1 |
NCT05325866 | Phase I | Bemarituzumab | A Study Evaluating Bemarituzumab in Solid Tumors With Fibroblast Growth Factor Receptor 2b (FGFR2b) Overexpression (FORTITUDE-301) | Recruiting | USA | ITA | GBR | FRA | ESP | CAN | BEL | AUT | AUS | 17 |
NCT05327010 | Phase II | Talazoparib + ZEN-3694 | Testing the Combination of the Anti-cancer Drugs ZEN003694 (ZEN-3694) and Talazoparib in Patients With Advanced Solid Tumors, The ComBET Trial | Recruiting | USA | 0 |
NCT05327946 | Phase I | BI 770371 BI 770371 + Ezabenlimab | A Study in People With Advanced Cancer to Test How Well Different Doses of BI 770371 Alone or in Combination With Ezabenlimab Are Tolerated | Recruiting | USA | CAN | 1 |
NCT05337735 | Phase II | XmAb20717 | A Phase II Clinical Trial to Evaluate Safety and Efficacy of XmAb20717 in Advanced Rare Cancers | Recruiting | USA | 0 |
NCT05338346 | Phase I | ATG-018 | A Study of ATG-018 (ATR Inhibitor) Treatment in Patients With Advanced Solid Tumors and Hematological Malignancies (ATRIUM) | Recruiting | AUS | 0 |
NCT05340621 | Phase Ib/II | Binimetinib + OKI-179 | NAUTILUS: OKI-179 Plus Binimetinib in Patients With Advanced Solid Tumors in the RAS Pathway (Phase 1b) and NRAS-mutated Melanoma (Phase 2) | Active, not recruiting | USA | 0 |
NCT05346484 | Phase I | CF33-hNIS + Pembrolizumab CF33-hNIS | A Study of CF33-hNIS (VAXINIA), an Oncolytic Virus, as Monotherapy or in Combination With Pembrolizumab in Adults With Metastatic or Advanced Solid Tumors (MAST) | Recruiting | USA | AUS | 0 |
NCT05352750 | Phase I | SON-1010 | Phase 1 Study of SON-1010 in Adult Patients With Advanced Solid Tumors | Recruiting | USA | 0 |
NCT05355701 | Phase I | Binimetinib + PF-07799933 PF-07799933 Cetuximab + PF-07799933 | A Study to Learn About the Study Medicine Called PF-07799933 in People With Advanced Solid Tumors With BRAF Alterations. | Recruiting | USA | CAN | 1 |
NCT05355753 | Phase Ib/II | CFT8634 | A Study to Assess the Safety and Tolerability of CFT8634 in Locally Advanced or Metastatic SMARCB1-Perturbed Cancers, Including Synovial Sarcoma and SMARCB1-Null Tumors | Terminated | USA | 0 |
NCT05356741 | Phase I | AMX-818 + Pembrolizumab AMX-818 | To Access the Safety and Effects of Intravenous Administration of AMX-818 Alone and in Combination With Pembrolizumab in Adult Participants With Locally Advanced or Metastatic HER2-Expressing Cancers | Recruiting | FRA | ESP | AUS | 1 |
NCT05357898 | Phase Ib/II | SQZ-eAPC-HPV Pembrolizumab + SQZ-eAPC-HPV | Study of SQZ-eAPC-HPV in Patients With HPV16+ Recurrent, Locally Advanced or Metastatic Solid Tumors | Terminated | USA | 0 |
NCT05358249 | Phase Ib/II | JDQ443 + Ribociclib JDQ443 + Trametinib Cetuximab + JDQ443 | Platform Study of JDQ443 in Combinations in Patients With Advanced Solid Tumors Harboring the KRAS G12C Mutation (KontRASt-03) | Recruiting | USA | ITA | FRA | ESP | DEU | BEL | 2 |
NCT05358379 | Phase Ib/II | CYC140 | A Study to Investigate CYC140, in Subjects With Advanced Solid Tumors and Lymphoma | Recruiting | USA | ESP | 1 |
NCT05359445 | Phase I | IMA401 | IMA401 TCER in Recurrent and/or Refractory Solid Tumors | Recruiting | DEU | 0 |
NCT05363605 | Phase Ib/II | 225Ac-FPI-1966 + Vofatamab | A Study of [225Ac]-FPI-1966 in Participants With Advanced Solid Tumours | Terminated | USA | AUS | 0 |
NCT05372614 | Phase I | Neratinib + Trastuzumab | Testing the Safety and Tolerability of the Anti-cancer Drugs Trastuzumab Deruxtecan and Neratinib for Cancers With Changes in the HER2 Gene | Recruiting | USA | 0 |
NCT05372640 | Phase I | Abemaciclib + ZEN-3694 | Testing the Safety and Efficacy of the Combination of Two Anti-cancer Drugs, ZEN003694 and Abemaciclib, for Adult and Pediatric Patients (12-17 Years) With Metastatic or Unresectable NUT Carcinoma, Breast Cancer and Other Solid Tumors | Recruiting | USA | 0 |
NCT05375825 | Phase I | LMB-100 | Phase I Evaluation of Immunotoxin LMB-100 Administered by Normothermic, Intrapleural Perfusion Following Cytoreductive Surgery in Participants With Pleural Mesotheliomas, or Pleural Effusions From Cancers Expressing Mesothelin | Withdrawn | USA | 0 |
NCT05377528 | Phase I | AGEN1571 + Balstilimab + Botensilimab AGEN1571 + Botensilimab AGEN1571 + Balstilimab AGEN1571 | Study of AGEN1571 in Participants With Advanced Solid Tumors | Recruiting | USA | 0 |
NCT05377996 | Phase I | XMT-1660 | A Study of XMT-1660 in Participants With Solid Tumors | Recruiting | USA | 0 |
NCT05378425 | Phase I | NTX-1088 NTX-1088 + Pembrolizumab | A Study of NTX-1088, a Monoclonal Antibody Targeting the Poliovirus Receptor (PVR, CD155), as Monotherapy and Combined With Pembrolizumab | Recruiting | USA | 1 |
NCT05379985 | Phase I | RMC-6236 | Study of RMC-6236 in Patients With Advanced Solid Tumors Harboring Specific Mutations in RAS | Recruiting | USA | 0 |
NCT05381909 | Phase I | BGB-24714 + Paclitaxel BGB-24714 | Study Investigating BGB-24714 as Monotherapy and in Combination With Chemotherapy in Participants With Advanced or Metastatic Solid Tumors | Recruiting | USA | AUS | 3 |
NCT05382325 | Phase I | MK-1484 MK-1484 + Pembrolizumab | A Study of MK-1484 as Monotherapy and in Combination With Pembrolizumab (MK-3475) In Advanced or Metastatic Solid Tumors (MK-1484-001) | Recruiting | USA | CAN | 2 |
NCT05382559 | Phase I | ASP3082 ASP3082 + Cetuximab | A Study of ASP3082 in Adults With Previously Treated Solid Tumors | Recruiting | USA | 1 |
NCT05382936 | Phase I | SL-901 | Study of the PI3K Inhibitor SL-901 in Patients With Advanced Solid Tumors With Advanced Solid Tumors | Completed | GBR | 0 |
NCT05384626 | Phase Ib/II | NUV-655 | A Study of NVL-655 in Patients With Advanced NSCLC and Other Solid Tumors Harboring ALK Rearrangement or Activating ALK Mutation (ALKOVE-1) | Recruiting | USA | GBR | FRA | ESP | CAN | AUS | 0 |
NCT05387265 | Phase I | CX-904 | A Trial to Find Safe and Active Doses for an Investigational Drug, CX-904, for Patients With Advanced Solid Tumors | Recruiting | USA | 0 |
NCT05388435 | Phase Ib/II | SKL27969 | Safety, Tolerability, PK/PD & Preliminary Efficacy of SKL27969 in Advanced Solid Tumors Patients | Active, not recruiting | USA | 0 |
NCT05389462 | Phase I | ADCT-601 + Gemcitabine ADCT-601 | A Study of Mipasetamab Uzoptirine (ADCT-601) in Participants With Solid Tumors | Recruiting | USA | GBR | FRA | ESP | 0 |
NCT05394350 | Phase Ib/II | MK-1088 MK-1088 + Pembrolizumab | A Study of MK-1088 as Monotherapy and in Combination With Pembrolizumab in Participants With Advanced Solid Tumors (MK-1088-002) | Terminated | USA | CAN | 3 |
NCT05394675 | Phase I | DS-9606a | A Study of DS-9606a in Patients With Advanced Solid Tumors | Recruiting | USA | GBR | 0 |
NCT05396833 | Phase I | M1774 | Study of M1774 in Combination With DNA Damage Response Inhibitor or Immune Checkpoint Inhibitor (DDRiver Solid Tumors 320) | Recruiting | USA | ESP | CAN | 0 |
NCT05399654 | Phase Ib/II | TAC-001 | A Dose Escalation and Expansion Study of TAC-001 in Patients With Select Advanced or Metastatic Solid Tumors (INCLINE-101) | Recruiting | USA | AUS | 0 |
NCT05405595 | Phase I | ADG126 | ADG126 in Combination With Pembrolizumab in Patients With Advanced/Metastatic Solid Tumors | Recruiting | USA | 1 |
NCT05407675 | Phase Ib/II | BMS-986408 + Ipilimumab + Nivolumab BMS-986408 + Nivolumab BMS-986408 | A Study to Evaluate the Safety and Tolerability of BMS-986408 Alone and in Combination With Nivolumab or Nivolumab and Ipilimumab in Participants With Advanced Solid Tumors | Active, not recruiting | USA | FRA | ESP | CAN | 1 |
NCT05410145 | Phase I | D3S-001 | A Study of D3S-001 as Monotherapy in Subjects With Advanced Solid Tumors With a KRAS p.G12C Mutation | Recruiting | USA | AUS | 3 |
NCT05415098 | Phase I | APG-5918 | Study of Safety, Pharmacokinetic and Efficacy of APG-5918 in Advanced Solid Tumors or Lymphomas | Recruiting | USA | 0 |
NCT05417321 | Phase Ib/II | HB0036 | A Study Evaluating the Safety and Efficacy of HB0036 in Subjects With Advanced Solid Tumors | Recruiting | USA | 1 |
NCT05419817 | Phase II | Pembrolizumab + Sitravatinib | Pembrolizumab With Sitravatinib in Recurrent Endometrial Cancer and Other Solid Tumors With Deficient Mismatch Repair System | Withdrawn | 0 | |
NCT05430555 | Phase Ib/II | TK-8001 | A Phase 1/2, First-in-Human, Open-Label, Accelerated-Titration, Two-Part Clinical Trial of TK-8001 in Patients With HLA-A*02:01 Genotype and Advanced-Stage/Metastatic MAGE-A1+ Solid Tumors (IMAG1NE) | Terminated | GBR | ESP | DEU | BEL | 1 |
NCT05431270 | Phase I | PT199 PT199 + unspecified PD-1 antibody | Dose Escalation/Expansion Study of PT199 (an Anti-CD73 mAb) Administered Alone and in Combination With a PD-1 Inhibitor | Recruiting | USA | 0 |
NCT05431582 | Phase I | Bevacizumab + Pembrolizumab + ZN-c3 Bevacizumab + ZN-c3 | Phase I Study of ZN-c3 and Bevacizumab +/- Pembrolizumab in Metastatic CCNE1 Amplified and TP53 Mutant Solid Tumors | Withdrawn | 0 | |
NCT05434234 | Phase I | YL201 | A Study of YL201 in Patients With Advanced Solid Tumors | Recruiting | USA | 1 |
NCT05435339 | Phase Ib/II | GEN1053 | A Study to Evaluate Safety, Tolerability, and Preliminary Effect of the GEN1053 Antibody on Malignant Solid Tumors as Monotherapy | Recruiting | USA | ESP | 0 |
NCT05438329 | Phase Ib/II | DB-1305 | First-in-human Study of DB-1305 for Advanced/Metastatic Solid Tumors | Recruiting | USA | 2 |
NCT05443126 | Phase Ib/II | EP0031 | A Study of EP0031 in Patients With Advanced RET-altered Malignancies | Recruiting | USA | GBR | ESP | 0 |
NCT05450562 | Phase Ib/II | Atezolizumab + SAR444200 SAR444200 | Dose Escalation and Expansion Study of SAR444200-based Regimen in Adult Participants With Advanced Solid Tumors | Recruiting | USA | CAN | 3 |
NCT05458219 | Phase I | IBI343 | A First-in-human Study of IBI343 in Subjects With Locally Advanced Unresectable or Metastatic Solid Tumors | Recruiting | AUS | 0 |
NCT05462717 | Phase I | RMC-6291 | Dose Escalation and Dose Expansion Study of RMC-6291 Monotherapy in Subjects With Advanced KRASG12C Mutant Solid Tumors | Recruiting | USA | ITA | FRA | ESP | AUS | 7 |
NCT05468359 | Phase Ib/II | Atezolizumab + Bevacizumab + Cyclophosphamide + Sorafenib | Safety and Efficacy of Cyclophosphamide, Sorafenib, Bevacizumab, and Atezolizumab in Pediatric Solid Tumor Patients | Recruiting | USA | 0 |
NCT05469490 | Phase I | Navoximod + NLG802 | Safety of Navoximod and NLG802 With Stereotactic Body Radiotherapy (SBRT) Treatment of Advanced Solid Tumors | Withdrawn | 0 | |
NCT05471856 | Phase I | BI 1703880 + Ezabenlimab | A Study to Test How Different Doses of BI 1703880 in Combination With Ezabenlimab Are Tolerated in People With Different Types of Advanced Cancer (Solid Tumours) | Recruiting | USA | GBR | ESP | 1 |
NCT05472220 | Phase I | Alpelisib + Carboplatin | Alpelisib in Combination With Carboplatin in Patients With Solid Tumors and HPV-Positive Squamous Cell Carcinoma | Withdrawn | 0 | |
NCT05479812 | Phase I | WTX-124 Pembrolizumab + WTX-124 | Dose Escalation Study of WTX-124 as Monotherapy and in Combination With Pembrolizumab (Pembro) in Patients With Selected Advanced or Metastatic Solid Tumors | Recruiting | USA | 0 |
NCT05480865 | Phase I | BBP-398 + Sotorasib | SHP2 Inhibitor BBP-398 in Combination With Sotorasib in Patients With Advanced Solid Tumors and a KRAS-G12C Mutation (Argonaut) | Recruiting | ITA | FRA | ESP | AUS | 3 |
NCT05483400 | Phase II | Atezolizumab + Tiragolumab | Open Label Phase 2 Basket Trial With Atezolizumab and Tiragolumab in Solid Tumors (TIRACAN) | Recruiting | 1 | |
NCT05483530 | Phase I | HLX60 + Serplulimab | A Study to Investigate the Safety, Tolerability and Efficacy of HLX60 Combination With HLX10 in Subjects With Advanced or Metastatic Solid Tumors | Recruiting | AUS | 0 |
NCT05485974 | Phase I | HBI-2438 | A Dose Escalation Study of HBI-2438 in Patients With Solid Tumors Harboring KRAS G12C Mutation | Recruiting | USA | 1 |
NCT05487170 | Phase Ib/II | RNK05047 | A Study of RNK05047 in Subjects With Advanced Solid Tumors/Diffuse Large B-cell Lymphoma (CHAMP-1) | Recruiting | USA | 0 |
NCT05487235 | Phase I | Atezolizumab + GDC-1971 Atezolizumab + GDC-1971 + Omeprazole | A Study to Evaluate the Safety, Pharmacokinetics, and Activity of GDC-1971 in Combination With Atezolizumab in Participants With Locally Advanced or Metastatic Solid Tumors | Recruiting | USA | ESP | CAN | AUS | 5 |
NCT05489211 | Phase II | Capecitabine + Datopotamab deruxtecan AZD5305 + Datopotamab deruxtecan + Durvalumab Capecitabine + Datopotamab deruxtecan + Nivolumab Carboplatin + Datopotamab deruxtecan Datopotamab deruxtecan + Fluorouracil AZD5305 + Datopotamab deruxtecan Datopotamab deruxtecan + Durvalumab Datopotamab deruxtecan + Fluorouracil + Nivolumab Bevacizumab + Datopotamab deruxtecan + Fluorouracil + Leucovorin Bevacizumab + Capecitabine + Datopotamab deruxtecan Datopotamab deruxtecan | Study of Dato-Dxd as Monotherapy and in Combination With Anti-cancer Agents in Patients With Advanced Solid Tumours | Recruiting | USA | ITA | GBR | FRA | ESP | DEU | CAN | 7 |
NCT05490472 | Phase Ib/II | JAB-2485 | JAB-2485 Activity in Adult Patients With Advanced Solid Tumors | Recruiting | USA | 1 |
NCT05491317 | Phase Ib/II | GEN1042 GEN1042 + Pembrolizumab | A Safety and Antitumor Activity Trial of Immunoradiotherapy Combinations as a Treatment Option for Subjects With Metastatic Solid Tumors | Recruiting | FRA | 0 |
NCT05491928 | Expanded access | Tempol | Treatment of Metastatic Cancer in Terminally Diagnosed Patients | Available | USA | 0 |
NCT05494762 | Phase I | BGB-B167 + Tislelizumab | Safety, Pharmacokinetics, and Antitumor Activity of BGB-B167 Alone and in Combination With Tislelizumab (BGB-A317) in Participants With Advanced Solid Tumors | Active, not recruiting | USA | AUS | 0 |
NCT05494918 | Phase I | JSKN003 | First-In-Human Study in Subjects With Advanced or Metastatic Solid Malignant Tumors | Recruiting | AUS | 0 |
NCT05496595 | Phase I | DCBY02 | DCBY02 or DCSZ11 as a Monotherapy in Patients With Advanced or Metastatic Solid Tumors | Terminated | USA | 0 |
NCT05497453 | Phase Ib/II | OTX-2002 | A Phase 1/2 Study to Evaluate OTX-2002 in Patients With Hepatocellular Carcinoma and Other Solid Tumor Types Known for Association With the MYC Oncogene (MYCHELANGELO I) | Recruiting | USA | 4 |
NCT05501821 | Phase I | KBA1412 + Pembrolizumab KBA1412 | Study of KBA1412 in Participants With Advanced Solid Malignant Tumors | Recruiting | BEL | 1 |
NCT05509985 | Phase I | ASKG315 | A Phase 1 Study of ASKG315 in Patients With Advanced Solid Tumors | Not yet recruiting | AUS | 0 |
NCT05514444 | Phase I | MK-4464 MK-4464 + Pembrolizumab | Study of MK-4464 as Monotherapy and in Combination With Pembrolizumab in Participants With Advanced/Metastatic Solid Tumors (MK-4464-001) | Recruiting | USA | CAN | 2 |
NCT05514496 | Phase I | NX-019 | A Study of NX-019 in Patients With Advanced, Epidermal Growth Factor Receptor (EGFR) Mutant Cancer | Recruiting | USA | 2 |
NCT05514717 | Phase I | XMT-2056 | A Study of XMT-2056 in Advanced/Recurrent Solid Tumors That Express HER2 | Recruiting | USA | 0 |
NCT05525247 | Phase Ib/II | Gemcitabine + SLC-3010 SLC-3010 | A Phase 1/2, Open-label, Multicenter, Dose Escalation and Expansion Study of SLC-3010 Monotherapy and in Combination | Recruiting | USA | AUS | 1 |
NCT05525455 | Phase Ib/II | TT-816 TT-816 + unspecified PD-1 antibody | A Study in Patients With Advanced Cancers | Terminated | USA | 0 |
NCT05525559 | Phase I | ET0038 | SHP2 Inhibitor ET0038 Monotherapy in Patients With Advanced Solid Tumors (FIRST) | Not yet recruiting | USA | 0 |
NCT05536141 | Phase I | AB521 | A Phase 1 Study of AB521 in Renal Cell Carcinoma and Other Solid Tumors (ARC-20) | Recruiting | USA | 1 |
NCT05537740 | Phase I | BAY 3375968 + Pembrolizumab BAY 3375968 | A First-in-human Study to Learn How Safe the Study Drug BAY3375968, an Anti-CCR8 Antibody, is, When Given Alone or in Combination With Pembrolizumab, How it Affects the Body, How it Moves Into, Through, and Out of the Body, and to Find the Best Dose in Participants With Advanced Solid Tumors | Recruiting | USA | GBR | CAN | BEL | 1 |
NCT05537987 | Phase I | ICP-723 | Evaluate the Safety, Tolerability, and Pharmacokinetics of ICP-723 in Patients With Advanced Solid Tumors | Active, not recruiting | USA | 0 |
NCT05538130 | Phase I | PF-07799544 Encorafenib + PF-07799544 PF-07284890 + PF-07799544 PF-07799544 + PF-07799933 | A Study to Learn About the Study Medicine Called PF-07799544 in People With Advanced Solid Tumors | Recruiting | USA | CAN | 0 |
NCT05539157 | Phase I | JCXH-211 | Study to Evaluate JCXH-211 as Monotherapy in Patients With Malignant Solid Tumors | Active, not recruiting | USA | 0 |
NCT05543629 | Phase Ib/II | BMS-986442 + Nivolumab BMS-986442 + Docetaxel + Nivolumab BMS-986442 + Carboplatin + Nivolumab + Pemetrexed Disodium BMS-986442 + Carboplatin + Nivolumab + Paclitaxel | A Study of BMS-986442 With Nivolumab With or Without Chemotherapy in Solid Tumors and Non-small Cell Lung Cancer | Recruiting | USA | ITA | ESP | AUS | 1 |
NCT05544552 | Phase Ib/II | TYRA-300 | Safety and Preliminary Anti-Tumor Activity of TYRA-300 in Advanced Urothelial Carcinoma and Other Solid Tumors With FGFR3 Gene Alterations (SURF301) | Recruiting | USA | FRA | ESP | AUS | 0 |
NCT05546268 | Phase Ib/II | MRT-2359 | Study of Oral MRT-2359 in Selected Cancer Patients | Recruiting | USA | CAN | 0 |
NCT05547321 | Phase I | OMTX705 + Pembrolizumab OMTX705 | Efficacy and Safety Study of OMTX705, Monotherapy and Pembrolizumab-combined, in Subjects With Advanced Solid Tumors. | Recruiting | USA | ESP | 0 |
NCT05547906 | Phase I | ASCA101 | Evaluation of the Safety and Efficacy of ASCA101 in Patients With Advanced Solid Tumors | Completed | USA | 1 |
NCT05548296 | Phase Ib/II | Prexasertib Gemcitabine + Prexasertib | A Study of ACR-368 in Ovarian Carcinoma, Endometrial Adenocarcinoma, and Urothelial Carcinoma | Recruiting | USA | 0 |
NCT05548634 | Phase I | TAVO412 | A Study of TAVO412 in Patients With Cancer (TAVO412) | Recruiting | USA | 0 |
NCT05554341 | Phase II | Nilotinib + Paclitaxel | Testing the Use of Nilotinib and Paclitaxel as a Treatment for Patients With Prior Taxane Treatment, A ComboMATCH Treatment Trial | Suspended | USA | 0 |
NCT05554367 | Phase II | Binimetinib + Palbociclib | Palbociclib and Binimetinib in RAS-Mutant Cancers, A ComboMATCH Treatment Trial | Recruiting | USA | 0 |
NCT05554380 | Phase II | Ipatasertib + Paclitaxel | Study of Chemotherapy Plus Ipatasertib for People With Solid Tumors With AKT Mutations, A ComboMATCH Treatment Trial | Recruiting | USA | 0 |
NCT05555251 | Phase Ib/II | BI-1607 + Trastuzumab | BI-1607 in Combination With Trastuzumab in Subjects With HER2-positive Advanced Solid Tumors (CONTRAST) | Active, not recruiting | GBR | ESP | DEU | 0 |
NCT05557045 | Phase I | JZP815 | A Study of JZP815 Oral Capsules in Adult Participants With Advanced or Metastatic Solid Tumors Harboring Mitogen Activated Protein Kinase (MAPK) Pathway Alterations to Investigate the Safety, Dosing, and Antitumor Activity of JZP815 | Recruiting | USA | 0 |
NCT05564377 | Phase II | Selumetinib Binimetinib + Fulvestrant Binimetinib + Palbociclib Nilotinib + Paclitaxel Binimetinib + Fluorouracil + Leucovorin + Oxaliplatin Panitumumab + Sotorasib Binimetinib Fulvestrant Olaparib Olaparib + Selumetinib Alpelisib + Olaparib Neratinib Neratinib + Palbociclib Fluorouracil + Leucovorin + Oxaliplatin Ipatasertib + Paclitaxel | Targeted Therapy Directed by Genetic Testing in Treating Patients With Locally Advanced or Advanced Solid Tumors, The ComboMATCH Screening Trial | Recruiting | USA | 1 |
NCT05566574 | Phase Ib/II | RP-3500 | A Study of RP-3500 in Combination With Standard Radiation Therapy in People With Solid Tumor Cancer | Recruiting | USA | 0 |
NCT05569057 | Phase I | SIM1811-03 | A Phase I Trial of SIM1811-03 in Subjects With Advanced Solid Tumors and Cutaneous T-cell Lymphoma | Recruiting | USA | 0 |
NCT05571969 | Phase I | Dovitinib + E7449 E7449 | Study to Determine the Maximum Tolerated Dose (MTD) of PARPi 2X-121 Monotherapy and the MTD of Dovitinib in Combination With 2X-121 in Patients With Advanced Solid Tumors | Recruiting | USA | 0 |
NCT05577182 | Phase I | INCA32459 | Study of INCA32459 a LAG-3 and PD-1 Bispecific Antibody in Participants With Select Advanced Malignancies | Recruiting | USA | ITA | FRA | ESP | BEL | 0 |
NCT05578092 | Phase Ib/II | Adagrasib + MRTX0902 MRTX0902 | A Phase 1/2 Study of MRTX0902 in Solid Tumors With Mutations in the KRAS MAPK Pathway | Recruiting | USA | 1 |
NCT05580770 | Phase Ib/II | BGB3245 + PD-0325901 | Mirdametinib + BGB-3245 in Advanced Solid Tumors | Recruiting | USA | AUS | 0 |
NCT05581004 | Phase I | Atezolizumab + RO7502175 RO7502175 | A Study to Evaluate the Safety, Pharmacokinetics, and Activity of RO7502175 as a Single Agent and in Combination With Atezolizumab in Participants With Locally Advanced or Metastatic Solid Tumors | Recruiting | USA | ESP | CAN | BEL | AUS | 2 |
NCT05581719 | Phase Ib/II | Allocetra-OTS Allocetra-OTS + Tislelizumab Allocetra-OTS + Nivolumab | A Phase 1/2a Study Evaluating Allocetra-OTS as Monotherapy or in Combination With Anti-PD-1 Therapy for the Treatment of Advanced Solid Tumor Malignancy | Recruiting | ESP | 1 |
NCT05582850 | Phase I | DT-9081 | DT-9081 Study in Participants With Advanced, Recurrent or Metastatic Solid Tumours (EPRAD) | Recruiting | FRA | BEL | 0 |
NCT05584111 | Phase I | STC-15 | Oral Administration of STC-15 in Subjects With Advanced Malignancies | Recruiting | USA | 0 |
NCT05584670 | Phase Ib/II | SAR445877 | A First-in-human, Dose Escalation and Dose Expansion Study of SAR445877 in Adult Participants With Advanced Solid Tumors | Recruiting | USA | ESP | 2 |
NCT05584709 | Phase I | STI-6129 | Study to Access Anti-CD38 Anibody Drug in Patients With Advanced Solid Tumors | Not yet recruiting | USA | 0 |
NCT05585320 | Phase Ib/II | IMM-1-104 | A Phase 1/2a Study of IMM-1-104 in Participants With Previously Treated, RAS-Mutant, Advanced or Metastatic Solid Tumors | Recruiting | USA | 0 |
NCT05586321 | Phase I | GEN1056 | Study of Safety and Antitumor Activity of GEN1056 in Participants With Advanced Solid Tumors | Active, not recruiting | ESP | 2 |
NCT05592626 | Phase Ib/II | STAR0602 | A Study of a Selective T Cell Receptor (TCR) Targeting, Bifunctional Antibody-fusion Molecule STAR0602 in Participants With Advanced Solid Tumors (START-001) | Recruiting | USA | CAN | 0 |
NCT05593094 | Phase I | ZN-A-1041 Ado-trastuzumab emtansine + ZN-A-1041 Trastuzumab deruxtecan + ZN-A-1041 Pertuzumab/trastuzumab/hyaluronidase-zzxf + ZN-A-1041 Pertuzumab + Trastuzumab + ZN-A-1041 | A Phase 1 Trial of ZN-A-1041 Enteric Capsules or Combination in Patients With HER2-Positive Advanced Solid Tumors | Recruiting | USA | 0 |
NCT05594043 | Phase I | MK-6598 + Pembrolizumab MK-6598 | A Study of MK-6598 as Monotherapy and in Combination With Pembrolizumab (MK-3475) in Advanced Solid Tumors (MK-6598-001) | Recruiting | USA | CAN | 1 |
NCT05594875 | Phase I | SHR-A1921 | A Trial of SHR-A1921 for Injection in Subjects With Advanced Solid Tumors | Active, not recruiting | AUS | 0 |
NCT05597839 | Phase Ib/II | DF9001 DF9001 + Nivolumab | Study of DF9001 in Patients With Advanced Solid Tumors | Recruiting | USA | 0 |
NCT05598151 | Phase I | HM97662 | Dose Escalation and Expansion Study of HM97662 in Advanced or Metastatic Solid Tumors | Recruiting | AUS | 1 |
NCT05601219 | Phase I | ADA-011 | A Phase 1 Study of ADA-011 for Subjects With Advanced Solid Tumors | Recruiting | USA | 0 |
NCT05605496 | Phase II | NP137 + unspecified PD-L1 antibody NP137 + unspecified PD-1 antibody | A Multicenter, Open-label, Proof of Concept Phase II Aiming to Assess the Clinical and Biological Activity of Anti-netrin-1 (NP137) as Add on Therapy in Patients With Advanced/Metastatic Solid Tumors Treated by Standard Immunotherapies (IMMUNONET) | Recruiting | FRA | 0 |
NCT05605509 | Phase II | Fluorouracil + Irinotecan + Leucovorin + RP-6306 RP-6306 + Trastuzumab Gemcitabine + RP-6306 | RP-6306 in Patients With Advanced Cancer | Recruiting | CAN | 0 |
NCT05607498 | Phase I | EMB-07 | First in Human Study of EMB-07 in Locally Advanced/Metastatic Solid Tumors | Recruiting | AUS | 1 |
NCT05614102 | Phase I | BAY2965501 | A First-in-human Study to Learn How Safe the Study Treatment BAY2965501 is, to Find the Best Dose, How it Affects the Body, What Maximum Amount Can be Given, How it Moves Into, Through and Out of the Body, and How it Acts on Different Tumors in Participants With Advanced Solid Tumors | Recruiting | USA | GBR | ESP | BEL | 3 |
NCT05614258 | Phase I | ADG206 | Study of ADG206 in Subjects With Advanced/Metastatic Solid Tumors | Recruiting | AUS | 0 |
NCT05614739 | Phase I | LOXO-435 + Pembrolizumab LOXO-435 | A Study of LOXO-435 in Participants With Cancer With a Change in a Gene Called FGFR3 | Recruiting | USA | GBR | FRA | ESP | DEU | CAN | AUS | 3 |
NCT05631327 | Phase I | JZP341 | JZP341 Phase 1 Dose-Finding Study in Adult Participants With Advanced or Metastatic Solid Tumors | Active, not recruiting | USA | 0 |
NCT05635643 | Phase Ib/II | SRF114 | Study of SRF114 in Patients With Advanced Solid Tumors | Recruiting | USA | 0 |
NCT05636215 | Phase Ib/II | Orismilast | A First-in-human Study of IBI354 in Subjects With Locally Advanced Unresectable or Metastatic Solid Tumors | Not yet recruiting | AUS | 0 |
NCT05638295 | Phase II | Sotorasib Panitumumab + Sotorasib | Testing the Use of AMG 510 (Sotorasib) and Panitumumab as a Targeted Treatment for KRAS G12C Mutant Solid Tumor Cancers (A ComboMATCH Treatment Trial) | Recruiting | USA | 0 |
NCT05639751 | Phase I | Docetaxel + PRT3789 PRT3789 | PRT3789 Monotherapy and in Combo w/Docetaxel in Participants w/Advanced or Metastatic Solid Tumors w/SMARCA4 Mutation | Recruiting | USA | ESP | 0 |
NCT05642949 | Phase Ib/II | MHB036C | Study of MHB036C in Participants With Advanced or Metastatic Solid Tumors | Not yet recruiting | AUS | 0 |
NCT05646797 | Phase I | ASP2074 | A Study of ASP2074 in Adults With Solid Tumors | Recruiting | USA | 1 |
NCT05650203 | Phase I | JS006 + JS009 + Toripalimab-tpzi JS009 | A Study of JS009 Monotherapy and JS009 as a Triple Combination Therapy in Patients With Advanced Malignancies | Withdrawn | 0 | |
NCT05650879 | Phase I | ELVN-002 ELVN-002 + Trastuzumab deruxtecan Ado-trastuzumab emtansine + ELVN-002 | ELVN-002 in HER2 Mutant Non-Small Cell Lung Cancer (HER2) | Recruiting | USA | ITA | FRA | ESP | AUS | 2 |
NCT05651022 | Phase I | Decoy20 | DECOY20 Study in Patients With Advanced Solid Tumors | Recruiting | USA | 0 |
NCT05652855 | Phase Ib/II | MHB088C | Study of MHB088C in Participants With Advanced or Metastatic Solid Tumors | Not yet recruiting | AUS | 0 |
NCT05653661 | Phase I | AP-160 | Nab-Paclitaxel/STI-3031 Complex (AP160-Complex) for the Treatment of Advanced or Metastatic Solid Tumors | Recruiting | USA | 0 |
NCT05653882 | Phase I | AB248 + Pembrolizumab AB248 | A Study Evaluating AB248 Alone or in Combination With Pembrolizumab in Adult Patients With Solid Tumors | Recruiting | USA | 0 |
NCT05661461 | Phase I | Nab-rapamycin | Dose-escalation Study to Assess Safety and Pharmacokinetics of Nab-Sirolimus in Patients With Locally Advanced or Metastatic Solid Tumors and Moderate Liver Impairment | Recruiting | USA | 0 |
NCT05661578 | Phase II | Atezolizumab + Tiragolumab | A Study to Evaluate the Safety and Pharmacokinetics of the Intravenous Fixed-Dose Combination (IV FDC) of Tiragolumab and Atezolizumab in Participants With Locally Advanced, Recurrent or Metastatic Solid Tumors (SKYSCRAPER-11) | Recruiting | USA | ESP | CAN | 8 |
NCT05662397 | Phase Ib/II | HST-1011 Cemiplimab + HST-1011 | A Study of HST-1011 Given as Monotherapy and in Combination With an Anti-PD1 Antibody | Recruiting | USA | 0 |
NCT05668585 | Phase Ib/II | CFT1946 + Trametinib CFT1946 | A Study to Characterize the Safety, Tolerability, and Preliminary Efficacy of CFT1946 as Monotherapy and in Combination With Trametinib in Subjects With BRAF V600 Mutant Solid Tumors | Recruiting | USA | FRA | ESP | 0 |
NCT05669430 | Phase I | GV20-0251 | A Study of GV20-0251 in Patients With Solid Tumor Malignancies | Recruiting | USA | 0 |
NCT05672459 | Phase Ib/II | IVS-3001 Cyclophosphamide + Fludarabine | A Safety And Efficacy Study Of HLA-G- Targeted CAR-T Cells IVS-3001 In Subjects With Previously Treated Advanced HLA-G-Positive Solid Tumors | Recruiting | USA | 0 |
NCT05673928 | Phase II | Ado-trastuzumab emtansine + Tucatinib | A Phase II Study of Tucatinib and Ado-trastuzumab Emtansine (T-DM1) in Patients With HER2-positive Metastatic Solid Tumors and Metastases to Brain (TUCATEMEB) | Recruiting | USA | 0 |
NCT05678010 | Phase I | AZD1390 | A Study of AZD1390 and Stereotactic Body Radiotherapy (SBRT) for People With Metastatic Solid Tumor Cancer | Recruiting | USA | 0 |
NCT05678998 | Phase I | WTX-330 | WTX-330 in Patients With Advanced or Metastatic Solid Tumors or Non-Hodgkin Lymphoma | Recruiting | USA | 0 |
NCT05684965 | Phase I | XTX301 | XTX301 in Patients With Advanced Solid Tumors | Recruiting | USA | 0 |
NCT05686226 | Phase II | E7 TCR T-cells | E7 TCR-T Cell Immunotherapy for Human Papillomavirus (HPV) Associated Cancers | Recruiting | USA | 0 |
NCT05687110 | Phase I | Novobiocin | Studying the Safety and Determining the Optimal Dose of Novobiocin in Patients With Tumors That Have Alterations in DNA Repair Genes | Suspended | USA | 0 |
NCT05687136 | Phase I | M1774 + Peposertib | Testing the Combination of Two Anti-cancer Drugs, Peposertib (M3814) and M1774 for Advanced Solid Tumors | Recruiting | USA | 0 |
NCT05691491 | Phase Ib/II | M1774 + Temozolomide | Testing the Combination of the Anti-Cancer Drugs Temozolomide and M1774 to Evaluate Their Safety and Effectiveness | Recruiting | USA | 0 |
NCT05694364 | Phase I | PRGN-3007 Cyclophosphamide Cyclophosphamide + Fludarabine | Dose Escalation/Dose Expansion Study of PRGN-3007 UltraCAR-T Cells in Patients With Advanced Hematologic and Solid Tumor Malignancies | Recruiting | USA | 0 |
NCT05694715 | Phase I | Irinotecan + Niraparib | Combination Therapy in Cancers With Mutations in DNA Repair Genes | Recruiting | USA | 0 |
NCT05698888 | Phase I | VP301 | Study of VP301 in Patients With Multiple Myeloma, Lymphoma, or Solid Tumors | Terminated | USA | 0 |
NCT05700721 | Phase II | Dostarlimab-gxly + Niraparib | Phase II Trial of the PARP Inhibitor Niraparib and PD-1 Inhibitor Dostarlimab in Patients With Advanced Cancers With Active Progressing Brain Metastases (STARLET) | Recruiting | USA | 0 |
NCT05701527 | Phase I | EBC-129 + Pembrolizumab EBC-129 | A Study of EBC-129 in Advanced Solid Tumours | Recruiting | USA | 1 |
NCT05702424 | Phase I | IGM-7354 | Evaluation of IGM-7354 in Adults With Relapsed and/or Refractory Cancer | Active, not recruiting | USA | 0 |
NCT05704985 | Phase I | DK210 DK210 + Nivolumab Paclitaxel DK210 + Pembrolizumab Oxaliplatin Capecitabine Fluorouracil Carboplatin | Evaluating Safety and Biomarkers Using DK210 (EGFR) for Locally Advanced or Metastatic EGFR+ Tumors | Recruiting | USA | 0 |
NCT05708950 | Phase Ib/II | KVA12123 + Pembrolizumab KVA12123 | A Clinical Trial of KVA12123 Treatment Alone and in Combination With Pembrolizumab In Advanced Solid Tumors (VISTA-101) | Recruiting | USA | 0 |
NCT05712889 | Phase I | VIP236 | Phase 1 Dose Escalation Study for VIP236 in Patients With Advanced Cancer | Recruiting | USA | AUS | 0 |
NCT05714553 | Phase Ib/II | Docetaxel + Leucovorin + NUC-3373 Leucovorin + NUC-3373 + Pembrolizumab | NUC-3373 in Combination With Other Agents in Patients With Advanced Solid Tumours | Recruiting | GBR | 0 |
NCT05715281 | Phase II | Atezolizumab + Tiragolumab | Testing the Combination of Anti-cancer Drugs Atezolizumab and Tiragolumab in People With Advanced Stage Rare Cancers, RARE3 Trial | Recruiting | USA | 0 |
NCT05716295 | Phase Ib/II | MDK-703 + unspecified immune checkpoint inhibitor MDK-703 | A Dose Escalation/Expansion Study of MDK-703 in Patients With Advanced or Metastatic Solid Tumors (ORCHID-1) | Active, not recruiting | USA | 0 |
NCT05718557 | Phase I | PYX-106 | Study of PYX-106 in Solid Tumors | Recruiting | USA | ESP | BEL | 0 |
NCT05718895 | Phase I | ATG-022 | A Study of ATG-022 in Patients With Advanced/Metastatic Solid Tumors (CLINCH) | Recruiting | AUS | 1 |
NCT05722886 | Phase II | Cobimetinib + Vemurafenib Alectinib Pertuzumab + Trastuzumab Entrectinib Atezolizumab | DETERMINE (Determining Extended Therapeutic Indications for Existing Drugs in Rare Molecularly Defined Indications Using a National Evaluation Platform Trial) - Master Screening Protocol (DETERMINE) | Recruiting | GBR | 0 |
NCT05725291 | Phase Ib/II | AMT-116 | AMT-116 in Patients With Selected Advanced Solid Tumors | Recruiting | AUS | 0 |
NCT05726864 | Phase Ib/II | ELI-002 | A Study of ELI-002 7P in Subjects With KRAS/NRAS Mutated Solid Tumors (AMPLIFY-7P) | Recruiting | USA | 0 |
NCT05731271 | Phase Ib/II | TST003 | A First-in-Human, Phase 1 Study of TST003 in Subjects With Solid Tumors | Recruiting | USA | 0 |
NCT05731947 | Phase Ib/II | Revumenib | Evaluation of SNDX-5613 in Participants With Colorectal Cancer and Other Solid Tumors | Recruiting | USA | 0 |
NCT05732831 | Phase Ib/II | TNG462 | Safety and Tolerability of TNG462 in Patients With MTAP-deleted Solid Tumors | Recruiting | USA | FRA | ESP | 0 |
NCT05734066 | Phase Ib/II | Lurbinectedin | Study of Lurbinectedin Monotherapy in Pediatric and Young Adult Participants With Relapsed/Refractory Ewing Sarcoma (EMERGE 101) | Recruiting | USA | CAN | 0 |
NCT05735080 | Phase Ib/II | INX-315 | Open-Label Study to Evaluate the Safety, Tolerability, PK, and Efficacy of INX-315 in Patients With Advanced Cancer (INX-315-01) | Recruiting | USA | AUS | 0 |
NCT05735366 | Phase I | SAIL66 + Tocilizumab | A Phase 1 Study of SAIL66 in Patients With CLDN6-positive Locally Advanced or Metastatic Solid Tumors | Recruiting | USA | 1 |
NCT05736731 | Phase Ib/II | A2B530 | A Study to Evaluate the Safety and Efficacy of A2B530, a Logic-gated CAR T, in Subjects With Solid Tumors That Express CEA and Have Lost HLA-A*02 Expression (EVEREST-1) | Recruiting | USA | 0 |
NCT05737706 | Phase Ib/II | MRTX-1133 | Study of MRTX1133 in Patients With Advanced Solid Tumors Harboring a KRAS G12D Mutation | Recruiting | USA | 0 |
NCT05746897 | Phase I | NM1F + Pembrolizumab NM1F | A First-in-human, Phase I, Open-label, Multicenter Study of NM1F(Anti-PVRIG) in Patients With Advanced Solid Tumors | Recruiting | USA | 0 |
NCT05751798 | Phase Ib/II | OSE-279 | Dose-finding and Dose Expansion Study of OSE-279 in Subjects With Advanced Solid Tumors or Lymphomas | Recruiting | FRA | BEL | 0 |
NCT05752552 | Phase I | DO-2 | Study to Determine the Safety and Pharmacokinetics of DO-2 in Patients With Advanced or Refractory Solid Tumours | Recruiting | FRA | BEL | 1 |
NCT05753722 | Phase I | Pembrolizumab + PRTH-101 PRTH-101 | A First-in-human Study of PRTH-101 Monotherapy +/- Pembrolizumab in Subjects With Advanced Malignancies | Recruiting | USA | 0 |
NCT05756907 | Phase Ib/II | Atezolizumab + SON-1010 SON-1010 | Combination of SON-1010 (IL12-FHAB) and Atezolizumab in Patients With Platinum-resistant Ovarian Cancer | Recruiting | USA | AUS | 0 |
NCT05757492 | Phase Ib/II | CHS-006 + Toripalimab-tpzi | Study to Evaluate Safety and PK of CHS-006 in Combination With Toripalimab in Patients With Advanced Solid Tumors | Active, not recruiting | USA | 0 |
NCT05759949 | Phase I | Fulvestrant + RLY-5836 RLY-5836 Fulvestrant + Palbociclib + RLY-5836 Abemaciclib + Fulvestrant + RLY-5836 Fulvestrant + Ribociclib + RLY-5836 | First-in-Human Study of RLY-5836 in Advanced Breast Cancer and Other Solid Tumors | Active, not recruiting | USA | 0 |
NCT05761223 | Phase Ib/II | FB849 FB849 + Pembrolizumab | A Phase I/II, Open-label Study to Investigate the Safety, Tolerability, PK, and Preliminary Efficacy of FB849 | Recruiting | USA | 0 |
NCT05763004 | Phase I | IOS-1002 IOS-1002 + unspecified PD-1 antibody | A Clinical Study to Evaluate the Safety, Tolerability and Efficacy of IOS-1002 Administered Alone and in Combination With a PD-1 Monoclonal Antibody in Advanced Solid Tumors | Recruiting | AUS | 0 |
NCT05765851 | Phase I | DS-1103a + Trastuzumab deruxtecan | A Study of DS-1103a Combination Therapy in Participants With Advanced Solid Tumors | Recruiting | USA | FRA | ESP | CAN | 0 |
NCT05768139 | Phase Ib/II | Fulvestrant + STX-478 STX-478 | First-in-Human Study of STX-478 as Monotherapy and in Combination With Other Antineoplastic Agents in Participants With Advanced Solid Tumors | Recruiting | USA | ESP | 0 |
NCT05768178 | Phase II | Cobimetinib + Vemurafenib | DETERMINE Trial Treatment Arm 05: Vemurafenib in Combination With Cobimetinib in Adult Patients With BRAF Positive Cancers. (DETERMINE) | Recruiting | GBR | 0 |
NCT05768932 | Phase I | BAL0891 + Carboplatin BAL0891 + Paclitaxel BAL0891 | BAL0891 in Patients With Advanced Solid Tumors | Recruiting | USA | 1 |
NCT05769075 | Phase I | TY-2136b | A Study of TY-2136b in Patients With Advanced Solid Tumors Harboring ALK, ROS1 or NTRK1-3 Alterations | Recruiting | USA | 0 |
NCT05769959 | Phase Ib/II | RO7515629 | Study of RO7515629 in Participants With HLA-G Positive Solid Tumors | Active, not recruiting | USA | 0 |
NCT05770037 | Phase II | Alectinib | DETERMINE Trial Treatment Arm 01: Alectinib in Adult, Teenage/Young Adults (TYA) and Paediatric Patients With ALK Positive Cancers (DETERMINE) | Recruiting | GBR | 0 |
NCT05770102 | Phase II | Atezolizumab | DETERMINE Trial Treatment Arm 02: Atezolizumab in Adult, Teenage/Young Adults and Paediatric Patients With Cancers With High Tumour Mutational Burden (TMB) or Microsatellite Instability-high (MSI-high) or Proven Constitutional Mismatch Repair Deficiency (CMMRD) Disposition (DETERMINE) | Recruiting | GBR | 0 |
NCT05770544 | Phase II | Entrectinib | DETERMINE Trial Treatment Arm 03: Entrectinib in Adult, Teenage/Young Adults and Paediatric Patients With ROS1 Gene Fusion-positive Cancers. (DETERMINE) | Recruiting | GBR | 0 |
NCT05774873 | Phase I | IBI334 | IBI334 in Subjects With Unresectable, Locally Advanced or Metastatic Solid Tumors | Recruiting | AUS | 0 |
NCT05775406 | Phase I | KT-253 | Safety and Clinical Activity of KT-253 in Adult Patients With High Grade Myeloid Malignancies, Acute Lymphocytic Leukemia, Lymphoma, Solid Tumors | Recruiting | USA | 0 |
NCT05781360 | Phase I | SIM0237 | A Study to Investigate the Safety, Tolerability, Pharmacokinetics and Preliminary Antitumor Activity of SIM0237 in Adult Participants With Advanced Solid Tumors | Recruiting | USA | 1 |
NCT05784688 | Phase Ib/II | Pembrolizumab + TU2218 | Study of TU2218 in Combination With Pembrolizumab in Patients With Advanced Solid Tumors | Recruiting | USA | 0 |
NCT05785728 | Phase Ib/II | DB-1202 | A Phase 1/2 Study of DB-1202 Monotherapy in Advanced Solid Tumors | Not yet recruiting | 1 | |
NCT05785741 | Phase Ib/II | DB-1310 | A Phase 1/2a Study of DB-1310 in Advanced/Metastatic Solid Tumors | Recruiting | USA | 1 |
NCT05785754 | Phase I | DCSZ11 | DCSZ11 as a Monotherapy in Patients With Advanced or Metastatic Solid Tumors | Recruiting | USA | AUS | 0 |
NCT05786716 | Phase II | Pertuzumab + Trastuzumab | DETERMINE Trial Treatment Arm 04: Trastuzumab in Combination With Pertuzumab in Adult, Teenage/Young Adult and Paediatric Patients With Cancers With HER2 Amplification or Activating Mutations (DETERMINE) | Recruiting | GBR | 0 |
NCT05786924 | Phase I | BDTX-4933 | A Study of BDTX-4933 in Patients With KRAS, BRAF and Select RAS/MAPK Mutation-Positive Cancers | Recruiting | USA | 0 |
NCT05787587 | Phase I | IDE161 | A Study of PARG Inhibitor IDE161 in Participants With Advanced Solid Tumors | Recruiting | USA | 0 |
NCT05788484 | Phase I | CDX-585 | A Study of CDX-585 in Patients With Advanced Malignancies | Recruiting | USA | 0 |
NCT05789589 | Phase Ib/II | Azeliragon + Methylprednisolone Azeliragon Azeliragon + Dexamethasone | Effect of Azeliragon Combined With Stereotactic Radiation Therapy in Patients With Brain Metastases (ADORATION) | Recruiting | USA | 0 |
NCT05791474 | Phase Ib/II | Capecitabine + Denosumab ATI-2231 + Capecitabine ATI-2231 Bisphosphonate + Capecitabine | ATI-2231 With in Advanced Solid Tumor Malignancies Followed by ATI-2231 in Combination With Capecitabine in Patients With Hormone Receptor-positive and HER2 Negative Metastatic Breast Cancer | Withdrawn | 0 | |
NCT05797168 | Phase Ib/II | AZD5305 + AZD5335 AZD5335 | Phase I/IIa Study for AZD5335 as Monotherapy and in Combination With Anti-cancer Agents in Participants With Solid Tumors (FONTANA) | Recruiting | USA | GBR | ESP | CAN | AUS | 4 |
NCT05798611 | Phase II | ART0380 | Study of ART0380 in Advanced/Metastatic Solid Tumors Patients (ARTIST) | Recruiting | USA | FRA | 0 |
NCT05803382 | Phase I | Capecitabine + ZEN-3694 | Testing the Addition of an Anti-Cancer Drug, ZEN003694, to the Usual Chemotherapy Treatment (Capecitabine) for Metastatic or Unresectable Cancers | Recruiting | USA | 0 |
NCT05826600 | Phase I | OMX-0407 | A Study of OMX-0407 in Patients With Previously Treated Solid Tumours That Can't be Removed Surgically | Recruiting | ESP | 0 |
NCT05827614 | Phase I | BBI-355 | Study of the CHK1 Inhibitor BBI-355, an ecDNA-directed Therapy, in Subjects With Tumors With Oncogene Amplifications (POTENTIATE) | Recruiting | USA | 0 |
NCT05828459 | Phase I | Lenalidomide + OT-A201 OT-A201 OT-A201 + Paclitaxel Bevacizumab + OT-A201 OT-A201 + Pomalidomide | First-in-human Study of OT-A201 in Patients With Selected Hematological Malignancies and Solid Tumors | Recruiting | FRA | 0 |
NCT05830097 | Phase Ib/II | CBP-1019 | A Study of Bi-Ligand-Drug Conjugate CBP-1019 in Patients With Advanced Solid Tumors | Recruiting | USA | 1 |
NCT05831995 | Phase I | ABM-168 | Safety and Effectiveness of ABM-168 in Adults With Advanced Solid Tumors. | Recruiting | USA | 0 |
NCT05836324 | Phase I | INCA33890 | A Study to Evaluate the Safety of INCA33890 in Participants With Advanced or Metastatic Solid Tumors | Recruiting | USA | ITA | GBR | FRA | ESP | 2 |
NCT05838768 | Phase I | HRO761 HRO761 + Tislelizumab HRO761 + Irinotecan | Study of HRO761 Alone or in Combination in Cancer Patients With Specific DNA Alterations Called Microsatellite Instability or Mismatch Repair Deficiency. | Recruiting | USA | FRA | ESP | DEU | BEL | 5 |
NCT05839600 | Phase I | BI 1821736 | A Study to Find a Suitable Dose of BI 1821736 and Test Whether it Helps People With Advanced Cancer | Recruiting | USA | ESP | CAN | 1 |
NCT05840224 | Phase I | GS-4528 + Zimberelimab GS-4528 | Study of GS-4528 in Adults With Solid Tumors | Recruiting | USA | GBR | ESP | CAN | 2 |
NCT05840510 | Phase Ib/II | Adagrasib + Nab-rapamycin | Adagrasib in Combination With Nab-Sirolimus in Patients With Advanced Solid Tumors and Non-Small Cell Lung Cancer With a KRAS G12C Mutation (KRYSTAL -19) | Recruiting | USA | 0 |
NCT05841563 | Phase I | PM54 | Clinical Trial of PM54 in Advanced Solid Tumors Patients. | Recruiting | USA | ESP | BEL | 0 |
NCT05846659 | Phase II | Nivolumab IMSA101 + Nivolumab IMSA101 + Pembrolizumab Pembrolizumab | Study of PULSAR-ICI +/- IMSA101 in Patients With Oligoprogressive Solid Tumor Malignancies | Recruiting | USA | 0 |
NCT05856981 | Phase I | ADU-1805 + Pembrolizumab ADU-1805 | Phase 1 Study Evaluating the Safety and PK of ADU-1805 in Advanced Solid Tumors | Recruiting | USA | 1 |
NCT05858164 | Phase I | BAY2862789 | A First-in-human Study to Learn How Safe the Study Treatment BAY2862789 is, to Find the Best Dose, How it Affects the Body, What Maximum Amount Can be Given, How it Moves Into, Through and Out of the Body, and How it Acts on Different Tumors in Participants With Advanced Solid Tumors | Recruiting | USA | AUS | 2 |
NCT05858736 | Phase I | AI-061 | Safety, PK and Efficacy of AI-061 in Advanced Solid Tumors (PRESERVE-009) | Recruiting | AUS | 0 |
NCT05859464 | Phase I | Pembrolizumab + ZL-1218 ZL-1218 | A Phase 1 Study of ZL-1218 in Subjects With Advanced Solid Tumors | Recruiting | USA | ESP | 0 |
NCT05861895 | Phase I | HF158K1 | A Clinical Study to Investigate the Safety, Tolerability, Pharmacokinetics, Immunogenicity and Preliminary Efficacy of HF158K1 in Participants With HER-2 Positive or HER-2 Low Expression Advanced Solid Tumors | Recruiting | USA | 1 |
NCT05862324 | Phase Ib/II | TAC01-CLDN18.2 | TAC T-cells for the Treatment of Claudin 18.2 Positive Solid Tumors (TACTIC-3) (TACTIC-3) | Recruiting | USA | CAN | 0 |
NCT05864144 | Phase Ib/II | Cemiplimab + SNS-101 SNS-101 | A Study of SNS-101 (Anti VISTA) Monotherapy and in Combination With Cemiplimab in Patients With Advanced Solid Tumors | Recruiting | USA | 0 |
NCT05865990 | Phase II | Patritumab deruxtecan | HER3-DXd in Breast Cancer and NSCLC Brain Metastases and Solid Tumor Leptomeningeal Disease (TUXEDO-3) | Recruiting | ESP | AUT | 0 |
NCT05867121 | Phase I | Atezolizumab + Gemcitabine + Nab-paclitaxel + RO7496353 Capecitabine + Nivolumab + Oxaliplatin + RO7496353 Nivolumab + Oxaliplatin + RO7496353 + Tegafur-gimeracil-oteracil Potassium Atezolizumab + RO7496353 | A Study to Evaluate the Safety, Pharmacokinetics, and Activity of RO7496353 in Combination With a Checkpoint Inhibitor With or Without Standard-of-Care Chemotherapy in Participants With Locally Advanced or Metastatic Solid Tumors | Recruiting | USA | ITA | ESP | AUS | 4 |
NCT05867251 | Phase Ib/II | ARTS-021 + Fulvestrant + Palbociclib ARTS-021 + Letrozole + Palbociclib ARTS-021 + Carboplatin ARTS-021 | Study of ARTS-021 in Patients With Advanced Solid Tumors | Recruiting | USA | 0 |
NCT05867303 | Phase I | RC198 | A Study of RC198 in Patients With Locally Advanced Unresectable/Metastatic Solid Tumours | Recruiting | AUS | 1 |
NCT05867420 | Phase I | ASKG915 | A Study of ASKG915 in Patients With Selected Advanced Solid Tumors. | Recruiting | USA | 0 |
NCT05868226 | Phase I | Evorpacept + Trastuzumab deruxtecan | PRE-I-SPY Phase I/Ib Oncology Platform Program (PRE-I-SPY-PI) | Recruiting | USA | 0 |
NCT05872295 | Phase I | IKS014 | IKS014 in Advanced Solid Tumors That Express HER2 | Recruiting | AUS | 0 |
NCT05873686 | Phase I | eCF506 | A Phase 1 Clinical Study of NXP900 in Subjects With Advanced Cancers | Recruiting | USA | GBR | 0 |
NCT05875168 | Phase Ib/II | DS-3939a | First-in-Human Study of DS-3939a in Participants With Advanced Solid Tumors | Recruiting | USA | 1 |
NCT05877599 | Phase I | NT-175 | A Study of NT-175 in Adult Subjects With Unresectable, Advanced, and/or Metastatic Solid Tumors That Are Positive for HLA-A*02:01 and the TP53 R175H Mutation | Recruiting | USA | 0 |
NCT05878691 | Phase I | GRC 54276 + Pembrolizumab Atezolizumab + GRC 54276 GRC 54276 | A Study of GRC 54276 in Participants With Advanced Solid Tumors and Lymphomas. | Recruiting | USA | 1 |
NCT05879822 | Phase II | INCB099280 | A Study to Evaluate INCB099280 in Participants With Select Solid Tumors Who Are Immune Checkpoint Inhibitor Naive | Recruiting | 11 | |
NCT05886868 | Phase I | BL0020 | Phase I Study of BL0020, a Novel Anti-tumor Drug, in Adult Subjects With Advanced Solid Tumors | Recruiting | AUS | 1 |
NCT05886920 | Phase I | D3S-002 | Study of D3S-002 as Monotherapy in Adult Subjects With Advanced Solid Tumors With MAPK Pathway Mutations | Recruiting | USA | AUS | 1 |
NCT05887492 | Phase Ib/II | Pembrolizumab + TNG260 | Study of TNG260 and an Anti-PD Antibody in STK11 Mutated Solid Tumors | Recruiting | USA | 0 |
NCT05888831 | Phase Ib/II | BMS-986449 + Nivolumab BMS-986449 | A Study of BMS-986449 With and Without Nivolumab in Participants With Advanced Solid Tumors | Recruiting | USA | ITA | FRA | ESP | BEL | 1 |
NCT05888857 | Phase II | MEDI5752 | A Multicentric Phase II Trial Evaluating MEDI5752 in Patients With Mature Tertiary Lymphoid Structures Solid Tumors. (TAYLOR) | Not yet recruiting | FRA | 0 |
NCT05892718 | Phase I | HCB101 | A Safety and Efficacy Study of HCB101, Fc-fusion Protein Targeting SIRPa-CD47 Pathway, in Solid or Hematological Tumors | Recruiting | USA | 1 |
NCT05898399 | Phase Ib/II | Olaparib ART6043 Talazoparib ART6043 + Olaparib ART6043 + Talazoparib | Study of ART6043 in Advanced/Metastatic Solid Tumors Patients | Recruiting | USA | 0 |
NCT05901285 | Phase I | VAX014 | Phase 1 Study of Intratumoral Administration of VAX014 in Subjects With Advanced Solid Tumors | Recruiting | USA | 0 |
NCT05902520 | Phase I | AGX148 + Aldesleukin | Adoptive Cell Therapy Using Cancer Specific CD8+ Tumor Infiltrating Lymphocytes in Adult Patients With Solid Tumors (ACT) | Recruiting | USA | 0 |
NCT05904236 | Phase I | ICVB-1042 | Safety and Tolerability of Intravenous Administration of ICVB-1042 | Recruiting | USA | 0 |
NCT05904496 | Phase I | BGB-30813 BGB-30813 + Tislelizumab | A Study Investigating the Safety, Tolerability, Pharmacokinetics, and Preliminary Antitumor Activity of BGB-30813 | Recruiting | USA | ESP | AUS | 0 |
NCT05906862 | Phase I | AMT-253 | AMT-253 in Patients With Selected Advanced Solid Tumours | Recruiting | AUS | 0 |
NCT05907304 | Phase I | LXH 254 + Trametinib | A Study to Assess Naporafenib (ERAS-254) Administered With Trametinib in Patients With RAS Q61X Mutations (SEACRAFT-1) | Recruiting | USA | GBR | CAN | AUS | 1 |
NCT05907980 | Phase I | Atezolizumab + ROSE12 ROSE12 | A Phase I Study of ROSE12 Alone and in Combination With Other Anti-tumor Agents in Patients With Solid Tumors | Recruiting | USA | 1 |
NCT05914116 | Phase Ib/II | DB-1311 | A Study of DB-1311 in Advanced/Metastatic Solid Tumors | Recruiting | USA | AUS | 0 |
NCT05918640 | Phase Ib/II | Lurbinectedin | Lurbinectedin in FET-Fused Tumors (LiFFT) | Recruiting | USA | 0 |
NCT05919264 | Phase Ib/II | FOG-001 | FOG-001 in Locally Advanced or Metastatic Solid Tumors | Recruiting | USA | 0 |
NCT05919537 | Phase Ib/II | Docetaxel + HMBD-001 HMBD-001 Gemcitabine + HMBD-001 + Nab-paclitaxel | Study of an Anti-HER3 Antibody, HMBD-001, With or Without Chemotherapy in Patients With Solid Tumors Harboring an NRG1 Fusion or HER3 Mutation | Recruiting | AUS | 0 |
NCT05923008 | Phase Ib/II | IBI130 | A Phase 1/2 Clinical Study to Evaluate the Safety and Tolerability of IBI130 for Subjects With Unresectable, Locally Advanced or Metastatic Solid Tumors | Recruiting | AUS | 0 |
NCT05929235 | Phase I | FX-909 | A Study of FX-909 in Patients With Advanced Solid Malignancies, Including Advanced Urothelial Carcinoma | Recruiting | USA | 0 |
NCT05933265 | Phase I | LP-184 | Study of LP-184 in Patients With Advanced Solid Tumors | Recruiting | USA | 0 |
NCT05935098 | Phase I | BGB-A3055 + Tislelizumab BGB-A3055 | A Study of BGB-A3055, Alone and in Combination With Tislelizumab in Participants With Selected Advanced or Metastatic Solid Tumors | Recruiting | USA | AUS | 0 |
NCT05937295 | Phase I | Fusion-VAC-XS15 Atezolizumab + Fusion-VAC-XS15 | FusionVAC22_01: Fusion Transcript-based Peptide Vaccine Combined With Immune Checkpoint Inhibition (FusionVAC22) | Recruiting | DEU | 0 |
NCT05940571 | Phase I | MBF-362 | First Phase Clinical Trial of Single Agent MBF-362 in Solid Tumors | Recruiting | ESP | 0 |
NCT05941507 | Phase Ib/II | LCB84 + unspecified PD-1 antibody LCB84 | Phase 1/2 Study to Evaluate TROP2 ADC LCB84 Single Agent and in Combination With an Anti-PD-1 Ab in Advanced Solid Tumors | Recruiting | USA | CAN | 0 |
NCT05944237 | Phase Ib/II | Atezolizumab + HTL0039732 HTL0039732 | HTL0039732 in Participants With Advanced Solid Tumours | Recruiting | GBR | 0 |
NCT05947474 | Phase I | ORB-011 | ORB-011 In Patients With Advanced Solid Tumors (ORB) | Recruiting | USA | 0 |
NCT05948826 | Phase I | TORL-3-600 | First in Human Study of TORL-3-600 in Participants With Advanced Cancer | Recruiting | USA | CAN | 0 |
NCT05948865 | Phase I | CPO301 | A Phase 1 Study of CPO301 in Adult Patients With Advanced or Metastatic Solid Tumors | Recruiting | USA | CAN | 0 |
NCT05954312 | Phase I | VVD-130037 | A First-in-Human (FIH) Study to Evaluate the Safety and Tolerability of VVD-130037 in Participants With Advanced Solid Tumors | Recruiting | USA | ESP | 0 |
NCT05957081 | Phase I | Pembrolizumab + PMC-309 PMC-309 | Study to Assess the Safety, Tolerability, and Blood Concentration of PMC-309 (MarkV-01) | Not yet recruiting | AUS | 0 |
NCT05957536 | Phase I | D3L-001 | A Study of D3L-001 as Monotherapy in Subjects With HER2-Positive Advanced Solid Tumors | Recruiting | USA | 1 |
NCT05958121 | Phase Ib/II | IMA402 | IMA402 T Cell-Engaging Receptor Molecule (TCER) in Recurrent and/or Refractory Solid Tumors | Recruiting | DEU | 0 |
NCT05970497 | Phase I | KB707 | A Study Assessing KB707 for the Treatment of Locally Advanced or Metastatic Solid Tumors | Recruiting | USA | 0 |
NCT05975073 | Phase Ib/II | AMG193 + IDE397 | A Phase 1/2 Study of AMG 193 in Combination With IDE397 in Participants With Advanced Methylthioadenosine Phosphorylase (MTAP)-Null Solid Tumors | Recruiting | USA | AUS | 0 |
NCT05980416 | Phase I | EO-3021 | Study of EO-3021 in Adult Patients With Solid Tumors Likely to Express CLDN18.2 | Recruiting | USA | 1 |
NCT05981703 | Phase I | BGB-26808 + Tislelizumab | A Study Investigating BGB-26808 Alone or in Combination With Tislelizumab in Participants With Advanced Solid Tumors | Recruiting | USA | AUS | 1 |
NCT05985083 | Phase I | IMM47 | A Study Of IMM47 In Subjects With Advanced Solid Tumors | Recruiting | AUS | 0 |
NCT05985161 | Phase II | Selinexor | A Study of Selinexor in People With Wilms Tumors and Other Solid Tumors | Recruiting | USA | 0 |
NCT05991349 | Phase Ib/II | IBI129 | A Study of IBI129 in Subjects With Unresectable, Locally Advanced or Metastatic Solid Tumors | Not yet recruiting | AUS | 0 |
NCT05999994 | Phase II | Docetaxel + Gemcitabine + Ramucirumab Cyclophosphamide + Ramucirumab + Vinorelbine Cyclophosphamide + Vinorelbine Irinotecan + Temozolomide Abemaciclib + Irinotecan + Temozolomide Docetaxel + Gemcitabine | A Master Protocol (LY900023) That Includes Several Clinical Trials of Drugs for Children and Young Adults With Cancer (CAMPFIRE) | Recruiting | USA | ITA | GBR | FRA | ESP | DEU | BEL | AUS | 1 |
NCT06003621 | Phase II | Atezolizumab + Tiragolumab | Tiragolumab and Atezolizumab in Advanced Pan-cancer Patients (MoST-TAP) | Recruiting | AUS | 0 |
NCT06004245 | Phase I | RO7589831 | A Study to Evaluate the Safety, Pharmacokinetics, and Anti-Tumor Activity of RO7589831 in Participants With Advanced Solid Tumors | Recruiting | USA | GBR | ESP | 0 |
NCT06005740 | Phase I | TORL-4-500 | First in Human Study of TORL-4-500 in Participants With Advanced Cancer | Recruiting | USA | 0 |
NCT06005974 | Phase II | TAK-733 | A Study of REC-4881 in Participants With Cancers Which Have an AXIN1 or APC Mutation | Recruiting | USA | 0 |
NCT06007482 | Phase I | ES009 | A Study of ES009 in Subjects With Locally Advanced or Metastatic Solid Tumors | Recruiting | AUS | 0 |
NCT06014502 | Phase I | IMGS-001 | Study to Evaluate IMGS-001 Treatment in Patients With Relapsed or Refractory Advanced Solid Tumors | Recruiting | USA | 0 |
NCT06014658 | Phase I | MBRC-101 | Safety & PK of MBRC-101 in Advanced Refractory Solid Tumors | Recruiting | USA | 0 |
NCT06016179 | Phase I | Tocilizumab | Tocilizumab Delivered Via Pleural and Peritoneal Catheters in Patients With Advanced Metastatic Cancer | Recruiting | USA | 0 |
NCT06021626 | Phase I | CRD3874 | A Study of CRD3874-SI in People With Sarcoma or Merkel Cell Cancer | Recruiting | USA | 0 |
NCT06022029 | Phase I | ONM-501 Cemiplimab + ONM-501 | A Dose Escalation and Dose Expansion Study of Intratumoral ONM-501 Alone and in Combination With Cemiplimab in Patients With Advanced Solid Tumors and Lymphomas. (ON-5001) | Recruiting | USA | 0 |
NCT06026410 | Phase I | Cabozantinib + KO-2806 KO-2806 | KO-2806 Monotherapy and Combination Therapies in Advanced Solid Tumors (FIT-001) | Recruiting | USA | 0 |
NCT06028074 | Phase Ib/II | GIM-122 | Safety and Tolerability Study of GIM-122 in Subjects With Advanced Solid Malignancies | Recruiting | USA | 0 |
NCT06031441 | Phase I | RO7566802 Atezolizumab + RO7566802 | A Study to Evaluate the Safety, Pharmacokinetics, and Activity of RO7566802 as a Single Agent and in Combination With Atezolizumab in Participants With Locally Advanced or Metastatic Solid Tumors | Recruiting | AUS | 0 |
NCT06034860 | Phase I | MT-8421 + Nivolumab MT-8421 | Study of MT-8421 as Monotherapy and in Combination With Nivolumab in Patients With Selected Advanced Solid Cancer Types | Recruiting | USA | 0 |
NCT06035744 | Phase I | CLN-617 + Pembrolizumab | CLN-617 Alone and in Combination With Pembrolizumab in Patients With Advanced Solid Tumors | Recruiting | USA | 0 |
NCT06039384 | Phase I | Adagrasib + INCB099280 | A Study of INCB099280 in Combination With Adagrasib in Adults With Advanced Solid Tumors Harboring a KRASG12C Mutation | Recruiting | USA | ITA | GBR | FRA | ESP | CAN | 0 |
NCT06040541 | Phase I | RMC-9805 | Study of RMC-9805 in Participants With KRASG12D-Mutant Solid Tumors | Recruiting | USA | 0 |
NCT06046066 | Phase I | NM6603 | A Phase 1 Study of NM6603 in Advanced Solid Tumors | Recruiting | USA | 0 |
NCT06047379 | Phase Ib/II | NEO212 NEO212 + Regorafenib Carboplatin + NEO212 + Paclitaxel Bevacizumab + Fluorouracil + Irinotecan + Leucovorin + NEO212 Ipilimumab + NEO212 NEO212 + Pembrolizumab NEO212 + Nivolumab | Safety and Efficacy of NEO212 in Patients With Astrocytoma IDH-mutant, Glioblastoma IDH-wildtype or Brain Metastasis | Recruiting | USA | 0 |
NCT06051695 | Phase Ib/II | A2B694 | A Study to Evaluate the Safety and Efficacy of A2B694, a Logic-gated CAR T, in Subjects With Solid Tumors That Express MSLN and Have Lost HLA-A*02 Expression (EVEREST-2) | Recruiting | USA | 0 |
NCT06056323 | Phase Ib/II | HB0045 | A Study of HB0045 Injection in Patients With Advanced Solid Tumors | Recruiting | USA | 0 |
NCT06058988 | Phase II | Trastuzumab deruxtecan | Trastuzumab Deruxtecan (T-DXd) for People With Brain Cancer | Recruiting | USA | 0 |
NCT06063317 | Phase I | CF33-CD19t Blinatumomab + CF33-CD19t | A Study of onCARlytics (CF33-CD19) in Combination With Blinatumomab in Adults With Advanced or Metastatic Solid Tumors (OASIS) (OASIS) | Recruiting | USA | 0 |
NCT06063681 | Phase I | SR-8541A | A Study of SR-8541A (ENPPI Inhibitor) in Advanced/Metastatic Solid Tumors | Recruiting | AUS | 0 |
NCT06065059 | Phase Ib/II | TNG348 Olaparib + TNG348 | Study to Evaluate TNG348 Alone and With a PARP Inhibitor in Patients With BRCA 1/2 Mutant or HRD+ Solid Tumors | Recruiting | USA | 0 |
NCT06066424 | Phase I | Cyclophosphamide + Fludarabine TROP2-CAR/IL15-transduced CBNK cells Rimiducid | Phase 1 Dose Escalation and Expansion Study of TROP2 CAR Engineered IL15-transduced Cord Blood-derived NK Cells in Patients With Advanced Solid Tumors (TROPIKANA) | Recruiting | USA | 0 |
NCT06074497 | Phase I | KGX101 | A Phase 1, First-in-Human of KGX101 to Patients With Advanced or Metastatic Solid Tumors | Not yet recruiting | AUS | 0 |
NCT06077877 | Phase Ib/II | GSK4524101 + Niraparib GSK4524101 Niraparib | A Study to Investigate the Safety, Tolerability, Pharmacokinetics (PK), and Preliminary Anticancer Activity of GSK4524101 Alone or With Niraparib in Participants With Solid Tumors | Recruiting | USA | CAN | 0 |
NCT06082960 | Phase I | GS-9911 + Zimberelimab GS-9911 | Study of GS-9911 With or Without Antibody Treatment for Adults With Solid Tumors | Recruiting | USA | CAN | AUS | 0 |
NCT06083883 | Phase I | Cyclophosphamide + Fludarabine + NY-ESO-1 TCR/IL-15 NK | Phase I/Ib Study of NK Expressing an Affinity-enhanced T-cell Receptor (TCR) Against the NY-ESO-1 | Not yet recruiting | USA | 0 |
NCT06096974 | Phase I | TEB-17231 | Pan-RAS Inhibitor YL-17231 in Patients With Advanced Solid Tumors Harboring Mutations in KRAS, HRAS, or NRAS | Not yet recruiting | USA | 0 |
NCT06098651 | Phase I | DCR-STAT3 | A Study of DCR-STAT3 in Adults With Solid Tumors | Recruiting | USA | 0 |
NCT06105021 | Phase Ib/II | AFNT-211 | Phase I Study of Autologous CD8+ and CD4+ Engineered T Cell Receptor T Cells in Subjects With Advanced or Metastatic Solid Tumor | Recruiting | USA | 0 |
NCT06108479 | Phase I | DF6215 | Study of DF6215 in Patients With Advanced Solid Tumors | Recruiting | USA | 0 |
NCT06120283 | Phase I | BGB-43395 BGB-43395 + Letrozole BGB-43395 + Fulvestrant | BGB-43395 Alone or as Part of Combination Therapies in Participants With Breast Cancer and Other Advanced Solid Tumors | Recruiting | USA | AUS | 0 |
NCT06128551 | Phase I | RMC-6236 + RMC-6291 | Study of RMC-6291 in Combination With RMC-6236 in Participants With Advanced KRAS G12C Mutant Solid Tumors | Recruiting | USA | 0 |
NCT06130254 | Phase I | Adagrasib + Olaparib | Phase Ib Trial of the KRAS G12C Inhibitor Adagrasib (MRTX849) in Combination With the PARP Inhibitor Olaparib in Patients With KRAS G12C Mutated Advanced Solid Tumors, With a Focus on Gynecological, Breast, Pancreatic and KEAP1 Mutated Non-small Cell Lung Cancers | Recruiting | USA | 0 |
NCT06130553 | Phase Ib/II | AZD3470 | A Study of AZD3470, a PRMT5 Inhibitor, in Patients With MTAP Deficient Advanced/Metastatic Solid Tumours (PRIMROSE) | Recruiting | USA | FRA | ESP | AUS | 4 |
NCT06131398 | Phase I | AMG 355 + Pembrolizumab AMG 355 | A Study of AMG 355 Alone and in Combination With Pembrolizumab in Participants With Advanced Solid Tumors | Recruiting | USA | 0 |
NCT06132503 | Phase I | LP-284 | A Study of LP-284 in Relapsed or Refractory Lymphomas and Solid Tumors | Recruiting | USA | 0 |
NCT06147037 | Phase I | FPI-2053 + FPI-2068 | A Phase 1, Dose-escalation Study of [225Ac]-FPI-2068 in Adult Patients With Advanced Solid Tumours | Recruiting | USA | CAN | 0 |
NCT06150183 | Phase Ib/II | BNT314 + Pembrolizumab BNT314 | Safety and Preliminary Efficacy of BNT314 With or Without an Immune Checkpoint Inhibitor in Cancer Patients With Malignant Solid Tumors | Recruiting | USA | GBR | 0 |
NCT06154291 | Phase Ib/II | XON7 | FIH XON7 in Advanced/Metastatic Solid Tumors (FIPO23) | Recruiting | FRA | BEL | 0 |
NCT06158958 | Phase I | ABBV-303 + Budigalimab ABBV-303 | A Study of Adverse Events, How Intravenously (IV) Infused ABBV-303 Moves Through the Body, and Change in Disease State, as Monotherapy and in Combination With IV Infused Budigalimab (ABBV-181), in Adult Participants With Advanced Solid Tumors | Recruiting | USA | 1 |
NCT06160752 | Phase I | TYRA-200 | Safety and Anti-Tumor Activity of TYRA-200 in Advanced Cholangiocarcinoma With Activating FGFR2 Gene Alterations (SURF201) | Recruiting | USA | 0 |
NCT06161493 | Phase I | Niraparib + ZEN-3694 | ZEN003694 Combined With Niraparib in Patients With Metastatic or Recurrent Solid Tumors | Recruiting | USA | 0 |
NCT06161558 | Phase I | Erlotinib + Lenvatinib Axitinib + Erlotinib | Erlotinib in Combination With Select Tyrosine Kinase Inhibitors in Adult Patients With Advanced Solid Tumors | Not yet recruiting | USA | 0 |
NCT06162221 | Phase Ib/II | Carboplatin + Pembrolizumab + Pemetrexed Disodium + RMC-6236 Pembrolizumab + RMC-6236 Cisplatin + Pembrolizumab + Pemetrexed Disodium + RMC-6236 Cisplatin + Pembrolizumab + Pemetrexed Disodium + RMC-6291 Carboplatin + Pembrolizumab + Pemetrexed Disodium + RMC-6291 Pembrolizumab + RMC-6291 | Study of RAS(ON) Inhibitor Combinations in Patients With Advanced RAS-mutated NSCLC | Recruiting | USA | 0 |
NCT06163391 | Phase I | SOT201 | A Study to Assess Safety and Efficacy of SOT201 in Patients With Advanced/Metastatic Cancer | Not yet recruiting | USA | FRA | ESP | BEL | 1 |
NCT06167317 | Phase I | GS-0201 + Sacituzumab govitecan-hziy GS-0201 | Study of GS-0201 Alone and in Combination in Participants With Advanced Solid Tumors | Recruiting | USA | 0 |
NCT06170190 | Phase Ib/II | IBI133 | A Multicentre,Study of IBI133 in Subjects With Unresectable, Locally Advanced or Metastatic Solid Tumours | Recruiting | AUS | 0 |
NCT06171178 | Phase I | ASP1012 + Pembrolizumab ASP1012 | A Study of ASP1012 in Adults With Solid Tumors | Recruiting | USA | 0 |
NCT06171750 | Phase I | ANK-101 | Phase I Study of ANK-101 in Advanced Tumors (ANCHOR) | Recruiting | USA | 0 |
NCT06171789 | Phase Ib/II | PRO1107 | PRO1107 in Patients With Advanced Solid Tumors | Recruiting | USA | 0 |
NCT06172894 | Phase I | APN401 | PBMC-based Leukocyte Immunotherapy (PALINDROM) | Recruiting | AUT | 0 |
NCT06177171 | Phase I | Decitabine and Cedazuridine + Olaparib | Olaparib and ASTX727 in BRCA1/2- and Homologous Recombination Deficient (HRD)-Mutated Tumors | Not yet recruiting | USA | 0 |
NCT06179160 | Phase I | Cetuximab + INCB161734 + Retifanlimab INCB161734 | A Study to Evaluate INCB161734 in Participants With Advanced or Metastatic Solid Tumors With KRAS G12D Mutation | Recruiting | USA | AUS | 0 |
NCT06182579 | Phase I | RiMO-401 | Phase I Study of RiMO-401 With Radiation in Advanced Tumors | Recruiting | USA | 0 |
NCT06184035 | Phase Ib/II | 177Lu-SN201 | A Dose Escalation and Expansion Study of [177Lu]Lu-SN201 in Participants With Advanced Cancer (Tumorad) | Recruiting | AUS | 0 |
NCT06187402 | Phase Ib/II | LM-24C5 | A Study of LM-24C5 For Advanced Solid Tumors | Recruiting | USA | 0 |
NCT06188208 | Phase I | Pembrolizumab + VVD-130850 VVD-130850 | A First-in-Human (FIH) Study to Evaluate the Safety and Tolerability of VVD-130850 in Participants With Advanced Solid and Hematologic Tumors | Recruiting | USA | 0 |
NCT06191796 | Phase Ib/II | AB521 + Nivolumab + XL092 AB521 + XL092 | Study of Zanzalintinib (XL092) + AB521 and Zanzalintinib + AB521 + Nivolumab in Participants With Advanced Clear Cell Renal Cell Carcinoma (ccRCC) or Other Advanced Solid Tumors (STELLAR-009) | Recruiting | USA | 0 |
NCT06198426 | Phase Ib/II | IBI3004 | A Study of IBI3004 in Subjects With Unresectable, Locally Advanced or Metastatic Solid Tumors | Not yet recruiting | AUS | 0 |
NCT06199908 | Phase I | AMT-562 | AMT-562 in Patients With Selected Advanced Solid Tumors | Not yet recruiting | AUS | 0 |
NCT06205706 | Phase Ib/II | BI-1910 + Pembrolizumab BI-1910 | BI-1910 as a Single Agent and in Combination With Pembrolizumab for the Treatment of Advanced Solid Tumors | Recruiting | ESP | 2 |
NCT06208124 | Phase Ib/II | IMM-6-415 | A Study of IMM-6-415 in RAS/RAF Mutant Solid Tumors | Recruiting | USA | 0 |
NCT06208657 | Phase Ib/II | GDC-0084 + Irinotecan + Temozolomide Pimasertib | Optimal Precision TherapIes to CustoMISE Care in Childhood and Adolescent Cancer | Not yet recruiting | CAN | AUS | 0 |
NCT06218914 | Phase I | NT-112 | A Study of NT-112 in HLA-C*08:02-Positive Adult Subjects With Unresectable, Advanced, and/ or Metastatic Solid Tumors Positive for the KRAS G12D Mutation | Recruiting | USA | 0 |
NCT06220864 | Phase I | SNV1521 | SNV1521 in Participants With Advanced Solid Tumors | Not yet recruiting | USA | 0 |
NCT06226766 | Phase Ib/II | JSKN033 | JSKN033 in Patients With Advanced or Metastatic Solid Malignant Tumors | Not yet recruiting | AUS | 0 |
NCT06227377 | Phase I | QTX3034 Cetuximab + QTX3034 | QTX3034 in Patients With KRAS G12D Mutation | Recruiting | USA | 0 |
NCT06234397 | Phase I | BH3120 | Dose Escalation and Expansion Study of BH3120 in Advanced or Metastatic Solid Tumors | Recruiting | USA | 1 |
NCT06241456 | Phase I | Cetuximab + FT825 Bendamustine + Cisplatin + Docetaxel FT825 Cyclophosphamide + Fludarabine | FT825/ONO-8250, an Off-the-Shelf, HER2 CAR-T, With or Without Monoclonal Antibodies in Advanced Solid Tumors | Recruiting | USA | 0 |
NCT06244771 | Phase Ib/II | FMC-376 | A Study Evaluating FMC-376 in Participants With KRAS G12C Mutated Solid Tumors (PROSPER) | Recruiting | USA | 0 |
NCT06246643 | Phase II | Regorafenib | A Study of Continued Treatment With Regorafenib in Participants With Solid Tumors Who Have Participated in Other Bayer Studies | Recruiting | FRA | ESP | 4 |
NCT06249048 | Phase Ib/II | Pembrolizumab + STX-001 STX-001 | Phase 1/2 Study of IT STX-001 in Patients With Advanced Solid Tumors as Monotherapy or in Combination With Pembrolizumab | Not yet recruiting | USA | AUS | 0 |
NCT06253520 | Phase I | Cyclophosphamide + Fludarabine Aldesleukin + Anti-KRAS G12V TCR cells + GRT-C903 + GRT-R904 Aldesleukin + Anti-KRAS G12D TCR cells + GRT-C903 + GRT-R904 | Autologous T-cells Genetically Engineered to Express Receptors Reactive Against KRAS Mutations in Conjunction With a Vaccine Directed Against These Antigens in Participants With Metastatic Cancer | Recruiting | USA | 0 |
NCT06253871 | Phase I | IAM1363 IAM1363 + Trastuzumab | A Phase 1/1b Study of IAM1363 in HER2 Cancers | Not yet recruiting | USA | 0 |
NCT06258304 | Phase I | GIGA-564 | A Dose Escalation and Expansion Study of GIGA-564 in Participants With Locally Advanced or Metastatic Solid Tumor Malignancies | Not yet recruiting | USA | 0 |
NCT06259552 | Phase I | SPX-303 | A Study of SPX-303, a Bispecific Antibody Targeting LILRB2 and PD-L1 in Patients With Solid Tumors (SPX-303) | Not yet recruiting | USA | 0 |
NCT06264921 | Phase I | NKT3447 | A Phase 1 Study With NKT3447 for Adults With Advanced/Metastatic Solid Tumors | Not yet recruiting | USA | 0 |
NCT06265688 | Phase I | CX-2051 | First In Human Study of CX-2051 in Advanced Solid Tumors | Not yet recruiting | USA | 0 |
NCT06265727 | Phase Ib/II | SYS6002 | A Phase 1/2 Study to Investigate the Safety, Pharmacokinetics, and Efficacy of CRB-701 | Not yet recruiting | USA | GBR | 0 |
NCT06270082 | Phase I | IK-595 | Study of IK-595 in RAS- or RAF-altered Advanced Tumors | Recruiting | USA | 0 |
NCT06270706 | Phase I | Pembrolizumab + PLN-101095 PLN-101095 | A Phase 1 Study of PLN-101095 in Adults With Advanced or Metastatic Solid Tumors | Recruiting | USA | 0 |
NCT06277219 | Phase Ib/II | LAT010 + unspecified PD-1 antibody LAT010 | A First-in-Human, Phase 1/2 Study of LAT010 in Patients With Advanced Solid Tumors (LIGHTSPEED-1) (LIGHTSPEED-1) | Not yet recruiting | USA | 0 |
NCT06279130 | Phase II | Balstilimab Balstilimab + Botensilimab | Pan-tumor Neoadjuvant Basket Study of Immune Check-point Inhibition and Novel Immuno-oncology Combinations (NEOASIS) | Recruiting | 1 | |
NCT06281678 | Phase II | IBI363 | A Study of IBI363 in Subjects With Advanced Solid Malignancies | Not yet recruiting | USA | 0 |
NCT06287918 | Phase I | 3HP-2827 | A First-in-human Study of 3HP-2827 in Patients With Unresectable or Metastatic Solid Tumours With FGFR2 Alterations | Not yet recruiting | USA | 0 |
NCT06299163 | Phase I | NM32-2668 | NM32-2668 in Adult Patients With Selected Advanced Solid Tumors | Recruiting | USA | 0 |